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SUMMARY 
The design and synthesis of bioisosteres has become a central instrument in drug development to improve 
restricting properties of a parent structure without diminishing its biological activity or other beneficial 
parameters. Especially the replacement of one or more amide bonds in small molecules or peptide mimetics 
has come to the fore due to the significance of this structural motif in biologically active compounds. 
Furthermore, amides are often associated with metabolic liabilities as they are susceptible to fast enzymatic 
hydrolysis. This necessitates the development and synthetic access toward suitable amide mimetics. The 
concept of trifluoroethylamines has gained in importance as they are metabolically stable isosteres with 
exceptional properties similar to those of an amide. Despite first examples of successful implementation, 
synthetic restrictions toward trifluoroethylamines including a small substrate scope and facile hydrolysis of the 
imine precursors still limit their applicability.  
In this context, we envisioned a convenient synthetic strategy toward a broad range of novel fluoroalkylated 
amines and fluorinated derivatives for possible applications in pharmaceutical research (Scheme 1). 
  
Scheme 1. Syntheses of various functionalized trifluoroethylamine derivatives. 
Initially, we focused on developing an efficient approach toward trifluoroethylamines from trifluoromethylated 
N-aryl N,O-acetals. These N-aryl N,O-acetals are stable imine surrogates and can be reacted with alkyl-, 
alkenyl- and arylmagnesium reagents to furnish a broad range of functionalized trifluoromethylated amines in 
good to excellent yield. First attempts toward a stereoselective synthesis of these compounds have been made. 
 
II 
 
Furthermore, this procedure was successfully extended to the synthesis of novel difluoroalkylated amines, 
which are also of great interest for medicinal chemistry applications as the difluoromethyl moiety can be used 
as a hydroxyl bioisostere and, similarly to trifluoromethyl groups, can be implemented to modulate the basicity 
of adjacent amines.  
To access novel fluoroalkylated moieties, the conversion of N-aryl N,O-acetals with heteroatom nucleophiles 
and in situ generated lithium enolates was studied. Thus, simple protocols with a broad substrate scope were 
developed which allow reaction of fluorinated N,O-acetals with a large variety of C- and heteroatom 
nucleophiles.  
In course of the synthesis of trifluoroethylamines, we found that N-aryl N,O-acetals with electron-withdrawing 
substituents can be treated with aryl magnesium halides to provide N-aryl trifluoromethylated imidazole 
derivatives in an one-pot reaction. At this point, the reaction was studied via NMR experiments to elucidate 
the mechanism pathway, which finally allowed the development of a modified procedure to access highly 
functionalized imidazole derivatives by reaction of trifluoroethylamines and N,O-acetals under basic reaction 
conditions (Scheme 2).  
 
Scheme 2. Synthesis of further functionalized trifluoromethylated imidazole derivatives. 
Furthermore, a synthetic strategy toward ψ[CH(CF3)NH]-Gly dipeptide building blocks was investigated 
(Scheme 3). Starting from N-aryl N,O-acetal the trifluoromethylated diamine was synthesized in five synthetic 
steps. First attempts toward the conversion of this diamine precursor by introduction of an appropriate leaving 
group and its subsequent reaction with a second amino acid were made.  
 
Scheme 3. Synthetic strategy toward ψ[CH(CF3)NH]-Gly dipeptide building block. 
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I. INTRODUCTION 
1. Modern Drug Discovery 
The development of new drugs from an initial idea to the launch of a product is known to be a time-consuming 
task, which can take up to 12 – 15 years and creates costs of about $800 million.[1] In the past decades it has 
evolved into a highly complex process, involving intensive analysis and optimization steps to create a potential 
drug candidate, which is subsequently tested in clinical trials. This process is constantly being enhanced by 
advancements in scientific research, such as the growing identification of novel targets and improved screening 
methods just to name two. However, pharmaceutical companies still face setbacks and failure of lead structures 
in late stages of drug development resulting in large financial losses and a lack of new chemical entities (NCEs). 
Gaining insight into the procedure of early drug discovery as shown in Figure 1 allows a better understanding 
of the existing limitations and tools used to overcome possible drawbacks. The screening and assay methods 
described below are not only applied at one stage of the discovery process but recur in many of the development 
steps.  
 
 
 
 
 
 
1.1  Early drug discovery – from target to preclinical candidate 
The first step in developing a novel drug involves the identification and validation of a suitable target that is 
safe, effective and most importantly drugable. The term drugable refers to a biological entity that binds to a 
possible drug and reacts with a biological response upon binding to this drug, which can be measured both 
in vitro and in vivo. There are three main approaches in target identification: (i) a bioinformatic approach using 
data mining to identify and rate possible targets, (ii) the search for genetic associations or (iii) phenotype 
screening. Once identified, a potential target is further validated using in vitro and in vivo methods such as 
antisense technology, biological examination of transgenic animals or monoclonal antibodies amongst others. 
These methods are often combined in a multi-validation approach to maximize the informational outcome.[2]  
Early Drug Discovery Preclinical Development
Clinical 
Development Approval
 Figure 1. Early drug discovery process from target identification to lead optimization. 
Target Identification
and Validation
Hit Compound
Screening Hit to Lead
Lead 
Optimization
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The target validation process is followed by the screening of hit compounds, which are defined as molecules 
that show the desired activity during the screening process and retain this activity upon retesting.[3] The current 
paramount method to identify hit compounds is high-throughput screening (HTS). In this screening process 
large compound libraries are tested in assays against the target or in cell-based assays. In case of cell-based 
assays additional screenings using secondary assays are required to confirm the site of action, due to multiple 
interactions in cells which can result in a false-positive activity of compounds. Despite this promising method, 
HTS-based hit discovery has a relatively low success rate of 45 – 55%[4-5] and has therefore undergone multiple 
transformational changes. Novel assay technologies, multipoint and tiered screening strategies are only a few 
examples which aim at improving the hit identification process.[6] In contrast to HTS, focused or knowledge-
based screening requires a preselection of compounds that have a higher potential of activity against the target. 
Fragment screening typically involves the screening of several thousands of small molecule fragments in high 
concentration to identify functionalities which exhibit weak activities against the target.[7] Subsequent 
combination of potent fragments to design molecules with high affinity requires knowledge of the crystal 
structure of the target. Additionally, nuclear magnetic resonance (NMR) screening has gained attention as a 
fragment screening method in hit discovery. Protein-ligand interactions can be observed by NMR shifts of 
signals derived from either the protein or the ligand revealing even weak activities of fragments. Crystal 
structures of target proteins can also be employed in structure-aided drug design and virtual screening methods, 
which use docking models of the target and molecules from a virtual compound library to generate a hit 
compound.[3] 
The hit molecules are tested in cell-based assays and animal models to examine both the efficacy and the safety 
profile. Stable cell lines over-expressing the target or overexpressed recombinant protein assays are well-
established to test the activity of a compound. Cell-based assays are used to evaluate molecules interacting 
with membrane receptors, ion channels and nuclear receptors, while biochemical assays are applied to receptor 
and enzyme targets to measure the affinity of the hit compound.[8-9] Besides a sufficient affinity toward the 
target and a tolerable safety profile, the compounds need to fulfill additional requirements to be considered for 
a hit series. The Lipinski Rule of Five aims at ensuring adequate bioavailability of a potential drug. A low 
molecular weight and a low LogP value, a guidance level for lipophilicity affecting the absorption level, are 
important parameters to ensure compound drugability. Since the lead optimization process often requires 
further substitution and involves an increase of molecular weight, application of the Lipinski Rule of Five is 
especially important in this early phase of finding a hit series.[10] 
Once a hit series is defined further investigation of the binding mode and required dosage is conducted by 
generating a dose-response curve to determine the half maximal inhibitory concentration. The mode of action 
and functional groups involved in target binding can be identified by secondary assays and structure-activity 
relationship (SAR) studies. In vitro testing provides important information concerning absorption, distribution, 
metabolism and excretion (ADME), physicochemical and pharmacokinetic (PK) parameters. This phase of 
drug development typically ends with a selection of hit compounds having a potency of 100 nM – 5 nM.[3] 
The subsequent hit-to-lead phase results in finding potent and selective compounds with sufficient drug-like 
properties to examine their efficacy in in vivo models. Based on information gathered from SAR studies the 
compounds can be analyzed in more detail in order to identify the core structures responsible for activity and 
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selectivity. This process can be supplemented by crystallographic and NMR investigations to disclose new 
binding sites of the target. Similarly, the compounds will be screened in more detail regarding their ADME 
and PK profiles. These detailed analyses serve the selection of potent candidates for more detailed but costly 
testing. Key hit structures, which meet the efficacy, selectivity, ADME and physicochemical properties 
required, are then analyzed concerning their PK properties in rats. At this point it is beneficial to investigate 
the selectivity of the compounds at the hERG (human ether-à-go-go-related gene) channel, whose inhibition is 
associated with cardiovascular toxicity.[3] 
The final phase in early drug discovery deals with lead optimization, which aims at reversing deficiencies, 
while maintaining the favorable properties of the selected compounds. This optimization is once again a big 
synthetic challenge for medicinal chemists and requires the interplay between biological profiling and synthetic 
strategies. The modified drug properties and synthetic strategies applied during lead optimization will therefore 
be elucidated more closely in the following chapter.  
Further properties of the final drug candidate are examined at the end of this phase as well as in the preclinical 
development in models of genotoxicity, in vivo models, high-dose pharmacology, PK/PD studies, dose linearity 
and metabolic profiling.[3]After lead discovery, optimization and preclinical development, one or two drug 
candidates are selected to enter the clinical phases and after successful clinical trial may reach drug approval 
to be administered to patients. 
1.2 Modified drug properties in lead optimization 
Active hit compounds which performed well in the initial screens hardly ever exhibit all the required properties 
of a final drug candidate. Therefore, hit and lead optimization is an indispensable and challenging task for 
medicinal chemists in order to find a promising candidate with appropriate potency, selectivity, ADME and 
toxicity characteristics. Numerous properties, which are partially dependent on each other, are evaluated and 
modulated in this process. They can be clustered in physicochemical, biochemical, PK properties and toxicity. 
Physicochemical properties can be subdivided in solubility and permeability, which are in turn dependent on 
the lipophilicity and pKa values amongst others. Biochemical properties include metabolism, protein and tissue 
binding, uptake and efflux of the drug. PK properties and toxicity are determined by clearance, half-life, 
bioavailability, drug-drug interactions and LD50 levels.[11]  
Aforementioned, the Lipinski Rule of Five provides an orientation to minimize absorption issues, which is one 
of the main factors influencing bioavailability. It states that a drug should have a molecular weight below 500, 
a distribution coefficient LogP below 5, a maximum of 5 hydrogen-bond donors and 10 hydrogen-bond 
acceptors.[10] This rule has proven to be useful to estimate drug properties, although more recent studies suggest 
that compounds with LogP values below 3 – 4 and a molecular weight below 400 are more successful.[12-14] 
Increasing lipophilicity often positively affects the binding efficacy of a molecule to the target, but it can 
likewise result in undesired interactions, creating a lack of selectivity and possible toxic side effects (e.g. hERG 
channel interaction). On the other hand, highly polar molecules exhibit an enhanced aqueous solubility but 
diminishing membrane permeability.[15-19]  
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Another fundamental physicochemical property often altered during lead optimization relies on the ionizability 
of a compound which in turn is determined by the pKa value. By modifying the substructure of a molecule to 
tune its pKa, the solubility and permeability parameters and thus the absorption and bioavailability of a drug 
can be improved.[20] Thereby, electron donating or withdrawing groups can be added adjacent to an acidic or 
basic moiety to alter the electron density at this group.  
One of the key aspects of lead optimization concerns the reduction of metabolic liabilities from the lead 
compound. Metabolism has the biochemical purpose to increase the polarity of the molecule and to alter its 
solubility to prepare its excretion from the body. However, fast metabolism of administered drugs has a large 
impact on several pharmacokinetic factors and therefore exhibits a potential restraint for a drug candidate. For 
instance, a decreased metabolic stability leads to an increase in clearance (Cl) and reduces the exposure of the 
drug. The PK half-life is directly related to the Cl and the volume of distribution and therefore determines how 
often a drug should be administered to a patient. What is more, the Cl along with the absorption affects the oral 
bioavailability (Figure 2).[21] 
 
Figure 2. Multilateral influence of physicochemical, biochemical and pharmacokinetic drug properties.[11] 
The biological strategies for metabolism are differentiated in phase I and phase II reactions. Phase I metabolism 
involves modifications of the molecular structure by oxidation/reduction or dealkylation. These reactions are 
promoted by various enzymes with the most prominent class being monooxygenases, namely the cytochrome 
P450 and the flavine monooxygenase family. Multiple approaches are applied by medicinal chemists to 
enhance the metabolic stability of phase I metabolism. Common tools are blocking metabolic sites by adding 
blocking groups and removing or replacing susceptible sites in the molecule if they are dispensable for target 
interaction. Cyclization, variation of ring size or chirality can also improve metabolic stability. Since 
metabolism is also associated with high lipophilicity, reducing lipophilicity of compounds can be an instrument 
to alter metabolism.  
In contrast, Phase II reactions present additions of polar moieties to the molecule structure to enhance its 
hydrophilicity and hence its elimination from the organism. These polar groups are commonly glucuronic acid, 
I. INTRODUCTION   
 
5 
 
carboxyl acids, amines or sulfates. Synthetic methods to reduce or hinder these addition reactions include the 
introduction of electron-withdrawing functionalities, steric hindrance or the implementation of bioisosteric 
moieties.[11, 21]  
The incorporation of fluorine and bioisosteric moieties are of particular interest for lead optimization and 
widely used throughout medicinal chemistry research. Due to its unique properties, fluorine substitution can 
be an instrument to alter many physicochemical and metabolic properties of a drug candidate and beyond that 
can positively contribute to the compound´s binding affinity. Bioisosteric moieties present a tool employed to 
replace parts of the drug candidate that contribute to metabolic or physicochemical liabilities, while 
maintaining its biological profile. In the following, both strategies and their effect will be illustrated with 
examples.  
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2. Fluorine in Medicinal Chemistry  
An important and widely used instrument in lead optimization is the incorporation of one or several fluorine 
atoms to dedicated positions of drug candidates. Fluorination can improve the metabolic stability, binding 
affinity and bioavailability of a drug, as well as its physicochemical properties and protein-ligand interactions. 
Even though organofluorine compounds are practically absent from natural occurring structures, it is estimated 
that 20 – 25% of all currently tested drugs contain at least one fluorine atom.[22-24] The first successful example 
of a fluorine substituted compound for pharmaceutical application was reported in 1957 with the synthesis of 
the anticancer agent 5-fluorouracil.[25] Enzymatically converted into 5-fluoro-2-α-deoxyuridylate, it prevents 
cellular synthesis of thymidine by acting as a competitive inhibitor of thymidylate synthase, which converts 
2´-deoxyuridine-5´-monophosphate (mUMP) into 2´-deoxythymidine-5´-monophosphate (mTMP).[26] Despite 
this successful implementation, it took until the 1980s for fluorinated drugs to become increasingly prominent 
in medicinal chemistry research. Until then fluorination was dependent on the use of elementary fluorine which 
is a harsh and extremely reactive agent and requires precautionary measures and special laboratory equipment. 
Thus, it was only after the development of the selective fluorination reagent (diethylamino)sulfur trifluoride 
(DAST) in 1973,[27-28] that mild fluorination reagents allowed an increasing application of fluorine in medicinal 
chemistry. The invention of DAST was followed by a growing number of nucleophilic fluorination reagents, 
which converted alcohols and aldehydes into the corresponding mono- and diorganofluorides. Further reagents 
commonly used are 2,2-difluoro-1,3-dimethylimidazolidine (DFI)[29] and bis(2-methoxyethyl) aminosulfur 
trifluoride (Deoxofluor®)[30] (Figure 3). Electrophilic fluorination reagents like 1-chloromethyl-4-
fluorodiazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor®) and N-fluorobenzene-sulfonimide 
(NFSI) holding a R2N-F or R3N+-F moiety further extended the synthetic repertoire by allowing electrophilic 
fluorination to be safely conducted without use of elemental fluorine.[31] Moreover, incorporation of 
trifluoromethyl groups, which are of growing interest in medicinal chemistry, can be accomplished by using 
trifluoromethylating reagents such as trifluoroacetamide[32] or the Ruppert-Prakash reagent[31].  
 
Figure 3. Examples of selective fluorination reagents. 
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These strategic fluorination methods fostered the design and investigation of diverse fluorinated compounds, 
the most prominent and significant examples will be discussed below (Figure 4). Fluoxetine is commonly 
known as Prozac® and acts as an antidepressant by selectively inhibiting the serotonin uptake activating its 
specific receptor. During lead structure optimization SAR studies showed a 6-fold increase in activity by 
trifluoromethylation of the para-position.[33] This increase in activity is not fully understood, however it is 
believed that the conformational change introduced upon introduction of the trifluoromethyl group enhances 
the binding affinity to the serotonin transporter.[34]  
Efavirenz is a non-nucleoside reverse transcriptase inhibitor which is used in antiretroviral therapy in the 
treatment of patients infected with HIV. SAR studies indicated that the trifluoromethyl moiety at the tertiary 
stereogenic center has a large effect on the pKa and the ionization of the carbamate, responsible for the enhanced 
potency.[35]  
The effect of fluorination was also studied in the case of atorvastatin, a lipid-lowering agent featuring a fluorine 
substitution in para-position of a phenyl substituent. During lead optimization this fluorinated substitution 
pattern was found to be superior to hydroxyl, hydrogen and methoxy substitution resulting in a 2- to 10-fold 
increase in potency.[36] This effect could later be elucidated by crystal structure analysis of atorvastatin in the 
active pocket of the HMG-CoA reductase, displaying a favorable interaction of the C–F bond with the 
guanidinium side chain of Arg590 (see crystal structure depicted in Figure 4).[37] While it is beyond dispute that 
the unique properties of fluorine can have a large impact on many factors relevant for drug development and 
fine-tuning, there are only few examples where the influence of fluorine substitution is fully understood. 
 
 
Figure 4. Examples of fluorinated drugs and crystal structure of atorvastatin in the binding pocket of the HMG-CoA 
reductase.[38]  
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2.1 Physicochemical properties 
2.1.1 Modulation of pKa 
Fluorination of an active lead structure can be a useful instrument to alter its physicochemical properties. It is 
often replaced with hydrogen in the modified structures resulting in a similar potency, albeit very different 
properties concerning van der Waals radius and electronegativity.[39] Due to its pronounced electronegativity, 
fluorine substitution considerably influences pKa values of neighboring functional moieties.[40-41] Modification 
of the pKa, in turn, may affect many relevant parameters including solubility, lipophilicity, binding potency 
and selectivity, as well as ADME restrictions including hERG potassium channel interactions.[42-44] 
As demonstrated in Figure 5, Niel et al. investigated the influence of fluorine substitution comparing a series 
of piperidinyl and piperazinyl indole 5-TH1D receptor inhibitors, which showed large potential in the treatment 
of migraine. Comparing the piperazine and piperidine analogs (1 and 2), it was found that the piperidine 
compound 2 exhibits a lower bioavailability and absorption. By introducing a fluorine in C-4 position of the 
piperidine ring (compound 3), its pKa could by shifted toward the pKa of the corresponding piperazine analog, 
inducing improved bioavailability and absorption.[45] 
 
Figure 5. pKa values of piperazine 1, piperidine 2 and 4-fluoropiperidine 3 inhibitors of the 5-TH1D receptor. 
Studies on predicting pKa values of basic amines by substitution with fluorine, oxygen, nitrogen and sulfur 
functionalities to optimize physical properties in drug-discovery research demonstrated that the pKa of amines 
can be tuned by position and number of substituted fluorine atoms. In open-chain molecules the value decreases 
by approximately 1.7 units with increasing number of fluorine atoms in the series CH3CH2NH2 (pKa 10.7) → 
FCH2CH2NH2 (pKa 9.0) → F2CHCH2NH2 (pKa 7.3) → F3CCH2NH2 (pKa 5.7). This can be explained by a 
rising destabilization of the protonated ammonium form when increasing fluorination. This effect decreases 
with growing distance to the amine functionality, but is even notable for -substitution.[41] Fluorine can also be 
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used to increase the acidity of functionalities as observed by fluorine substitution in close proximity to alcohols, 
carboxylic acids, heterocycles and phenols.  
2.1.2 Influence on lipophilicity 
Apart from influencing the ADME parameters by pKa modification of adjacent functionalities, fluorine 
substitution directly affects lipophilicity and solubility. The absorption and distribution of orally administered 
drugs is to a high degree dependent on sufficient lipophilicity to enable the compound to pass through the cell 
lipid membrane, while simultaneously exhibiting good solubility. However, the effect of fluorine substitution 
on the lipophilicity is by no means easy to predict and can differ strongly depending on the substrate. 
Monofluorination and trifluorination are found to decrease lipophilicity in small saturated alkanes due to their 
strong C-F and C-CF3 bond dipoles, whereas aromatic fluorination, introduction of perfluoroalkyl groups and 
fluorination adjacent to -bonds enhance lipophilicity.[46] The exchange of hydrogen with fluorine was found 
to increase the logD value by approximately 0.25 units. This effect was even more significant when the fluorine 
was located near a basic amine.[47]  
Jacobs et al. investigated the effect of fluorination on the activity and lipophilicity of leukotriene receptor 
inhibitors. They observed a loss of potency toward the inhibition of the leukotriene receptor after extension of 
an alkyl chain length to enhance lipophilicity of the original substrate. Therefore, they addressed the loss in 
activity by fluorination of the parent compound. The fluorinated compound shows a 10-fold increase in potency 
compared to non-fluorinated analogs in vitro, which is a result of the enhanced lipophilicity.[48]  
2.1.3 Conformational changes 
Since the van der Waals radius of fluorine (1.47 Å) lies between that of a hydrogen (1.20 Å) and an oxygen 
atom (1.52 Å),[39] substitution of hydrogen and hydroxyl groups are often well tolerated without major changes 
in potency. In contrast, substitution of a methyl by a trifluoromethyl moiety leads to profound changes in 
conformation due to a larger steric demand. Studies investigating van der Waals volumes of trifluoromethyl 
groups suggest they are similar to an ethyl, isopropyl or even tert-butyl group depending on the method 
employed.[49-51]  
Comparing the conformation of methoxyphenyl and trifluoromethoxyphenyl groups illustrates the large steric 
demand. Whereas anisol adopts a planar conformation due to the preferred conjugation of the oxygen p-orbital 
with the -system of the aromatic ring, the trifluoromethoxy moiety is rotated out of plane because of its larger 
steric demand and stereoelectronic properties, favoring a sp3 hybridization of the oxygen atom.[52] Furthermore 
the influence of the preferred conformation owing to fluorination can be demonstrated by 1,2-difluoroethane, 
in which the fluorine atoms adopt a gauche orientation. In this orientation, the C-F bonds are antiperiplanar to 
the C-H-bonds resulting in a stabilizing hyperconjugative (→) interaction (Figure 6).  
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Figure 6. Gauche effect of 1,2-difluoroethane.[53] 
Such conformational effects should be included in lead structure research to optimize the binding efficacy. A 
natural conformation close to the bound ligand-protein structure may result in a minimal loss of energy and 
optimal binding properties.[53] This was confirmed by a conformational study of fluorinated analogs of the 
HIV-1 protease inhibitor Indinavir. It was shown that the gauche effect stabilizes the carbon backbone of the 
syn, syn fluorinated analog resulting in similar activities of the fluorinated and non-fluorinated compounds in 
contrast to the syn, anti analogs.[54] 
2.2 Metabolic stability 
Improving the metabolic stability of active lead structures is a key challenge in lead optimization. Fluorination 
can enhance metabolic stability by blocking sites susceptible to degradation. A particularly interesting example 
is the discovery of the cholesterol inhibitor ezetimib, in which fluorine substitution is used to reduce oxidative 
degradation by cytochrome P450 monooxygenases. Examination of the potent radiolabeled substrate SCH 
48461 during lead optimization exhibits several sites susceptible to metabolism (Figure 7). This resulted in a 
compound mixture even more potent than the parent drug itself. To enhance both the metabolic stability and 
in vivo potency, those metabolic modifications beneficial for potency were introduced in the substrate, while 
susceptible sites not affecting the potency were blocked by incorporation of fluorine. Fluorine substitution in 
para-position of phenyl rings is commonly used to prevent phenyl oxidation by deactivation of the aromatic 
system. These modifications finally lead to ezetimib, a 400-fold more potent drug with improved metabolic 
stability.[55-57] 
 
Figure 7. Metabolically susceptible sites of SCH 48461 and discovery of ezetimib.[55-57]  
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The strong stabilizing effect of fluorine can also be adverse, as was demonstrated in the case of celecoxib. 
Celecoxib is an inhibitor of cyclooxygenase-2 (COX-2), which is administered to treat patients with arthritis 
amongst others. In contrast to the discovery of exetimib, the synthesized substrates showed an exceeding 
metabolic stability which could be attributed to the fluorine substituent of the phenyl ring. Replacing this 
fluorine atom by a metabolically more labile methyl moiety reduced the half-life of the drug to an acceptable 
time of 3.5 hours (Figure 8).[58-59]  
 
Figure 8. Development of celecoxib by replacing fluorine with a methyl moiety.[58-59] 
Fluorination can also be applied to enhance the hydrolytic stability of a compound as exemplified by the lead 
optimization of prostacyclin (PGI2), used to treat vascular diseases. The substrate features an enol ether which 
is susceptible to hydrolysis and thus limits the applicability despite its high potency. Introduction of a fluorine 
atom adjacent to the hydrolytic site (7-F-PGI2) reduced the electron density of the enol ether and significantly 
increases its half-life. Further fluorination (AFP-07) could multiply this effect by increasing the half-life of the 
unfluorinated species from 10 minutes to 90 days for the difluorinated analog (Figure 9).[60-62] 
 
Figure 9. Hydrolytic metabolism of prostacyclin and chemical half-lives of prostacyclin analogs at pH 7.4.[60-62] 
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2.3 Binding affinity 
Fluorine substitution can have a great influence on the binding affinity of a drug. On the one hand, fluorine-
induced modification of polarity and other physiochemical properties of the drug can indirectly affect the 
potency of a drug. On the other hand, fluorine is also known to interact directly in ligand-protein binding. 
As previously discussed, fluorine substitution can be used as a tool to manipulate the lipophilicity, polarity and 
pKa of a given drug, thereby influencing its uptake and bioavailability. However, these modifications can also 
influence the binding affinity of the compound, as is illustrated by comparison of fluorinated and 
non-fluorinated inhibitors of carbonic anhydrase II (CAII). The metalloenzyme CAII catalyzes the hydration 
of CO2 to bicarbonate and a proton. Sulfonamides have been studied as inhibitors of CAII, since they can bind 
to Zn2+ in the active site in their deprotonated state as R-SO2NH-. Maren and Conroy compared the binding 
affinities for aliphatic sulfonamides and trifluoromethanesulfonamide as a function of the pKa value (see  
Figure 10). They found that the higher acidity of the fluorinated sulfonamide corresponds to its greatly 
enhanced binding affinity. Trifluoromethanesulfonamide (pKa 5.8) is dissociated at neutral pH due to the strong 
electron withdrawing effect of the trifluoromethyl moiety, illustrating an indirect influence of fluorine 
modification on drug potency.[63]  
 
Figure 10. Binding affinity and pKa values for carbonic anhydrase inhibitors.  
Fluorine is also known to interact directly with the ligand-protein binding as illustrated by the previously 
discussed example of the drug atorvastatin. A further example is represented by fluorine-containing inhibitors 
of the thrombin receptor (Figure 11). Diederich and co-workers studied the influence of fluorine substitution 
on the binding affinity of various tricyclic thrombin inhibitors. They discovered that proper positioning of 
fluorine substituents within the hydrophobic binding pocket of the receptor strongly enhances the binding 
affinity of these compounds. The para-fluorinated analog 4 showed a 5-fold higher binding affinity compared 
to the parent non-fluorinated species, which can be explained by a favorable polar interaction of the fluorine 
atom and the H–Cα–C═O group of the Asn98 in the X-ray structure of the serine protease.[64-65] Similarly, 
attractive fluorine interactions with carbonyl moieties in other ligand-protein binding patterns, especially in 
inhibitors of p38 kinase, where shown to positively affect binding affinities.[66-67]  
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Figure 11. Class of inhibitors of thrombin and effect of fluorination position on the binding affinity. X-ray structure of 
4-fluorobenzyl-substituted inhibitor in the thrombin active site.[64-65]  
The possibility to use fluorine substitution as a synthetic tool to modulate physiochemical properties, metabolic 
stability and binding affinity has led to a steadily rising number of prominent fluorine containing drugs in 
recent years. Promoting the understanding of the effect of fluorine substitution in lead structures, together with 
advances in synthetic fluorine-organic chemistry, will certainly result in the development of more novel, highly 
effective fluorinated drugs.    
R Ki (μM) 
benzyl 0.27 
2-fluorobenzyl 0.50 
3-fluorobenzyl 0.36 
4-fluorobenzyl 0.057 
I. INTRODUCTION   
 
14 
 
3. Bioisosteres in Medicinal Chemistry  
The concept of bioisosterism is another commonly used technique to modulate specific properties of drug 
candidates, such as selectivity, toxicity and ADME parameters, while maintaining their bioactivity.[68-71] In this 
process the susceptible moiety in the compound is exchanged by another functional group exhibiting similar 
biological properties. The idea of bioisosterism emerged from the concept of isosterism, which was coined by 
Langmuir in 1919.[72] During his studies on the properties of various molecules, Langmuir observed that certain 
molecules like CO2 and N2O exhibit similar physical properties. Based on his observations he defined a group 
of 21 isosteres. This concept was later extended by Grimm´s Hydride Replacement Law in 1925 and 
Erlenmeyer’s definition of isosteres as atoms, ions and molecules in which the peripheral layers of electrons 
are identical.[73-75] It was also Erlenmeyer, who first illustrated examples of bioisosterism in experimental 
studies with antibodies (Figure 12). He studied the reaction of various diazonium ions 5 with the tyrosine 
phenol ring of proteins 6, showing that the antibodies can neither differentiate between thienyl and phenyl 
substitution nor between O-, N- or CH2-linkages connecting the two aromatic systems.[76-77]  
 
Figure 12. Reaction of diazonium ions 5 with the tyrosine phenol ring of proteins 6.[77] 
Despite this early research, the term bioisosterism itself was defined by Friedman in 1950 as isosteric atoms 
and molecules, which exhibit similar biological properties.[78] As research progressed it was observed that the 
applicability of bioisosterism is not always dependent on similarity concerning structural properties but instead 
focuses on biochemical mimicry. This led to a distinction of two classes of bioisosteres: classical bioisosteres 
that follow the earlier defined rules of isosteric behavior and non-classical bioisosteres which mimic the 
replaced moiety by biochemical functional aspects without displacing large overlap in steric and electronic 
properties.[79] Classical bioisosteres are distinguished by the number of bonds affected through the formal 
replacement process and are therefore structured in mono-, di- and trivalent atoms and groups, tetrasubstituted 
atoms and ring equivalents. Non-classical bioisosteres are clustered in rings, noncyclic isosteres and 
exchangeable groups. An outline of classical bioisosteres is depicted in Table 1:[80] 
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Table 1. Selected examples of classical bioisosteres[80] 
Classical bioisosteres 
Monovalent bioisosteres: 
H and F 
OH and NH 
F, OH, NH or CH3 for H 
SH, OH 
Cl, Br, CF3 
Divalent bioisosteres: 
─C═S, ─C═O, ─C═NH, ─C═C─ 
 
Trivalent atoms and groups:  
─CH═, ─N═ 
─P═, ─As═ 
Tetrasubstituted atoms:  
 
Ring equivalents: 
 
 
The replacement of functional groups in a lead compound by bioisosteric moieties can have a significant 
influence on the properties of the drug candidate. Bioisosteres are known to tune the ADME criteria by 
affecting physiochemical properties like polarizability, polarity, lipophilicity and pKa values and improving the 
metabolic stability of compounds, if susceptible sites are replaced by more stable functionalities. However, 
depending on the functionality of the replaced group and the binding mode of the ligand to the target, effects 
of bioisosteric replacements can vary substantially. Taking this into account, the implementation of bioisosteres 
in drug design will be highlighted based on specific examples in the following. 
3.1 Physicochemical properties 
One of the major challenges in lead development represents the optimization of lipid permeability, which is 
mostly influenced by the physicochemical properties of lipophilicity and hydrogen bonding. Next to amide 
moieties, which will be discussed in detail later, guanidine and amidine groups are often responsible for poor 
lipid permeability. Guanidines and amidines are commonly used in inhibitors of serine proteases. They are 
highly basic moieties, which are protonated under physiological conditions and lead to very poor membrane 
permeability. To reduce the basic pKa of about 13 – 14, the adjacent CH2 to the guanidine or amidine moiety 
can be replaced by either isosteric oxygen (pKa 7 – 7.5) or a carbonyl group (pKa 8). The resulting 
oxyguanidines have been successfully used as thrombin inhibitors (Figure 13a, compound 7),[81-82] while 
acylguanidines are structural elements of a family of histamine H2 agonists.[83-84]  
Direct replacement of the basic amidino moiety has been studied for a series of factor Xa inhibitors, which 
finally led to the development of the anticoagulant apixaban (Figure 13b). Replacement of an arginine residue 
involved in direct ligand-protein binding usually results in a loss or reduction of potency. Yet there are cases, 
such as apixaban, where this loss in potency is compensated by a great improvement of PK properties. It was 
shown, that a series of neutral bioisosteres revealed a reduced potency compared to 3-amidino parent 
compound. This was presumably a result of a disappearing favorable interaction of the amidino substituent 
with the carboxylic side chain of the Asparagine Asp189. However, the good pharmacokinetic profile of the 
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4-methoxyphenyl substituted drug candidate and its sufficient potency (Ki = 11 nM) permitted clinical testing 
of the compound and its Food and Drug Administration (FDA) approval in 2011.[85-86] 
 
Figure 13. Structures of potent guanidine and arginine inhibitors. 
Another prominent example of a bioisosteric replacement to alter the physicochemical properties of a 
compound is represented by the development of losartan (Figure 14). Early antagonists of the angiotensin II 
receptor (compound 8) bearing a carboxylic acid demonstrated promising effects on the blood pressure, if 
administered intravenously, but showed no oral activity. During lead optimization, various bioisosteric 
replacements for the carboxylic moiety were evaluated to improve oral activity and metabolic stability. The 
introduction of a tetrazole moiety finally resulted in a 10-fold increase in potency compared to the carboxylic 
analog, due to an increase in lipophilicity of the tetrazole ring and a slight increase in pKa resulting in a 
suppression of ionization.[87-88] 
 
Figure 14. Structure of early angiotensin II receptor antagonists and tetrazole bioisostere losartan.[87-88] 
3.2 Metabolic stability 
As mentioned before, rapid metabolism is mostly a consequence of an unfavorable overall lipophilicity or 
unstable metabolic sites in the lead compound. The introduction of bioisosteric moieties is a helpful tool to 
enhance and tune the metabolic stability of a compound and is therefore widely used in modern drug design. 
One common metabolic derivatization is the hydroxylation of phenyl rings, which can be avoided by proper 
substitution, e.g. upon replacement of a CH-group with a nitrogen atom. This was evaluated in a series of 
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benzimidazole-based inhibitors 9 of the respiratory syncytial virus (RSV). After exchanging the CH moiety in 
all four available positions of the benzimidazole the antiviral activity and cytotoxicity of the compounds were 
compared (Table 2). The incorporation of a nitrogen atom had a strong effect on the metabolic stability and the 
solubility of the drug, while the potency of the inhibitors was clearly dependent on the position of the 
substitution. After further optimization a clinical candidate emerged based on the structure of a 
6-aza-benzimidazol-2-one scaffold.[89-90] 
Table 2. RSV inhibition activity and cytotoxicity found in a series of RSV fusion inhibitors 
  
The development and implementation of phenol and catechol isosteres has been of particular interest due to 
their potential activity as agonists and antagonists of biogenic amines, such as adrenaline, serotonine and 
dopamine. Phenol can be hydroxylated in ortho- and para-position forming catechols which can subsequently 
be oxidized by CYP 450 enzymes to ortho- and para-quinones. These active metabolites have the potential to 
bind irreversibly to proteins resulting in an increased toxicity of the drugs. Thus, bioisosteric replacements 
using phenol isosteres as dopamine D1/D5 antagonists are particularly interesting (Figure 15). 
 
Figure 15. Phenolic and phenol mimetics in dual dopamine D1/D5 antagonists. 
The original phenol-containing compound 10 showed poor oral bioavailability due to oxidation of the phenol 
moiety and was therefore replaced by different heterocyclic isosteres. The two initial isosteres (11 and 12) gave 
insight into the preferred orientation of compound 10 and its H-bonding in the binding pocket of the enzyme, 
as illustrated by comparison of the corresponding binding affinities.[91] Further optimization of potency resulted 
W X Y Z Inhibition of 
RSC replication 
EC50 (nM) 
Cytotoxicity 
CC50 (μM) 
CH  CH CH CH 5 13 
N CH CH CH 3 >216 
CH N CH CH 7 236 
CH CH CH N 200 264 
I. INTRODUCTION   
 
18 
 
in the development of compound 13, demonstrating improved metabolic stability and similar potency when 
compared to the original phenolic antagonist.[91]  
3.3 Binding affinity 
Bioisosteric replacement is not only a means to enhance the ADME and toxicity parameters of drugs, but it 
can also directly affect the binding affinity toward the target. The binding affinity is highly dependent on 
various interactions, like hydrogen bonds, ionic and van der Waals interactions of the drug with its receptor, 
enzyme or ion channel. The development of bioisosteres of the phosphodiesterase 5 (PDE5) inhibitor sildenafil, 
better known as Viagra®, which is used to treat erectile dysfunction, is a particularly interesting example 
(Figure 16). Entering a highly profitable market encouraged increased research efforts toward new therapeutics 
with a longer duration of action and higher potency. These resulted in the development of the bioisosteric 
analog vardenafil which exhibits a 32-fold higher potency despite only small structural differences in the 
heterocycle.[92-93] One explanation was found in binding studies of co-crystals of PDE5 and the drugs, revealing 
two interactions of the heterocycles of vardenafil and sildenafil with Tyr612 via a hydrogen bond over a water 
bridge and a hydrophobic interaction of the heterocycle and the tyrosine ring. Thus, the hydrophobic interaction 
between vardenafil and the Tyr612 was much stronger compared to the interaction with sildenafil.[94]  
 
Figure 16. Structure of PDE5 inhibitors sildenafil and vardenafil and schematic depiction of interactions of Tyr612 with 
sildenafil and vardenafil. Dotted lines illustrate hydrogen bonds between nitrogen of the heterocycle and water, which is 
also forming hydrogen bonds with the phenolic hydroxyl moiety of Tyr612. The blue line illustrates hydrophobic interaction 
between the heterocycle and the aromatic ring of Tyr612.[94] 
The collected examples illustrate that bioisosteric replacements can have a substantial effect on both the 
potency and stability of a drug candidate, while demonstrating structural similarity to the parent compound. 
On the other hand, bioisosteres can exhibit essential structural differences from their analog, yet eliminate 
deficient properties of the replaced functionality. An appropriate selection of bioisosteric replacements and 
their success is therefore hard to foresee. Nevertheless, bioisosteres have become one of the most useful tools 
in tuning active compounds toward drug candidates.  
Amide moieties present an exceptional functional group in medicinal chemistry and will therefore be discussed 
in the next chapter. Due to their biological activity, they have a large scope of application in drug research. 
However, amides are often susceptible toward enzymatic hydrolysis fostering the search for appropriate 
bioisosteres, a few of which will be discussed in the following.  
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4. Amide Bond Replacements and Peptidomimetics  
Amide bond replacements are of particular interest in bioisosteric research due to the increasing demand for 
peptide-based drugs and the development of peptidomimetics. Additionally, in the context of small molecule 
research, replacing an amide bond with a different moiety is a common tool to modulate polarity and 
bioavailability. Since amide bonds are naturally present in peptide backbones they are susceptible to hydrolysis 
by multiple enzymes which cleave the amide bonds into their amino acid building blocks. Consequentially, 
amide containing drug candidates often show poor metabolic stability and bioavailability demonstrating an 
urgent need for stable surrogates with improved stability toward proteolytic cleavage. There are many isosteric 
replacements of amides featuring diverse properties known that find versatile applications in lead compound 
optimization. A brief synopsis of different amide surrogates is presented in Figure 17. 
 
Figure 17. Synopsis of amide isosteres.  
Amides feature a planar geometry due to the delocalization of the nitrogen lone pair into the antibonding orbital 
of the carbonyl moiety. In this rigid structure the carbonyl group and the NH bond are mostly aligned in a 
trans orientation. The first examples of amide bond bioisosteres, that will be discussed in the following, retain 
this planar structure due to sp2 hybridized atoms in the core structure.  
Amide surrogates that essentially mimic the geometry of a peptide bond are E-alkene and fluoroalkene 
groups.[95-97] However, there are substantial differences in electronic properties of alkenes compared to amides. 
The dipole moment of the alkene bond is evanescently small (0.1 D), leading to a low ability of alkenes to form 
dipolar interactions. In contrast, fluoroalkenes in which a fluorine atom mimics the carbonyl oxygen have a 
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stronger dipole moment (1.4 D).[97] Nevertheless, both alkenes and fluoroalkenes are poor hydrogen-bond 
donors and acceptors and additionally hydrophobic. (Z)- and (E)-fluoroalkenes have been studied as mimics of 
peptide bonds in peptide nucleic acids (PNAs). The results indicated that both olefinic peptide nucleic acids 
(OPAs) bound to the DNA forming a duplex.[98-99] However, the formed duplexes were less stable than the 
corresponding PNA:DNA duplex most presumably due to the missing interaction of the lone pair of the 
carbonyl oxygen with the aromatic ring of the nucleobases.[100-101] 
The substitution of an amide bond with a thioamide presents a classical isosteric replacement with a large 
overlap in structure. However, there are several properties of this surrogate, which again differ from an amide 
bond in key aspects. Comparison of bond lengths in the thioamide and amide functionality reveal a shorter 
C═S and a longer C–N bond length in the thioamide resulting from a pronounced charge separated resonance 
structure with a double bond between the nitrogen and carbonyl carbon atom.[102] Furthermore, thioamides are 
weaker hydrogen-bond acceptors and stronger hydrogen-bond donors than amides. The replacement of an 
amide bond with a thioamide in α-helix peptide scaffolds can therefore result in both an increase and a decrease 
of helix stability.[103-104] 
Depsipeptides, in which one or more amide bonds are substituted by an ester moiety, find applications in drugs 
with versatile biological activities including anticancer, antibiotic and antiviral drugs or enzyme 
inhibitors.[105-108] Esters show a comparable geometric structure to amides with regard to the delocalization of 
the oxygen lone pair into the antibonding orbital of the carbonyl group.[109] In contrast to this structural analogy, 
esters and also ketones exhibit different hydrogen bonding properties. Both moieties are only weak hydrogen-
bond acceptors and cannot donate hydrogen bonds.[110-111] In addition, they are susceptible to hydrolysis, 
making them poor bioisosteric replacements regarding proteolytic stability.  
Tetrazole groups have often proven beneficial and find versatile applications in medicinal research due to their 
good pharmacokinetic profiles. They exhibit high metabolic stability and broad biological activity in many 
different modes of action although they are structurally different from amides. Tetrazolyl moieties have been 
introduced in compounds as 1,5- and 2,5-tetrazole-diyl derivatives replacing a cis- or trans-amide bond.[112-113]  
Sulfonamides play an significant role in medicinal chemistry research and are widely used in the design of new 
drugs.[114] There are also examples for their incorporation into peptides,[115-118] even though they show crucial 
discrepancies in hydrogen-bonding properties and geometric structure. Sulfonamides have two hydrogen-bond 
accepting oxygen atoms as well as a strong hydrogen-donating nitrogen due to the increased acidity of the      
N–H bond. Regarding the geometric structure, sulfonamides often represent transition state isosteres since they 
exhibit a dihedral angle in contrast to the planar conformation of the amide backbone.[119] Sanjayan and 
co-workers studied the effect of amide bond replacements with sulfonamides in hetero foldamers (Figure 18). 
They demonstrated that the difference in the torsion angles of the sulfamide 14 and the amide backbone 15 had 
substantial impact on hydrogen bonds within the oligomers and hence governs the folding of the helical 
structures.[120] 
I. INTRODUCTION   
 
21 
 
 
Figure 18. Differences in hydrogen bonding in tripeptide hetero foldamers studied by Sanjayan and co-workers.[120] 
The introduction of amines as amide replacements bears many disadvantages, making them poor bioisosteric 
surrogates in many regards. In contrast to an amide bond, amines lack the ability to form hydrogen accepting 
bonds due to the missing carbonyl oxygen atom. Furthermore, the geometric structure is not planar and is very 
flexible due to the sp3 hybridization of the neighboring carbon atoms. However, the main challenge in 
incorporating amines into drug candidates is the basicity of the amine. Pronounced basicity of amines facilitate 
protonation under physiological conditions, leading to a reduced lipophilicity and membrane permeability as 
well as interference with the hERG potassium ion channel.[43-44, 121-122]  
Other amide surrogates like hydroxyethylene, dihydroxyethylene or epoxide have been studied, but will not be 
discussed here in further detail. Most bioisosteres mimic specific properties of the amide but show deficits in 
other aspects. Alkenes and fluoroalkenes primarily mimic the planar structure of an amide bond, while ester or 
ketomethylene moieties show similar proton accepting properties. Depending on the position of the 
functionality in the molecule and its impact on protein interactions, these replacements can nevertheless be 
useful tools to modify a drugable compound. However, there are only few examples of bioisosteres which 
mimic the hydrogen-donating character of the amide N–H. Next to sulfamides and amine moieties more 
recently trifluoroethylamines have attracted attention due to their unique properties.  
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5. Trifluoroethylamines as Amide Surrogates  
Trifluoroethylamines as amide surrogates were first described by Zanda and co-workers who replaced a glycine 
amide bond and a malonamide to synthesize partially-modified ψ[CH(CF3)NH]- and retro-ψ [NHCH(CF3)]-
peptides (Figure 19). They proposed that the replacement of an amide moiety with a trifluoroethylamine unit 
should increase the metabolic stability toward proteolytic degradation. Furthermore the stereoelectronically 
demanding trifluoromethyl moiety might act as a good hydrogen bond acceptor.[123-124]  
 
Figure 19. Structure of natural and partially-modified peptides by Zanda and co-workers. [123-124] 
The C–CF3 bond is isopolar with the C═O bond and the backbone angle of the CH(CF3)–NH–CH unit is close 
to 120° resembling an amide bond. As discussed earlier, amine isosteres with hydrogen donating properties 
bear the risk of protonation in a biological milieu to form a R2NH+ species.[125] Morgenthaler et al. stated that 
the pKa value of a compound can be decreased upon fluorination, leading to an approximate pKa of 5.7 in 
trifluoroethylamines, which eliminates the risk of protonation under physiological conditions.[41] This was 
confirmed by studies on fluorinated and non-fluorinated piperidine and pyrazine derivatives which represent 
active 5-HT1D inhibitors (Figure 20). Mono- and difluorination of a propyllinker close to the amine moiety had 
a profound effect, improving the oral absorption of the drug candidates 16 and 17, due to a reduction in the 
pKa value.[45] 
 
Figure 20. Mono- and Difluorinated 5-HT1D inhibitors.[45] 
The trifluoroethylamine moiety preserves the hydrogen-donating character of the parent amide, generating a 
metabolically stable non-basic amine. A possible restriction of this surrogate may be the bulkiness of the 
trifluoromethyl moiety which could influence the conformation of a compound, limiting the number of 
conformational isomers. Depending on the target, these conformational changes may improve or reduce the 
binding affinity. Furthermore, the trifluoromethyl group is only a weak hydrogen-bond acceptor.[126] Therefore, 
it was suggested that the trifluoroethylamine should only replace amide bonds where the carbonyl oxygen is 
not involved in substantial hydrogen-bonding with the receptor.[125] 
The development of odanacatib, a very potent and selective cathepsin K inhibitor, is a remarkable example for 
the application of trifluoroethylamines in lead optimization.[127-128] Cathepsin K (Cat K) is a lysosomal cysteine 
protease which plays a major role in cells responsible for bone degradation in type I collagen. Type I collagen 
is the main component of the bone, therefore Cat K is considered a valuable target.[129] It has been shown that 
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Cat K deficiency results in a higher bone mineral density.[130] Thus, inhibitors of Cat K are urgently needed in 
treatment of osteoporosis. Previously developed inhibitors of Cat K contained amide bonds and therefore 
showed peptide-like properties, limiting their applicability for drug use. The initial lead structure L-006235 
turned out to be lysomotropic due to the basicity and lipophilicity of the compound (Figure 21). This led to a 
loss of selectivity in cell-based assays as opposed to the promising results in enzyme assays.[131-132] Thus, drug 
optimization of the initial compound resulted in the replacement of one amide bond with a trifluoroethylamine 
group and the removing of the basic substituents. The neutral Cat K inhibitor L-873724 showed a 10- to 20-fold 
higher potency than the initial compound and more than 800-fold increase in selectivity against other 
cathepsins.[128, 133] However, the optimized candidate still displayed liabilities as regards its short half-life (2 h) 
and clearance (Cl = 7.5 mL/min/kg). These concerns resulted in the blocking of metabolic sites to adjust the 
pharmacokinetic properties by minimizing leucine hydroxylation, amide hydrolysis and lactonization. The 
final drug candidate odanacatib (MK-0822) is currently being tested in phase III of clinical trials.[127]  
 
Figure 21. The development of odanacatib, a potent inhibitor of Cathepsin K.[127-128, 133] 
The modification of teleprevir, a potent hepatitis C virus (HCV) NS3 protease inhibitor (IC50 = 70 nM), points 
to the impact of amide replacement with trifluoroethylamine moieties concerning the selectivity of the drug 
toward different targets (Figure 22).[134] Teleprevir can also act as an inhibitor against cysteine proteases like 
cathepsin B (IC50 = 210 nM). Replacing one of the amide moieties by trifluoroethylamine surrogates identified 
two active inhibitors of cathepsin S (compounds 18a and b) which, in contrast to the unfluorinated parent 
compound, only exhibited a weak inhibition of HCV NS3. Since cathepsin S activity is connected to 
Alzheimer´s disease and autoimmune disorders, Cat S inhibitors are potentially useful drugs.[135] 
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Figure 22. Structure of teleprevir and trifluoromethylated cathepsin S inhibitors 18a and b.[135] 
Despite these promising results of amide replacement with trifluoroethylamines, there are only few examples 
presented in literature. This seems to be due to limited synthetic access toward these compounds, evidencing 
the need for improved methods with a broad substrate range and variable substitution patterns. 
 
25 
 
II. OBJECTIVE 
The growing importance of fluorinated entities in medicinal chemistry is a result of the exceptional properties 
of the element fluorine. Fluorination is an instrument to fine-tune lead compounds toward drug candidates, 
eliminating physicochemical or metabolic liabilities and optimizing target binding.[22, 47, 53, 136-137] Despite a 
limited number of investigated drugs presented so far,[127, 135] implementation of trifluoroethylamines as 
carboxamide surrogates in drug candidates is an unique opportunity to develop drug candidates with improved 
properties. The lack of applications may be a result of the limitations regarding the synthetic access to this 
structural motif. Most common routes to synthesize trifluoroethylamines are based on addition reactions of 
nucleophiles to trifluoromethylated imines.[138-143] Alternatively, hydrogenation and aromatic substitution of 
activated imines have been described.[144-149] These imine-based strategies are hampered by the tendency of 
fluorinated imines to form hydrates which leads to their subsequent deactivation. Other approaches using 
trifluoromethylated hemiaminal ethers are often dependent on the use of auxiliary protection of the nitrogen.[150] 
However, a few examples of N-functionalized N,O-acetals which have been converted into the corresponding 
trifluoroethylamines using C-nucleophiles have been described in the literature.[151-152]  
The aim of this work was to establish synthetic routes toward novel trifluoromethylated amine derivatives 
starting from trifluoromethylated N-aryl N,O-acetals. The focus was set on the synthesis of yet unknown 
functionalized trifluoroethylamines and trifluoromethylated amine derivatives which might be promising 
building blocks for drug development. Initially in our first project, we envisioned the development of a practical 
and readily applicable synthetic strategy based on functionalized N-aryl N,O-acetals and simple alkyl 
magnesium reagents (Scheme 4). The requisite N,O-acetals could be obtained by reaction of various 
(hetero-)arylamines and 1-ethoxy-2,2,2-trifluoroethanol as previously shown by Gong et al.[153] 
  
Scheme 4. Previous and targeted approach toward the synthesis of trifluoroethylamines.  
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After establishing a convenient procedure using commercially available alkyl Grignard reagents, we aimed at 
synthesizing more complex substituted trifluoroethylamines by extending the project to the use of 
functionalized organomagnesium reagents. Subsequently, we envisaged to implement our synthetic protocol 
in more complex syntheses for generation of bioisosteric analogs of pharmaceutically active compounds to 
illustrate its applicability. Finally, we planned to develop a stereoselective synthesis of these compounds by 
employing copper-catalyzed reactions for which chiral ligands could be screened.  
Besides trifluoroethylamines, the synthesis of difluoroethylamines is of interest in the pharmaceutical context. 
For instance, replacement of a trifluoromethyl moiety with a difluoromethyl group can be used to alter pKa 
values of the adjacent amines in cases where an increase in basicity is beneficial. Furthermore, difluoromethyl 
moieties have been studied as hydroxyl bioisosteres, exhibiting weak hydrogen-bond donating properties. 
However, a difluoromethyl group usually enhances the lipophilicity compared to hydroxyl or amine moieties 
which may improve membrane permeability. Therefore, we envisioned to extend our methodology toward 
difluoromethylated N,O-acetals in a second project to furnish previously unknown difluoroethylamines as 
potential scaffolds for pharmaceutical applications.  
 
Figure 23. Compounds of interest and synthetic strategies toward their synthesis. 
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In a further project, we planned to establish a simple methodology to synthesize -amino- -fluoroalkyl 
carbonyl compounds by converting N,O-acetals with other nucleophiles such as lithium enolates via a 
Mannich-type reaction. These compounds are particularly interesting as peptide surrogates which may be 
incorporated as building blocks for pharmaceutical and biological application.  
Finally, we envisioned the application of the methods described above to access trifluoromethylated amino 
acid precursors which should subsequently be integrated in manual or automatic solid-phase peptide synthesis 
(SPPS). The investigation of such modified peptide derivatives regarding the structural and metabolic 
deviations from naturally occurring peptides may be of particular interest for future application in medicinal 
chemistry. 
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III. RESULTS AND DISCUSSION 
1. Synthesis of Functionalized α-Trifluoroethylamine Scaffolds 
via Grignard Addition to N-Aryl Hemiaminal Ethers 
A. Deutsch, H. Glas, A. Hoffmann-Röder* and C. Deutsch*, RSC Adv. 2014, 4, 9288–9291. 
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Based on an idea initialized and supervised by Dr. Carl Deutsch, Herbert Glas performed first experiments to 
access trifluoroethylamines in the laboratories of Merck KGaA (Darmstadt). In collaboration with Dr. Carl 
Deutsch, I then developed a protocol and optimized the reaction conditions for the synthesis of functionalized 
N-aryl trifluoroethylamines. Additionally, I applied this methodology to synthesize a set of 
trifluoroethylamines by variation of the trifluoromethylated hemiaminal ethers and the alkyl- and 
phenylmagnesium reagents.  
 
Background 
The importance of trifluoroethylamines as bioisosteric replacement for amides has been illustrated in the 
introductory chapter (see I.5). Even though trifluoroethylamines were used for the optimization of CatK 
inhibitors quite successfully, only a limited number of lead structures comprising this moiety are described in 
the literature. This is most likely due to various limitations of the reported synthetic strategies accessing these 
structures, namely a small substrate scope, hydrolysis of the starting material or the necessity of activating 
N-protecting groups. A brief outline of the current methods and their possible limitations will be highlighted 
in the following.  
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Hydrogenation of trifluoromethylated imines is a common synthetic strategy often applied toward the synthesis 
of trifluoroethylamines (Scheme 5).[144-148] In this context, Chen et al. reported the reduction of fluorinated 
N-protected imines into the corresponding amines by enantioselective Pd-catalyzed hydrogenation in good 
enantiomeric excess (ee) of ≥ 84%.[149] Recently, Zhang and co-workers presented a Rh-catalyzed asymmetric 
hydrogenation of α-trifluoromethylated enamides to synthesize both aryl- and alkyl-substituted 
trifluoromethylated amines.[154] However, both synthetic approaches require subsequent N-deprotection for 
further functionalization. 
 
Scheme 5. Synthesis of trifluoroethylamines via hydrogenation of imines and enamides.[149, 154] 
Furthermore, asymmetric [1,3]-proton shifts of trifluoromethyl ketimines have been described to give 
enantioenriched aldimines (see Scheme 6 for a selected example by Liu et al.), which can be readily converted 
into the corresponding amines by hydrolyzation. However, this strategy is limited by the necessity of electron-
withdrawing benzylic protecting groups to facilitate the [1,3]-proton shift.[155-157] 
 
Scheme 6. [1,3]-proton shift of trifluoromethylated imines.[155] 
Moreover, trifluoromethylated aldimines can be converted into amines by nucleophilic addition of various 
organometallic reagents (Scheme 7).[138-142] As described by Truong et al., 2-methyl-N-(2,2,2-
trifluoroethylidene)propane-2-sulfinamide, accessible by condensation of N-tert-butanesulfinamide and 
trifluoroacetaldehyde hydrate, can be reacted with different aryllithium and arylmagnesium reagents.[143] 
Similarly, lithium and magnesium organyls were reported to react with trifluoromethylated hydrazone 
derivatives (see Enders et al., Scheme 7).[158-159] 
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Scheme 7. Addition of lithium organyls to trifluoromethylated imines and hydrazones.[143, 158]  
A different synthetic approach converts imines with nucleophilic trifluoromethylating agents such as 
trimethyl(trifluoromethyl)silane (TMSCF3) which itself does not react with an imine but has to be activated 
using a nucleophilic initiator.[160-162] A prominent example represents the enantioselective trifluoromethylation 
of N-(tert-butylsulfinyl)-imines developed by Prakash et al. (Scheme 8). The trifluoromethide anion, which is 
liberated by a tetraalkylammonium fluoride source, was used to introduce the trifluoromethyl group into 
imines. Interestingly, depending on the type and amount of fluoride source used, difluoromethylated amines 
can also be accessed from the transient imine species after in situ reduction with NaBH4 (Scheme 8).[163] 
 
Scheme 8. Synthesis of tri- and difluoroamines using TMSCF3.[163] 
Most of the synthetic strategies described so far rely on imines which can be converted into 
trifluoroethylamines. However, the disadvantage associated with their use is a high tendency to form hydrates. 
This has led to a search for more stable substrates and the discovery of hemiaminal ethers being synthetically 
useful and readily available surrogates of imines.[164-165] For instance, Lauzon and Charette described an 
asymmetric synthesis of trifluoroethylamines by copper-catalyzed addition of diorgano zinc reagents to in situ 
generated N-phosphinoylimines from the corresponding hemiaminal ethers (Scheme 9). Dimethyl and diethyl 
zinc were successfully reacted to the desired amines with an ee above 90% using a chiral diphosphine ligand. 
However, this conversion is restricted to the introduction of methyl and ethyl substituents and requires cleavage 
of the N-phosphinoyl moiety under relatively harsh reaction conditions to allow further functionalization of the 
amine.[151]  
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Scheme 9. Synthesis of methyl and ethyl substituted trifluoroethylamines.[151] 
Grellepois et al. reported a method using N-tert-butanesulfinyl protected hemiaminal ethers, which can be 
converted into trifluoromethylated amines by addition of simple lithium and magnesium organyls as illustrated 
in Scheme 10. Thereby a six-membered chair transition state is formed in which the sulfinyl oxygen atom of 
the intermediate imine coordinates to magnesium. Due to steric hindrance exerted by the trifluoromethyl 
moiety, the equatorial position in this transition state is preferred, favoring the addition of the organometallic 
reagent from the re-side.[150] 
 
Scheme 10. Synthesis of N-tert-butanesulfinyl trifluoroethylamines.[150]  
A further procedure worth mentioning is the Pd-catalyzed addition of arylboroxines to in situ generated 
trifluoromethylacetaldimines by Johnson and Lautens (Scheme 11). Using chiral pyridine-oxazolidine ligands, 
a variety of N,O-acetals were reacted with electron-neutral or electron-rich arylboroxines, which were 
accessible by dehydration of boronic acids.[152] In 2016, this method was extended to the use of electron-poor 
boroxines by addition of an ammonium or silver salt.[166] Despite this important development, the addition 
reaction is again restricted to the synthesis of α-substituted aryl amines and requires relatively harsh reaction 
temperatures which may exclude the use of particulary sensitive substrates.  
 
Scheme 11. Synthesis of trifluoroethylamines from hemiaminal ethers.[152]  
Despite the large effort put into the development of a convenient synthesis of trifluoroethylamines, the methods 
presented so far are hampered by several disadvantages. The asymmetric addition reaction to imines or 
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hemiaminal ethers often rely on N-activating protecting or chiral auxiliary groups, which need to be cleaved to 
enable a further functionalization of the amine moiety. Furthermore, many procedures are limited to a small 
substrate scope or require harsh reaction conditions.  
Based on the methods established in the literature and their limitations mentioned above, we therefore decided 
to investigate the use of Grignard reagents in a direct addition reaction to functionalized, trifluoromethylated 
N,O-acetals. Our main objective was to develop a convenient method which allows access to a wide variety of 
substituted trifluoroethylamines. Moreover, the applicability of the procedure in multistep synthesis should 
initialize a possible embedment of the strategy in lead structure research and optimization. After initial 
experiments to determine the basic requirements for a successful formation of the desired trifluoroethylamines, 
we optimized the reaction conditions toward a high yielding procedure. The N,O-acetal substrates used in this 
synthesis were readily available by condensation of the corresponding arylamines and 
1-ethoxy-2,2,2-trifluoroethanol (TFAE) as described by Gong et al.[153] Upon treatment of these substrates with 
organomagnesium halides the corresponding trifluoromethylated aldimines are formed in situ. Subsequent 
addition of a second equivalent of the Grignard nucleophile then results in the formation of the desired 
trifluoroethylamines (Scheme 12). With the optimized reaction conditions in hands, we studied the substrate 
scope of the reaction by variation of the N,O-acetals and the Grignard reagents. To our delight we found that 
this efficient procedure can be applied to a broad variety of aromatic and heteroaryl hemiaminal ethers with a 
large tolerance for functional moieties. Furthermore the application of alkyl, alkenyl and aryl Grignard 
reagents was successfully demonstrated in high yields.[167]  
 
Scheme 12. Synthesis of trifluoromethylated amines.[167] 
Synthesis of functionalized a-trifluoroethyl amine
scaffolds via Grignard addition to N-aryl
hemiaminal ethers†
Amrei Deutsch,a Herbert Glas,b Anja Hoffmann-Röder*a and Carl Deutsch*b
The synthesis of a variety of a-branched trifluoroethyl amines was
achieved by reaction of N-aryl hemiaminal ethers with organo-
magnesium reagents.
The design of compounds suitable for drug development is a
multi-dimensional process that requires the ne tuning of
molecular properties beyond potency. For instance, physical–
chemical properties that directly affect hydrolytic stability and
bioavailability of the compound must be addressed to avoid
side effects in vivo. Due to the excellent pharmacological prole
of uorinated drugs, the strategic incorporation of uorine
atoms has nowadays become routine in medicinal chemistry
development programs.1 For instance, incorporation of a tri-
uoromethyl substituent adjacent to an amine is a means to
improve the metabolic stability and to attenuate the basicity of
the compound by shiing its pKa value more towards those of
amides.2 Furthermore the C–CF3 bond is substantially isopolar
with the C]O bond and the triuoroethyl amine moiety has a
structural similarity to the tetrahedral proteolytic transition state.3
As a consequence, triuoroethyl amines can be used as versatile
hydrolysis-resistant bioisosteres of amides4 which retain the
geometry of the amide bond and, in contrast to other mimetics5,
also preserve the donating properties of the N–H bond. An illus-
trative example for the successful replacement of the amide
functionality by a triuoroethyl amine is given by Odanacatib, a
highly potent drug candidate for the inhibition of Cathepsin K.6
Various methods for the synthesis of a-triuoromethylated
amines have been described so far,7 including hydrogenation8
and aromatic substitution9 of activated imines, as well as base-
catalyzed asymmetric isomerization reactions of ketoimines.10
Furthermore, nucleophilic addition reactions of various organo-
metallics to triuoromethylated imines11 and hydrazones12 have
been reported. In this context, Lauzon and Charette have shown
that triuoromethyl amine derivatives can be prepared by
copper-catalyzed nucleophilic addition of diorganozinc reagents
toN-phosphinoylimines, using an excess of organozinc reagent.13
Similarly, triuoromethylated a,a-dibranched carbinamines can
be obtained from N-tert-butylsulnyl hemiaminals with organo-
magnesium or organolithium reagents.14 However, most of these
approaches are either hampered by the high tendency of a,a,a-
triuorethylimines to form hydrates or by the need of additional
deprotection steps for further functionalization of the nitrogen
atom. In a seminal paper, Mikami and coworkers showed
that an excess of Grignard reagents can be used to prepare a-
triuoromethylated amines from stable N,O-acetals of tri-
uoroacetaldehyd.15,16 This work was recently extended to the use
of arylboroxines for palladium(II)-catalyzed synthesis of a-(tri-
uoromethyl)arylmethyl amines.17
Herein, we report a systematic study on the synthesis of
functionalized a-substituted triuoromethyl amines using
Grignard reagents and readily available triuoromethylated
hemiaminal ethers.18 The latter are shelf-stable compounds
derived from 1-ethoxy-2,2,2-triuoroethanol and aromatic
amines and can be converted into triuoromethylated aldi-
mines in situ. Thus, upon treatment with Grignard reagent
deprotonation should provide the corresponding imine which
would then undergo nucleophilic attack by excess Grignard
reagent to furnish the desired triuoromethyl amine
(Scheme 1). Formation of the transient imine species was
conrmed by observing the corresponding imine hydrate via
HPLC-MS aer addition of MeMgBr to the reaction mixture.
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To determine the optimal conditions, 3-chloro-N-(1-ethoxy-
2,2,2-triuoroethyl)aniline 1a was treated with MeMgBr in dry
THF under argon at different reaction temperatures (Table 1).
Thus, the addition proceeded smoothly at 78 C furnishing
the desired triuoroethyl amine 2a in 74% yield aer one hour.
Whereas higher temperatures above 0 C led to signicant
formation of side and decomposition products, best yields were
obtained at a temperature of 15 C (Table 1, entries 1–5). For
complete conversion of the triuoromethyl N,O-acetals at least
2 eq. MeMgBr are required. However, larger excess of the
nucleophile did not improve the yield signicantly. Similar
results were obtained with N-(1-ethoxy-2,2,2-triuoroethyl)-
aniline 1b bearing a neutral aryl ring (Table 1, entries 7–9).
With the optimized reaction conditions in hands, the
substrate scope of the nucleophilic addition was tested using
various functionalized aryl N,O-acetals 1 and MeMgBr (Table 2).
We were pleased to nd that besides halides also ester, triazole,
triuoromethyl groups and morpholino substituents are well
tolerated to provide the desired triuoroethyl amines 2 in fair to
excellent yields (Table 2, entries 1, 5, 6 and 8). However, elec-
tron-rich aniline derivatives proceeded more sluggishly and led
to formation of the desired product with only diminished yields
(Table 2, entry 4). In contrast, both electron-decient and
moderately electron-rich heteroaromatic N,O-acetals 1c and
1g–j were readily converted to the corresponding amines 2c,
2g–j (Table 2, entries 3, 7–10), thus giving access to compounds
with potential applications in drug design.
Next, we turned our attention to other Grignard reagents for
nucleophilic addition to triuoromethylated N,O-acetals. Thus,
Table 1 Optimization studies
Entry Ar Eq. [MeMgBr] T [C] Yield (%)a Product
1 3-ClC6H4 2 40 65 2a
2 3-ClC6H4 2 25 70 2a
3 3-ClC6H4 2 0 84 2a
4 3-ClC6H4 2 15 87 2a
5 3-ClC6H4 2 78 74 2a
6 3-ClC6H4 3 15 75 2a
7 C6H5 1 15 34
b 2b
8 C6H5 2 15 63 2b
9 C6H5 3 15 65 2b
a Yield of isolated product aer ash chromatography. b Reaction time
of 2 h.
Table 2 Addition of MeMgBr to (hetero)aromatic N,O-acetalsa
Entry Ar Yield (%)b Product
1 3-ClC6H4 87 2a
2 C6H5 63 2b
3 4-pyridyl 81 2c
4 4-OMeC6H4 40 2d
5 4-COOEtC6H4 94
c 2e
6 57 2f
7 69 2g
8 96d 2h
9 80 2i
10 74 2j
a All reactions were performed according to the optimized procedure.
b Aer ash chromatography. c Use of 3 eq. MeMgBr. d Without
further purication.
Table 3 Addition of Grignard reagents to 3-chlorophenyl N,O-acetala
Entry RMgX Yield of 3 (%)b Yield of 4 (%)b
1 i-PrMgCl 3a, 70 16
2 i-PrMgCl$LiCl 3a, 67 30
3 n-BuMgBr 3b, 94 ndc
4 t-BuMgCl 3c, 57 nd
5 3d, 78 nd
6 3e, 26 19
7 3f, 62 nd
8 3g, 84 nd
9 3h, 85 nd
a All reactions were performed according to the optimized procedure.
b Aer ash chromatography. c nd ¼ not detected.
This journal is © The Royal Society of Chemistry 2014 RSC Adv., 2014, 4, 9288–9291 | 9289
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upon treatment of 3-chlorophenyl hemiaminal 1a with several
alkyl Grignard reagents, various a-branched triuoromethyl N-
arylamines 3a–e were obtained in moderate to good yields
(Table 3, entries 1–6). Notably, even highly sterically hindered
nucleophiles like t-BuMgCl or cyclohexylmagnesium bromide
can be successfully employed in this reaction (Table 3, entries 4
and 5). Interestingly, by using i-PrMgCl, i-PrMgCl$LiCl and
cyclohexylmethylmagnesium chloride as nucleophiles, also
generation of the formal reduction product 3-chloro-N-(2,2,2-
triuoroethyl)aniline 4 was observed. It is worth mentioning
that the yield of this side-product was substantially higher with
i-PrMgCl$LiCl (up to 30%) than with i-PrMgCl and cyclo-
hexylmethylmagnesium chloride (Table 3, entries 1, 2 and 6).
This is presumably due to the higher degree of complexation in
the presence of LiCl, which facilitates hydride transfer to the
substrate. Furthermore, nucleophilic addition of alkenyl
Grignard reagents proceeded smoothly and provided the
desired unsaturated triuoromethyl N-arylamines 3f, 3g and 3h
in moderate to good yields (Table 3, entries 7–9).
Finally, PhMgCl can be used for conversion of tri-
uoromethyl N,O-acetals into triuoromethylated benzylamine
derivatives. For instance, treatment of the pyrazine derivative 1i
and the isoxazolyl hemiaminal ether 1j with 2 eq. PhMgCl
afforded amines 5 and 6 in good yields (Scheme 2).
In summary, an efficient procedure for the synthesis of a-
branched triuoromethylated amines has been developed
starting from stable N-aryl triuoromethyl hemiaminal ethers.
Whereas alkyl amines were incompatible with N,O-acetal
formation, a broad range of aromatic and heteroaromatic
substrates can be applied successfully to allow for rapid
generation of functionalized amine scaffolds for medicinal
chemistry purposes aer addition of alkyl, alkenyl and aryl
Grignard reagents. Moreover and in contrast to other known
protocols, protecting group manipulations are not required if
the resulting triuoromethylated amines are to be used as
amide bio-isosteres for use in lead optimization. Further
investigations in this direction and on the use of functionalized
organometallic reagents are ongoing and will be reported in due
course.
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2. Convenient Access to Di- and Trifluoroethylamines for Lead 
Structure Research  
A. Deutsch, C. Wagner, C. Deutsch* and A. Hoffmann-Röder*, Eur. J. Org. Chem. 2016, 5, 930–945. 
 
 
 
 
Declaration of Contribution 
Based on the synthesis described in our earlier protocol, Christian Wagner extended the synthesis to the use of 
an external base under my supervision to decrease the necessary amount of Grignard reagent for this 
conversion.[168] We then synthesized a large number of pyridyl- and pyrazyl-substituted trifluoroethylamines 
together using functionalized magnesium organyls. Furthermore, I synthesized various difluoroethylamines 
and developed a method to access novel trifluoromethylated scaffolds via addition of heteroatom nucleophiles. 
To demonstrate the synthetic applicability of the newly modified protocol, I prepared two previously unknown 
trifluoroethylamine analogs of reported biologically active compounds via multistep synthesis.  
 
Synopsis 
As a logic extension of our first project, we then aimed at increasing the degree of functionalization of the 
synthesized trifluoroethylamines. To access trifluoromethylated N,O-acetals bearing electron withdrawing 
substituents we initially developed a microwave protocol for the conversion of heteroaryl- and electron-poor 
arylamines. Subsequently, we modified our previously developed protocol to reduce the amount of 
organometallic reagent required for the complete conversion of the starting material by addition of an external 
base. This efficient methodology could then be applied to a wide range of functionalized Grignard reagents. 
Next to the synthesis of these amide surrogates, we focused our attention on the synthesis of 
difluoroethylamines, since they were so far underrepresented but very promising motifs in medicinal chemistry 
research. Therefore, we successfully converted difluoromethylated N,O-acetals which were accessible by 
condensation of the corresponding amines with 1-ethoxy-2,2-difluoroethanol with functionalized Grignard 
reagents. Finally, we developed a procedure to allow the addition of simple heteroatom nucleophiles to 
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N,O-acetals. To underline the synthetic applicability of the reported protocol for multistep synthesis two 
potential bioisosteres of 1,2-dihydroquinazolin-4-(1H)-thione and the androgen receptor antagonist DIMN 
were successfully prepared.[169]  
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Fluorinated Amines
Convenient Access to Di- and Trifluoroethylamines for Lead
Structure Research
Amrei Deutsch,[a] Christian Wagner,[a] Carl Deutsch,*[b] and Anja Hoffmann-Röder*[a]
Dedicated to Professor Paul Knochel on the occasion of his 60th birthday
Abstract: Much research effort has been devoted to the syn-
thesis of fluorinated organic compounds in medicinal chemistry
programs. For instance, incorporation of fluorine substituents
and trifluoromethyl groups has become a widespread lead opti-
mization strategy owing to the often favorable influence of
such moieties on affinity and physicochemical properties. How-
ever, introduction of fluoroalkyl groups into dedicated positions
of pharmacophores is synthetically challenging. In particular, ef-
ficient syntheses of di- and trifluoroethylamines are needed as
Introduction
One of the major challenges in medicinal chemistry, aside from
the identification of new lead structures, is their development
into clinical candidates, which requires inter alia optimization
of pharmacokinetic properties like absorption, distribution, me-
tabolism, and excretion.[1] For instance, the use of hydrolytically
stable and bioisosteric functional entities that block metabolic
sites not involved in the enzyme-binding mechanism, has be-
come an important strategy to increase the metabolic resist-
ance of a given compound without reducing its potency.[2]
The development of the drug candidate and cathepsin K in-
hibitor, Odanacatib (MK-0822), which is currently in clinical
trials, is an illustrative example of this approach.[3] Previous am-
ide-containing lead structures showed poor selectivity relative
to other cathepsins under physiologically relevant conditions,
whereas replacement of the amide bond by a trifluoroethylam-
ine surrogate granted sufficient selectivity and potency towards
cathepsin K, and excellent metabolic stability in rat, dog and
rhesus monkey hepatocytes.[4] Except for this successful
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they are an interesting, yet underrepresented, class of carbox-
amide mimics. Thus, a practical and reliable protocol for their
preparation is described by using functionalized di- and tri-
fluoromethylated N-aryl-substituted N,O-acetals as synthetic
aldimine equivalents. Moreover, previously unknown -tri-
fluoroethylamine analogs of 1,2-dihydroquinazolin-4(1H)-thione
and the androgen receptor antagonist DIMN are prepared to
demonstrate the method's applicability.
example, further applications of amide-bond substitution by tri-
fluoroethylamine surrogates are scarce, most likely owing to the
lack of convenient synthetic methods to access substituted tri-
fluoroethylamine derivatives.[5] So far, most approaches towards
these building blocks rely upon the use of trifluoromethylated
imines, the preparation of which is often very challenging.[6] In
contrast, a recently developed protocol applies to electron-rich
and moderately electron-deficient N-aryl-trifluoromethyl N,O-
acetals, which after addition of Grignard reagents allows forma-
tion of the corresponding functionalized trifluoroethylamines in
good yields.[7] The requisite shelf-stable N,O-acetals are readily
accessible by condensation of an amine and trifluoroacetalde-
hyde ethyl hemiacetal (TFAE) in the presence of catalytic
amounts of p-toluenesulfonic acid (pTSA).[8] Because these con-
ditions preclude the use of amines with electron-withdrawing
groups or heteroaromatic amines, both of which are common
substructures of pharmaceutically relevant scaffolds, a modified
version of this reaction is now being reported. This protocol
allows preparation of electron-deficient N-(hetero)-aryl-tri-
fluoromethyl N,O-acetals and their difluoromethylated conge-
ners. In addition, the subsequent Grignard addition has success-
fully been extended to the use of functionalized organomagne-
sium reagents to provide a broad range of complex substituted
α-difluoro- and α-trifluoromethylated amines in good to excel-
lent yields. Such compounds are of particular interest with re-
gard to potential medicinal chemistry applications, e.g. during
lead optimization studies and diversifying the family of peptide
mimics.[9] Finally, new trifluoromethylated analogs of a 1,2-di-
hydroquinazolin-4(1H)-thione scaffold and the nicotinamide an-
drogen receptor antagonist 6-(3,4-dihydro-1H-isoquinolin-2-yl)-
Full Paper
N-(6-methylpyridin-2-yl)nicotinamide (DIMN) are presented,
which corroborate the synthetic applicability of the reported
protocol.
Results and Discussion
Synthesis of CF2H- and CF3-Substituted N,O-Acetals
Although only a few examples of difluoromethylated N,O-acet-
als have been reported,[10] various syntheses of their trifluoro-
methylated congeners are known. For instance, electron-rich
arylamines readily condense with TFAE under acidic conditions
by following the procedure by Gong and Kato.[8] However,
when applied to electron-deficient amines or heteroaromatic
amines, this protocol only furnished the desired products in
diminished yields of < 30 %. In particular, the preparation of
electron-poor N-aryl-substituted N,O-acetals, such as N-(1-
ethoxy-2,2,2-trifluoroethyl)-pyridine-2-amine (1a), proved diffi-
cult and required optimization of the reaction conditions.
Therefore, a revised microwave-assisted protocol was devel-
oped, which furnished 1a in a satisfying yield of 82 %. More-
over, electron-poor trifluoromethylated N-aryl-substituted N,O-
acetals 1c–1e were easily accessible upon heating the corre-
sponding amines and TFAE in toluene at 180 °C under micro-
Table 1. Synthesis of difluoromethylated and trifluoromethylated N,O-acetals.
[a] Reactions were performed in accordance with the optimized microwave
procedure. [b] Reactions were performed by following a literature proce-
dure.[8]
Scheme 1. Synthesis of functionalized trifluoromethylated amines.
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wave irradiation (Table 1). In contrast, yields of corresponding
difluoromethylated N,O-acetals 1f and 1g were higher under
conventional heating, i.e. without the use of microwave irradia-
tion, which is presumably a result of their lower intrinsic stabil-
ity (vide infra).
Synthesis of CF2H- and CF3-Substituted N-Arylethylamines
Trifluoromethylated N-arylamines can be directly prepared from
their corresponding N,O-acetals, upon addition of a suitable
Grignard reagent (2 equiv.), as previously reported.[7a] Unfortu-
nately, this procedure is less beneficial when precious (poly-)-
functionalized Grignard reagents are used. To reduce the nec-
essary amount of Grignard reagent, the aim was to separate
the nucleophilic addition reaction from the initial deprotona-
tion step by using an external non-nucleophilic base. Fortu-
nately, initial deprotonation of hemiaminal ethers 1 with lithium
bis(trimethylsilyl)amide (LiHMDS; 1 equiv.) to form the transient
imine species and subsequent addition of Grignard reagent
(1 equiv.) furnished desired α-trifluoromethylated amines 2 in
similar yields to those already achieved (Scheme 1). Because a
broad spectrum of functionalized Grignard reagents can readily
be obtained from the corresponding aryl and heteroaryl halides
by using iPrMgCl[11] or iPrMgCl·LiCl (Turbo-Grignard),[12] the re-
vised protocol now offers a convenient route towards the syn-
thesis of various complex trifluoroethylamine scaffolds. To illus-
trate this, a range of new trifluoroethylamines is depicted in
Table 2.
Grignard reagents, prepared from 2-, 3-, or 4-bromobenzo-
nitrile and iPrMgCl·LiCl in tetrahydrofuran (THF), were added at
–78 to –30 °C to a solution of the in situ generated imine of
pyridine N,O-acetal 1a. In all cases, smooth formation of the
nitrile-functionalized trifluoroethylamines was observed to give
desired compounds 2a–2c in 75, 71, and 68 % yield, respec-
tively, after column chromatography (Table 2, Entries 1–3). Simi-
larly, addition of the 4-bromobenzonitrile-derived Grignard rea-
gent to pyrazyl N,O-acetal 1c furnished corresponding amine
2p, albeit in slightly lower yield of 56 % (Table 2, Entry 16).
Moreover, the use of 1-bromo-3-chlorobenzene and 1-bromo-
4-chlorobenzene allowed chemoselective transmetalations to
take place to afford the corresponding chlorophenylmagnesium
reagents, which after reaction with N,O-acetal 1a furnished
N-[1-(3-chlorophenyl)-2,2,2-trifluoroethyl]pyridin-2-amine (2d;
75 %) and N-[1-(4-chlorophenyl)-2,2,2-trifluoroethyl]pyridin-2-
amine (2e; 66 %; Table 2, Entries 4 and 5). The latter compounds
are easily further functionalized, e.g. through metal-catalyzed
Full Paper
Table 2. Synthesis of trifluoromethylated amines by addition of functionalized Grignard reagents to hemiaminal ethers.[a]
[a] Reactions were performed in accordance with the optimized procedure. [b] Total yield after flash chromatography. [c] The Grignard reagent was prepared
from the corresponding aryl bromide and iPrMgCl.
cross-coupling reactions to enhance the level of scaffold com-
plexity.
The Grignard reagent derived from 5-bromo-2-chloropyr-
idine reacted analogously with N,O-acetal 1e to yield corre-
sponding amine product 2i in 65 % yield and with an intact C–
Eur. J. Org. Chem. 2016, 930–945 www.eurjoc.org © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim932
Cl bond at the pyridine ring (Table 2, Entry 9). Heteroaromatic
Grignard reagents, which include pyridine, pyrimidine, thio-
phene, and benzothiophene derivatives, were also successfully
employed. In some cases the yields of the targeted trifluoro-
methylated amines were somewhat reduced as a result of in-
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trinsic low reactivities of the corresponding Grignard species.
For instance, addition of 2-thiophenylmagnesium chloride to
Table 3. Synthesis of difluoromethylated amines by addition of Grignard rea-
gents to hemiaminal ethers.
[a] Reactions were performed by following the reported procedure.[7a] [b] Re-
actions were performed in accordance with the optimized procedure.
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N,O-acetal 1c proceeded sluggishly and resulted in a dimin-
ished yield of only 55 % of desired amine 2s (Table 2, Entry 19).
Similarly, reaction of 2-pyridylmagnesium chloride with 1c was
hampered and furnished amine 2q in 56 % yield with concomi-
tant amounts of unreacted N,O-acetal 1c (Table 2, Entry 17).
Lastly, trifluoroethylamines with triple bonds are particularly
useful synthetic building blocks for larger scaffolds. Hence, N-
pyrazyl N,O-acetal 1c was treated with ethynylmagnesium
chloride and ethynylcyclopropylmagnesium chloride to afford
corresponding amines 2u and 2w in 96 and 80 % yield, respec-
tively (Table 2, Entries 21 and 23). The examples presented so
far demonstrate the versatility of the protocol to access func-
tionalized trifluoroethylamines.
To address the syntheses of related CHF2-substituted deriva-
tives, Grignard additions with the corresponding difluorometh-
ylated N,O-acetals were investigated (Table 3). As expected,
their conversion with simple commercially available alkyl and
aryl Grignard reagents proceeded smoothly and furnished tar-
get difluoroethylamines 3a–3j in good yields. Application of
functionalized Grignard reagents in combination with LiHMDS
provided access to more complex difluoromethylated amine
scaffolds (Table 3, Entries 11–13). In some cases, such as amines
3h and 3l, reduced stability of the difluoroethylamines was ob-
served, which resulted in significantly lower yields of isolated
products.
The addition reactions described above are not restricted to
the use of Grignard or organolithium reagents but also allow
heteroatom nucleophiles to be employed. Hence, n-butylamine
was deprotonated and subjected to N,O-acetal 1a. In this case,
the highest yield of desired product 4a (75 %) was obtained
with n-butyllithium in dry n-hexane at 0 °C (Table 4, Entry 1).
Further transformations with N-nucleophiles included the use
of 4-methylbenzylamine and benzamidine, both of which fur-
Table 4. Addition of N-, O-, S-nucleophiles to hemiaminal ethers.
[a] Reactions were performed with nBuLi as a base and n-hexane as solvent.
[b] Reaction was performed with microwave irradiation and toluene as a
solvent.
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Scheme 2. Synthesis of DIMN trifluoroethylamine bioisostere 5. (i) pTSA, MW, 180 °C, 30 min, 54 %; (ii) 3-bromo-6-chloropyridine, iPrMgCl·LiCl, –30 °C, 2 h;
(iii) NaHMDS, THF, –78 °C, 15 min, then organyl magnesium, –30 °C, 2 h, 65 %; (iv) 1,2,3,4-tetrahydroisoquinoline, 2-propanol, reflux, 48 h, 33 %.
nished desired products 4b and 4c in good yields of 87 and
86 %, respectively (Table 4, Entries 2 and 3). Notably, for
amine 4c the best results were obtained under microwave
irradiation at 160 °C in toluene and without the use of an exter-
nal base.
O- and S-Nucleophiles can also be successfully employed in
addition reactions to N,O-acetal 1a (Table 4, Entries 4 and 5),
which leads to the formation of corresponding hemiaminal
ether 4d and hemiaminal thioether 4e, respectively.
Finally, a hitherto unknown trifluoromethylated analog of
the non-steroidal androgen receptor (AR) antagonist DIMN[13]
has been synthesized to demonstrate the versatility of this pro-
tocol to prepare scaffolds for potential pharmaceutical applica-
tions (Scheme 2). DIMN (6) has been reported recently as a
promising new anti-androgenic compound for the treatment of
both early-stage androgen-dependent and later-stage andro-
gen-independent prostate cancers.[13,14] In regard to the ineffi-
ciencies of many classical AR antagonists in the treatment of
advanced prostate cancers, new lead scaffolds for better AR an-
tagonists are still urgently needed. Besides, the development of
metabolically more resistant compounds might be particularly
rewarding. The synthesis of corresponding -trifluoroethylam-
ine analog 5 of DIMN commenced with microwave-assisted
conversion of commercially available 2-amino-5-methylpyridine
into requisite N,O-acetal 1e, as described. Subsequent addition
of the Grignard reagent prepared from 3-bromo-6-chloropyr-
idine and iPrMgCl·LiCl afforded intermediate 2i, which was suc-
cessfully coupled to 1,2,3,4-tetrahydroisoquinoline to provide
target compound 5 over three steps.
In addition, preparation of trifluoromethylated 1,2-dihydro-
quinazolin-4(1H)-thione 7 was tackled as outlined in Scheme 3.
Sulfur analogs of quinazolinone alkaloids are interesting phar-
macophores with diverse biological activities, such as antipsy-
chotic and antihypertensive effects.[15]
Based on a recent report from Oschatz et al.[16] and by start-
ing from 2-aminobenzonitrile, target compound 7 was synthe-
sized in three steps. Thus, 2-aminobenzonitrile was converted
into N,O-acetal 1i, followed by thiolysis of the nitrile group, as
described before.[16] Ring closure to the target trifluoromethyl-
ated 1,2-dihydroquinazolin-4(1H)-thione 7 was accomplished by
stirring compound 8 in THF under basic conditions to yield
compound 7 in 86 %.
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Scheme 3. Synthesis of 1,2-dihydroquinazolin-4(1H)-thione 7. (i) TFAE, pTSA,
ethanol, reflux, 30 min, 35 %; (ii) NaSH·H2O, MgCl2, DMF, 1.5 h, quant.
(iii) KOtBu, THF, molecular sieves 4 Å, room temp., 48 h, 86 %.
Conclusions
In summary, a practical and efficient approach towards prepara-
tion of various functionalized difluoromethylated and trifluoro-
methylated N-arylamines was devised. Thereby, the use of fluo-
roalkylated N,O-acetals as shelf-stable, easily applicable ald-
imine equivalents in combination with (poly-)functional Grig-
nard reagents or heteroatom nucleophiles allows access to a
broad range of fluoroalkylated N-arylamines in synthetically
useful yields. The resulting α-difluoro- and α-trifluoromethyl N-
arylamines belong to an interesting, yet underrepresented, class
of carboxamide bioisosteres and are of interest for potential
pharmaceutical applications. To illustrate our approach, synthe-
ses of hitherto unknown -trifluoroethylamine analog to the
nicotinamide-derived androgen receptor (AR) antagonist DIMN
and 1,2-dihydroquinazolin-4(1H)-thione were reported. Further
studies on the application of difluoromethylated and trifluoro-
methylated amine derivatives are currently underway.
Experimental Section
General Remarks: All reactions were carried out under an argon
atmosphere in flame-dried glassware. Syringes, which were used to
transfer anhydrous solvents or reagents, were purged with argon
prior to use. Dry THF was freshly distilled from sodium and benzo-
phenone under argon. Commercially available reagents and sol-
vents were used without further purification. Grignard reagents
were purchased from Aldrich or synthesized according to the proce-
dures described. All microwave irradiation experiments were carried
out in a CEM ExplorerTM microwave apparatus, which operated at a
frequency of 2.45 GHz with continuous irradiation power from 0 to
200 W, and used the standard absorbance level of 300 W maximum
power. The reactions were carried out in 10 mL Pyrex vessels sealed
with CEM plastic crimp tops equipped with magnetic stirrers. The
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temperature was measured with an infrared sensor on the outer
surface of the process vial. After the irradiation period, the reaction
vessel was cooled rapidly (1–2 min) to ambient temperature by
using a nitrogen jet.
Reactions were monitored by TLC with pre-coated silica gel 60 F254
aluminum plates (Merck KGaA, Darmstadt) with UV light as the visu-
alizing agent. The crude products were purified by standard flash
chromatography with silica gel (35–70 µm) from Acros Organics.
Analytical RP-HPLC was measured on a JASCO system with a Phe-
nomenex Luna C18 column (5 µm, 250 × 4.6 mm). Low resolution
(ESI) and high resolution (ESI) mass spectra were recorded with a
Thermo Finnigan LTQ FT or with a Bruker maXis equipped with a
Waters Acquity UPLC and a Kinetex C18 column (2.6 µ, 100 A) at
40 °C. In all cases, mixtures of water (eluent A) and acetonitrile (elu-
ent B) were used as solvents; if required, formic acid (0.05 %) or
trifluoroacetic acid (TFA; 0.1 %) were added. 1H, 13C, and 19F NMR
spectra were recorded with a Varian 300 or 600 MHz spectrometer
or with a Bruker Avance II 400 MHz spectrometer in [D6]DMSO or
CDCl3. The chemical shifts are reported relative to the signal of the
deuterated solvent. Multiplicities are given as: s (singlet), br. s (broad
singlet), d (doublet), t (triplet), and m (multiplet). Melting points
were measured with a Melting Point B-540 Büchi.
Typical Procedure for the Microwave Synthesis of Hemiaminal
Ethers (TP1): A dry microwave tube equipped with a magnetic
stirrer was charged with an arylamine (1 equiv.) and pTSA·H2O
(0.05 equiv.). The starting material was dissolved in toluene and
TFAE/difluoroacetaldehyde ethyl hemiacetal (1.2 equiv.) was added.
The microwave tube was sealed and the reaction mixture was re-
acted at 180 °C for 30 min (max. 200 W).
The solvent was evaporated and the crude product was purified by
flash chromatography (SiO2).
Typical Procedure for the Synthesis of Hemiaminal Ethers (TP2):
A round-bottomed flask equipped with a magnetic stirrer was
charged with an arylamine (1 equiv.) and pTSA·H2O (0.05 equiv.).
The starting material was dissolved in ethanol and TFAE/difluoro-
acetaldehyde ethyl hemiacetal (1.2 equiv.) was added. The reaction
mixture was heated under reflux (90 °C) until the reaction showed
no further conversion.
The solvent was evaporated and the product was purified by flash
chromatography (SiO2).
Typical Procedure for the Magnesium Insertion (TP3):[11] A dry
and argon-flushed 10 mL flask equipped with a magnetic stirrer
and a septum was charged with iPrMgCl·LiCl (1.25 M in THF,
1.1 equiv.). Neat aryl bromide (1 equiv.) was added at the appropri-
ate temperature. The reaction mixture was stirred at the stated tem-
perature, and completion of the Br/Mg exchange was monitored by
GC analysis.
Typical Procedure for the Addition of the Functionalized Grig-
nard Reagent to Hemiaminal Ethers (TP4): Hemiaminal ether
(0.045 mmol, 1 equiv.) was dissolved in freshly distilled THF (5 mL)
in a dry and argon-flushed 10 mL flask equipped with a magnetic
stirrer and a septum and cooled to –78 °C. NaHMDS or LiHMDS (1 M
in THF, 0.045 mmol, 1 equiv.) was added and the reaction was
stirred for 15 min until the deprotonation was complete. The Grig-
nard reagent was added dropwise with a syringe and the solution
was warmed to the appropriate temperature. The reaction was
stirred until GC analysis showed that conversion was complete.
After the reaction was complete satd. NH4Cl solution was added
and the mixture was extracted three times with Et2O. The solvent
was evaporated and the product was purified by flash chromatogra-
phy (SiO2).
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Typical Procedure for the Synthesis of CF2H-Amines with RMgX
(TP5): In a dry, argon-flushed Schlenk flask hemiaminal ether
(1 equiv.) was dissolved in dry THF. The solution was cooled to 0 °C,
RMgX (2 equiv.) was added dropwise, and the solution was stirred
at 0 °C until complete consumption of the starting material (≈ 2 h,
TLC control). Then the solution was quenched with saturated NH4Cl
solution (10 mL) and extracted with diethyl ether (3 × 20 mL). The
combined organic phases were dried with MgSO4, filtered, and the
solvent was evaporated in vacuo. Purification by flash chromatogra-
phy (SiO2) furnished the desired amines.
N-(1-Ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (1a): Hemiami-
nal ether 1a was prepared in accordance with TP1. 2-Aminopyridine
(100 mg, 1.06 mmol), pTSA·H2O (10 mg, 0.05 mmol), and TFAE
(0.15 mL, 1.28 mmol) were reacted in a CEM microwave reactor in
toluene (2 mL). Flash column chromatography (cyclohexane/ethyl
acetate/NEt3, 8:1:0.1) furnished 1a as a white solid (196 mg, 82 %).
Rf = 0.45 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1), m.p. 84 °C. 1H
NMR (300 MHz, CDCl3): δ = 8.13 (ddd, JH6,H5 = 5.0, JH6,H4 = 1.9 Hz,
J = 0.9 Hz, 1 H, H6), 7.48 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 =
1.9 Hz, 1 H, H4), 6.73 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.1 Hz, JH5,H3 =
1.0 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.3, J = 5.1 Hz, 1 H, H3), 6.01 (dq,
JCH,NH = 10.2, JCH,CF3 = 5.1 Hz, 1 H, CH), 4.89 (d, JNH,CH = 10.4 Hz,
1 H, NH), 3.86–3.66 (m, 2 H, CH2), 1.22 (t, JCH3,CH2 = 7.0 Hz, 3 H,
CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –80.66 (d, JCF3,CH = 5.0 Hz,
CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.19 (C2), 148.06 (C6),
138.13 (C4), 123.27 (q, JC,F = 282.2 Hz, CF3), 115.66 (C5), 109.24 (C3),
78.50 (q, JC,F = 33.9 Hz, CHCF3), 65.35 (CH2), 15.30 (CH3) ppm. HRMS
(ESI+): m/z calcd. for C9H12ON2F3+ [M + H]+ 221.0902; found
221.0898. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 9.21 min, λ = 214 nm.
N-(1-Ethoxy-2,2-difluoroethyl)pyridine-2-amine (1b): In accord-
ance with TP1, 2-aminopyridine (100 mg, 1.06 mmol), pTSA·H2O
(10 mg, 0.05 mmol), and difluoroacetaldehyde ethyl hemiacetal
(0.15 mL, 1.28 mmol) were reacted in a CEM microwave reactor
in toluene (2.5 mL). Flash column chromatography (SiO2, gradient:
cyclohexane/ethyl acetate/NEt3, 100:1:1 → 10:2:0.1) furnished 1b
(84 mg, 39 %) as a white solid. Rf = 0.74 (cyclohexane/ethyl acetate,
1:1), m.p. <40 °C. 1H NMR (400 MHz, CDCl3): δ = 8.11 (ddd, JH6,H5 =
5.0, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.45 (ddd, JH4,H3 = 8.4,
JH4,H5 = 7.3 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.70 (ddd, JH5,H4 = 7.2,
JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.3, JH3,H6 =
JH3,H5 = 0.9 Hz, 1 H, H3), 5.86 (ddd, JH,F = 55.1, JH,F = 53.3 Hz,
JCHF2,CH = 2.3 Hz, 1 H, CHF2), 5.74–5.70 (m, 1 H, CH), 4.94 (d, JNH,CH =
10.0 Hz, 1 H, NH), 3.71 (ddq, JCH2,CH = 44.3, JCH2,CH2 = 9.6 Hz,
JCH2,CH3 = 7.0 Hz, 1 H, CH2), 1.21 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm.
19F NMR (376 MHz, CDCl3): δ = –129.66 (ddd, JF,F = 286.6, JF,H =
54.7 Hz, JF,CH = 8.2 Hz, CHF2), –133.95 (ddt, JF,F = 286.7, JF,H = 55.8 Hz,
JF,CH = 12.4 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 156.84
(C2), 148.00 (C6), 137.89 (C4), 115.09 (C5), 113.74 (dd, JC,F = 246.4,
JC,F = 244.7 Hz, CHF2), 108.90 (C3), 79.35 (dd, JC,F = 26.8, JC,F =
22.7 Hz, CH), 64.36 (CH2), 15.31 (CH3) ppm. HRMS (ESI+): m/z calcd.
for C9H13F2N2O+ [M + H]+ 203.0990; found 203.0991. HPLC (0.1 %
TFA; 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 7.41 min,
λ = 214 nm.
N-(1-Ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (1c): Hemiami-
nal ether 1c was prepared in accordance with TP1. Aminopyrazine
(100 mg, 1.05 mmol), pTSA·H2O (10 mg, 0.05 mmol) and TFAE
(0.17 mL, 1.26 mmol) were reacted together in a CEM microwave
reactor in toluene (2 mL). Flash column chromatography (cyclohex-
ane/ethyl acetate/NEt3, 3:1:0.1) furnished 1c as a white solid
(181 mg, 78 %). Rf = 0.55 (cyclohexane/ethyl acetate/NEt3, 2:1:0.05),
m.p. 110 °C. 1H NMR (300 MHz, CDCl3): δ = 8.05 (ddd, JH6,H5 = 2.7,
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JH6,H3 = 1.5 Hz, JH6,NH = 0.4 Hz, 1 H, H6), 8.03 (dd, JH3,H6 = 1.5,
JH3,H5 = 0.4 Hz, 1 H, H3), 7.99 (dd, JH5,H6 = 2.8, JH5,H3 = 0.4 Hz, 1 H,
H5), 5.94 (dq, JCH,NH = 10.0, JCH,CF3 = 5.0 Hz, 1 H, CH), 5.26 (d, JNH,CH =
10.1 Hz, 1 H, NH), 3.93–3.64 (m, 2 H, CH2), 1.23 (t, JCH3,CH2 = 7.0 Hz,
3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –80.71 (d, JCF3,CH =
5.1 Hz, CHCF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 152.56 (C2),
141.73 (C6), 135.68 (C5), 133.17 (C3), 122.87 (q, JC,F = 282.2 Hz, CF3),
78.01 (q, JC,F = 34.3 Hz, CHCF3), 65.69 (CH2), 15.11 (CH3) ppm. HRMS
(ESI+): m/z calcd. for C9H12F3N3O+ [M + H]+ 222.0849; found
222.0848. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 13.99 min, λ = 214 nm.
N-(1-Ethoxy-2,2-difluoroethyl)pyrazin-2-amine (1d): In accord-
ance with TP1, aminopyrazine (100 mg, 1.05 mmol), pTSA·H2O
(10 mg, 0.05 mmol), and difluoroacetaldehyde ethyl hemiacetal
(0.15 mL, 1.28 mmol) were reacted together in a CEM microwave
reactor in toluene (2.5 mL). Flash column chromatography (SiO2,
gradient: cyclohexane/ethyl acetate/NEt3, 100:2:1 → 10:2:0.1) fur-
nished 1d (95 mg, 44 %) as a white solid. Rf = 0.55 (cyclohexane/
ethyl acetate, 1:1), m.p. 64–65 °C. 1H NMR (600 MHz, CDCl3): δ =
8.03–8.01 (m, 2 H, H3, H6), 7.95 (dd, JH5,H6 = 2.7, JH5,H3 = 1.0 Hz,
1 H, H5), 5.87 (dddd, JH,F = 55.7, JH,F = 54.8 Hz, JCHF2,CH = 2.2 Hz,
JCHF2,NH = 1.3 Hz, 1 H, CHF2), 5.75–5.68 (m, 1 H, CH), 5.26 (d, JNH,CH =
9.9 Hz, 1 H, NH), 3.78–3.62 (m, 1 H, CH2), 1.21 (td, JCH3,CH2 = 7.0,
JCH3,CH = 1.2 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ =
–129.03 (ddd, JF,F = 288.0, JF,H = 55.0 Hz, JCHF2,CH = 7.9 Hz, CHF2),
–134.70 (ddt, JF,F = 287.9, JF,H = 55.7 Hz, JCHF2,CH = 12.1 Hz,
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 153.27 (C2), 141.73 (C6),
135.17 (C5), 133.10 (C3), 113.41 (t, JC,F = 245.7 Hz, CHF2), 78.94 (dd,
JC,F = 27.6, JC,F = 22.5 Hz, CH), 64.73 (CH2), 15.20 (CH3) ppm. HRMS
(ESI+): m/z calcd. for C8H12F2N3O+ [M + H]+ 204.0943; found
204.0943. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 11.43 min, λ = 214 nm.
N-(1-Ethoxy-2,2,2-trifluoroethyl)-6-methylpyridin-2-amine (1e):
Hemiaminal ether 1e was prepared in accordance with TP1. 6-
Methylpyridinamine (300 mg, 2.77 mmol), pTSA·H2O (26 mg,
0.14 mmol), and TFAE (0.43 mL, 3.32 mmol) were reacted together
in a CEM microwave reactor in toluene (4 mL). Flash column chro-
matography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3,
20:1:0.1 → 10:1:0.1) furnished 1e as a colorless oil (350 mg, 54 %).
Rf = 0.40 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR
(300 MHz, CDCl3): δ = 7.36 (dd, JH4,H3 = 8.1, JH4,H5 = 7.4 Hz, 1 H,
H4), 6.59 (dq, JH5,H4 = 7.3, JH5,CH3 = 0.6 Hz, 1 H, H5), 6.31 (dt, JH3,H4 =
8.2, J = 0.6 Hz, 1 H, H3), 5.99 (dq, JCH,NH = 10.3, JCH,CF3 = 5.1 Hz, 1 H,
CH), 4.84 (d, JNH,CH = 10.4 Hz, 1 H, NH), 3.90–3.62 (m, 2 H, CH2), 2.39
(s, 3 H, CH3), 1.22 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH2CH3) ppm. 19F NMR
(282 MHz, CDCl3): δ = –80.49 (d, JCF3,CH = 4.8 Hz, CF3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 157.53 (C6), 155.96 (C2), 138.69 (C4), 123.72
(q, JC,F = 282.3 Hz, CF3), 115.18 (C5), 106.04 (C3), 78.88 (q, JC,F =
33.7 Hz, CHCF3), 65.57 (CH2CH3), 24.89 (CCH3), 15.61 (CH2CH3) ppm.
HRMS (ESI+): m/z calcd. for C10H14F3N2O+ [M + H]+ 235.1053; found
235.1054. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 9.79 min, λ = 214 nm.
N-(1-Ethoxy-2,2-difluoroethyl)-3,5-bis(trifluoromethyl)aniline
(1f): In accordance with TP2, 3,5-bis(trifluoromethyl)aniline (0.50 g,
2.18 mmol), difluoroacetaldehyde ethyl hemiacetal (0.32 mL,
2.62 mmol), and pTSA·H2O (21 mg, 0.11 mmol) were dissolved in
EtOH (15 mL) and the reaction mixture was heated to reflux for
18 h. After removal of the solvent, flash column chromatography
(SiO2, gradient: cyclohexane/ethyl acetate/NEt3, 100:1:1 → 100:2:1)
furnished 1f (485 mg, 66 %) as a white solid. Rf = 0.66 (cyclohexane/
ethyl acetate, 4:1), m.p. 50–52 °C. 1H NMR (400 MHz, CDCl3): δ =
7.32 (s, 1 H, H4), 7.14 (s, 2 H, H2, H6), 5.87 (ddd, JH,F = 55.5, JH,F =
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54.7 Hz, JCHF2,CH = 2.5 Hz, 1 H, CHF2), 5.00–4.88 (m, 1 H, CH), 4.69
(d, JNH,CH = 9.3 Hz, 1 H, NH), 3.70 (ddq, JCH2,CH2 = 41.2, JCH2,CH =
9.2 Hz, JCH2,CH3 = 7.0 Hz, 2 H, CH2), 1.24 (t, JCH3,CH2 = 7.0 Hz, 3 H,
CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = 63.27 (2 × CF3), –128.05
(dd, JF,F = 289.6, JF,H = 54.7 Hz, CHF2), –133.54 (ddd, JF,F = 289.6,
JF,H = 55.6 Hz, JCHF2,CH = 10.7 Hz, CHF2) ppm. 13C NMR (101 MHz,
CDCl3): δ = 146.30 (C1), 132.96 (q, JC,F = 33.1 Hz, C3, C5), 123.40 (q,
JC,F = 272.7 Hz, 2 × CF3), 113.81 (C2, C6), 113.34 (t, JC,F = 246.9 Hz,
CHF2), 113.14–112.94 (m, C4), 82.68 (dd, JC,F = 27.8, JC,F = 23.3 Hz,
CH), 64.21 (CH2), 15.21 (CH3) ppm. HRMS (ESI–): m/z calcd. for
C12H11F8NO– [M – H]– 336.0640; found 336.0646. HPLC (0.1 % TFA;
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 20.02 min,
λ = 214 nm.
N-(1-Ethoxy-2,2-difluoroethyl)-2,3,4,5,6-pentafluoroaniline
(1g): In accordance with TP2, 2,3,4,5,6-pentafluoroaniline (1.00 g,
5.45 mmol), difluoroacetaldehyde ethyl hemiacetal (0.77 mL,
6.56 mmol), and pTSA·H2O (52 mg, 0.27 mmol) were solved in EtOH
(15 mL) and the reaction mixture was heated to reflux for 18 h.
After removal of the solvent, flash column chromatography (SiO2,
gradient: cyclohexane/NEt3, 100:1 → cyclohexane/ethyl acetate/
NEt3, 100:3:1) furnished 1g (574 mg, 36 %) as a colorless oil. Rf =
0.73 (cyclohexane/ethyl acetate, 7:1). 1H NMR (400 MHz, CDCl3): δ =
5.81 (ddd, JH,F = 55.6, JH,F = 54.6 Hz, JCHF2,CH = 2.2 Hz, 1 H, CHF2),
4.99–4.87 (m, 1 H, CH), 4.13 (d, JNH,CH = 11.1 Hz, 1 H, NH), 3.73 (ddq,
JCH2,CH = 67.9, JCH2,CH2 = 9.4 Hz, JCH2,CH3 = 7.0 Hz, 1 H, CH2), 1.22 (t,
JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (377 MHz, CDCl3): δ =
–129.19 (ddd, JF,F = 289.8, JF,H = 54.8 Hz, JF,H = 7.1 Hz, CHF2), –135.38
(ddt, JF,F = 289.2, JF,H = 55.3 Hz, JCHF2,CH = 9.9 Hz, CHF2), –156.49 –
–156.63 (m, 2 F, F2; F6), –163.13 (td, JF5,F4 = JF5,F6 = JF3,F2 = JF3,F4 =
22.1, JF5,F3 = JF3,F5 = 4.8 Hz, 2 F, F3, F5), –167.38 (tt, JF4,F3 = JF4,F5 =
21.9, JF4,F2 = JF4,F6 = 4.7 Hz, F4) ppm. 13C NMR (101 MHz, CDCl3): δ =
140.33–137.45 (m), 139.84–137.00 (m), 136.89–133.89 (m), 121.01–
120.55 (m), 113.49 (t, JC,F = 246.4 Hz, CHF2), 84.43 (ddt, JC,F = 27.1,
JC,F = 23.1 Hz, JC,F = 3.9 Hz, CH), 65.07 (CH2), 15.16 (CH3) ppm. HRMS
(ESI–): m/z calcd. for C10H7F7NO– [M – H]– 290.0421; found 290.0422.
HPLC (0.1 % TFA; 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 18.81 min, λ = 214 nm.
N-(2,2,2-Trifluoro-1-ethoxyethyl)aminopyridine (1h): In accord-
ance with TP1, 4-aminopyridine (200 mg, 2.12 mmol), pTSA·H2O
(20 mg, 0.11 mmol), and TFAE (0.33 mL, 2.55 mmol) were reacted
in a CEM microwave reactor in toluene (2.5 mL). Flash column chro-
matography (SiO2, gradient: ethyl acetate → ethyl acetate/MeOH,
10:1) furnished 1h as a white solid (258 mg, 55 %). Rf = 0.11 (cyclo-
hexane/ethyl acetate/NEt3, 1:1:0.01), m.p. 84 °C. 1H NMR (400 MHz,
[D6]DMSO): δ = 8.24–8.05 (m, 2 H, H2, H6), 7.37 (d, JNH,CH = 10.0 Hz,
1 H, NH), 6.97–6.80 (m, 2 H, H3, H5), 5.70 (dq, JCH,NH = 10.3, JCH,CF3 =
5.2 Hz, 1 H, CH), 3.82–3.47 (m, 2 H, CH2), 1.13 (t, JCH3,CH2 = 7.0 Hz,
3 H, CH3) ppm. 19F NMR (377 MHz, [D6]DMSO): δ = –78.80 (d,
JCF3,CH = 5.8 Hz, CF3) ppm. 13C NMR (101 MHz, [D6]DMSO): δ =
151.94 (C4), 149.84 (C2, C6), 123.06 (q, JC,F = 283.8 Hz, CF3), 108.31
(C3, C5), 78.89 (q, JC,F = 33.3 Hz, CHCF3) , 63.52 (CH2), 14.86
(CH3) ppm. HRMS (ESI+): m/z calcd. for C9H12F3N2O+ [M + H]+
221.0896; found 221.0898. HPLC-MS (0.1 % formic acid; 0 min: 4 %
B → 2.8 min: 100 % B, flow: 2.4 mL/min): tR = 1.18 min, λ = 220 nm.
2-[2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl]benzonitrile (2a):
(2-Cyanophenyl)magnesium chloride was prepared in accordance
with TP3 from 2-bromobenzonitrile (91 mg, 0.50 mmol) in 1 h at
0 °C. The addition reaction was performed In accordance with TP4
with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2a as a light yel-
low oil (94 mg, 75 %). Rf = 0.45 (cyclohexane/ethyl acetate/NEt3,
Full Paper
8:1:0.1). 1H NMR (300 MHz, CDCl3): δ = 8.44 (ddd, JH6′,H5′ = 4.9,
JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 8.04 (s, 2 H, NH, H3′),
7.85–7.75 (m, 2 H, H4, H4′), 7.71–7.52 (m, 3 H, H3, H5, H6), 7.11
(ddd, JH5′,H4′ = 7.3, JH5′,H6′ = 4.9 Hz, JH5′,H3′ = 1.0 Hz, 1 H, H5′), 6.59–
6.46 (m, 1 H, CH) ppm. 19F NMR (282 MHz, CDCl3): δ = –73.06 (dd,
JCF3,CH = 5.7, JCF3,NH = 1.2 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3):
δ = 152.50 (C2′), 148.23 (C6′), 138.11 (C4′), 134.87 (d, JC,F = 1.5 Hz,
CF3), 133.78 (C1), 132.16 (C6), 130.23 (C5), 130.21–118.74 (m, CF3),
124.49 (d, JC,F = 1.9 Hz, C3), 122.84 (C4), 120.17 (C5′), 117.66 (CN),
61.67 (q, JC,F = 32.7 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for
C14H10F3N3+ [M + H]+ 278.0905; found 278.0899. HPLC (0.1 % TFA,
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 9.83 min,
λ = 214 nm.
3-[2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl]benzonitrile (2b):
(3-Cyanophenyl)magnesium chloride was prepared in accordance
with TP3 from 3-bromobenzonitrile (91 mg, 0.50 mmol) in 2 h at
0 °C. The addition reaction was performed in accordance with TP4
with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2b as a light yel-
low oil (89 mg, 71 %). Rf = 0.45 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1). 1H NMR (300 MHz, CDCl3): δ = 8.09 (ddd, JH6′,H5′ = 5.1,
JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 7.80 (td, JH6,H2 = JH6,H4 =
1.4, JH6,H3 = 0.6 Hz, 1 H, H6), 7.74 (dtt, JH4,H3 = 7.9, JH4,H2 = JH4,H6 =
1.3 Hz, JH4,CH = JH4,NH = 0.7 Hz, 1 H, H4), 7.65 (dt, JH2,H3 = 7.9, JH2,H4 =
JH2,H6 = 1.4 Hz, 1 H, H2), 7.50 (t, JH3,H2 = JH3,H4 = 7.5 Hz, 1 H, H3),
7.45 (ddd, JH4′,H3′ = 8.3, JH4′,H5′ = 7.1 Hz, JH4′,H6′ = 1.8 Hz, 1 H, H4′),
6.69 (dddd, JH5′,H4′ = 7.2, JH5′,H6′ = 5.0 Hz, JH6′,H5′ = 0.9 Hz, JH6′,NH =
0.3 Hz, 1 H, H5′), 6.53 (ddd, JH3′,H4′ = 8.4, JH3′,H5′ = JH3′,NH = 0.7 Hz,
1 H, H3′), 6.01 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.04 (d, JNH,CH =
8.7 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –73.60 (d,
JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 155.77
(C2′), 148.11 (C6′), 138.02 (C4′), 136.57 (d, JC,F = 1.1 Hz, C5), 132.77
(C4), 132.68 (C2), 132.05–131.64 (m, C6), 129.83 (C3), 124.98 (q, JC,F =
281.7 Hz, CF3), 118.56 (CN), 115.38 (C5′), 113.31 (C1), 109.22 (C3′),
55.92 (q, JC,F = 30.6 Hz, CH) ppm. HRMS (ESI+): m/z calcd. for
C14H11N3F3+ [M + H]+ 278.0905; found 278.0898. HPLC (0.1 % TFA,
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 10.30 min,
λ = 214 nm.
4-[2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl]benzonitrile (2c):
(4-Cyanophenyl)magnesium chloride was prepared in accordance
with TP3 from 4-bromobenzonitrile (91 mg, 0.50 mmol) in 2 h at
0 °C. The addition reaction was performed in accordance with TP4
with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2c as a light yel-
low oil (85 mg, 68 %). Rf = 0.45 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1). 1H NMR (300 MHz, CDCl3): δ = 8.08 (ddd, JH6′,H5′ = 5.0,
JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 7.72–7.65 (m, 2 H, H2,
H6), 7.64–7.59 (m, 2 H, H3, H5), 7.44 (ddd, JH4′,H3′ = 8.3, JH4′,H5′ =
7.2 Hz, JH4′,H6′ = 1.9 Hz, 1 H, H4′), 6.68 (ddd, JH5′,H4′ = 7.2, JH5′,H6′ =
5.0 Hz, JH6′,H5′ = 0.9 Hz, 1 H, H5′), 6.51 (dt, JH3′,H4′ = 8.3, J = 0.9 Hz,
1 H, H3′), 6.01 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.06 (d, JNH,CH =
8.9 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –73.38 (d,
JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 155.81
(C2′), 148.09 (C6′), 140.02 (d, JC,F = 0.9 Hz, C4), 138.01 (C4′), 129.07
(q, JC,F = 1.2 Hz, C3, C5), 128.17 (C2, C6), 124.96 (q, JC,F = 281.8 Hz,
CF3), 118.50 (CN), 115.36 (C5′), 113.13 (C1), 109.15 (C3′), 56.23 (q,
JC,F = 30.6 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N3F3+
[M + H]+ 278.0905; found 278.0897. HPLC (0.1 % TFA, 0 min: 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 7.28 min, λ = 214 nm.
N-[1-(3-Chlorophenyl)-2,2,2-trifluoroethyl]pyridin-2-amine (2d):
(3-Chlorophenyl)magnesium chloride was prepared in accordance
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with TP3 from 1-bromo-3-chlorobenzene (96 mg, 0.50 mmol) in 3 h
at 0 °C. The addition reaction was performed in accordance with
TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 3 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2d as a light yel-
low oil (97 mg, 75 %). Rf = 0.40 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1). 1H NMR (400 MHz, CDCl3): δ = 8.11 (dddd, JH6,H5 = 5.1,
JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, JH6,NH = 0.3 Hz, 1 H, H6), 7.48 (ddt,
JH2′,H6′/H4′ = 1.9, JH2′,H6′/H4′ = 1.3 Hz, JH2′,H5′ = JH2′,CH = 0.7 Hz, 1 H,
H2′), 7.44 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4),
7.39–7.36 (m, 1 H, H6′), 7.36–7.29 (m, 2 H, H4′, H5′), 6.68 (ddd,
JH5,H4 = 7.2, JH5,H6 = 5.0 Hz, JH6,H5 = 0.9 Hz, 1 H, H5), 6.49 (dt, JH3,H4 =
8.3, JH3,H5 = JH3,NH = 0.9 Hz, 1 H, H3), 5.95–5.85 (m, 1 H, CH), 5.00
(d, JNH,CH = 9.4 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ =
–80.36 (d, JCF3,CH = 4.6 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3):
δ = 156.19 (C2), 148.25 (C6), 138.05 (C4), 136.57 (d, JC,F = 1.0 Hz,
C1′), 135.05 (C3′), 130.39 (C5′), 129.47 (C4′), 128.45 (q, JC,F = 1.2 Hz,
C2′), 126.56 (q, JC,F = 1.2 Hz, C6′), 129.59–120.84 (CF3), 115.24 (C5),
109.04 (C3), 56.13 (q, JC,F = 30.7 Hz, CHCF3) ppm. HRMS (ESI+): m/z
calcd. for C14H11N3F3+ [M + H]+ 287.0557; found 287.0557. HPLC
(0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR =
11.35 min, λ = 214 nm.
N-[1-(4-Chlorophenyl)-2,2,2-trifluoroethyl]pyridin-2-amine (2e):
(4-Chlorophenyl)magnesium chloride was prepared in accordance
with TP3 from 1-bromo-4-chlorobenzene (96 mg, 0.50 mmol) in 2 h
at 0 °C. The addition reaction was performed in accordance with
TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2e as a light yel-
low oil (85 mg, 66 %). Rf = 0.40 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1). 1H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, JH6,H5 = 5.1,
JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47–7.38 (m, 3 H, H4,
H2′, H6′), 7.38–7.33 (m, 2 H, H3′, H5′), 6.67 (dddd, JH5,H4 = 7.2,
JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, JH5,NH = 0.3 Hz, 1 H, H5), 6.47 (dt,
JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 5.87 (dq, JCH,NH = 8.7, JCH,CF3 =
7.9 Hz, 1 H, CH), 4.99 (d, JNH,CH = 9.0 Hz, 1 H, NH) ppm. 19F NMR
(282 MHz, CDCl3): δ = –73.88 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 156.20 (C2), 148.16 (C6), 137.93 (C4), 135.16
(C4′), 133.35–133.04 (m, C1′), 129.55 (q, JC,F = 1.2 Hz, C2′, C6′),
129.26 (C3′, C5′), 125.22 (q, JC,F = 281.8 Hz, CF3), 115.10 (C5), 108.88
(C3), 56.04 (q, JC,F = 30.6 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd.
for C13H11ClN2F3+ [M + H]+ 287.0563; found 287.0557. HPLC (0.1 %
TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR =
11.43 min, λ = 214 nm.
N-{2,2,2-Trifluoro-1-[4-(trifluoromethyl)phenyl]ethyl}pyridin-2-
amine (2f): [4-(Trifluoromethyl)phenyl]magnesium chloride was
prepared in accordance with TP3 from 1-bromo-4-(trifluoro-
methyl)benzene (113 mg, 0.50 mmol) in 2 h at 0 °C. The addition
reaction was performed in accordance with TP4 with N-(1-ethoxy-
2,2,2-trifluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol) at –30 °C
in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acet-
ate/NEt3, 8:1:0.1) furnished 2f as a light yellow oil (105 mg, 73 %).
R f = 0.50 (cyclohexane/ethyl acetate/NEt3 , 8:1:0.1). 1H NMR
(300 MHz, CDCl3): δ = 8.10 (d, JH6,H5 = 4.0 Hz, 1 H, H6), 7.66 (d,
JH3′,H2′ = JH5′,H6′ = 8.9 Hz, 2 H, H3′, H5′), 7.61 (d, JH2′,H3′ = JH6′,H5′ =
8.8 Hz, 2 H, H2′, H6′), 7.44 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 =
1.9 Hz, 1 H, H4), 6.68 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.0 Hz, JH5,H3 =
0.9 Hz, 1 H, H5), 6.50 (dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 6.00 (p,
JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.04 (d, JNH,CH = 8.9 Hz, 1 H,
NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –62.84 (s, CCF3), –73.60
(d, JCF3,CH = 7.9 Hz, CHCF3) ppm. 13C NMR (75 MHz, CDCl3): δ =
156.03 (C2), 148.14 (C6), 138.69 (C1′), 138.00 (C4), 131.38 (q, JC,F =
32.3 Hz, C4′), 128.68 (q, JC,F = 1.2 Hz, C2′, C6′), 126.00 (q, JC,F =
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3.8 Hz, C3′, C5′), 125.13 (q, JC,F = 282.3 Hz, CHCF3), 124.09 (q, JC,F =
272.2 Hz, CCF3), 115.26 (C5), 109.02 (C3), 56.21 (q, JC,F = 30.6 Hz,
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N2F3+ [M + H]+
321.0826; found 321.0820. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 11.98 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(pyridin-2-yl)ethyl]pyridin-2-amine (2g):
Pyridin-2-ylmagnesium chloride was prepared in accordance with
TP3 from 2-bromopyridine (50 µL, 0.55 mmol) in 2 h at 0 °C. The
addition reaction was performed in accordance with TP4 with N-
(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol)
at –30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/
ethyl acetate/NEt3, 8:1:0.1) furnished 2g as a light yellow oil (71 mg,
62 %). Rf = 0.35 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR
(300 MHz, CDCl3): δ = 8.64 (ddd, JH6′,H5′ = 4.9, JH6′,H4′ = 1.8 Hz, J =
1.0 Hz, 1 H, H6′), 8.12 (ddd, JH6,H5 = 5.1, JH6,H4 = 1.9 Hz, J = 0.9 Hz,
1 H, H6), 7.78–7.67 (m, 1 H, H4′), 7.48–7.39 (m, 2 H, H3′, H4), 7.30
(ddd, JH5′,H4′ = 7.6, JH5′,H6′ = 4.9 Hz, JH5′,H3′ = 1.2 Hz, 1 H, H5′), 6.67–
6.59 (m, 2 H, H3, H5), 6.17 (d, JNH,CH = 8.5 Hz, 1 H, NH), 6.08 (p,
JCH,NH = JCH,CF3 = 7.4 Hz, 1 H, CH) ppm. 19F NMR (282 MHz, CDCl3):
δ = –74.10 (d, JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3):
δ = 156.75 (C2), 152.26 (C2′), 149.49 (C6′), 147.76 (C6), 137.59 (C4),
136.89 (C4′), 125.08 (q, JC,F = 281.8 Hz, CF3), 124.39 (C3′), 124.00
(C5′), 114.56 (C5), 109.77 (C3), 55.83 (q, JC,F = 31.0 Hz, CHCF3) ppm.
HRMS (ESI+): m/z calcd. for C12H11F3N3+ [M + H]+ 254.0900; found
254.0899. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 9.13 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(pyridin-3-yl)ethyl] pyridin-2-amine (2h):
Pyridin-3-ylmagnesium chloride was prepared in accordance with
TP3 from 3-bromopyridine (50 µL, 0.55 mmol) in 2 h at 0 °C. The
addition reaction was performed in accordance with TP4 with N-
(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol)
at –30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/
ethyl acetate/NEt3, 8:1:0.1) furnished 2h as a light yellow oil (79 mg,
69 %). Rf = 0.50 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR
(600 MHz, CDCl3): δ = 8.75 (d, JH2′,H4′ = 2.2 Hz, 1 H, H2′), 8.60 (dd,
JH6′,H5′ = 4.8, JH6′,H4′ = 1.6 Hz, 1 H, H6′), 8.10 (ddd, JH6,H5 = 5.1,
JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.81 (dt, JH4′,H5′ = 8.2,
JH4′,H2′ = JH4′,H6′ = 1.8 Hz, 1 H, H4′), 7.43 (ddd, JH4,H3 = 8.8, JH4,H5 =
7.3 Hz, JH4,H6 = 1.8 Hz, 1 H, H4), 7.32 (ddd, JH5′,H4′ = 8.0, JH5′,H6′ =
4.8 Hz, JH5′,H2′ = 1.0 Hz, 1 H, H5′), 6.68 (ddd, JH5,H4 = 7.1, JH5,H6 =
5.1 Hz, JH5,H3 = 1.0 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.4, J = 1.0 Hz,
1 H, H3), 6.02 (p, JCH,CF3 = JCH,NH = 8.2 Hz, 1 H, CH), 5.14 (d, JNH,CH =
9.0 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –74.63 (q, J =
8.0 Hz, CF3) ppm. 13C NMR (151 MHz, CDCl3): δ = 155.74 (C2), 150.14
(C6′), 149.59 (C2′), 147.85 (C6), 137.76 (C4), 135.41 (C4′), 130.51
(C3′), 124.94 (q, JC,F = 281.8 Hz, CF3), 123.62 (C5′), 115.02 (C5), 108.91
(C3), 54.37 (q, JC,F = 31.0 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd.
for C12H11N3F3+ [M + H]+ 254.0905; found 254.0899. HPLC (0.1 %
TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR =
10.33 min, λ = 214 nm.
N-[1-(6-Chloropyridin-3-yl)-2,2,2-trifluoroethyl]-6-methyl-
pyridin-2-amine (2i): (6-Chloropyridin-3-yl)magnesium chloride
was prepared in accordance with TP3 from 5-bromo-3-chloropyr-
idine (218 mg, 1.13 mmol) in 1 h at 0 °C. The addition reaction was
performed in accordance with TP4 with N-(1-ethoxy-2,2,2-trifluoro-
ethyl)-6-methylpyridin-2-amine (100 mg, 0.43 mmol) at 0 °C in 5 h.
Flash column chromatography (SiO2, cyclohexane/ethyl acetate/
NEt3, 20:1:0.1) furnished 2i as a white solid (84 mg, 65 %). Rf =
0.40 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1), m.p. 74 °C. 1H NMR
(600 MHz, CDCl3): δ = 8.53 (s, 1 H, H2′), 7.77 (dd, JH4′,H5′ = 8.4,
JH4′,CH = 2.4 Hz, 1 H, H4′), 7.35 (d, JH5′,H4′ = 8.0 Hz, 1 H, H5′), 7.32 (d,
JH5,H4 = 8.2 Hz, 1 H, H4), 6.60–6.47 (d, JH5,H4 = 7.0 Hz, 1 H, H5), 6.29
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(d, JH5,H4 = 8.2 Hz, 1 H, H3), 5.95 (p, JCH,CF = JCH,NH = 8.1 Hz, 1 H,
CH), 4.92 (d, JNH,CH = 8.7 Hz, 1 H, NH), 2.35 (s, 3 H, CH3) ppm. 19F
NMR (282 MHz, CDCl3): δ = –73.59 (d, JCF3,CH = 8.1 Hz, CF3) ppm.
13C NMR (150 MHz, CDCl3): δ = 157.18 (C6), 154.96 (C2), 152.05
(C6′), 149.85 (C2′), 138.23 (C4, C4′), 129.92 (C3′), 124.88 (q, JC,F =
281.3 Hz, CF3), 124.52 (C5′), 114.56 (C5), 105.54 (C3), 54.22 (q, JC,F =
31.2 Hz, CHCF3), 24.40 (CH3) ppm. HRMS (ESI+): m/z calcd. for
C13H12ClF3N3+ [M + H]+ 302.0666; found 302.0664. HPLC (0.1 % TFA,
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 10.50 min,
λ = 214 nm.
N-[2,2,2-Trifluoro-1-(perfluorophenyl)ethyl]pyridin-2-amine
(2j): (Perfluorophenyl)magnesium chloride was prepared from 1-
bromo-2,3,4,5,6-pentafluorobenzene (60 µL, 0.50 mmol) dissolved
in THF (0.50 mL). iPrMgCl (1.25 M, 0.44 mL, 0.55 mL) was added
dropwise at –78 °C and the reaction mixture was stirred for 45 min.
The addition reaction was performed in accordance with TP4 with
N-(1-ethoxy-2,2,2-trif luoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –78 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2j as a light yel-
low oil (131 mg, 85 %). Rf = 0.45 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1). 1H NMR (400 MHz, CDCl3): δ = 8.13 (ddd, JH6,H5 = 5.2,
JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47 (ddd, JH4,H3 = 8.3,
JH4,H5 = 7.2 Hz, JH3,H6 = 1.9 Hz, 1 H, H4), 6.72 (ddd, JH5,H4 = 7.2,
JH5,H6 = 5.2 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.72–6.63 (m, 1 H, CH), 6.55
(dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 5.21 (d, JNH,CH = 10.6 Hz, 1 H,
NH) ppm. 19F NMR (376 MHz, CDCl3): δ = –74.63 (q, J = 7.9 Hz, CF3),
–141.29 (s, F2′, F6′), –152.01 (tt, JF4′,F3′ = JF4′,F5′ = 20.9, JF4′,F2′ =
JF4′,F6′ = 2.7 Hz, F4′), –160.80 (td, JF5′,F4′ = JF5′,F6′ = JF3′,F2′ = JF3′,F4′ =
22.0, JF5′,F3′ = JF3′,F5′ = 7.8 Hz, F5′, F3′) ppm. 13C NMR (101 MHz,
CDCl3): δ = 155.30 (C2), 148.07 (C6), 147.54–144.58 (m, C2′, C6′),
143.52–140.32 (m, C3′, C5′), 138.12 (C4), 139.48–136.17 (m, C4′),
124.44 (q, JC,F = 282.9 Hz, CF3), 115.66 (C5), 109.47 (C3), 109.21–
108.71 (m, C1′), 48.11 (q, JC,F = 34.3 Hz, CHCF3) ppm. HRMS (ESI+):
m/z calcd. for C13H7N2F8+ [M + H]+ 343.0481; found 343.0474. HPLC
(0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR =
14.56 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)ethyl]pyridin-2-
amine (2k): (4-Methylnaphthalen-1-yl)magnesium chloride was
prepared in accordance with TP3 from 1-bromo-4-methylnaphth-
alen (158 mg, 0.50 mmol) in 18 h at 25 °C. The addition reaction
was performed in accordance with TP4 with N-(1-ethoxy-2,2,2-tri-
fluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol) at 25 °C in 18 h.
Flash column chromatography (SiO2, cyclohexane/ethyl acetate/
NEt3, 8:1:0.1) furnished 2k as a light yellow oil (83 mg, 58 %). Rf =
0.45 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR (400 MHz,
CDCl3): δ = 8.29–8.22 (m, 1 H, H8′), 8.17 (dddd, JH6,H5 = 5.1, JH6,H4 =
1.9 Hz, JH6,H3 = 0.9 Hz, JH6,NH = 0.3 Hz, 1 H, H6), 8.09–8.03 (m, 1 H,
H5′), 7.64 (dd, JH2′,H3′ = 7.3, JH2′,CH = 1.2 Hz, 1 H, H2′), 7.62–7.54 (m,
2 H, H6′, H7′), 7.39 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz,
1 H, H4), 7.35 (dd, JH3′,H2′ = 7.4, JH3′,CH3 = 0.9 Hz, 1 H, H3′), 6.81 (p,
JCH,CF3 = JCH,NH = 7.7 Hz, 1 H, CH), 6.66 (ddd, JH5,H4 = 7.2, JH5,H6 =
5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.41 (dt, JH3,H4 = 8.3, J = 0.9 Hz,
1 H, H3), 5.04 (d, JNH,CH = 8.8 Hz, 1 H, NH), 2.71 (d, JCH3,C3′ = 0.9 Hz,
3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –80.38 (d, JCF3,CH =
4.7 Hz, CHCF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 156.56 (C2),
148.34 (C6), 137.95 (C4), 136.25 (C8′a), 133.31 (C4′a), 132.02 (C4′),
129.29 (d, JC,F = 1.0 Hz, C1′), 126.93 (C7′), 126.39 (C3′), 126.23 (C6′),
126.11 (q, JC,F = 282.9 Hz, CF3), 125.31 (C5′), 124.88 (q, JC,F = 1.8 Hz,
C2′), 123.94 (d, JC,F = 0.9 Hz, C8′), 114.88 (C5), 108.70 (C3), 51.67 (q,
JC,F = 30.6 Hz, CH), 20.04 (CH3) ppm. HRMS (ESI+): m/z calcd. for
C18H16F3N2+ [M + H]+ 317.1260; found 317.1262. HPLC (0.1 % TFA,
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 12.09 min,
λ = 214 nm.
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N-[1-(2,4-Dimethoxypyrimidin-5-yl)-2,2,2-trifluoroethyl]pyridin-
2-amine (2l): (2,4-Dimethoxypyrimidin-5-yl)magnesium chloride
was prepared in accordance with TP3 from 5-bromo-2,4-dimethoxy-
pyrimidine (110 mg, 0.50 mmol) in 1 h at 0 °C. The addition reaction
was performed in accordance with TP4 with N-(1-ethoxy-2,2,2-tri-
fluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol) at –30 °C in 2 h.
Flash column chromatography (SiO2, cyclohexane/ethyl acetate/
NEt3, 8:1:0.1) furnished 2l as a light yellow oil (120 mg, 85 %). Rf =
0.40 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR (400 MHz,
CDCl3): δ = 8.30 (s, 1 H, H6′), 8.11 (ddd, JH6,H5 = 5.1, JH6,H4 = 1.8 Hz,
JH6,H3 = 0.8 Hz, 1 H, H6), 7.43 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz,
JH4,H6 = 1.9 Hz, 1 H, H4), 6.66 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.1 Hz,
JH5,H3 = 0.9 Hz, 1 H, H5), 6.49 (dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3),
6.07 (dqd, JCH,NH = 9.7, JCH,CF3 = 8.0 Hz, JCH,H5 = 0.5 Hz, H, CH), 5.34
(d, JNH,CH = 9.6 Hz, 1 H, NH), 4.07 (s, 3 H, OCH3), 3.99 (s, 3 H,
OCH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –74.27 (d, JCF3,CH =
8.0 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 169.61 (C4′),
165.72 (C2′), 159.12 (q, JC,F = 1.1 Hz, C6′), 156.22 (C2), 148.20 (C6),
137.99 (C4), 125.29 (q, JC,F = 282.6 Hz, CF3), 115.08 (C5), 109.07 (C3),
108.68 (d, JC,F = 1.2 Hz, C5′), 55.29 (OCH3), 54.82 (OCH3), 50.95 (q,
JC,F = 32.4 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N3F3+
[M + H]+ 315.1063; found 315.1064. HPLC (0.1 % TFA, 0 min: 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 9.46 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(thiophen-2-yl)ethyl]pyridin-2-amine (2m):
Thiophen-2-ylmagnesium chloride was prepared in accordance with
TP3 from 2-bromothiophene (0.05 mL, 0.50 mmol) in 2 h at 0 °C.
The addition reaction was performed in accordance with TP4 with
N-(1-ethoxy-2,2,2-trif luoroethyl)pyridin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2m as a colorless
oil (84 mg, 72 %). Rf = 0.60 (cyclohexane/ethyl acetate, 10:1). 1H
NMR (400 MHz, CDCl3): δ = 8.15 (dddd, JH6,H5 = 5.1, JH6,H4 = 1.8 Hz,
JH6,H3 = 0.8 Hz, JH6,NH = 0.3 Hz, 1 H, H6), 7.45 (ddd, JH4,H3 = 8.3,
JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.30 (dd, JH5′,H4′ = 5.1,
JH5′,H3′ = 1.2 Hz, 1 H, H5′), 7.21 (ddt, JH3′,H4′ = 3.6, JH3′,H5′ = 1.3 Hz,
JH3′,CH = 0.7 Hz, 1 H, H3′), 7.02 (dd, JH4′,H5′ = 5.1, JH4′,H3′ = 3.6 Hz,
1 H, H4′), 6.70 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H,
H5), 6.51 (dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 6.30 (dqd, JCH,NH =
9.5, JCH,CF3 = 7.6 Hz, J = 0.8 Hz, 1 H, CH), 4.87 (d, JNH,CH = 9.5 Hz,
1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –74.72 (d, JCF3,CH =
7.7 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 156.04 (C2), 148.07
(C6), 137.98 (C4), 137.13–137.08 (m, C2′), 127.43 (C4′), 127.21 (q,
JC,F = 1.3 Hz, C3′), 126.15 (C5′), 124.95 (q, JC,F = 281.9 Hz, CF3),
115.22 (C5), 109.07 (C3), 52.28 (q, JC,F = 32.2 Hz, CHCF3) ppm. HRMS
(ESI+): m/z calcd. for C11H10N2F3+ [M + H]+ 259.0517; found
259.05113. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 10.10 min, λ = 214 nm.
N-[1-(Benz[b]thiophen-3-yl)-2,2,2-trifluoroethyl]pyridin-2-
amine (2n): Benzo[b]thiophen-3-ylmagnesium chloride was pre-
pared in accordance with TP3 from 3-bromobenz[b]thiophene
(107 mg, 0.50 mmol) in 3 h at 0 °C. The addition reaction was
performed in accordance with TP4 with N-(1-ethoxy-2,2,2-trifluoro-
ethyl)pyridin-2-amine (100 mg, 0.45 mmol) at –30 °C in 3 h. Flash
column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/
NEt3, 50:1:0.1 → 15:1:0.1) furnished 2n as a yellow oil (115 mg,
83 %). Rf = 0.40 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1). 1H NMR
(300 MHz, CDCl3): δ = 8.22 (ddd, JH6,H5 = 5.0, JH6,H4 = 1.9 Hz, JH6,H3 =
0.9 Hz, 1 H, H6), 7.86 (dddd, JH4′,H5′ = JH7′,H6′ = 6.8, JH4′,H6′ = JH7′,H5′ =
5.4 Hz, JH4′,H7′ = JH7′,H4′ = 3.3 Hz, JH4′,H2′ = JH7′,H2′ = 0.7 Hz, 2 H,
H4′, H7′), 7.62 (dd, JH2′,CH = 1.5, JH2′,H4′ = JH2′,H7′ = 0.7 Hz, 1 H, H2′),
7.43 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.40–
7.35 (m, 2 H, H5′, H6′), 6.71 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.1 Hz, JH5,H3 =
0.9 Hz, 1 H, H5), 6.44 (dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 6.54 (dqd,
Eur. J. Org. Chem. 2016, 930–945 www.eurjoc.org © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim939
JCH,NH = 9.9, JCH,CF3 = 7.6 Hz, JCH,H2′ = 0.8 Hz, 1 H, CH), 4.79 (d,
JNH,CH = 9.3 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –73.10
(d, JCF3,CH = 7.6, JCF3,NH = 1.1 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3):
δ = 156.09 (C2), 147.85 (C6), 139.97 (C7′a), 137.90 (C3′a), 137.69 (C4),
129.24 (d, JC,F = 1.1 Hz, C3′), 125.43 (q, JC,F = 282.6 Hz, CF3), 124.94
(C2′), 124.89 (C5′), 124.61 (C6′), 122.77 (C4′), 121.94 (C7′), 114.73
(C5), 108.62 (C3), 50.20 (q, JC,F = 31.8 Hz, CHCF3) ppm. HRMS (ESI+):
m/z calcd. for C15H12F3N3S+ [M + H]+ 309.0668; found 309.0667.
HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 11.71 min, λ = 214 nm.
N-(1-Cyclopropyl-2,2,2-trifluoroethyl)pyridin-2-amine (2o): The
addition reaction was performed in accordance with TP4 with N-
(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (100 mg, 0.45 mmol)
and cyclopropylmagnesium bromide (1.0 M, 0.55 mL, 0.55 mmol) at
0 °C in 2 h. Flash column chromatography (SiO2, gradient: cyclohex-
ane/ethyl acetate/NEt3, 50:1:0.1 → 10:1:0.1) furnished 2o as a white
solid (83 mg, 85 %). Rf = 0.45 (cyclohexane/ethyl acetate/NEt3,
8:1:0.1), m.p. 77 °C, 1H NMR (300 MHz, CDCl3): δ = 8.07 (ddd, JH6,H5 =
5.1, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.42 (ddd, JH4,H3 = 8.3,
JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.63 (ddd, JH5,H4 = 7.2,
JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.44 (dt, JH3,H4 = 8.4, JH3,H5 =
JH3,H6 = 0.9 Hz, 1 H, H3), 4.47 (d, JNH,CH = 9.5 Hz, 1 H, NH), 4.36–4.17
(m, 1 H, CH), 1.17–1.04 [m, 1 H, CH(CH2)2], 0.76–0.63 (m, 1 H, CH2),
0.61–0.49 (m, 2 H, CH2), 0.46–0.32 (m, 1 H, CH2) ppm. 19F NMR
(282 MHz, CDCl3): δ = –75.58 (d, JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 157.26 (C2), 147.98 (C6), 137.81 (C4), 126.26
(q, JC,F = 283 Hz, CF3), 114.47 (C5), 108.50 (C3), 55.82 (q, JC,F =
29.3 Hz, CHCF3), 10.86 [q, JC,F = 2.3 Hz, CH(CH2)2], 3.82 (d, JC,F =
0.9 Hz, CH2), 1.91 (CH2) ppm. HRMS (ESI+):m/z calcd. for C10H12F3N2+
[M + H]+ 217.0953; found 217.0946. HPLC (0.1 % TFA, 0 min: 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 9.14 min, λ = 214 nm.
4-[2,2,2-Trifluoro-1-(pyrazin-2-ylamino)ethyl]benzonitrile (2p):
(4-Cyanophenyl)magnesium chloride was prepared in accordance
with TP3 from 4-bromobenzonitrile (91 mg, 0.50 mmol) in 2 h at
0 °C. The addition reaction was performed in accordance with TP4
with N-(1-ethoxy-2,2,2-trifluorethyl)pyrazin-2-amine (100 mg,
0.45 mmol) at –30 °C in 2 h. Flash column chromatography (SiO2,
gradient: cyclohexane/ethyl acetate, 10:1 → 3:1) furnished 2p as a
light yellow oil (70 mg, 56 %). Rf = 0.37 (cyclohexane/ethyl acetate,
1:1). 1H NMR (600 MHz, CDCl3): δ = 8.07 (d, JH3′,H6′ = 1.5 Hz, 1 H,
H3′), 8.00 (dd, JH6′,H5′ = 2.7, JH6′,H3′ = 1.5 Hz, 1 H, H6′), 7.93 (d,
JH5′,H6′ = 2.7 Hz, 1 H, H5′), 7.72–7.67 (m, 2 H, H3, H5), 7.61 (d, J =
8.1 Hz, 2 H, H2, H6), 5.97 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.48
(d, JNH,CH = 8.8 Hz, 1 H, NH) ppm. 19F NMR (280 MHz, CDCl3): δ =
–73.33 (d, JCF3,CH = 7.7 Hz, CF3) ppm. 13C NMR (150 MHz, CDCl3):
δ = 152.18 (C2′), 141.71 (C6′), 139.01 (C1), 135.19 (C5′), 133.32
(C3′), 132.77 (C3, C5), 128.98 (C2, C6), 124.41 (q, JC,F = 281.8 Hz,
CF3), 118.27 (CN), 113.32 (C4), 55.48 (q, JC,F = 31.0 Hz, CHCF3) ppm.
HRMS (ESI+): m/z calcd. for C13H10F3N4+ [M + H]+ 279.0852; found
279.0852. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 13.16 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(pyridin-2-yl)ethyl]pyrazin-2-amine (2q):
Pyridin-2-ylmagnesium chloride was prepared in accordance with
TP3 from 2-bromopyridine (50 µL, 0.55 mmol) in 2 h at 0 °C. The
addition reaction was performed in accordance with TP4 with N-
(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (100 mg, 0.45 mmol)
at –30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/
ethyl acetate/NEt3, 8:1:0.1) furnished 2q as a light yellow oil (65 mg,
56 %). Rf = 0.48 (cyclohexane/ethyl acetate, 1:1). 1H NMR (300 MHz,
CDCl3): δ = 8.68–8.62 (m, 1 H, H6′), 8.13–8.10 (m, 1 H, H3), 8.03
(ddd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, J = 0.5 Hz, 1 H, H6), 7.89 (dt,
JH5,H6 = 2.7, J = 0.5 Hz, 1 H, H5), 7.75 (tdd, JH4′,H3′ = JH4′,H5′ = 7.7,
Full Paper
J = 1.8 Hz, J = 0.5 Hz, 1 H, H4′), 7.46 (dd, JH3′,H4′ = 8.1, JH3′,H5′ =
1.3 Hz, 1 H, H3′), 7.39–7.31 (m, 1 H, H5′), 6.51 (d, JNH,CH = 8.2 Hz,
1 H, NH), 6.00 (m, 1 H, CH) ppm. 19F NMR (280 MHz, CDCl3): δ =
–74.15 (d, JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ =
153.08 (C2), 151.21 (C2′), 149.52 (C6′), 141.53 (C6), 137.08 (C4′),
134.46 (C5), 134.03 (C3), 124.78 (q, JC,F = 283.3 Hz, CF3), 124.33 (C3′/
C5′), 124.29 (C3′/C5′), 55.16 (q, JC,F = 31.1 Hz, CHCF3) ppm. HRMS
(ESI+): m/z calcd. for C11H10F3N4+ [M + H]+ 255.0852; found
255.0852. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 10.98 min, λ = 214 nm.
N-[1-(2,4-Dimethoxypyrimidin-5-yl)-2,2,2-trifluoroethyl]pyr-
azine-2-amine (2r): (2,4-Dimethoxypyrimidin-5-yl)magnesium
chloride was prepared in accordance with TP3 from 5-bromo-2,4-
dimethoxypyrimidine (77 mg, 0.35 mmol) in 1 h at 0 °C. The addi-
tion reaction was performed in accordance with TP4 with N-(1-
ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (66 mg, 0.3 mmol) at
–30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/
ethyl acetate/NEt3, 8:1:0.1) furnished 2r as a light yellow oil (75 mg,
79 %). Rf = 0.24 (cyclohexane/ethyl acetate/NEt3, 6:4:0.1). 1H NMR
(400 MHz, CDCl3): δ = 8.30 (s, 1 H, H6′), 8.05–8.00 (m, 2 H, H3, H5),
7.92 (d, JH6,H5 = 2.6 Hz, 1 H, H6), 6.04 (dq, JCH,NH = 9.6, JCH,CF3 =
7.9 Hz, 1 H, CH), 5.60 (d, JNH,CH = 9.6 Hz, 1 H, NH), 4.09 (s, 3 H,
OCH3), 4.00 (s, 3 H, OCH3) ppm. 19F NMR (376 MHz, CDCl3): δ =
–74.21 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (100 MHz, CDCl3):
δ = 169.38 (C4′), 165.71 (C2′), 159.08 (C6′), 152.39 (C2), 141.69 (C6),
134.94 (C5), 133.29 (C3), 124.84 (q, JC,F = 282.6 Hz, CF3), 107.71
(C5 ′ ) , 55.28 (OCH3 ) , 54.74 (OCH3 ) , 50.41 (q, JC,F = 33.0 Hz,
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C12H13F3N5O2+ [M + H]+
316.1016; found 316.1014.
N-[2,2,2-Trifluoro-1-(thiophen-2-yl)ethyl]pyrazin-2-amine (2s):
Thiophen-2-ylmagnesium chloride was prepared in accordance with
TP3 from 2-bromothiophene (0.07 mL, 0.70 mmol) in 2 h at 0 °C.
The addition reaction was performed in accordance with TP4 with
N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazine-2-amine (100 mg,
0.45 mmol) at –30 °C in 8 h. Flash column chromatography (SiO2,
cyclohexane/ethyl acetate/NEt3, 8:1:0.1) furnished 2s as a light red
oil (64 mg, 55 %). Rf = 0.38 (cyclohexane/ethyl acetate/NEt3, 4:2:0.1).
1H NMR (400 MHz, CDCl3): δ = 8.06 (ddd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz,
J = 0.4 Hz, 1 H, H6), 8.03 (dd, JH3,H6 = 1.5, J = 0.4 Hz, 1 H, H3), 7.95
(dd, JH5,H6 = 2.8, J = 0.4 Hz, 1 H, H5), 7.33 (dd, JH5′,H4′ = 5.1, JH5′,H3′ =
1.2 Hz, 1 H, H5′), 7.22 (ddt, JH3′,H4′ = 3.6, JH3′,H5′ = 1.3 Hz, JH3′,CH =
0.7 Hz, 1 H, H3′), 7.04 (dd, JH4′,H5′ = 5.1, JH4′,H3′ = 3.6 Hz, 1 H, H4′),
6.27 (dqd, JCH,NH = 9.4, JCH,CF3 = 7.4 Hz, JCH,H3′ = 0.8 Hz, 1 H, CH),
5.11 (d, JNH,CH = 9.4 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3):
δ = –74.67 (d, JCF3,CH = 7.6 Hz, CF3) ppm. 13C NMR (100 MHz, CDCl3):
δ = 152.28 (C2), 141.73 (C6), 135.84 (C2′), 135.12 (C5), 133.21 (C3),
127.51 (q, JC,F = 1.3 Hz, C3′), 127.45 (C4′), 126.44 (C5′), 124.58 (q,
JC,F = 281.9 Hz, CF3), 51.60 (q, JC,F = 32.7 Hz, CHCF3) ppm. HRMS
(ESI+): m/z calcd. for C11H10N2F3+ [M + H]+ 260.0464; found
260.0463. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 13.50 min, λ = 214 nm.
N-[1-(Benz[b]thiophen-3-yl)-2,2,2-trifluoroethyl]pyrazine-2-
amine (2t): Benzo[b]thiophen-3-ylmagnesium chloride was pre-
pared in accordance with TP3 from 3-bromobenz[b]thiophene
(192 mg, 0.90 mmol) in 3 h at 0 °C. The addition reaction was
performed in accordance with TP4 with N-(1-ethoxy-2,2,2-trifluoro-
ethyl)pyrazin-2-amine (100 mg, 0.45 mmol) at 0 °C in 6 h. Flash
column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/
NEt3, 20:1:0.1 → 8:1:0.1) furnished 2t as a yellow oil (120 mg, 86 %).
Rf = 0.38 (cyclohexane/ethyl acetate/NEt3 , 2:1:0.05). 1H NMR
(300 MHz, CDCl3): δ = 8.13 (dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, 1 H,
H6), 7.96 (d, JH5,H6 = 2.8 Hz, 2 H, H3, H5), 7.92–7.85 (m, 1 H, H5′),
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7.82–7.75 (m, 1 H, H8′), 7.67–7.62 (m, 1 H, H2′), 7.46–7.32 (m, 2 H,
H6′, H7′), 6.59–6.42 (m, 1 H, CH), 5.02 (d, JNH,CH = 9.1 Hz, 1 H,
NH) ppm. 19F NMR (282 MHz, CDCl3): δ = –73.06 (dd, JCF3,CH = 7.5,
JCF3,NH = 1.2 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 152.58
(C2), 141.76 (C6), 140.14 (C4′, C9′), 137.84 (C3′), 134.94 (C5), 133.13
(C3), 125.53 (C2′), 125.32 (q, JC,F = 282.5 Hz, CF3), 125.24 (C6′/C7′),
124.93 (C6′/C7′), 123.07 (C5′), 121.76, 49.69 (q, JC,F = 32.3 Hz,
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M + H]+
310.0620; found 310.0619, HPLC (0.1 % TFA, 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 15.13 min, λ = 214 nm.
N-(1,1,1-Trifluoro-but-3-yn-2-yl)pyrazin-2-amine (2u): The addi-
tion reaction was performed in accordance with TP4 with N-(1-
ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (100 mg, 0.45 mmol)
and ethynylmagnesium bromide (0.5 M, 1.4 mL, 0.67 mmol) at
–78 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/
ethyl acetate/NEt3, 10:1:0.1) furnished 2u as a light yellow oil
(88 mg, 96 %). Rf = 0.46 (cyclohexane/ethyl acetate/NEt3, 8:1:0.1).
1H NMR (300 MHz, CDCl3): δ = 8.07 (dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz,
1 H, H6), 8.04 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.99 (d, JH5,H6 = 2.7 Hz,
1 H, H5), 5.82 (dqd, JCH,NH = 9.1, JCH,CF3 = 6.6 Hz, JCH,C≡CH = 2.5 Hz,
1 H, CH), 4.93 (d, JNH,CH = 9.2 Hz, 1 H, NH), 2.46 (d, JC≡CH,CH = 2.5 Hz,
1 H, C≡CH) ppm. 19F NMR (282 MHz, CDCl3): δ = –76.14 (d, JCF3,CH =
6.5 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 151.74 (C2), 141.62
(C6), 135.60 (C5), 133.34 (C3), 123.36 (q, JC,F = 281.8 Hz, CF3), 75.30
(C≡CH), 74.45 (C≡CH), 44.83 (q, JC,F = 35.8 Hz, CHCF3) ppm. HRMS
(ESI+): m/z calcd. for C8H7F3N3+ [M + H]+ 202.0587; found 202.0586.
HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 11.99 min, λ = 214 nm.
N-[2,2,2-Trifluoro-1-(perfluorophenyl)ethyl]pyrazin-2-amine
(2v): (Perfluorophenyl)magnesium chloride was prepared from 1-
bromo-2,3,4,5,6-pentafluorobenzene (90 µL, 0.70 mmol) dissolved
in THF (0.50 mL). iPrMgCl (2 M, 0.39 mL, 0.77 mL) was added drop-
wise at –78 °C and the reaction mixture was stirred for 45 min. The
addition reaction was performed in accordance with TP4 with N-
(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (100 mg, 0.45 mmol)
at –78 °C in 5 h. Flash column chromatography (SiO2, gradient: cy-
clohexane/ethyl acetate, 30:1 → 8:1) furnished 2v as a colorless oil
(143 mg, 92 %). Rf = 0.58 (cyclohexane/ethyl acetate/NEt3, 2:1:0.05).
1H NMR (300 MHz, CDCl3): δ = 8.09 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 8.06
(dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, 1 H, H6), 7.99 (d, JH5,H6 = 2.7 Hz,
1 H, H5), 6.56 (dq, JCH,NH = 10.2, JCH,CF3 = 7.8 Hz, 1 H, CH), 5.48 (d,
JNH,CH = 10.4 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ =
–74.56 (d, JCF3,CH = 7.8 Hz, CF3), –141.10 (s, F2′, F6′), –151.01 (tt,
JF4′,F3′ = JF4′,F5′ = 20.9, JF4′,F2′ = JF4′,F6′ = 2.9 Hz, F4′), –159.73 to
–160.77 (m, F5′, F3′) ppm. 13C NMR (75 MHz, CDCl3): δ = 151.71
(C2), 147.95–144.10 (m, C2′, C6′), 143.95–140.22 (m, C3′, C5′), 141.66
(C6), 139.91–135.96 (m, C4′), 135.71 (C5), 133.45 (C3), 124.04 (q,
JC,F = 281.9 Hz, CF3), 108.30–107.72 (m, C1′), 47.60 (q, JC,F = 34.3 Hz,
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M + H]+
344.0428; found 344.0427. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 15.72 min, λ = 214 nm.
N-(4-Cyclopropyl-1,1,1-trifluorobut-3-yn-2-yl)pyrazin-2-amine
(2w): (Cyclopropylethynyl)magnesium chloride was prepared from
ethynylcyclopropane (45 µL, 0.54 mmol) in THF (1 mL), which was
treated with nBuMgBr (2.0 M in Et2O, 0.27 mL, 0.54 mmol) for 2 h
at 0 °C. The addition reaction was performed in accordance with
TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (100 mg,
0.45 mmol) and (cyclopropylethynyl)magnesium chloride at –20 °C
in 2 h. Flash column chromatography (SiO2, gradient: cyclohexane/
ethyl acetate/NEt3, 10:1:0.1 → 4:1:0.05) furnished 2w as a colorless
oil (87 mg, 80 %). Rf = 0.38 (cyclohexane/ethyl acetate/NEt3,
2:1:0.05). 1H NMR (400 MHz, CDCl3): δ = 8.05 (ddd, JH6,H5 = 2.8,
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JH6,H3 = 1.5 Hz, J = 0.4 Hz, 1 H, H6), 8.00 (dd, JH3,H6 = 1.5, J = 0.4 Hz,
1 H, H3), 7.95 (dd, JH5,H6 = 2.8, J = 0.4 Hz, 1 H, H5), 5.74–5.62 (m,
1 H, NHCH), 4.81 (d, JNH,CH = 9.2 Hz, 1 H, NH), 1.32–1.20 (m, 1 H,
CH), 0.85–0.77 (m, 2 H, CH2), 0.75–0.69 (m, 2 H, CH2) ppm. 19F NMR
(282 MHz, CDCl3): δ = –76.45 (d, JCF3,CH = 6.6 Hz, CF3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 152.04 (C2), 141.65 (C6), 135.10 (C5), 133.20
(C3), 123.66 (q, JC,F = 281.7 Hz, CF3), 90.12 [C≡C-CH(CH2)2], 66.43
[C≡C-CH(CH2)2], 45.15 (q, JC,F = 35.4 Hz, CHCF3), 8.42 (2 × CH2), –0.58
[C≡C-CH(CH2)2] ppm. HRMS (ESI+): m/z calcd. for C11H11F3N3+ [M +
H]+ 242.0900; found 242.0898. HPLC (0.1 % TFA, 0 min: 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 13.83 min, λ = 214 nm.
N-(1,1-Difluoropropan-2-yl)pyridine-2-amine (3a): In accordance
with TP5, hemiaminal ether 1b (100 mg, 0.50 mmol) was treated
with MeMgBr (1.4 M in toluene/THF, 3:1, 0.78 mL, 1.09 mmol) in dry
THF (5 mL) for 2 h at 0 °C. The crude product was purified by flash
chromatography (SiO2, cyclohexane/ethyl acetate/NEt3, 100:10:1) to
give desired amine 3a (61 mg, 72 %) as an orange, amorphous solid.
Rf = 0.70 (cyclohexane/ethyl acetate, 1:1). 1H NMR (300 MHz, CDCl3):
δ = 8.09 (ddd, JH6,H5 = 5.1, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6),
7.41 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.61
(ddd, JH5,H4 = 7.2, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.42 (dt,
JH3,H4 = 8.4, JH3,H6 = JH3,H5 = 0.9 Hz, 1 H, H3), 5.90 (ddd, JF,H = 57.7,
JF,H = 55.7 Hz, JCHF2,CH = 2.0 Hz, 1 H, CHF2), 4.54–4.36 (m, 1 H, CH),
4.32 (br. s, 1 H, NH), 1.30 (dt, JCH3,CH = 6.7, J = 1.0 Hz, 3 H, CH3) ppm.
19F NMR (282 MHz, CDCl3): δ = –125.78 (ddd, JF,F = 280.1, JF,H =
55.6 Hz, JCHF2,CH = 6.8 Hz, CHF2), –134.19 (ddt, JF,F = 280.2, JF,H =
57.9 Hz, JCHF2,CH = 20.4 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3):
δ = 157.28 (C2), 148.10 (C6), 137.57 (C4), 115.65 (dd, JC,F = 245.4,
JC,F = 244.2 Hz, CHF2), 113.92 (C5) 108.47 (C3), 48.23 (dd, JC,F = 26.1,
JC,F = 21.7 Hz, CH), 12.79 (CH3) ppm. HRMS (ESI+): m/z calcd. for
C8H11F2N2+ [M + H]+ 173.0885; found 173.0885. HPLC (0.1 % TFA;
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 3.55 min,
λ = 214 nm.
N-(1,1-difluoropropan-2-yl)pyrazin-2-amine (3b): In accordance
with TP5, hemiaminal ether 1d (100 mg, 0.49 mmol) was treated
with MeMgBr (1.4 M in toluene/THF, 3:1, 0.77 mL, 1.08 mmol) in dry
THF (5 mL) for 1.5 h at 0 °C. The crude product was purified by
preparative HPLC [0.1 % TFA; 0 min: 4 % MeCN (B) → 15 min: 100 %
B, flow: 20 mL/min, tR = 16.51 min] to give desired amine 3b (80 mg,
94 %) as a colorless oil. Rf = 0.36 (cyclohexane/ethyl acetate, 1:1).
1H NMR (400 MHz, CDCl3): δ = 8.01–7.91 (m, 2 H, H3, H6), 7.85 (d,
JH5,H6 = 2.8 Hz, 1 H, H5), 5.89 (ddd, JH,F = 57.4, JH,F = 55.4 Hz,
JCHF2,CH = 2.0 Hz, 1 H, CHF2), 4.61 (br. s, 1 H, NH), 4.55–4.39 (m, 1 H,
CH), 1.32 (d, JCH3,CH2 = 6.9 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz,
CDCl3): δ = –126.59 (ddd, JF,F = 281.4, JF,H = 55.4 Hz, JCHF2,CH =
7.8 Hz, CHF2), –133.24 (ddd, JF,F = 281.5, JF,H = 57.4 Hz, JCHF2,CH =
19.3 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 153.52 (C2),
141.78 (C6), 133.82 (C5), 133.13 (C3), 115.17 (t, JC,F = 244.8 Hz, CHF2),
47.83 (dd, JC,F = 26.2, JC,F = 21.8 Hz, CH), 12.84 (dd, JC,F = 5.7, JC,F =
2.1 Hz, CH3) ppm. HRMS (ESI+): m/z calcd. for C7H10F2N3+ [M + H]+
174.0837; found 174.0837. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 10.16 min, λ = 214 nm.
N-(1,1-Difluoropropan-2-yl)-3,5-bis(trifluoromethyl)aniline (3c):
In accordance with TP5, hemiaminal ether 1f (101 mg, 0.30 mmol)
was treated with MeMgBr (1.4 M in toluene/THF, 3:1, 0.47 mL,
0.69 mmol) in dry THF (5 mL) for 3 h at 0 °C. The crude product was
purified by flash chromatography (SiO2, cyclohexane/ethyl acetate/
NEt3, 100:5:1) to give desired amine 3c (65 mg, 71 %) as a colorless
oil. Rf = 0.64 (cyclohexane/ethyl acetate, 5:1). 1H NMR (400 MHz,
CDCl3): δ = 7.21 (s, 1 H, H4), 7.00 (s, 2 H, H2, H6), 5.79 (ddd, JH,F =
56.2, JH,F = 55.5 Hz, JCHF2,CH = 2.6 Hz, 1 H, CHF2), 4.06 (d, JNH,CH =
9.0 Hz, 1 H, NH), 3.98–3.79 (m, 1 H, CH), 1.34 (dt, JCH3,CH2 = 6.7,
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JCH3,CH = 1.1 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ =
63.30 (2 × CF3), –127.08 (ddd, JF,F = 282.9, JF,H = 55.6 Hz, JCHF2,CH =
9.9 Hz, CHF2), –128.03 (ddd, JF,F = 282.9, JF,H = 56.2 Hz, JCHF2,CH =
14.0 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 147.31 (C1),
132.87 (q, JC,F = 33.0 Hz, C3, C5), 123.53 (q, JC,F = 272.7 Hz, 2 × CF3),
115.69 (t, JC,F = 245.8 Hz, CHF2), 112.62 (m, C2, C6), 111.57 (dq, J =
3.9 Hz, C4), 50.63 (dd, JC,F = 24.0, JC,F = 22.6 Hz, CH), 13.81
(CH3) ppm. HRMS (ESI–): m/z calcd. for C11H8F8N– [M – H]– 306.0534;
found 306.0538. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min: 100 % B,
flow: 1 mL/min): tR = 19.89 min, λ = 214 nm.
N-(1,1-Difluorohexan-2-yl)-2,3,4,5,6-pentafluoroaniline (3d): In
accordance with TP5, hemiaminal ether 1g (113 mg, 0.39 mmol)
was treated with nBuMgBr (2.0 M in Et2O, 0.43 mL, 0.85 mmol) in
dry THF (5 mL) for 1.5 h at 0 °C. Desired amine 3d (108 mg, 92 %)
was isolated after workup as a yellow liquid without further purifica-
tion. Rf = 0.80 (cyclohexane/ethyl acetate, 7:1). 1H NMR (400 MHz,
CDCl3): δ = 5.79 (td, JH,F = 55.7, JCHF2,CH = 2.1 Hz, 1 H, CHF2), 3.88–
3.70 (m, 1 H, CH), 3.46 (d, JNH,CH = 10.7 Hz, 1 H, NH), 1.82–1.68 (m,
1 H, CH2), 1.60–1.45 (m, 2 H, CH2), 1.42–1.33 (m, 2 H, CH2), 0.93 (t,
JCH3,CH2 = 7.2 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ =
–127.32 (ddd, JF,F = 282.6, JF,H = 55.8 Hz, JCHF2,CH = 13.0 Hz, CHF2),
–129.96 (ddt, JF,F = 282.6, JF,H = 55.6 Hz, JCHF2,CH = 13.0 Hz, CHF2),
–158.23 (d, JF2,F3 = JF6,F5 = 21.8 Hz, F2, F6), –163.86 (td, JF5,F4 =
JF5,F6 = JF3,F2 = JF3,F4 = 21.8, JF5,F3 = JF3,F5 = 6.4 Hz, F3, F5), –169.88
(td, JF4,F3 = JF4,F5 = 21.9, J = 6.0 Hz, F4) ppm. 13C NMR (101 MHz,
CDCl3): δ = 140.07–137.12 (m), 136.10–132.99 (m), 123.47–122.92
(m), 116.28 (t, JC,F = 245.1 Hz, CHF2), 57.35 (ddt, JC,F = 24.0, JC,F =
20.4 Hz, JC,F = 3.6 Hz, CH), 29.21 (CH2), 27.79 (CH2), 22.55 (CH2),
13.99 (CH3) ppm. HRMS (ESI–): m/z calcd. for C12H11F7N– [M – H]–
302.0785; found 302.0787. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 21.58 min, λ = 214 nm.
N-(1,1-Difluorohexan-2-yl)pyridine-2-amine (3e): In accordance
with TP5, hemiaminal ether 1b (100 mg, 0.50 mmol) was treated
with nBuMgBr (2.0 M in Et2O, 0.54 mL, 1.08 mmol) in dry THF (5 mL)
for 2.5 h at 0 °C. The crude product was purified by flash chroma-
tography (SiO2, cyclohexane/ethyl acetate/NEt3, 100:10:1) to give
desired amine 3e (72 mg, 68 %) as a white solid. Rf = 0.88 (cyclohex-
ane/ethyl acetate, 1:1), m.p. 30 °C. 1H NMR (400 MHz, CDCl3): δ =
8.07 (ddd, JH6,H5 = 5.1, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.40
(ddd, JH4,H3 = 8.4, JH4,H5 = 7.1 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.60 (ddd,
JH5,H4 = 7.1, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.43 (dt, JH3,H4 =
8.4, JH3,H6 = JH3,H5 = 1.0 Hz, 1 H, H3), 5.87 (ddd, JH,F = 57.3, JH,F =
55.9 Hz, JCHF2,CH = 1.9 Hz, 1 H, CHF2), 4.42–4.19 (m, 2 H, CH, NH),
1.92–1.75 (m, 1 H, CH2), 1.58–1.40 (m, 2 H, CH2), 1.42–1.28 (m, 3 H,
CH2), 0.89 (t, JCH3,CH = 7.2 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz,
CDCl3): δ = –126.07 (ddd, JF,F = 279.8, JF,H = 55.6 Hz, JCHF2,CH =
8.6 Hz, CHF2), –131.59 (ddt, JF,F = 280.0, JF,H = 57.2 Hz, JCHF2,CH =
18.4 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 157.87 (C2),
148.07 (C6), 137.58 (C4), 115.86 (t, JC,F = 244.6 Hz, CHF2), 113.74 (C5)
108.16 (C3), 52.45 (dd, JC,F = 24.4, JC,F = 21.1 Hz, CH), 27.91 (CH2),
27.48 (CH2), 22.70 (CH2), 14.02 (CH3) ppm. HRMS (ESI+): m/z calcd.
for C11H17F2N2+ [M + H]+ 215.1354; found 215.1354. HPLC (0.1 %
TFA; 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 9.96 min,
λ = 214 nm.
N-(1,1-Difluorohexan-2-yl)pyrazin-2-amine (3f): In accordance
with TP5, hemiaminal ether 1d (100 mg, 0.49 mmol) was treated
with nBuMgBr (2.0 M in Et2O, 0.54 mL, 1.08 mmol) in dry THF (5 mL)
for 1.5 h at 0 °C. The crude product was purified by flash chroma-
tography (SiO2 , gradient: cyclohexane/ethyl acetate/NEt3 ,
100:10:1 → 100:15:1) to give desired amine 3f (112 mg, quant.) as
a yellow oil. Rf = 0.61 (cyclohexane/ethyl acetate, 1:1). 1H NMR
(400 MHz, CDCl3): δ = 7.97 (dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, 1 H,
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H6), 7.94 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.84 (d, JH5,H6 = 2.8 Hz, 1 H,
H5), 5.86 (ddd, JH,F = 56.9, JH,F = 55.6 Hz, JCHF2,CH = 2.0 Hz, JCHF2,NH =
1.3 Hz, 1 H, CHF2), 4.56 (d, JNH,CH = 8.9 Hz, 1 H, NH), 4.48–4.30 (m,
1 H, CH), 1.90–1.77 (m, 2 H, CH2), 1.62–1.24 (m, 4 H, 2 × CH2), 0.89
(t, JCH3,CH2 = 7.1 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ =
–126.96 (ddd, JF,F = 281.2, JF,H = 55.6 Hz, JCHF2,CH = 10.6 Hz, CHF2),
–130.63 (ddt, JF,F = 281.1, JF,H = 56.9 Hz, JCHF2,CH = 17.4 Hz,
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 154.14 (C2), 141.78 (C6),
133.69 (C5), 132.93 (C3), 115.43 (t, JC,F = 244.8 Hz, CHF2), 51.93 (dd,
JC,F = 24.1, JC,F = 21.0 Hz, CH), 27.82 (CH2), 27.45 (CH2), 22.59 (CH2),
13.97 (CH3) ppm. HRMS (ESI+): m/z calcd. for C10H16F2N3+ [M + H]+
216.1307; found 216.1307. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 14.57 min, λ = 214 nm.
N-(1,1-Difluorohexan-2-yl)-3,5-bis(trifluoromethyl)aniline (3 g):
In accordance with TP5, hemiaminal ether 1f (100 mg, 0.30 mmol)
was treated with nBuMgBr (2.0 M in Et2O, 0.33 mL, 0.65 mmol) in
dry THF (5 mL) for 2 h at 0 °C. Desired amine 3g (100 mg, 96 %)
was isolated after workup as an orange liquid without further purifi-
cation. 1H NMR (600 MHz, CDCl3): δ = 7.20 (s, 1 H, H4), 7.00 (s, 2 H,
H2, H6), 5.79 (td, JH,F = 55.7, JCHF2,CH = 2.5 Hz, 1 H, CHF2), 3.99 (d,
JNH,CH = 9.3 Hz, 1 H, NH), 3.78–3.66 (m, 1 H, CH), 1.86–1.77 (m, 1 H,
CH2), 1.58–1.46 (m, 2 H, CH2), 1.43–1.30 (m, 3 H, CH2), 0.96–0.89 (m,
3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = –63.33 (2 × CF3),
–126.33 (ddd, JF,F = 282.7, JF,H = 55.8 Hz, JCHF2,CH = 12.3 Hz, CHF2),
–128.03 (ddd, JF,F = 282.7, JF,H = 55.7 Hz, JCHF2,CH = 12.3 Hz,
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 148.08 (C1), 132.83 (q,
JC,F = 32.9 Hz, C3, C5), 123.56 (q, JC,F = 272.6 Hz, 2 × CF3), 115.80 (t,
JC,F = 245.7 Hz, CHF2), 112.40 (m, C2, C6), 111.35 (C4), 55.12 (t, JC,F =
21.8 Hz, CH), 28.76 (CH2), 27.86 (CH2), 22.65 (CH2), 13.94 (CH3) ppm.
HRMS (ESI–): m/z calcd. for C14H14F8N– [M – H]– 348.1004; found
348.1010. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 21.70 min, λ = 214 nm.
N-(1,1-Difluoro-1-phenylethyl)-2,3,4,5,6-pentafluoroaniline
(3h): In accordance with TP5 , hemiaminal ether 1g (91 mg,
0.31 mmol) was treated with PhMgBr (3 M in Et2O, 0.23 mL,
0.69 mmol) in dry THF (5 mL) for 4 h at 0 °C. The crude product was
purified by flash chromatography (SiO2, cyclohexane/NEt3, 100:1)
to give desired amine 3h (51 mg, 50 %) as a yellow oil. Rf = 0.56
(cyclohexane/ethyl acetate, 7:1). 1H NMR (400 MHz, CDCl3): δ =
7.42–7.31 (m, 5 H, 5 × HPhenyl), 6.07 (ddd, JH,F = 55.8, JH,F = 55.0 Hz,
JCHF2,CH = 2.3 Hz, 1 H, CHF2), 4.96 (tdd, JCH,F = 13.5, JCH,NH = 10.6 Hz,
JCH,CHF2 = 2.2 Hz, 1 H, CH), 4.33 (d, JNH,CH = 10.5 Hz, 1 H, NH) ppm.
19F NMR (376 MHz, CDCl3): δ = –125.23 (ddd, JF,F = 282.4, JF,H =
55.9 Hz, JCHF2,CH = 14.0 Hz, CHF2), –129.32 (ddt, JF,F = 282.2, JF,H =
55.0 Hz, JCHF2,CH = 13.6 Hz, CHF2), –157.21 (dd, JF2,F3 = JF6,F5 = 21.0,
JF2,F4 = JF6,F4 = 4.0 Hz, F2, F6), –163.40 (td, JF5,F4 = JF5,F6 = JF3,F2 =
JF3,F4 = 21.6, JF5,F3 = JF3,F5 = 4.4 Hz, 2 F, F3, F5), –168.14 (td, JF4,F3 =
JF4,F5 = 21.9, J = 4.8 Hz, F4) ppm. 13C NMR (101 MHz, CDCl3): δ =
140.06–137.38 (m), 139.48–136.64 (m), 136.26–133.48 (m), 134.41
(C1Phenyl), 129.08 (CPhenyl), 129.02 (CPhenyl), 127.48 (CPhenyl), 121.68–
121.40 (m, CPhenyl), 115.22 (dd, JC,F = 248.1, JC,F = 246.1 Hz, CHF2),
61.17 (tt, JC,F = 21.5, JC,F = 4.1 Hz, CH) ppm. HRMS (ESI–): m/z calcd.
for C14H7F7N– [M – H]– 322.0472; found 322.0474. HPLC (0.1 % TFA;
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 19.82 min,
λ = 214 nm.
N-(1,1-Difluoro-1-phenylethyl)pyridine-2-amine (3i): In accord-
ance with TP5, hemiaminal ether 1b (100 mg, 0.49 mmol) was
treated with PhMgBr (3 M in Et2O, 0.36 mL, 1.07 mmol) in dry THF
(5 mL) for 2 h at 0 °C. The crude product was purified by flash
chromatography (SiO2, cyclohexane/ethyl acetate/NEt3, 100:10:1) to
give desired amine 3i (118 mg, quant.) as a colorless oil. Rf = 0.83
(cyclohexane/ethyl acetate, 1:1). 1H NMR (400 MHz, CDCl3): δ = 8.10
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(ddd, JH6,H5 = 5.0, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47–7.43
(m, 2 H, 2 × HPhenyl), 7.43–7.32 (m, 4 H, 3 × HPhenyl, H4), 6.63 (ddd,
JH5,H4 = 7.1, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.43 (dt, JH3,H4 =
8.4, JH3,H6 = JH3,H5 = 1.0 Hz, 1 H, H3), 6.12 (td, JH,F = 55.9, JCHF2,CH =
2.4 Hz, 1 H, CHF2), 5.48–5.33 (m, 1 H, CH), 5.07 (d, JNH,CH = 7.9 Hz,
1 H, NH) ppm. 19F NMR (376 MHz, CDCl3): δ = –126.42 (ddd, JF,H =
56.0, JF,H = 33.8 Hz, JCHF2,CH = 14.7 Hz, CHF2) ppm. 13C NMR
(101 MHz, CDCl3): δ = 157.13 (C2), 148.17 (C6), 137.66 (C4), 135.43
(C1Phenyl), 128.91 (CPhenyl), 128.61 (CPhenyl), 128.06 (CPhenyl), 115.51 (t,
JC,F = 246.6 Hz, CHF2), 114.34 (C5) 108.43 (C3), 57.15 (t, JC,F = 22.1 Hz,
CH) ppm. HRMS (ESI+) : m/z calcd. for C13H13F2N2+ [M + H]+
235.1041; found 235.1041. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 8.77 min, λ = 214 nm.
N-(1,1-difluoro-1-phenylethyl)pyrazin-2-amine (3j): In accord-
ance with TP5, hemiaminal ether 1d (100 mg, 0.49 mmol) was
treated with PhMgBr (3 M in Et2O, 0.39 mL, 1.08 mmol) in dry THF
(5 mL) for 1.5 h at 0 °C. The crude product was purified by flash
chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3,
100:6:1 → 100:25:1) to give desired slightly impure amine 3j
(145 mg, quant.). A fraction of the product was further purified by
preparative HPLC [0.1 % TFA; 0 min: 4 % MeCN (B) → 30 min: 100 %
B, flow: 20 mL/min, tR = 19.37 min] to give desired amine 3j as a
colorless oil. Rf = 0.55 (cyclohexane/ethyl acetate, 1:1). 1H NMR
(400 MHz, CDCl3): δ = 7.99 (dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, 1 H,
H6), 7.98 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.86 (d, JH5,H6 = 2.7 Hz, 1 H,
H5), 7.45–7.33 (m, 5 H, 5 × HPhenyl), 6.11 (ddd, JH,F = 56.0, JH,F =
55.2 Hz, JCHF2,CH = 2.3 Hz, 1 H, CHF2), 5.52–5.42 (m, 1 H, CH), 5.35
(d, JNH,CH = 8.2 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ =
–125.38 (ddd, JF,F = 280.3, JF,H = 56.1 Hz, JCHF2,CH = 15.3 Hz, CHF2),
–127.47 (ddd, JF,F = 280.3, JF,H = 55.2 Hz, JCHF2,CH = 13.7 Hz,
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 153.21 (C2), 141.73 (C6),
134.68 (C1Phenyl) 134.12 (C5), 132.90 (C3), 128.90 (CPhenyl), 128.72
(CPhenyl), 127.80 (CPhenyl), 115.08 (t, JC,F = 246.2 Hz, CHF2), 56.35 (dd,
JC,F = 22.6, JC,F = 21.3 Hz, CH) ppm. HRMS (ESI+): m/z calcd. for
C12H12F2N3+ [M + H]+ 236.0994; found 236.0994. HPLC (0.1 % TFA;
0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR = 13.59 min,
λ = 214 nm.
4-[2,2-Difluoro-1-(pyridin-2-ylamino)ethyl]benzonitrile (3k): (4-
Cyanophenyl)magnesium chloride was prepared from 4-bromo-
benzonitrile (82 mg, 0.45 mmol) and iPrMgCl·LiCl (1.25 M in THF,
0.36 mL, 0.45 mmol) in accordance with TP3 within 3 h at 0 °C. In
accordance with TP4 , a solution of N-(1-ethoxy-2,2-difluor-
oethyl)pyridine-2-amine 1b (76 mg, 0.38 mmol) in dry THF (5 mL)
was treated with LiHMDS (1 M in THF, 0.38 mL, 0.38 mmol) at –78 °C.
The Grignard reagent was added after 15 min and the reaction
mixture was stirred at –30 °C for 4 h. After workup and flash chro-
matography (SiO2, gradient: cyclohexane/ethyl acetate, 20:1 → 5:1)
desired amine 3k (60 mg, 56 %) was furnished as a light yellow oil.
Rf = 0.47 (cyclohexane/ethyl acetate, 2:1). 1H NMR (400 MHz, CDCl3):
δ = 8.06 (d, JH6′,H5′ = 5.1 Hz, 1 H, H6′), 7.74–7.63 (d, JH3,H2 = JH5,H6 =
8.4 Hz, 2 H, H3, H5), 7.58 (d, JH2,H3 = JH6,H5 = 7.9 Hz, 2 H, H2, H6),
7.48–7.38 (t, JH4′,H3′ = JH4′,H5′ = 7.7 Hz, 1 H, H4′), 6.66 (dd, JH5′,H4′ =
7.2, JH5′,H6′ = 5.2 Hz, 1 H, H5′), 6.48 (d, JH3′,H4′ = 8.3 Hz, 1 H, H3′),
6.12 (td, JH,F = 55.7, JCHF2,CH = 2.4 Hz, 1 H, CHF2), 5.67–5.48 (m, 1 H,
CH), 5.11 (d, JNH,CH = 8.2 Hz, 1 H, NH) ppm. 19F NMR (376 MHz,
CDCl3): δ = –124.67 (ddd, JF,F = 282.9, JF,H = 55.1 Hz, JCHF2,CH =
11.2 Hz, CHF2), –127.41 (ddd, JF,F = 282.8, JF,H = 56.2 Hz, JCHF2,CH =
18.2 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 156.39 (C2′),
148.05 (C6′), 140.97 (C1), 137.85 (C4′), 132.54 (C3, C5), 129.00 (C2,
C6), 118.60 (CN), 114.96 (t, JC,F = 247.0 Hz, CHF2), 114.85 (C5′),
112.51 (C4), 108.86 (C3′), 56.61 (dd, JC,F = 23.7, JC,F = 21.1 Hz,
CH) ppm. HRMS (ESI+) : m/z calcd. for C14H12F2N3+ [M + H]+
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260.0994; found 260.0996. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 9.56 min, λ = 214 nm.
N-[2,2-Difluoro-1-(pyridin-2-yl)ethyl]pyridin-2-amine (3l): Pyr-
idin-2-ylmagnesium chloride was prepared from 2-bromopyridine
(43 µL, 0.45 mmol) and iPrMgCl·LiCl (1.25 M in THF, 0.36 mL,
0.45 mmol) in accordance with TP3 within 2 h at 0 °C. In accordance
with TP4, a solution of N-(1-ethoxy-2,2-difluoroethyl)pyridine-2-
amine (1b; 76 mg, 0.38 mmol) in dry THF (5 mL) was treated with
LiHMDS (1 M in THF, 0.38 mL, 0.38 mmol) at –78 °C. The Grignard
reagent was added after 15 min and the reaction mixture was
stirred at –30 °C for 4 h. After workup and flash chromatography
(SiO2, gradient: cyclohexane/ethyl acetate, 10:1 → 5:1) desired
amine 3l (39 mg, 44 %) was furnished as a light yellow oil. Rf = 0.26
(cyclohexane/ethyl acetate, 3:1). 1H NMR (400 MHz, CDCl3): δ = 8.56
(d, JH6′,H5′ = 4.7 Hz, 1 H, H6′), 8.04 (d, JH6,H5 = 4.9 Hz, 1 H, H6), 7.63
(td, JH4′,H3′ = JH4′,H5′ = 7.7, JH4′,H6′ = 1.7 Hz, 1 H, H4′), 7.35 (m, 2 H,
H4, H3′), 7.24–7.19 (m, 1 H, H5′), 6.56 (dd, JH5,H4 = 7.1, JH5,H6 =
5.1 Hz, 1 H, H5), 6.51 (d, JH3,H4 = 8.3 Hz, 1 H, H3), 6.34–6.00 (m, 1 H,
CHF2), 5.96 (d, JNH,CH = 7.3 Hz, 1 H, NH), 5.61–5.48 (m, 1 H, CH) ppm.
19F NMR (376 MHz, CDCl3): δ = –124.85 (ddd, JF,F = 278.5, JF,H =
55.5 Hz, JCHF2,CH = 9.6 Hz, CHF2), –129.09 (ddd, JF,F = 278.6, JF,H =
56.6 Hz, JCHF2,CH = 17.3 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3):
δ = 157.24 (C2), 153.85 (C2′), 149.31 (C6′), 147.96 (C6), 137.54 (C4),
136.76 (C4′), 123.86 (C3′), 123.41 (C5′), 115.43 (t, JC,F = 246.8 Hz,
CHF2), 114.03 (C5), 109.28 (C3), 56.93 (dd, JC,F = 24.1, JC,F = 22.7 Hz,
CH) ppm. HRMS (ESI+) : m/z calcd. for C12H12F2N3+ [M + H]+
236.0994; found 236.0997. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 7.48 min, λ = 214 nm.
N-[1-(2,4-Dimethoxypyrimidin-5-yl)-2,2-difluoroethyl]pyridin-2-
amine (3m): (2,4-Dimethoxypyrimidin-5-yl)magnesium chloride
was prepared from 5-bromo-2,4-dimethoxypyrimidine (99 mg,
0.45 mmol) and iPrMgCl·LiCl (1.25 M in THF, 0.36 mL, 0.45 mmol) in
accordance with TP3 within 3 h at 0 °C. In accordance with TP4, a
solution of N-(1-ethoxy-2,2-difluoroethyl)pyridine-2-amine (1b;
76 mg, 0.38 mmol) in dry THF (5 mL) was treated with LiHMDS (1 M
in THF, 0.38 mL, 0.38 mmol) at –78 °C. The Grignard reagent was
added after 15 min and the solution was stirred at –30 °C for 4 h.
After workup and flash chromatography (SiO2, gradient: cyclohex-
ane/ethyl acetate, 10:1 → 5:1) desired amine 3m (85 mg, 75 %) was
furnished as a light yellow oil. Rf = 0.36 (cyclohexane/ethyl acetate,
2:1). 1H NMR (400 MHz, CDCl3): δ = 8.26 (s, 1 H, H6′), 8.11–8.03 (d,
JH6,H5 = 4.0 Hz, 1 H, H6), 7.39 (ddd, JH4,H3 = 8.6, JH4,H5 = 7.2 Hz, J =
1.9 Hz, 1 H, H4), 6.61 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.0 Hz, J = 0.9 Hz,
1 H, H5), 6.46 (dt, JH3,H4 = 8.3, J = 1.0 Hz, 1 H, H3), 6.09 (td, JH,F =
56.1, JCHF2,CH = 3.1 Hz, 1 H, CHF2), 5.68–5.52 (m, 1 H, CH), 5.26 (d,
JNH,CH = 9.1 Hz, 1 H, NH), 4.04 (s, 3 H, OCH3), 3.96 (s, 3 H, OCH3) ppm.
19F NMR (376 MHz, CDCl3): δ = –125.00 (ddd, JF,F = 279.0, JF,H =
56.1 Hz, JCHF2,CH = 13.8 Hz, CHF2), –126.88 (ddd, JF,F = 279.0, JF,H =
56.0 Hz, JCHF2,CH = 13.8 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3):
δ = 169.13 (C4′), 165.33 (C2′), 158.45 (C6′), 156.70 (C2), 148.01 (C6),
137.65 (C4), 114.47 (t, JC,F = 246.0 Hz, CHF2), 114.40 (C5), 109.28
(C5′), 108.63 (C3), 55.02 (OCH3), 54.42 (OCH3), 51.16 (t, JC,F = 23.6 Hz,
CH) ppm. HRMS (ESI+): m/z calcd. for C13H15F2N4O2+ [M + H]+
297.1158; found 297.1160. HPLC (0.1 % TFA; 0 min: 4 % B → 15 min:
100 % B, flow: 1 mL/min): tR = 8.61 min, λ = 214 nm.
N-Butyl-2,2,2-trifluoro-N′-phenylethan-1,1-diamine (4a): In a
dry, argon-flushed Schlenk-flask nBuLi (2.48 M in hexane, 0.36 mL,
0.90 mmol) was slowly added to a solution of n-butylamine
(0.10 mL, 0.90 mmol) in dry n-hexane (3 mL) at 0 °C. The suspension
was stirred at 0 °C for 30 min. A solution of N-(1-ethoxy-2,2,2-tri-
fluoroethyl)pyridine-2-amine (1a; 100 mg, 0.45 mmol) in dry THF
(3 mL) was added to the reaction mixture. After stirring the reaction
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mixture for 2 h, the reaction was quenched with satd. NH4Cl solu-
tion (10 mL) and extracted with diethyl ether (3 × 20 mL). The com-
bined organic phases were dried with MgSO4, filtered, and the sol-
vent was evaporated in vacuo. Purification by flash chromato-
graphy (SiO2 , gradient : cyclohexane/ethyl acetate/NEt3 ,
100:20:1 → 100:50:1) furnished desired diamine 4a (84 mg, 75 %)
as a light yellow oil. Rf = 0.56(cyclohexane/ethyl acetate/NEt3,
2:1:0.05). 1H NMR (600 MHz, CDCl3): δ = 8.13–8.08 (d, JH6,H5 = 5.0 Hz,
1 H, H6), 7.45 (dddd, JH4,H3 = 8.2, JH4,H5 = 7.2 Hz, J = 1.9 Hz, J =
1.0 Hz, 1 H, H4), 6.68 (ddt, JH5,H4 = 7.0, JH5,H6 = 4.9 Hz, J = 0.9 Hz,
1 H, H5), 6.47 (dt, JH3,H4 = 8.4, J = 1.0 Hz, 1 H, H3), 5.49 (m, 1 H, CH),
4.57 (d, JNH,CH = 9.4 Hz, 1 H, NH), 2.72 (m, 2 H, CH2), 1.53–1.40 (m,
2 H, CH2), 1.37–1.24 (m, 2 H, CH2), 0.88 (td, JCH3,CH2 = 7.3, J = 1.1 Hz,
3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –78.80 (d, JCF3,CH =
6.1 Hz, CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 156.90 (C2), 148.04
(C6), 137.81 (C4), 124.61 (q, JC,F = 282.6 Hz, CF3), 114.76 (C5), 108.54
(C3), 65.57 (q, JC,F = 31.4 Hz, CHCF3), 45.29 (CH2), 32.21 (CH2), 20.33
(CH2), 14.00 (CH3) ppm. HRMS (ESI+): m/z calcd. for C11H18F3N3+ [M
+ H]+ 248.1369; found 248.1368. HPLC (0.1 % TFA, 0 min: 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 3.82 min, λ = 214 nm.
2,2,2-Trifluoro-N-(4-methylbenzyl)-N′-(pyridin-4-yl)ethane-
1,1-diamine (4b): In a dry, argon-flushed Schlenk-flask nBuLi (1.7 M
in hexane, 0.53 mL, 0.90 mmol) was slowly added to a solution of
4-methylbenzylamine (0.12 mL, 0.90 mmol) in dry n-hexane (4 mL)
at 0 °C. The white suspension was stirred at 0 °C for 3 h. A solution
of N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-4-amine (1h; 100 mg,
0.45 mmol) in dry THF (2 mL) was added to the reaction mixture.
After stirring the reaction mixture for 2 h at 0 °C, the solution was
quenched with satd. NH4Cl solution (10 mL) and extracted with
diethyl ether (3 × 20 mL). The combined organic phases were dried
with MgSO4, filtered, and the solvent was evaporated in vacuo. Puri-
fication by flash chromatography (SiO2, gradient: cyclohexane/ethyl
acetate, 10:1 → 5:1) furnished desired diamine 4b (116 mg, 87 %)
as a light yellow oil. Rf = 0.12 (ethyl acetate/MeOH, 10:1). 1H NMR
(400 MHz, CDCl3): δ = 8.24 (d, JH2,H3 = JH6,H5 = 5.5 Hz, 2 H, H2, H6),
7.13 (m, 4 H, H2′, H3′, H5′, H6′), 6.47–6.39 (m, 2 H, H3, H5), 4.67 (dq,
JCH,NH = 10.0, JCH,CF3 = 5.1 Hz, 1 H, CH), 4.29 (d, JNH,CH = 9.3 Hz, 1 H,
NH), 3.98–3.78 (m, 2 H, CH2), 2.35 (s, 3 H, CH3) ppm. 19F NMR
(376 MHz, CDCl3): δ = –78.91 (d, JCF3,CH = 5.1 Hz, CF3) ppm. 13C NMR
(101 MHz, CDCl3): δ = 151.39 (C4), 150.37 (C2, C6), 137.48 (C4′),
134.97 (C1′), 129.40 (C3′, C5′), 128.19 (C2′, C6′), 108.40 (C3, C5),
66.22 (q, JC,F = 32.1 Hz, CHCF3), 48.92 (CH2), 21.11 (CH3) ppm. HRMS
(ESI+): m/z calcd. for C15H17F3N3+ [M + H]+ 296.1369; found
296.13696.
N-[2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl]benzimidamide
(4c): A dry microwave vial equipped with a magnetic stirrer was
charged with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine (1a;
50 mg, 0.23 mmol) and benzamidine (27 mg, 0.23 mmol) in toluene
(2 mL). The reaction mixture was stirred at 160 °C in a CEM micro-
wave reactor that operated at 200 W (maximum power) for 1 h.
After removal of the solvent under reduced pressure, purification
by flash column chromatography (SiO2, cyclohexane/ethyl acetate,
4:1 → 1:1) afforded desired product 4c (58 mg, 86 %) as a white
solid. Rf = 0.18 (cyclohexane/ethyl acetate, 4:1), m.p. 99 – 105 °C.
1H NMR (400 MHz, CDCl3): δ = 8.09 (dd, JH6′,H5′ = 5.2, JH6′,H4′ = 1.8 Hz,
1 H, H6′), 7.75 (d, JH2,H3 = JH6,H5 = 7.4 Hz,. 2 H, H2, H6), 7.48–7.31
(m, 4 H, H4′, H3, H4, H5), 6.68 (ddd, JH5′,H4′ = 7.2, JH5′,H6′ = 5.1 Hz,
JH5′,H3′ = 1.0 Hz, 1 H, H5′), 6.49 (d, JH3′,H4′ = 8.3 Hz, 1 H, H3′), 6.20 (s,
2 H, NH) 6.12 (dq, JCH,NH = 10.0, JCH,CF3 = 6.2 Hz, 1 H, CH), 5.05 (d,
JNH,CH = 10.0 Hz, 1 H, NH) ppm. 19F NMR (376 MHz, CDCl3): δ =
–79.59 (d, JCF3,CH = 6.2 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3):
δ = 160.68 (C=NH), 156.73 (C2′), 147.24 (C6′), 138.28 (C4′), 136.54
(C1), 130.69 (C4), 128.59 (C3, C5), 127.07 (C2, C6), 124.79 (q, JC,F =
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280.8 Hz, CF3), 114.64 (C5′), 110.06 (C3′), 63.82 (q, JC,F = 31.9 Hz,
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H14F3N4+ [M + H]+
295.1165; found 295.11646. HPLC (0 .1 % TFA, 0 min : 4 %
B → 15 min: 100 % B, flow: 1 mL/min): tR = 9.78 min, λ = 214 nm.
N-(2,2,2-Trifluoro-1-methoxyethyl)pyridin-2-amine (4d): In a dry,
argon-flushed Schlenk-flask nBuLi (2.48 M in hexane, 2.00 mL,
5.00 mmol) was slowly added to a solution of MeOH (0.20 mL,
5.00 mmol) in dry n-hexane (5 mL) at 0 °C. The suspension was
stirred at 0 °C for 1 h. N-(1-Ethoxy-2,2,2-trifluoroethyl)pyridine-2-
amine (1a; 220 mg, 1.00 mmol) was added and the reaction mixture
was warmed to room temperature. After stirring the reaction mix-
ture for 48 h the solvent was evaporated in vacuo. Purification by
flash chromatography (SiO2, gradient: cyclohexane/ethyl acetate,
10:1 → 2:1) furnished desired hemiaminal ether 4d (100 mg, 49 %)
as a yellow solid. Rf = 0.51 (cyclohexane/ethyl acetate/NEt3,
2:1:0.05), m.p. 63–64 °C. 1H NMR (300 MHz, CDCl3): δ = 8.16 (d,
JH6,H5 = 5.1 Hz, 1 H, H6), 7.55–7.46 (m, 1 H, H4), 6.76 (ddd, JH5,H4 =
7.3, JH5,H6 = 5.1 Hz, J = 0.9 Hz, 1 H, H5), 6.59–6.51 (m, 1 H, H3), 5.87
(dq, JCH,NH = 10.1, JCH,CF3 = 5.0 Hz, 1 H, CH), 5.08 (d, JNH,CH = 7.6 Hz,
1 H, NH), 3.52 (s, 3 H, OCH3) ppm. 19F NMR (282 MHz, CDCl3): δ =
–80.37 (d, JCF3,CH = 5.0 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ =
156.14 (C2), 147.91 (C6), 138.34 (C4), 123.06 (q, JC,F = 282.5 Hz, CF3),
115.76 (C5), 109.18 (C3), 79.97 (q, JC,F = 33.9 Hz, CHCF3), 56.85
(OCH3) ppm. HRMS (EI): m/z calcd. for C8H9F3N2O* [M*] 206.0667;
found 206.0661. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B,
flow: 1 mL/min): tR = 8.25 min, λ = 214 nm.
N-[1-(Ethylthio)-2,2,2-trifluoroethyl]pyridin-2-amine (4e): In a
dry, argon-flushed Schlenk-flask nBuLi (1.7 M in hexane, 1.32 mL,
2.25 mmol) was slowly added to a solution of EtSH (0.17 mL,
2.25 mmol) in dry n-hexane (6 mL) at 0 °C. The white suspension
was stirred at 0 °C for 1 h. N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-
2-amine (1a; 100 mg, 0.45 mmol) was added to the reaction mixture
and the reaction was warmed to room temperature. After stirring
for 3 d, the reaction was quenched with satd. NH4Cl solution
(10 mL) and extracted with ethyl acetate (3 × 20 mL). The combined
organic phases were dried with MgSO4, filtered, and the solvent
was evaporated in vacuo. Desired product 4e (160 mg, quant.) was
obtained as a light yellow solid without further purification. Rf =
0.60 (cyclohexane/ethyl acetate, 3:1), m.p. 54 °C. 1H NMR (300 MHz,
CDCl3): δ = 8.15 (ddd, JH6,H5 = 5.0, JH6,H4 = 1.9 Hz, J = 0.9 Hz, 1 H,
H6), 7.47 (ddd, JH4,H3 = 8.3, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4),
6.72 (ddd, JH5,H4 = 7.2, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.51
(dt, JH3,H4 = 8.3, J = 0.9 Hz, 1 H, H3), 6.03 (dq, JCH,NH = 10.3, JCH,CF3 =
7.4 Hz, 1 H, CH), 4.63 (d, JNH,CH = 10.4 Hz, 1 H, NH), 2.74 (tdd,
JCH2,CH3 = 7.7, JCH2,CH3 = 6.9, J = 1.7 Hz, 2 H, CH2), 1.29 (t, JCH3,CH2 =
7.4 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –74.24 (d,
JCF3,CH = 7.5 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 155.62
(C2), 148.04 (C6), 137.94 (C4), 115.37 (C5), 109.22 (C3), 56.55 (q, JC,F =
33.0 Hz, CHCF3), 25.38 (CH2), 14.97 (CH3) ppm. HRMS (ESI+): m/z
calcd. for C9H12F3N2S+ [M + H]+ 237.0668; found 237.06672. HPLC
(0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min): tR =
10.33 min, λ = 214 nm.
N-(1-{6-[3,4-Dihydroisoquinolin-2(1H)-yl]pyridin-3-yl}-2,2,2-tri-
fluoroethyl)-6-methylpyridin-2-amine (5): N-[1-(6-Chloropyridin-
3-yl)-2,2,2-trifluoroethyl]-6-methylpyridin-2-amine (2i; 1.01 g,
3.35 mmol) and tetrahydroisoquinoline (1.76 g, 13.2 mol) were
heated to reflux in 2-propanol (40 mL) for 48 h. After removal of
the solvent the crude product was purified by preparative HPLC
[0 min: 4 % MeCN (B) → 30 min: 100 % B, flow: 20 mL/min, tR =
26.28 min] to give desired DIMN bioisostere 5 (438 mg, 33 %) as a
colorless oil. Rf = 0.35 (cyclohexane/ethyl acetate/NEt3, 4:1:0.1). 1H
NMR (600 MHz, CDCl3): δ = 8.29 (d, JH2′′,H4′′ = 2.4 Hz, 1 H, H2′′), 7.59
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(dd, JH4′′,H5′′ = 8.9, JH4′′,H2′′ = 2.3 Hz, 1 H, H4′′), 7.31 (t, JH4,H3,H5 =
7.7 Hz, 1 H, H4), 7.22–7.14 (m, 4 H, H5′, H6′, H7′, H8′), 6.66 (d,
JH5′′,H4′′ = 8.9 Hz, 1 H, H5′′), 6.52 (d, JH5,H4 = 7.3 Hz, 1 H, H5), 6.25
(d, JH3,H4 = 8.3 Hz, 1 H, H3), 5.59 (p, JCH,CF3 = JCH,NH = 8.1 Hz, 1 H,
CH), 5.12 (s, 1 H, NH), 4.70 (s, 2 H, 2 × H1′), 3.84 (t, JH3′,H4′ = 5.9 Hz,
2 H, 2 × H3′), 2.96 (t, JH4′,H3′ = 6.0 Hz, 2 H, 2 × H4′), 2.38 (s, 3 H,
CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = –74.15 (d, JCF3,CH = 8.0 Hz,
CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 158.82 (C6′′), 157.02 (C6),
155.82 (C2), 148.12 (C2′′), 138.26 (C4), 136.71 (C4′′), 135.43 (C5a′/
C8a′), 134.21 (C5a′/C8a′), 128.48 (C5′/C6′/C7′/C8′), 126.66 (C5′/C6′/
C7′/C8′), 126.41 (C5′/C6′/C7′/C8′), 125.37 (q, JC,F = 281.6 Hz, CF3),
118.23 (H3′′), 114.06 (H5), 106.49 (H5′′), 104.85 (H3), 54.83 (q, JC,F =
30.9 Hz, CHCF3), 47.15 (C1′), 42.59 (C3′), 29.10 (C4′), 24.30 (CH3) ppm.
HRMS (ESI+): m/z calcd. for C22H22F3N4+ [M + H]+ 399.1791; found
399.1787. HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow:
1 mL/min): tR = 10.06 min, λ = 214 nm.
2-[(1-Ethoxy-2,2,2-trifluoroethyl)amino]benzonitrile (1i): In ac-
cordance with TP2, 2-aminobenzonitrile (2.00 g, 17.0 mmol), TFAE
(2.58 mL, 22.0 mmol), and pTSA·H2O (160 mg, 0.86 mmol) were
solved in EtOH (20 mL) and the reaction mixture was heated to
reflux for 6 h until no further conversion was observed. After re-
moval of the solvent under reduced pressure, flash column chroma-
tography (SiO2, cyclohexane/ethyl acetate, 20:1) furnished hemi-
aminal ether 1i (1.46 g, 35 %) as a colorless solid. Rf = 0.29 (cyclo-
hexane/ethyl acetate, 10:1), m.p. 31 °C. 1H NMR (400 MHz, CDCl3):
δ = 7.52–7.43 (m, 2 H, H4, H6), 6.90 (m, 2 H, H3, H6), 5.16–5.06 (m,
1 H, CH), 4.99 (d, JNH,CH = 9.5 Hz, 1 H, NH), 3.85–3.59 (m, 2 H, CH2),
1.25 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3):
δ = –80.14 (d, JCF3,CH = 4.2 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3):
δ = 147.13 (C2), 134.53 (C4), 133.25 (C6), 122.60 (q, JC,F = 283.7 Hz,
CF3), 120.01 (C5), 116.90 (C≡N), 112.93 (C3), 98.68 (C1), 81.76 (q,
JC,F = 34.4 Hz, CHCF3), 64.93 (CH2), 15.03 (CH3) ppm. HRMS (ESI–):
m/z calcd. for C11H10F3N2O– [M – H]– 243.0751; found 243.07511.
HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 17.69 min, λ = 214 nm.
2-[(1-Ethoxy-2,2,2-trifluoroethyl)amino]benzothioamide (8): By
following a literature procedure,[15] 2-[(1-ethoxy-2,2,2-trifluoro-
ethyl)amino]benzonitrile (1i; 448 mg, 2.00 mmol), MgCl2 (190 mg,
2.00 mmol), and NaHS·H2O (296 mg, 4.00 mmol) were solved in dry
dimethylformamide (DMF; 8 mL). The reaction mixture was stirred
at room temperature for 1.5 h. After complete conversion, the reac-
tion was quenched with distilled water and extracted with ethyl
acetate (3 × 30 mL). The aqueous phase was acidified (pH 6.5) with
an aqueous solution of HCl (1 N) and extracted with ethyl acetate
(3 × 30 mL) again. The combined organic phases were dried with
MgSO4. After filtration and removal of the solvent desired thioamide
8 (570 mg, quant.) was obtained as a yellow oil without further
purification. Rf = 0.34 (cyclohexane/ethyl acetate, 3:1). 1H NMR
(400 MHz, [D6]DMSO): δ = 9.83 (d, J = 158.6 Hz, 2 H, NH2), 7.71 (d,
JNH,CH = 10.1 Hz, 1 H, NH), 7.30 (t, JH4,H3 = JH4,H5 = 7.8 Hz, 1 H, H4),
7.24 (d, JH6,H5 = 7.7 Hz, 1 H, H6), 7.10 (d, JH3,H4 = 8.3 Hz, 1 H, H3),
6.80 (t, JH5,H4 = JH5,H6 = 7.5 Hz, 1 H, H5), 5.73 (dq, JCH,NH = 10.0,
JCH,CF3 = 4.8 Hz, 1 H, CH), 3.78–3.55 (m, 2 H, CH2), 1.11 (t, JCH2,CH3 =
7.0 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, [D6]DMSO): δ = –79.31
(d, JCF3,CH = 4.8 Hz, CF3) ppm. 13C NMR (101 MHz, [D6]DMSO): δ =
199.51 (C=S), 143.21 (C2), 131.09 (C4), 127.12 (C6), 126.49 (C1),
123.38 (q, JC,F = 283.8 Hz, CF3), 118.20 (C5), 113.59 (C3), 80.12 (q,
JC,F = 32.3 Hz, CHCF3), 63.51 (CH2), 15.08 (CH3) ppm. HRMS (ESI–):
m/z calcd. for C11H12F3N2OS– [M – H]– 277.0628; found 277.06283.
HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 16.29 min, λ = 214 nm.
2-(Trifluoromethyl)-2,3-dihydroquinazoline-4(1H)-thione (7): 2-
[(1-Ethoxy-2,2,2-trifluoroethyl)amino]benzothioamide (8; 40 mg,
Full Paper
0.14 mmol) was solved in dry THF (2 mL) with molecular sieves (4 Å)
and cooled to 0 °C. KOtBu (16 mg, 0.14 mmol) was added and the
reaction mixture was stirred at room temperature for 48 h. After
complete conversion of the starting material, the reaction was
quenched with distilled water, extracted with diethyl ether (3 ×
20 mL) and dried with MgSO4. After filtration and removal of the
solvent desired dihydroquinazoline thione 7 (28 mg, 86 %) was fur-
nished by crystallization from CH2Cl2/cyclohexane as yellow crys-
tals. 1H NMR (400 MHz, [D6]DMSO): δ = 10.67 (d, JNH,CH = 5.0 Hz,
1 H, NH), 8.07 (dd, JH5,H6 = 8.1, JH5,H7 = 1.6 Hz, 1 H, H5), 7.81 (d,
JNH,CH = 4.0 Hz, 1 H, NH), 7.33 (ddd, JH7,H8 = 8.5, JH7,H6 = 7.2 Hz,
JH7,H5 = 1.6 Hz, 1 H, H7), 6.82 (dd, JH8,H7 = 8.2, JH8,H6 = 1.1 Hz, 1 H,
H8), 6.73 (ddd, JH6,H5 = 8.1, JH6,H7 = 7.2 Hz, JH6,H8 = 1.1 Hz, 1 H, H6),
5.43 (dt, JCH,CF3 = 6.7, JCH,NH = 4.7 Hz, 1 H, CH) ppm. 19F NMR
(376 MHz, [D6]DMSO): δ = –80.74 (d, JCF3,CH = 6.6 Hz, CF3) ppm. 13C
NMR (101 MHz, [D6]DMSO): δ = 190.73 (C=S), 141.12 (C8a), 134.53
(C7), 131.24 (C5), 123.33 (q, JC,F = 291.7 Hz, CF3), 118.77 (C4a), 118.02
(C6), 114.51 (C8), 61.55 (q, JC,F = 33.4 Hz, CHCF3) ppm. HRMS (ESI+):
m/z calcd. for C9H8F3N2S+ [M + H]+ 233.0355; found 233.03556.
HPLC (0.1 % TFA, 0 min: 4 % B → 15 min: 100 % B, flow: 1 mL/min):
tR = 14.43 min, λ = 214 nm.
Acknowledgments
Support for this work by the Excellence Cluster Center of Inte-
grated Protein Science Munich (CIPSM) is gratefully acknowl-
edged. The authors thank Ulla Hülsmann for laboratory support
and M.Sc. Diana Haas for assistance with the synthesis of func-
tionalized Grignard reagents.
Keywords: Synthetic methods · Medicinal chemistry ·
Grignard reaction · Amines · Fluorine
[1] G. Wess, M. Urmann, B. Sickenberger, Angew. Chem. Int. Ed. 2001, 40,
000–000; Angew. Chem. 2001, 113, 3443–3453.
[2] N. A. Meanwell, J. Med. Chem. 2011, 54, 2529–2591.
[3] a) Y. Yasuda, J. Kaleta, D. Brömme, Adv. Drug Delivery Rev. 2005, 57, 973–
993; b) O. Vasiljeva, T. Reinheckel, C. Peters, D. Turk, V. Turk, B. Turk, Curr.
Pharm. Des. 2007, 13, 387–403.
[4] a) J. Y. Gauthier, N. Chauret, W. Cromlish, S. Desmarais, L. T. Duong, J.-P.
Falgueyret, D. B. Kimmel, S. Lamontagne, S. Léger, T. LeRiche, C. S. Li, F.
Massé, D. J. McKay, D. A. Nicoll-Griffith, R. M. Oballa, J. T. Palmer, M. D.
Percival, D. Riendeau, J. Robichaud, G. A. Rodan, S. B. Rodan, C. Seto, M.
Thérien, V.-L. Truong, M. C. Venuti, G. Wesolowski, R. N. Young, R. Zam-
boni, W. C. Black, Bioorg. Med. Chem. Lett. 2008, 18, 923–928; b) K. Kassa-
hun, W. C. Black, D. Nicoll-Griffith, I. McIntosh, N. Chauret, S. Day, E. Ro-
senberg, K. Koeplinger, Drug Metab. Dispos. 2011, 39, 1079–1087; c) W. C.
Black, C. I. Bayly, D. E. Davis, S. Desmarais, J.-P. Falguyret, S. Léger, F.
Massé, D. J. McKay, J. T. Palmer, M. D. Percival, J. Robichaud, N. Tsou, R.
Zamboni, Bioorg. Med. Chem. Lett. 2005, 15, 4741–4744.
[5] For a review on fluorine in the pharmaceutical industry, see: a) J. Wang,
M. Sánchez-Roselló, J. L. Aceña, C. del Pozo, A. E. Sorochinsky, S. Fustero,
V. A. Soloshonok, H. Liu, Chem. Rev. 2014, 114, 2432–2506; For a selected
example, see: b) Y. Kohno, K. Awano, M. Miyashita, T. Ishizaki, K. Kuri-
yama, Y. Sakoe, S. Kudoh, K. Saito, E. Kojima, Bioorg. Med. Chem. Lett.
1997, 7, 1519–1524.
Eur. J. Org. Chem. 2016, 930–945 www.eurjoc.org © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim945
[6] For reviews about CF3-containing scaffolds, see: a) J. Nie, H. C. Guo, D.
Cahard, J. A. Ma, Chem. Rev. 2011, 111, 455–529; b) W. Zhu, J. Wang, S.
Wang, Z. Gu, J. L. Aceña, K. Izawa, H. Liu, V. A. Soloshonok, J. Fluorine
Chem. 2014, 167, 37–54; For selected examples, see: c) F. Gosselin, P. D.
O'Shea, S. Roy, R. A. Reamer, C.-y. Chen, R. P. Volante, Org. Lett. 2004, 7,
355–358; d) M.-W. Chen, Y. Duan, Q.-A. Chen, D.-S. Wang, C.-B. Yu, Y.-G.
Zhou, Org. Lett. 2010, 12, 5075–5077; e) A. Henseler, M. Kato, K. Mori, T.
Akiyama, Angew. Chem. Int. Ed. 2011, 50, 000–000; Angew. Chem. 2011,
123, 8330–8333; f ) Y. Gong, K. Kato, H. Kimoto, Bull. Chem. Soc. Jpn. 2002,
75, 2637–2645; g) M. Liu, J. Li, X. Xiao, Y. Xie, Y. Shi, Chem. Commun.
2013, 49, 1404–1406; h) V. A. Soloshonok, T. Ono, J. Org. Chem. 1997,
62, 3030–3031; i) D. Enders, K. Funabiki, Org. Lett. 2001, 3, 1575–1577; j)
G. K. S. Prakash, M. Mandal, G. A. Olah, Angew. Chem. Int. Ed. 2001, 40,
000–000; Angew. Chem. 2001, 113, 609–610; k) J. Legros, F. Meyer, M.
Coliboeuf, B. Crousse, D. Bonnet-Delpon, J.-P. Bégué, J. Org. Chem. 2003,
68, 6444–6446; l) C. Lauzon, A. B. Charette, Org. Lett. 2006, 8, 2743–2745;
m) P. Liu, Z.-J. Liu, F. Wu, Adv. Synth. Catal. 2015, 357, 818–822; n) Y.-Q.
Zhang, J.-D. Liu, H. Xu, Org. Biomol. Chem. 2013, 11, 6242–6245.
[7] a) A. Deutsch, H. Glas, A. Hoffmann-Röder, C. Deutsch, RSC Adv. 2014, 4,
9288–9291; For further examples with organometallic reagents, see: b)
F. Grellepois, A. Ben Jamaa, A. Gassama, Eur. J. Org. Chem. 2013, 6694–
6701; c) F. Grellepois, J. Org. Chem. 2013, 78, 1127–1137; d) S. D. Kuduk,
C. N. D. Marco, S. M. Pitzenberger, N. Tsou, Tetrahedron Lett. 2006, 47,
2377–2381; e) A. Ishii, K. Higashiyama, K. Mikami, Synlett 1997, 1381–
1382; f ) A. Ishii, F. Miyamoto, K. Higashiyama, K. Mikami, Tetrahedron Lett.
1998, 39, 1199–1202; g) T. Johnson, M. Lautens, Org. Lett. 2013, 15,
4043–4045.
[8] Y. Gong, K. Kato, J. Fluorine Chem. 2004, 125, 767–773.
[9] For selected examples of CF3-containing peptide and amino acid mimet-
ics, see: a) A. Volonterio, P. Bravo, M. Zanda, J. Org. Chem. 2000, 65, 1827–
1830; b) A. Volonterio, P. Bravo, M. Zanda, Tetrahedron Lett. 2001, 42,
3141–3144; c) A. Volonterio, S. Bellosta, F. Bravin, M. C. Bellucci, L. Bruché,
G. Colombo, L. Malpezzi, S. Mazzini, S. V. Meille, M. Meli, C. Ram-
irez de Arellano, M. Zanda, Chem. Eur. J. 2003, 9, 4510–4522; d) M. Mol-
teni, M. C. Bellucci, S. Bigotti, S. Mazzini, A. Volonterio, M. Zanda, Org.
Biolog. Chem. 2009, 7, 2286–2296; e) M. Sani, A. Volonterio, M. Zanda,
ChemMedChem 2007, 2, 1693–1700; f ) H. Lubin, J. Pytkowicz, G. Chaume,
G. Sizun-Thomé, T. Brigaud, J. Org. Chem. 2015, 80, 2700–2708; g) F.
Huguenot, T. Brigaud, J. Org. Chem. 2006, 71, 7075–7078; h) G. Chaume,
J. Simon, C. Caupène, N. Lensen, E. Miclet, T. Brigaud, J. Org. Chem. 2013,
78, 10144–10153.
[10] a) G.-W. Zhang, L. Wang, J. Nie, J.-A. Ma, Adv. Synth. Catal. 2008, 350,
1457–1463; b) T. Fuchigami, S. Ichikawa, J. Org. Chem. 1994, 59, 607–
615.
[11] a) C. Prévost, Bull. Soc. Chim. Fr. 1931, 49, 1372; b) P. Knochel, W. Dohle,
N. Gommermann, F. F. Kneisel, F. Kopp, T. Korn, I. Sapountzis, V. A. Vu,
Angew. Chem. Int. Ed. 2003, 42, 4302–4320; Angew. Chem. 2003, 115,
4438–4456.
[12] A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333–3336;
Angew. Chem. 2004, 116, 3396–3394.
[13] C.-H. Song, S. H. Yang, E. Park, S. H. Cho, E.-Y. Gong, D. B. Khadka, W.-J.
Cho, K. Lee, J. Biol. Chem. 2012, 287, 30769–30780.
[14] S. H. Yang, C.-H. Song, H. T. M. Van, E. Park, D. B. Khadka, E.-Y. Gong, K.
Lee, W.-J. Cho, J. Med. Chem. 2013, 56, 3414–3418.
[15] a) M.-b. Yin, B. Guo, A. Panadero, C. Frank, C. Wrzosek, H. K. Slocum, Y. M.
Rustum, Exp. Cell Res. 1999, 247, 189–199; b) R. Agarwal, A. D. Sinha, J.
Am. Soc. Hypertens. 2012, 6, 299–308.
[16] S. Oschatz, T. Brunzel, X.-F. Wu, P. Langer, Org. Biomol. Chem. 2015, 13,
1150–1158.
Received: December 15, 2015
Published Online: Blockade
III. RESULTS AND DISSCUSION   
 
57 
 
3. One-Pot Synthesis of Functionalized -Fluoroalkylated 
Mannich-Type Products from N-Aryl N,O-Acetals 
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Declaration of Contribution  
Based on our synthesis of trifluoroethylamines starting from N-aryl N,O-acetals and Grignard reagents and 
literature reports, Swetlana Wunder developed and optimized a protocol toward a one-pot synthesis of -amino-
-fluoroalkyl carbonyl compounds during her internship at Merck KGaA (Darmstadt). We then studied the 
scope of this method using acetophenone and a variety of fluorinated N,O-acetals together. Therefore, I 
synthesized fluoroalkylated N,O-acetals and subsequently converted these substrates into the corresponding 
fluorinated carbonyl compounds using benzophenone. Furthermore, Swetlana Wunder extended the method to 
other C-nucleophiles to access a larger number of Mannich-type products for possible pharmaceutical 
applications.  
 
Background 
After the successful application of our developed method for the synthesis of functionalized di- and 
trifluoroethylamines, we aimed at extending the scope of nucleophiles suitable for addition reactions to 
trifluoromethylated N,O-acetals. As Mannich-type reactions are particularly significant carbon-carbon bond-
forming processes allowing access to a wide range of potential pharmacophores, we focused our attention on 
developing a procedure to react trifluoromethylated N,O-acetals as imine precursors under Mannich-type 
conditions. The application of trifluoromethylated imines in Mannich-type reactions facilitates the synthesis of 
fluorinated -amino carbonyl precursors of trifluoromethylated peptidic building blocks.  
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In 2000, Akiyama and co-workers reported the conversion of silyl enol ethers with trifluoromethylated 
N,O-hemiacetals in the presence of GaCl3 and benzoyl chloride (Scheme 13). Under these conditions smooth 
formation of the corresponding α-amino-α-trifluoromethyl carbonyl compounds was observed. However, the 
trifluoromethylated substrates were restricted to N-protected N,O-hemiacetals, requiring subsequent 
deprotection of the para-methoxyphenyl (PMP) moiety under oxidative reaction conditions, which restricts the 
application of this useful method.[170]  
 
Scheme 13. Synthesis of α-amino-α-trifluoromethyl carbonyl compounds from N,O-hemiacetals and silyl enol ethers.[170] 
Sonoshonok and co-workers also contributed to this field by describing various reactions of (S)-N-tert-
butylsulfinyl-3,3,3-trifluoroacetaldimines with -keto-acids, imines, indoles and other carbon nucleophiles to 
synthesize fluoromethylated scaffolds (Scheme 14).[171-180] Among those examples chiral imines were 
converted into -trifluoromethyl- -amino ketones by application of an asymmetric Ni-catalyzed 
decarboxylative Mannich-reaction.[178] Moreover, imines were reacted with enolates derived from various 
substituted indolin-2-ones furnishing the corresponding trifluoromethylated heterocyclic structures with three 
chiral centers.[173] Despite a pleasingly broad substrate scope regarding the carbon nucleophiles applicable to 
this reaction, the use of the expensive Ellman´s auxiliary is mandatory.  
 
Scheme 14. Conversion of (S)-N-tert-butylsulfinyl-3,3,3-trifluoroacetaldimines with C-nucleophiles.[173, 178] 
Apart from N-sulfinyl imines, further N-protected trifluoromethylated imines have been used as substrates in 
Mannich-type reactions (Scheme 15). For instance, Fioravanti et al. highlighted a L-proline catalyzed 
conversion of in situ formed benzyl-protected imines with aldehydes to furnish -amino alcohols. The ratio of 
syn and anti-diastereomeres was strongly dependent on the reaction conditions, i.e. temperature and time.[181] 
Moreover, Hu and co-workers employed trifluoromethylated N-aryl imines in a thiourea catalyzed asymmetric 
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reaction with -keto esters. The resulting products with two vicinal chiral centers were obtained with good 
yield and diastereoselectivity, albeit low to moderate enantioselectivity.[182]  
 
Scheme 15. Conversion of trifluoromethylated imines with carbonyl compounds.[181-182] 
Recently, Yang et al. demonstrated an aza-Michael addition of N-aryl amines to -fluoroalkylated acrylates 
providing various fluoroalkylated -amino acid derivatives (Scheme 16). Here, the substrates have to be reacted 
under solvent- and catalyst-free reaction conditions to furnish the desired fluorinated products in high 
yields.[183]  
 
Scheme 16. Synthesis of trifluoromethylated carbonyl compounds from amines and trifluoromethylated acrylates.[183] 
The procedures toward preparation of trifluoromethylated carbonyl compounds in Mannich-type reactions 
described above are either limited using N-protecting groups or a small substrate scope. We therefore decided 
to investigate the conversion of trifluoromethylated N,O-acetals under Mannich reaction conditions. Based on 
the advantageous use of N,O-acetals for the generation of trifluoroethylamines, we converted these imine 
surrogates with the lithium enolate formed in situ by treating acetophenone with LiHMDS. After establishing 
an efficient protocol which allows a high yielding synthesis of -fluoroalkylated Mannich-type products, we 
demonstrate its applicability and scope by reacting a variety of N-aryl N,O-acetals with lithium enolates of 
ketones, esters and nitriles (Scheme 17). This simple one-pot procedure allows a large variety in substitution 
patterns of Mannich-type products, most ideally, without the restriction of protecting groups.[184] 
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Scheme 17. Synthesis of -fluoroalkylated Mannich-type products.[184]  
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Abstract A variety of functionalized β-amino-β-fluoroalkyl carbonyl 
compounds are accessible via a novel one-pot Mannich-type reaction of CF2- 
and CF3-containing N-aryl N,O-acetals with lithium enolates of ketones, esters 
and nitriles. The resulting β-fluoroalkylated β-amino carbonyl compounds are 
promising peptide surrogates to be used in drug development and for 
biological applications. 
Key words fluoroalkylated compounds, N,O-acetals, trifluoroethylamine, 
difluoroethylamines, Mannich-type reaction. 
 
Drug-development based on a multidimensional optimization 
(MDO) approach is a great challenge and includes the fine-tuning 
of physicochemical properties and ADME (absorption, 
distribution, metabolism and excretion).1 In particular nitrogen-
containing compounds mostly require modulation of their 
basicity, as this affects properties such as lipophilicity, membrane 
permeability, binding potency including side effects like hERG 
inhibition2 and metabolic stability, all of which will be addressed 
in the course of the MDO process. In recent years the strategic 
placement of fluorine atoms in close proximity to nitrogen has 
become a common tool to fine-tune the molecular properties of 
biologically active amines by affecting their absorption and 
distribution behavior.3 In general, the incorporation of 
fluorinated groups leads to a lower basicity of neighboring 
amines, due to the high electrophilicity of fluorine atoms. Lead 
optimization studies have shown that introduction of a 
trifluoromethyl group adjacent to an amine enhances the 
metabolic stability of the compound significantly. Moreover, this 
transformation leads to a decrease in the pKa value of 
approximately 5.7 units, thus matching the pKa values of 
amides.1,4 However, despite structural similarities and isopolarities between C−CF3 and C=O entities, as well as their increased metabolic stability, -trifluoromethylated amines have 
remained an underrepresented, yet interesting class of amide 
bioisosteres.5 Thus, only a few examples of pharmaceuticals 
featuring −N(−C( CF3  or −N=C CF3) motifs are currently 
available.6 The cathepsin K inhibitor Odanacatib7 is a prominent example for compounds featuring a −N(−C( CF3) group, 
whereas the corresponding imine derivatives are represented by 
the small-molecule systemic inhibitor of enteroviruses and 
rhinoviruses Pleconaril.8 Mannich bases -amino ketones) are particularly useful building 
blocks9 for the preparation of nitrogen containing biologically 
active compounds.10 Their chemistry has been intensively 
studied and they can be easily converted into other 
multifunctional compounds (e.g. -amino esters, -amino 
alcohols or 1,3-diamines).11 Likewise, the corresponding -trifluoromethylated -amino ketones are promising units for 
bioorganic and medicinal chemistry applications and various 
approaches towards their syntheses have been reported. 
Mannich-type nucleophilic addition reaction represents an 
established methodology for synthesis of -amino- -
trifluoromethyl carbonyl compounds whereby efficient 
asymmetric syntheses can be achieved through the application of 
chiral auxiliaries.12 In most of these methods preformed N-tert-
butanesulfinyl (3,3,3)-trifluoro-acetaldimines13 or other 
trifluoromethyl aldimines14 are used, whereas only a few 
reactions based on trifluoroacetaldehyde ethyl hemiacetal15 or 
N,O-acetals16 derived from trifluoroacetaldehyde are known. 
Since this latter approach does not require expensive chiral N-
sulfinyl amides and controlled reaction conditions, it would be 
particularly useful for initial biological testing and lead 
optimization studies, for which enantiomerically pure 
compounds are not necessarily required. Thus, the development 
of a simple and economical one-pot protocol for the synthesis of 
-amino- -trifluoromethyl carbonyl compounds via Mannich-
type nucleophilic addition reaction to various N-aryl N,O-acetals 
is highly desirable and presented herein. 
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In contrast to the corresponding aldimines, trifluoromethylated 
N,O-acetals derived from 1-ethoxy-2,2,2-trifluoroethanol are 
readily available and shelf-stable compounds.17,18 Upon base 
treatment a transient aldimine intermediate is formed, which 
subsequently can be attacked by C-nucleophiles to furnish the desired -amino- -trifluoromethyl carbonyl compounds. In our studies we focused on ketones, but also other C−( acidic 
compounds (esters, nitriles) can be employed as nucleophiles. 
Hence, by using 3-chloro-N-(1-ethoxy-2,2,2-trifluoro-ethyl)-
aniline 1a as a model compound and LHMDS for deprotonation, 
the corresponding imine species was generated and reacted with 
an in situ forming lithium enolate of acetophenone. Low to 
moderate yields of the desired product 2a were obtained in 
various solvents at 55 °C (Table 1, entries 1−4). However, the 
yield of 2a was significantly improved when the reaction was 
performed at a temperature of -78 °C to RT using 
dichloromethane as solvent (Table 1, entry 7). Even higher yields 
were achieved by using N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b as substrate under the same 
conditions (Table 1, entry 8). The application of tetrahydrofuran, 
which is usually the solvent of choice in Mannich-type reactions, 
and diethyl ether at -78 °C to RT resulted in slightly lower yields 
of the desired product 2b (Table 1, entries 9 and 10). The 
employment of alternative non-nucleophilic bases such as DBU, 
NaHMDS, KHMDS or LDA was found detrimental (data not 
shown). 
Table 1 Optimization studies 
 
Entry solvent T [°C] Yield [%]a 
1 Toluene 55 38 
2 THF 55 26 
3 DCM 55 46 
4 Acetonitrile 55 8 
5 CH2Cl2 RT 61 
6 CH2Cl2 0 38 
7 CH2Cl2 −  to RT 71 
 
Entry solvent T [°C] Yield [%]a 
8 DCM −  to RT 92 
9 THF −  to RT 89 
10 Et2O −  to RT 91 
a Yield of isolated product after flash chromatography. 
 
Having identified suitable conditions for the Mannich-type 
reaction, we briefly looked at its scope by varying the 
substitution pattern of the aromatic ring within the hemiaminal 
ether (Table 2). Thus it was found that electron-poor N,O-acetals 
comprising pyrazine and quinoline groups are particularly well 
suited for this reaction and provide the target -
trifluoromethylated -amino ketones 2b and 2d in high yields 
(Table 2, entries 2 and 4). Interestingly, the corresponding N,O-
acetal featuring a (4-trifluoromethyl)phenyl substituent only 
afforded the desired reaction product 2e with a moderate yield 
of 52% (Table 2, entry 5), most presumably due to difficulties 
during the purification step. In contrast, difluoromethylated and pentafluoroethylated -amino ketones are accessible in almost 
quantitative yields by subjecting the corresponding N,O-acetals 
1h and 1i to the reaction conditions described above (Table 2, 
entries 8 and 9). 
Table 2 Reaction of acetophenone with aromatic N,O-acetals 
 
Entry Ar Rf t [h] Yield [%]a product 
1b 
 
CF3 1 71 2a 
2 
 
CF3 1 92 2b 
3 
 
CF3 1 72 2c 
4 
 
CF3 0.3 92 2d 
5 
 
CF3 1 52 2e 
6 
 
CF3 2 64 2f 
7 
 
CF3 1 78 2g 
8 
 
CF2H 2 quant. 2h 
9 
 
CF2CF3 1 quant. 2i 
a Yield of isolated product after flash chromatography. 
b Use of 2 equiv LHMDS. 
 
With regard to the scope of C-nucleophiles applicable to this 
Mannich-type reaction, we examined at first acetophenone-
derived ketones with both electron-withdrawing and electron-
donating substituents on the aromatic ring. To our delight, 
halogen, methoxy and nitro groups, as well as nitrile and ester-
functionalities are tolerated by the reaction conditions to furnish the desired -trifluoromethylated -amino ketones 3a−f in 
reasonable yields (Table 3, entries 2−7). Moreover, ketones 
carrying furan or indole residues, as well as (E)-4-phenylbut-3-
en-2-one reacted smoothly to give the corresponding Mannich-
type products 3h−j (Table 3, entries 9− , whereas ’, ’, ’, ’, ’-
pentafluoroacetophenone only afforded low yields of -amino 
ketone 3g (Table 3, entry 8), due to the formation of significant 
amounts of side products. A more sluggishly proceeding reaction 
was also observed for sterically hindered substrates such as 2-
methyl-1-phenylpropan-1-one, as expected (Table 3 entry 13). 
Last but not least, successful applications of diethyl malonate, 
ethyl acetate as well as 2,6-dichlorophenylacetonitrile as 
substrates demonstrated once more the synthetic versatility of 
this approach to readily access functionalized -
trifluoromethylated -amino carbonyl compounds 3m−o (Table 
3, entries 14−16). 
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Table 3 Reaction of pyrazyl N,O-acetals with various nucleophiles 
 
Entry R1 R2 R3 Yield [%]a product 
1 H H 
 
92 2b 
2 H H 
 
62 3a 
3 H H 
 
90 3b 
4 H H 
 
88 3c 
5 H H 
 
82 3d 
6 H H 
 
75 3e 
7 H H 
 
91 3f 
8 H H 
 
35 3g 
9 H H 
 
58 3h 
10 H H 
 
67 3i 
11 H H 
 
64 3j 
12 H CH3 
 
68 3k 
13 CH3 CH3 
 
22 3l 
14 H CN 
 
60 3m 
15 H CO2Et CO2Et 59 3n 
16 H H CO2Et 25 3o 
a Yield of isolated product after flash chromatography 
 
In summary, we devise an efficient one-pot procedure for the synthesis of a broad range of functionalized -amino- -
trifluoromethyl carbonyl derivatives using readily accessible, 
shelf-stable N-aryl N,O-acetals and lithium enolates derived from 
ketones, esters, as well as nitriles. The reaction is easy to perform 
and allows rapid formation of novel trifluoromethylated 
Mannich-type products, which are useful potential building 
blocks for pharmaceutical and biological applications. Moreover, 
the reaction protocol can be successfully applied to the synthesis 
of functionalized -difluoromethylated and -
pentafluoroethylated Mannich-type products.  
 
All reactions were carried out under an argon atmosphere using dried 
glassware. Commercially available reagents and solvents were used 
without further purification. Dry CH2Cl2 (SeccoSolv®) was purchased from 
Merck KGaA. N,O-acetal substrates were synthesized according to 
standard procedures from 1-ethoxy-2,2,2-trifluoroethanol and the 
corresponding amines using pTSA in EtOH.17 Purification was performed 
by flash chromatography and N,O-acetal substrates were dried under 
reduced pressure prior to use. Reactions were monitored by TLC with pre-
coated silica gel 60 F254 aluminium plates (Merck KGaA) using UV light as 
the visualizing agent. The crude -amino- -trifluoromethyl carbonyl 
compounds were purified by MPLC with a CombiFlash Rf Teledyne ISCO or 
by standard flash chromatography using silica gel (35–70 μm) from Acros 
Organics. Analytical RP-HPLC was measured on a JASCO system with a 
Phenomenex Luna C18 column (5 μm, 250 × 4.6 mm). HR-EI-mass spectra 
were recorded on a Finnigan MAT95Q or on a Finnigan MAT90. HR-ESI-
mass spectra were recorded on a Thermo Finnigan LTQ FT or on a Bruker 
maXis equipped with a Waters Acquity UPLC using a Kinetex C18 column 
(2.6 μ, 100 A) at 40 °C and HPLC-MS was performed on Agilent 1100 and 
Agilent 1200 systems using Chromolith Speed ROD RP-18e columns. In all 
cases, mixtures of water (eluent A) and acetonitrile (eluent B) were used 
as solvents; if required, 0.05 % formic acid or 0.1 % TFA were added. 1H, 
13C, and 19F spectra were recorded on a Varian 400 MHz, 600 MHz and 
800 MHz spectrometer or on a Bruker Avance II 300 MHz, 400 MHz and 
500 MHz spectrometer in DMSO-d6 or CDCl3. The chemical shifts are 
reported in ppm relative to the signal of the deuterated solvent. 
Multiplicities are given as: s (singlet), br s (broad singlet), d (doublet), t 
(triplet), q (quartet) and m (multiplet). Melting points were measured on 
a Melting Point B-540 Büchi. 
Addition of Ketones to N-Aryl N,O-Acetals 1a-I; General Procedure 
N-aryl hemiaminal ether 1 was placed in a dry Schlenk flask equipped 
with a magnetic stirrer and a septum, and dissolved in dry CH2Cl2 (ca. 
0.06 M). The solution was flushed with argon and cooled to −78 °C before 
lithium bis(trimethylsilylamide) (LHMDS, 1.0 M solution in toluene, 
2.0−3.3 eq.) was added dropwise. Stirring was continued at −78 °C for 10 
min, the ketone (1.5−2.5 eq.) was added, the reaction mixture was allowed 
to warm up to room temperature and stirred for 1−2 h (TLC and LC-MS 
control). After complete consumption of the starting material the solution 
was quenched with H2O (10 mL) and extracted with CH2Cl2 (3 × 20 mL). 
The combined organic phases were dried over Na2SO4 and the solvent was 
removed under reduced pressure. Purification by flash- or column 
chromatography and optional subsequent crystallization from 
chex/EtOAc furnished the desired -amino -fluoroalkylated carbonyl 
compounds 2a−2i and 3a−3o. 
 
3-((3-Chlorophenyl)amino)-4,4,4-trifluoro-1-phenylbutan-1-one (2a) 
According to the general procedure, 3-Chloro-N-(1-ethoxy-2,2,2-
trifluoroethyl)aniline 1a (150 mg, 0.59 mmol) was dissolved in 7 mL dry 
CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.18 mL, 
1.18 mmol) and reacted with acetophenone (0.10 mL, 0.89 mmol). After 
stirring at rt (2 h), aqueous workup, flash chromatography 
(chex → chex/EtOAc 9/1) and recrystallization (chex) the -amino ketone 
2a (138 mg, 0.42 mmol, 71 %) was obtained as a colorless crystalline 
solid. 1H NMR (400 MHz, DMSO-d6):  = 8.07 – 7.93 (m, 2H, H2ph, H6ph), 
7.73 – 7.62 (m, 1H, H4ph), 7.55 (m, 2H, H3ph, H5ph), 7.11 (t, 
JH5,H4/H6 = 8.1 Hz, 1H, H5), 6.77 (br s, 1H, H2), 6.65 (m, 2H, H4, H6), 6.30 (d, 
JNH,CH = 8.4 Hz, 1H, NH), 4.87 – 4.76 (m, 1H, CH), 3.62 (dd, JCH2,CH2 = 17.8 Hz, 
JCH2,CH = 10.0 Hz, 1H, CH2), 3.44 (dd, JCH2,CH2 = 17.8 Hz, JCH2,CH = 2.5 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6):   = 194.97 (C=O), 148.96 (C1), 
136.13(C1ph), 133.55 (C3), 133.52 (C4ph) 130.34 (C5), 128.73 (C3ph, C5ph), 
128.09 (C2ph, C6ph), 126.58 (q, 1JC,F = 283.8 Hz, CF3), 116.47 (C4), 111.93 
(C2), 111.35 (C6), 50.16 (q, 2JC,F = 29.7 Hz, CH), 37.54 (CH2) ppm. 19F NMR 
(376 MHz, DMSO-d6):  = − 74.25 (d, JCF3,CH = 7.4 Hz, CF3) ppm. HR-EI-MS 
(m/z) calc. for C16H13ClF3NO+ [M]+ 327.0638; found 327.0641. HPLC-MS 
(0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): 
tR = 1.98 min, λ = 220 nm. m.p.: 98 °C. Rf (cHex/EtOAc = 2:1) = 0.61. 
 
4,4,4-Trifluoro-1-phenyl-3-(pyrazin-2-ylamino)butan-1-one (2b) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with acetophenone (0.08 mL, 0.68 mmol). After 
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stirring at rt (1h), aqueous workup, flash chromatography 
(chex → chex/EtOAc 4/1) and recrystallization (chex) the -amino ketone 
2b (123 mg, 0.42 mmol, 92 %) was obtained as a colorless crystalline 
solid. 1H NMR (400 MHz, DMSO-d6):  = 8.04 (dd, JH6,H5 = 2.8 Hz, 
JH6,H3 = 1.5 Hz, 1H, H6), 8.01 – 7.94 (m, 3H, H3, H2ph, H6ph), 7.82 (d, 
JH5,H6 = 2.8 Hz, 1H, H5), 7.70 – 7.63 (m, 1H, H4ph), 7.58 – 7.51 (m, 2H, H3ph, 
H5ph), 7.48 (d, JNH,CH = 8.2 Hz, 1H, NH), 5.50 – 5.38 (m, 1H, CH), 3.65 (dd, 
JCH2,CH2 = 17.8 Hz, JCH2,CH = 9.8 Hz, 1H, CH2), 3.52 (dd, JCH2,CH2 = 17.8 Hz, 
JCH2,CH = 3.3 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):   = 195.03 
(C=O), 153.90 (C2), 141.26 (C6), 136.08 (C1ph), 133.55 (C5), 133.02 (C4ph), 
132.91 (C3), 128.74 (C3ph, C5ph), 128.07 (C2ph, C6ph), 126.22 (q, 
1JC,F = 282.8 Hz, CF3) 47.17 (q, 2JC,F = 30.5 Hz, CH), 37.12 (CH2) ppm. 
19F NMR (376 MHz, DMSO-d6):  = − 74.37 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 
HR-EI-MS (m/z) calc. for C14H12F3N3O+ [M]+ 295.0932; found 295.0931. 
HPLC-MS (0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 
mL/min): tR = 1.59 min, λ = 220 nm. m.p.: 128 °C. Rf (cHex/EtOAc 
= 2:1) = 0.20. 
 
4,4,4-Trifluoro-3-(4-methylpyrimidin-2-ylamino)-1-phenylbutan-1-one 
(2c) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-
methylpyrimidin-2-amine 1c (100 mg, 0.43 mmol) was dissolved in 7 mL 
dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.98 mL, 
0.98 mmol) and reacted with acetophenone (0.08 mL, 0.64 mmol). After 
stirring at rt (2 h), aqueous workup, flash chromatography 
(chex → chex/EtOAc 4/1) and recrystallization (chex) the -amino ketone 
2c (97 mg, 0.31 mmol, 72 %) was obtained as a colorless crystalline solid. 
1H NMR (400 MHz, DMSO-d6):  = 8.19 (br s, 1H, H6), 8.00 – 7.91 (m, 2H, 
H2ph, H6ph), 7.65 (tt, JH4ph,H3ph/H5ph = 7.4 Hz, JH4ph,H2ph/H6ph = 1.1 Hz, H4ph), 
7.53 (m, 3H, NH, H3ph, H5ph), 6.60 (d, JH5,H6 = 5.0 Hz, 1H, H5), 5.54 – 5.39 
(m, 1H), 3.74 (dd, JCH2,CH2 = 17.7 Hz, JCH2,CH = 10.3 Hz, 1H, CH2), 3.39 (dd, 
JCH2,CH2 = 17.6 Hz, JCH2,CH = 2.9 Hz, 1H, CH2), 2.25 (s, 3H, CH3) ppm. 13C NMR 
(101 MHz, DMSO-d6):  = 195.89 (C=O), 167.89 (C4), 162.05 (C2), 157.85 
(C6), 136.70 (C1ph), 134.02 (C4ph), 129.24 (C2ph, C6ph), 128.19 (C3ph, C5ph), 
126.78 (q, 1JC,F = 283.1 Hz, CF3), 111.53 (C5), 48.51 (q, 2JC,F = 30.2 Hz, CH), 
37.21 (CH2), 24.00 (CH3) ppm. 19F NMR (376 MHz, DMSO-d6):  = − 74.48 
(br s, CF3) ppm. HR-ESI-MS (positive, m/z) calc. for C15H15F3N3O+ [M+H]+ 
310.1162; found 310.1162. HPLC (0.1 % TFA; 0 min, 4 % B →  min, 
100 % B, flow: 1 mL/min): tR = 13.93 min, λ = 214 nm. m.p.: 109 °C. Rf 
(cHex/EtOAc = 2:1) = 0.35. 
 
4,4,4-Trifluoro-1-phenyl-3-(quinolin-8-ylamino)butan-1-one (2d) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)quinolin-8-amine 1d (100 mg, 0.37 mmol) was dissolved in 
5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.85 mL, 
0.85 mmol) and reacted with acetophenone (0.65 mL, 0.56 mmol). After 
stirring at rt (20 min), aqueous workup and flash chromatography 
(chex → chex/EtOAc 9/1  the -amino ketone 2d (117 mg, 0.34 mmol, 
92 %) was obtained as a light yellow oil. 1H NMR (400 MHz, 
CDCl3):  = 8.68 (dd, JH2,H3 = 4.2 Hz, JH2,H4 = 1.7 Hz, 1H, H2), 8.06 (dd, 
JH4,H3 = 8.2 Hz, JH4,H2 = 1.7 Hz, 1H, H4), 7.99 – 7.93 (m, 2H, H2ph, H6ph), 
7.62 – 7.54 (m, 1H, H4ph), 7.51 – 7.40 (m, 3H, H6, H3ph, H5ph), 7.36 (dd, 
JH3,H4 = 8.2 Hz, JH3,H2 = 4.2 Hz, 1H, H3), 7.16 (dd, JH5,H6 = 8.2 Hz, 
JH5,H7 = 1.1 Hz, 1H, H5), 7.07 (d, JH7,H6 = 7.6 Hz, 1H, H7), 6.44 (d, 
JNH,CH = 9.9 Hz, 1H, NH), 5.10 (dtd, JCH,NH = 9.9 Hz, JCH,CF3 = 7.2 Hz, 
JCH,CH2 = 4.7 Hz, 1H, CH), 3.63 – 3.49 (m, 2H, CH2) ppm. 13C NMR (101 MHz, 
CDCl3):   = 195.05 (C=O), 147.32 (C2), 142.75 (C4a), 138.16 (C8a), 136.42 
(C1ph), 136.20 (C4), 133.82 (C4ph), 128.91 (C3ph, C5ph), 128.73 (C8), 
128.34 (C2ph, C6ph), 127.71 (C6), 126.40 (q, 1J C,F = 283.3 Hz, CF3), 121.61 
(C3), 116.12 (C5), 106.54 (C7), 51.40 (q, 2JC,F = 30.5 Hz, CCF3), 39.06 
(CH2) ppm. 19F NMR (376 MHz, CDCl3):  = − 75.63 (d, JCF3,CH = 7.1 Hz, 
CF3) ppm. HR-ESI-MS (positive, m/z) calc. for C19H16F3N2O+ [M+H]+ 
345.1209; found 345.1210. HPLC (0.1 % TFA; 0 min, 4 % B →  min, 
100 % B, flow: 1 mL/min): tR = 18.93 min, λ = 214 nm. Rf (cHex/EtOAc 
= 3:1) = 0.50.  
 
4,4,4-Trifluoro-1-phenyl-3-((4-(trifluoromethyl)phenyl)amino)butan-1-
one (2e) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-
(trifluoromethyl)aniline 1e (50 mg, 0.17 mmol) was dissolved in 5 mL dry 
CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.40 mL, 
0.40 mmol) and reacted with acetophenone (0.03 mL, 0.26 mmol). After 
stirring at rt (1 h), aqueous workup and flash chromatography 
(chex → chex/EtOAc 5/1) the -amino ketone 2e (33 mg, 0.09 mmol, 
52 %) was obtained  as a light brown solid. 1H NMR (400 MHz, 
CDCl3):  = 7.98 – 7.92 (m, 2H, H2ph, H6ph), 7.65 – 7.59 (m, 1H, H4ph), 7.50 
(dd, J = 8.3 Hz, J = 7.1 Hz, 2H, H3ph, H5ph), 7.44 (d, JH3,H2 = JH5,H6 = 8.5 Hz, 
2H, H3, H5), 6.79 (d, JH2,H3 = JH6,H5 = 8.4 Hz, 2H, H2, H6), 4.87 (dtd, 
JCH,NH = 9.6 Hz, JCH,CF3 = 7.2 Hz, JCH,CH2 = 4.3 Hz, 1H, CH), 4.14 (d, 
JNH,CH = 9.9 Hz, 1H, NH), 3.45 – 3.37 (m, 2H, CH2) ppm. 13C NMR (101 MHz, 
CDCl3):  = 194.90 (C=O), 148.67 (C1), 136.16 (C1ph), 134.14 (C4ph), 
129.05 (C3ph, C5ph), 128.31 (C2ph, C6ph), 126.92 (q, 3JC,F = 3.8 Hz, C3, C5), 
125.97 (q, 1J C,F = 283.2 Hz, CF3), 124.77 (d, 1JC,F = 270.6 Hz, CF3), 121.15 
(q, 2JC,F = 32.8 Hz, C4), 113.19 (C2, C6), 51.80 (q, 2JC,F = 30.7 Hz, CCF3), 
38.34 (CH2) ppm. 19F NMR (376 MHz, CDCl3):  = − 61.40 (CF3 , − 75.66 (d, 
JCF3,CH = 7.1 Hz, CF3) ppm. HR-ESI-MS (negative, m/z) calc. for C17H12F6NO− [M−(]− 360.0828; found 360.0835. HPLC (0.1 % TFA; 0 min, 4 % B → 
15 min, 100 % B, flow: 1 mL/min): tR = 19.85 min, λ = 214 nm. m.p.: 
127 °C. Rf (cHex/EtOAc = 3:1) = 0.46.  
 
4,4,4-Trifluoro-3-((4-methoxyphenyl)amino)-1-phenylbutan-1-one (2f) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-
methoxyaniline 1f (170 mg, 0.68 mmol) was dissolved in 10 mL dry 
CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with acetophenone (0.12 mL, 1.02 mmol). After 
stirring at rt (2 h), aqueous workup and flash chromatography 
(chex → chex/EtOAc 4/1) and recrystallization (chex) the -amino ketone 
2f (140 mg, 0.43 mmol, 64 %) was obtained  as a colorless crystalline 
solid. 1H NMR (600 MHz, CDCl3):  = 7.95 (m, 1H, H2ph/H6ph), 7.94 (m, 1H, 
H2ph/H6ph), 7.60 (m, 1H, H4ph), 7.51 – 7.46 (m, 2H, H3ph, H5ph), 6.80 – 6.76 
(m, 2H, H2, H6), 6.76 – 6.72 (m, 2H, H3, H5), 4.69 (m, 1H, CH), 3.74 (s, 3H, 
OMe), 3.40 – 3.29 (m, 2H, CH2) ppm. 13C NMR (151 MHz, 
CDCl3):  = 195.53 (C=O), 153.58 (C4), 139.93 (C1), 136.48 (C1ph), 133.85 
(C4ph), 129.94 (C2ph, C6ph), 128.29 (C3ph, C5ph), 126.34 (q, 1J C,F = 283.5 Hz, 
CF3), 116.13 (C3ph, C5ph), 114.98 (C2ph, C1ph), 55.79 (OMe), 53.97 (q, 
2JC,F = 29.5 Hz, CCF3), 38.47 (CH2) ppm. 19F NMR (376 MHz, 
CDCl3):  = − 75.48 (CF3) ppm. HR-ESI-MS (positive, m/z) calc. for 
C17H17F3NO2+ [M+H]+ 324.1206; found 324.1210. HPLC (0.1 % TFA; 0 min, 
4 % B →  min, 100 % B, flow: 1 mL/min): tR = 18.43 min, λ = 214 nm. 
m.p.: 90 °C. Rf (cHex/EtOAc = 4:1) = 0.53.  
 
4,4,4-Trifluoro-1-phenyl-3-(pyridin-2-ylamino)butan-1-one (2g) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyridin-2-amine 1g (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
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1.04 mmol) and reacted with acetophenone (0.08 mL, 0.68 mmol). After 
stirring at rt (1 h), aqueous workup, flash chromatography 
(chex → chex/EtOAc 4/1) and recrystallization (chex) the -amino ketone 
2g (104 mg, 0.35 mmol, 78 %) was obtained as a colorless crystalline 
solid. 1H NMR (400 MHz, DMSO-d6):  = 8.02 (dd, JH6,H5 = 5.0 Hz, 
JH6,H4 = 1.2 Hz, 1H, H6), 8.00 – 7.95 (m, 2H, H2ph, H6ph), 7.69 – 7.63 (m, 1H, 
H4ph), 7.56 – 7.51 (m, 2H, H3ph, H5ph), 7.41 (ddd, JH4,H3 = 8.8 Hz, 
JH4,H5 = 7.1 Hz, JH4,H6 = 1.9 Hz, 1H, H4), 6.94 (d, JNH,CH = 8.4 Hz, 1H, NH), 6.59 
(ddd, JH5,H4 = 7.0 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.8 Hz, 1 H, H5), 6.51 (d, 
JH3,H4 = 8.4 Hz, 1H, H3), 5.60 – 5.44 (m, 1H, CH), 3.60 (dd, JCH2,CH2 = 17.5 Hz, 
JCH2,CH = 9.6 Hz, 1H, CH2), 3.43 (dd, JCH2,CH2 = 17.5 Hz, JCH2,CH = 3.5 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6):   = 195.50 (C=O), 157.47 (C1), 
147.33 (C6), 137.18 (C4), 136.34 (C1ph), 133.67 (C4ph), 128.92 (C3ph, 
C5ph), 128.21 (C2ph, C6ph), 126.59 (q, 1JC,F = 283.8 Hz, CF3), 113.32 (C5), 
108.74 (C3), 47.56 (q, 2JC,F = 30.0 Hz, CH), 37.55 (CH2) ppm. 19F NMR 
(376 MHz, DMSO-d6):  = − 74.34 (d, JCF3,CH = 8.0 Hz, CF3) ppm. HR-EI-MS 
(m/z) calc. for C15H13F3N2O+ [M]+ 294.0980; found 294.0977. HPLC-MS 
(0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): 
tR = 1.25 min, λ = 220 nm. m.p.: 124 °C. Rf (cHex/EtOAc = 2:1) = 0.46. 
 
4,4-Difluoro-1-phenyl-3-(pyridin-2-ylamino)butan-1-one (2h) 
According to the general procedure, N-(1-ethoxy-2,2-
difluoroethyl)pyridin-2-amine 1h (100 mg, 0.49 mmol) was dissolved in 
5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.13 mL, 
1.13 mmol) and reacted with acetophenone (0.09 mL, 0.74 mmol). After 
stirring at rt (2 h), aqueous workup and flash chromatography 
(chex → chex/EtOAc 4/1) the -amino ketone 2h (136 mg, 0.49 mmol, 
quant.) was obtained as a light brown solid. 1H NMR (400 MHz, 
CDCl3):  = 8.07 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1H, H6), 
8.00 – 7.92 (m, 2H, H2ph, H6ph), 7.65 – 7.54 (m, 1H, H4ph), 7.53 – 7.44 (m, 
2H, H3ph, H5ph), 7.40 (ddd, JH4,H3 = 8.4 Hz, JH4,H5 = 7.1 Hz, JH4,H6 = 1.9 Hz, 1H, 
H4), 6.62 (ddd, JH5,H4 = 7.1 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1H, H5), 6.48 
(dt, JH3,H4 = 8.3 Hz, JH3,H5 = 0.9 Hz, 1H, H3), 6.20 (td, JCHF2,CHF2 = 56.7 Hz, 
JCHF2,CH = 3.1 Hz, 1H, CHF2), 5.08 – 4.91 (m, 1H, CH), 4.89 (d, JNH,CH = 9.0 Hz, 
1H, NH), 3.46 – 3.38 (m, 2H, CH2) ppm. 13C NMR (101 MHz, 
CDCl3):   = 197.85 (C=O), 157.16 (C2), 147.97 (C6) , 137.61 (C4), 136.58 
(C1ph), 133.76 (C4ph), 128.89 (C3ph, C5ph), 128.34 (C2ph, C6ph), 115.45 (t, 
1JCHF2,CHF2 = 244.9 Hz, CHF2), 113.02 (C5), 108.87 (C3), 49.94 (dd, 
2JCH,CHF2 = 24.5 Hz, 2JCH,CHF2 = 22.8 Hz, CH), 36.73 (CH2) ppm. 19F NMR 
(376 MHz, CDCl3):  = − 125.78 (ddd, JCHF2,CHF2 = 281.1 Hz, 
JCHF2,CHF2 = 56.4 Hz, JCHF2,CH = 10.4 Hz, CHF2), − 128.96 (ddd, 
JCHF2,CHF2 = 281.1 Hz, JCHF2,CHF2 = 56.9 Hz, JCHF2,CH = 16.0 Hz, CHF2) ppm. HR-
ESI-MS (positive, m/z) calc. for C15H15F2N2O+ [M+H]+ 277.1147; found 
277.1146. HPLC (0.1 % TFA; 0 min, 4 % B →  min, 100 % B, flow: 
1 mL/min): tR = 10.23 min, λ = 214 nm. m.p.: 115 °C. Rf (cHex/EtOAc 
= 3:1) = 0.24.  
 
4,4,5,5,5-Pentafluoro-1-phenyl-3-(pyrazin-2-ylamino)pentan-1-one (2i) 
Following the general procedure, N-(1-ethoxy-2,2,3,3,3-
pentafluoropropyl)pyrazin-2-amine 1i (100 mg, 0.37 mmol) was 
dissolved in 5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in 
toluene, 0.85 mL, 0.85 mmol) and reacted with acetophenone (0.07 mL, 
0.55 mmol). After stirring at rt (1 h), aqueous workup and flash 
chromatography (chex → chex/EtOAc 2/1) the -amino ketone 2i 
(130 mg, 0.37 mmol, quant.) was obtained as a light yellow solid. 1H NMR 
(400 MHz, CDCl3):  = 8.01 (dd, JH6,H5 = 2.8  Hz, JH6,H3 = 1.5 Hz, 1 H, H6), 
7.99 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.95 – 7.91 (m, 2 H, H2ph; H6ph), 7.90 (m, 
1 H, H5), 7.60 (m, 1 H, H4ph), 7.48 (m, 2 H, H3ph; H5ph), 5.73 (m, 1 H, CH), 
5.06 (d, JNH,CH = 10.0 Hz, 1 H, NH), 3.51 – 3.46 (m, 2 H, CH2) ppm. 13C NMR 
(101 MHz, CDCl3):   = 195.68 (C=O), 152.61 (C2), 141.68 (C6), 136.31 
(C1ph), 134.84 (C5), 134.01 (C4ph), 132.96 (C3), 129.01 (C3ph; C5ph), 128.27 
(C2ph; C6ph), 46.94 (dd, 2JCH,CF2 = 27.1 Hz, 2JCH,CF2 = 21.4 Hz, CH), 37.07 
(CH2) ppm. 19F NMR (376 MHz, CDCl3):  = − 81.84 (CF3), − 118.54 (dd, 
JCF2,CF2 = 273.6 Hz, JCF2,CF3 = 7.3 Hz, CF2), − 124.82 (dd, JCF2,CF2 = 273.6 Hz, 
JCF2,CF3 = 19.8 Hz, CF2) ppm. HR-ESI-MS (positive, m/z) calc. for 
C15H13F5N3O+ [M+H]+ 346.0973; found 346.0973. . HPLC (0.1 % TFA; 
0 min, 4 % B →  min, 100 % B, flow: 1 mL/min): tR = 16.28 min, λ = 
214 nm.  m.p.: 105 °C. Rf (cHex/EtOAc = 2:1) = 0.23.  
 
1-(4-Bromophenyl)-4,4,4-trifluoro-3-(pyrazin-2-ylamino)butan-1-one 
(3a) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 4-bromoacetophenone (203 mg, 
1.02 mmol). After stirring at 40 °C (2 h), aqueous workup, flash 
chromatography (chex/EtOAc 3/1 → 2/1) and recrystallization 
(chex/EtOAc /  the -amino ketone 3a (132 mg, 0.35 mmol, 62 %) was 
obtained as a colorless crystalline solid. 1H NMR (500 MHz, 
DMSO-d6):  = 8.04 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.4 Hz, 1H, H6), 7.96 (d, 
JH3,H6 = 1.4 Hz, 1H, H3), 7.94 – 7.89 (m, 2H, H2ph, H6ph), 7.82 (d, 
JH5,H6 = 2.7 Hz, 1H, H5), 7.78 – 7.73 (m, 2H, H3ph, H5ph), 7.46 (d, 
JNH,CH = 8.2 Hz, 1H, NH), 5.48 – 5.35 (m, 1H, CH), 3.62 (dd, JCH2,CH2 = 17.8 Hz, 
JCH2,CH = 9.8 Hz, 1H, CH2), 3.52 (dd, JCH2,CH2 = 17.8 Hz, JCH2,CH = 3.3 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6):   = 194.57 (C=O), 154.01 (C2), 
141.46 (C6), 135.19 (C1), 133.13 (C3), 133.09 (C5), 131.98 (C3ph, C5ph), 
130.26 (C2ph, C6ph), 127.87 (C-Br), 126.29 (q, 1JC,F = 282.8 Hz, CF3), 47.26 
(q, 2JC,F = 30.3 Hz, CH), 37.28 (CH2) ppm. 19F NMR (471 MHz, DMSO-
d6):  = − 74.37 (d, JCF3,CH = 7.6 Hz, CF3) ppm. HR-ESI-MS (positive, m/z) 
calc. for C14H12BrF3N3O+ [M+H]+ 374.0110; found 374.0112. HPLC-MS 
(0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): 
tR = 1.74 min, λ = 220 nm. m.p.: 112 °C. Rf (cHex/EtOAc = 2:1) = 0.24. 
 
4,4,4-Trifluoro-1-(4-methoxyphenyl)-3-(pyrazin-2-ylamino)butan-1-one 
(3b) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 4-methoxyacetophenone (153 mg, 
1.02 mmol). After stirring at rt (2 h), aqueous workup, flash 
chromatography (chex/EtOAc 3/1 → 2/1) and recrystallization 
(chex/EtOAc 9/1) the -amino ketone 3b (199 mg, 0.61 mmol, 90 %) was 
obtained as a colorless crystalline solid. 1H NMR (500 MHz, DMSO-
d6):  = 8.03 (dd, JH6,H5 = 2.6 Hz, JH6,H3 = 1.4 Hz, 1H, H6), 7.99 – 7.93 (m, 3H, 
H3, H2ph, H6ph), 7.81 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.47 (d, JNH,CH = 8.3 Hz, 1H, 
NH), 7.05 (m, 2H, H3ph, H5ph), 5.52 – 5.34 (m, 1H, CH), 3.85 (s, 3H, OMe), 
3.57 (dd, JCH2,CH2 = 17.5 Hz, JCH2,CH = 9.9 Hz, 1H, CH2), 3.42 (dd, 
JCH2,CH2 = 17.5 Hz, JCH2,CH = 3.2 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, 
DMSO-d6):   = 193.51 (C=O), 163.59 (C-OMe), 154.04 (C2), 141.47 (C6), 
133.10 (C3), 133.01 (C5), 130.64 (C2ph, C6ph), 129.17 (C1ph), 126.40 (q, 
1JC,F = 283.0 Hz, CF3), 114.11 (C3ph, C5ph), 55.73 (OMe), 47.36 (q, 
2JC,F = 30.3 Hz, CH), 36.84 (CH2) ppm. 19F NMR (376 MHz, DMSO-
d6):  = − 74.34 (d, JCF3,CH = 7.8 Hz, CF3) ppm. HR-EI-MS (m/z) calc. for 
C15H14F3N3O2+ [M]+ 325.1038; found 325.1043. HPLC-MS (0.05 % formic 
acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): tR = 1.60 min, λ 
= 220 nm. m.p.: 135 °C. Rf (cHex/EtOAc = 2:1) = 0.11. 
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4,4,4-Trifluoro-1-(2-methoxyphenyl)-3-(pyrazin-2-ylamino)butan-1-one 
(3c) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 2-methoxyacetophenone (0.14 mL, 
1.02 mmol). After stirring at rt (2 h), aqueous workup, flash 
chromatography (chex/EtOAc 3/1 → 2/1) and recrystallization 
(chex/EtOAc 9/1) the -amino ketone 3c (194 mg, 0.59 mmol, 88 %) was 
obtained as a colorless crystalline solid 1H NMR (500 MHz, DMSO-
d6):  = 7.97 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.95 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 7.79 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.60 – 7.49 (m, 3H, 
H2ph, H4ph, H5ph), 7.20 (d, JNH,CH = 8.2 Hz, 1H, NH), 7.03 – 6.97 (m, 1H, 
H3ph), 5.47 – 5.37 (m, 1H, CH), 3.91 (s, 3H, OMe), 3.46 (dd, 
JCH2,CH2 = 17.4 Hz, JCH2,CH = 4.2 Hz, 1H, CH2), 3.40 (dd, JCH2,CH2 = 17.4 Hz, 
JCH2,CH = 9.2 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):   = 196.16 
(C=O), 158.68 (C-OMe), 153.95 (C2), 141.39 (C6), 134.64 (C4ph), 133.16 
(C3), 132.95 (C5), 129.99 (C2ph), 126.51 (C1ph), 126.30 (q, 1JC,F = 282.9 Hz, 
CF3) 120.71 (C3ph), 112.68 (C5ph), 55.97 (OMe), 47.31 (q, 2JC,F = 30.1 Hz, 
CH), 42.49 (CH2) ppm.  19F NMR (471 MHz, DMSO-d6):  = − 74.52 (d, 
JCF3,CH = 7.7 Hz, CF3) ppm. HR-EI-MS (m/z) calc. for C15H14F3N3O2+ [M]+ 
325.1038; found 325.1044. HPLC-MS (0.05 % formic acid; 0 min, 0 % B → 
2.0 min, 100 % B, flow: 3.3 mL/min): tR = 1.62 min, λ = 220 nm. m.p.: 
134 °C. Rf (cHex/EtOAc = 2:1) = 0.14. 
 
Methyl 4-(4,4,4-trifluoro-3-(pyrazin-2-ylamino)butanoyl)benzoate (3d) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with methyl-4-acetylbenzoate (120 mg, 
0.68 mmol). After stirring at rt (2.5 h), aqueous workup, flash 
chromatography (chex → chex/EtOAc 4/1) and recrystallization (chex) the desired -amino ketone 3d (130 mg, 0.37 mmol, 82 %) was obtained as a 
colorless crystalline solid. 1H NMR (400 MHz, DMSO-d6):  = 8.10 (d, 
JH2ph,H3ph = JH5ph,H6ph = 2.1 Hz, 4H, H2ph, H3ph, H5ph, H6ph), 8.04 (dd, 
JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.96 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.82 
(d, JH5,H6 = 2.8 Hz, 1H, H5), 7.46 (d, JNH,CH = 8.2 Hz, 1H, NH), 5.49 – 5.36 (m, 
1H, CH), 3.69 (dd, JCH2,CH2 = 17.9 Hz, JCH2,CH = 9.7 Hz, 1H, CH2), 3.59 (dd, 
JCH2,CH2 = 17.5 Hz, JCH2,CH = 3.1 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, 
DMSO-d6):   = 194.84 (C=O), 165.46 (COOMe), 153.85 (C2), 141.22 (C6), 
139.39 (C1ph), 133.47 (C5), 133.00 (C4ph), 132.96 (C3), 129.42 (C3ph, 
C5ph), 128.38 (C2ph, C6ph), 52.47 (CH3), 47.12 (q, 2JC,F = 30.5 Hz, CH), 37.50 
(CH2) ppm.* 19F NMR (376 MHz, DMSO-d6):  = − 74.38 (d, JCF3,CH = 8.0 Hz, 
CF3) ppm. HR-ESI-MS (positive, m/z) calc. for C16H15F3N3O3+ [M+H]+ 
354.1060; found 354.1061. HPLC-MS (0.05 % formic acid; 0 min, 0 % B → 
2.0 min, 100 % B, flow: 3.3 mL/min): tR = 1.62 min, λ = 220 nm. m.p.: 
121 °C. Rf (cHex/EtOAc = 2:1) = 0.17. 
* Due to low intensity the signal of CF3 could not be observed. 
 
4,4,4-Trifluoro-1-(4-nitrophenyl)-3-(pyrazin-2-ylamino)butan-1-one 
(3e) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 4'-nitroacetophenone (111 mg, 0.68 mmol). 
After stirring at rt (1 h) followed by stirring at 40 °C (2 h) TLC and LC-MS 
control showed that large amounts of starting material remained. The reaction mixture was cooled to −78 °C before LHMDS (1.0 M solution in 
toluene, 0.45 mL, 0.45 mmol  was added. Stirring was continued at −  °C 
for 10 min, 4'-nitroacetophenone (75 mg, 0.45 mmol) was added and the 
reaction mixture was stirred at 40 °C (20 h). Subsequent aqueous workup, 
flash chromatography (chex → chex/EtOAc 4/1) and recrystallization 
(chex/EtOAc 9/1) furnished the -amino ketone 3e (115 mg, 0.34 mmol, 
75 %) as a yellow crystalline solid. 1H NMR (400 MHz, DMSO-
d6):  = 8.41 – 8.30 (m, 2H, H3ph, H5ph), 8.26 – 8.18 (m, 2H, H2ph, H6ph), 
8.04 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.96 (d, JH3,H6 = 1.5 Hz, 1H, 
H3), 7.83 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.47 (d, JNH,CH = 8.1 Hz, 1H, NH), 
5.52 – 5.33 (m, 1H, CH), 3.77 – 3.60 (m, 2H, 2 × CH2) ppm. 13C NMR 
(101 MHz, DMSO-d6):  = 194.63 (C=O), 154.01 (C2), 150.24 (C-NO2), 
141.46 (C6), 140.72 (C3), 133.17 (C5), 129.70 (C2ph, C6ph), 126.23 (q, 
1JC,F = 282.8 Hz, CF3) 123.98 (C3ph, C5ph), 47.25 (q, 2JC,F = 30.5 Hz, CH), 
37.90 (CH2) ppm. 19F NMR (376 MHz, DMSO-d6):  = − 74.47 (d, 
JCF3,CH = 7.8 Hz, CF3) HR-ESI-MS (positive, m/z) calc. for C14H12F3N4O3+ 
[M+H]+ 341.0856; found 341.0859. HPLC-MS (0.05 % formic acid; 0 min, 
0 % B → .  min, 100 % B, flow: 3.3 mL/min): tR = 1.62 min, λ = 220 nm. 
m.p.: 163 °C. Rf (cHex/EtOAc = 2:1) = 0.14. 
 
4-(4,4,4-Trifluoro-3-(pyrazin-2-ylamino)butanoyl)benzonitrile (3f) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 4'-cyanoacetophenone (99 mg, 0.68 mmol). 
After stirring at rt (1 h) followed by stirring at 40 °C (1h) TLC and LC-MS 
control showed that large amounts of starting material remained. The reaction mixture was cooled to −  °C before LHMDS (1.0 M solution in 
toluene, 0.45 mL, 0.45 mmol  was added. Stirring was continued at −78 °C 
(10 min), 4'-cyanoacetophenone (65 mg, 0.45 mmol) was added and the 
reaction mixture was stirred at 40 °C (1 h). Subsequent aqueous workup, 
flash chromatography (chex → chex/EtOAc 4/1) and recrystallization 
(chex) furnished the -amino ketone 3f (131 mg, 0.41 mmol, 91 %) as a 
colorless crystalline solid. 1H NMR (400 MHz, DMSO-d6):  = 8.18 – 8.09 
(m, 2H, H3ph, H5ph), 8.05 – 8.02 (m, 2H, H2ph, H6ph), 8.01 (m, 1H, H6), 7.96 
(d, JH3,H6 = 1.4 Hz, 1H, H3), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.46 (d, 
JNH,CH = 8.1 Hz, 1H, NH), 5.53 – 5.28 (m, 1H, CH), 3.68 (dd, JCH2,CH2 = 18.1 Hz, 
JCH2,CH = 9.3 Hz, 1H, CH2), 3.61 (dd, JCH2,CH2 = 18.0 Hz, JCH2,CH = 3.9 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  = 194.84 (C=O), 154.01 (C2), 
141.45 (C6), 139.30 (C1ph), 133.16 (C3), 133.15 (C5), 132.94 (C2ph, C6ph), 
128.88 (C3ph, C5ph), 126.24 (q, 1JC,F = 282.7 Hz, CF3 , .  C≡N , .  
(C-CN), 47.24 (q, 2JC,F = 30.5 Hz, CH), 37.69 (CH2) ppm. 19F NMR (376 MHz, 
DMSO-d6):  = − 74.37 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HR-ESI-MS (positive, 
m/z) calc. for C15H12F3N4O+ [M+H]+ 321.0958; found 321.0959. HPLC-MS 
(0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): 
tR = 1.56 min, λ = 220 nm. m.p.: 185 °C. Rf (cHex/EtOAc = 1:1) = 0.37. 
 
4,4,4-Trifluoro-1-(perfluorophenyl)-3-(pyrazin-2-ylamino)butan-1-one 
(3g) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 2',3',4',5',6'-pentafluoroacetophenone 
(0.10 mL, 0.68 mmol). After  stirring at rt (1 h) followed by stirring at 
40 °C (2 h) TLC and LC-MS control showed that large amounts of starting 
material remained. The reaction mixture was cooled to −78 °C before 
LHMDS (1.0 M solution in toluene, 0.45 mL, 0.45 mmol) was added. Stirring was continued at −78 °C (10 min), 2',3',4',5',6'-
pentafluoroacetophenone (0.07 mL, 0.45 mmol) was added and the 
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reaction mixture was stirred at 40 °C (20 h). Subsequent aqueous workup, 
flash chromatography (chex → chex/EtOAc 4/1) and recrystallization 
(chex/EtOAc 9/1) furnished the -amino ketone 3g (61 mg, 0.16 mmol, 
35 %) as a light yellow solid. 1H NMR (400 MHz, DMSO-d6):  = 8.03 – 7.97 
(m, 2H, H6, H3), 7.84 (d, JH5,H6 = 2.3 Hz, 1H, H5), 7.70 (d, JNH,CH = 8.8 Hz, 1H, 
NH), 5.51 – 5.37 (m, 1H, CH), 3.55 (dd, JCH2,CH2 = 17.7 Hz, JCH2,CH = 4.0 Hz, 
1H, CH2), 3.40 (dd, JCH2,CH2 = 17.7 Hz, JCH2,CH = 9.7 Hz, 1H, CH2) ppm. 
13C NMR (101 MHz, DMSO-d6):   = 189.83 (C=O), 153.88 (C2), 
146.07 – 145.78 (m, C-F), 144.42 – 144.10 (m, C-F), 143.55 - 143.31 (m, C-
F), 141.56 (C6), 139.00 - 138.65 (m, C-F), 136.52 - 136.16 (m, C-F), 133.64 
(C5), 133.49 (C3), 126.01 (q, 1JC,F = 283.0 Hz, CF3), 113.99 - 113.63 (m, C-
F), 47.15 (q, 2JC,F = 30.8 Hz, CH), 43.49 (CH2) ppm. 19F NMR (376 MHz, 
DMSO-d6):  = − 74.68 (d, JCF3,CH = 7.8 Hz, CF3 , − 140.87 – − .  m, F , F , − 149.30 (tt, JF4,F3 = JF4,F5 = 22.2 Hz, JF4,F2 = JF4,F6 = 4.4 Hz, F4), − 160.93 – − .  m, F , F  ppm. HR-ESI-MS (positive, m/z) calc. for 
C14H8F8N3O+ [M+H]+ 386.0534; found 386.0534. HPLC-MS (0.05 % formic 
acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): tR = 1.74 min, λ 
= 220 nm. m.p.: 115 °C. Rf (cHex/EtOAc = 2:1) = 0.30. 
 
4,4,4-Trifluoro-1-(furan-2-yl)-3-(pyrazin-2-ylamino)butan-1-one (3h) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMSD (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 2-acetylfuran (75 mg, 0.68 mmol). After 
stirring at rt (2 h), aqueous workup and column chromatography 
(chex/EtOAc 1.5/1 → 1/1) the -amino ketone 3h (75 mg, 0.26 mmol, 
58 %) was obtained as a light yellow oil. 1H NMR (800 MHz, DMSO-
d6):  = 8.02 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 8.00 (dd, 
JH5furan,H4furan = 1.7 Hz, JH5furan,H3furan = 0.7 Hz, 1H, H5furan), 7.95 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 7.80 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.57 (d, 
JNH,CH = 8.5 Hz, 1H, NH), 7.52 (dd, JH3furan,H4furan = 3.6 Hz, 
JH3furan,H5furan = 0.7 Hz 1H, H3furan), 6.73 (dd, JH4furan,H3furan = 3.6 Hz, 
JH4furan,H5furan = 1.7 Hz, 1H, H4furan), 5.47 – 5.29 (m, 1H, CH), 3.43 – 3.37 (m, 
1H, CH2), 3.31 (dd, JCH2,CH2 = 17.1 Hz, JCH2,CH = 3.8 Hz, 1H, CH2) ppm. 
13C NMR (101 MHz, DMSO-d6):  = 183.44 (C=O), 153.91 (C2), 151.57 
(C2furan), 148.36 (C5furan), 141.45 (C6), 133.15 (C3, C5), 129.19 (q, 
1JC,F = 282.8 Hz, CF3), 119.42 (C3furan), 112.92 (C4furan), 47.02 (q, 
2JC,F = 30.5 Hz, CH), 36.95 (CH2) ppm. 19F NMR (376 MHz, DMSO-
d6):  = − 74.52 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HR-ESI-MS (positive, m/z) 
calc. for C12H11F3N3O2+ [M+H]+ 286.0798; found 286.0797 HPLC (0.1 % 
TFA; 0 min, 4 % B →  min, 100 % B, flow: 1 mL/min): tR = 12.68 min, λ 
= 214 nm. Rf (cHex/EtOAc = 1:1) = 0.32. 
 
4,4,4-Trifluoro-1-(1-methyl-1H-indol-3-yl)-3-(pyrazin-2-ylamino)butan-
1-one (3i) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 1-(1-methyl-1H-indol-3-yl)ethan-1-one 
(117 mg, 0.68 mmol). After stirring at rt (2 h), aqueous workup, flash 
chromatography (CH2Cl2 → CH2Cl2/( CH2Cl2/MeOH 10:1) 7/3) and 
recrystallization (chex) the -amino ketone (105 mg, 0.30 mmol, 67 %) 
was obtained as a colorless solid. 1H NMR (400 MHz, DMSO-d6):  = 8.46 
(s, 1H, H2in), 8.12 (d, JH7in,H6in = 7.6 Hz, 1H, H7in), 8.03 (dd, JH6,H5 = 2.8 Hz, 
JH6,H3 = 1.5 Hz, 1H, H6), 7.98 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.79 (d, 
JH5,H6 = 2.8 Hz, 1H, H5), 7.54 (m, 2H, NH, H4in), 7.32 – 7.25 (m, 1H, H5in), 
7.21 (td, JH6in,H7in/H5in = 7.6 Hz, 4JH6in,H4in = 1.0 Hz, 1H, H6in), 5.59 – 5.41 (m, 
1H, CH), 3.89 (s, 3H, NCH3), 3.45 (dd, JCH2,CH2 = 16.5 Hz, JCH2,CH = 9.8 Hz, 1H, 
CH2), 3.26 (dd, JCH2,CH2 = 16.5 Hz, JCH2,CH = 3.5 Hz, 1H, CH2) ppm. 13C NMR 
(101 MHz, CDCl3):   = 188.98 (C=O), 154.06 (C2), 141.51 (C6), 138.37 
(C2in), 137.39 (Cquart-N), 133.11 (C3), 132.92 (C5), 126.53 (q, 
1JC,F = 283.0 Hz, CF3) 125.75 (C3in), 123.21 (C5in), 122.46 (C6in), 121.47 
(C7in), 115.00 (Cquart), 110.81 (C4in), 47.42 (q, 2JC,F = 30.1 Hz, CH), 37.64 
(CH2), 33.35 (CH3) ppm. 19F NMR (376 MHz, DMSO-d6):  = − 74.34 (d, 
JCF3,CH = 8.0 Hz, CF3) ppm. HR-ESI-MS (positive, m/z) calc. for 
C17H16F3N4O+ [M+H]+ 349.1271; found 349.1273. HPLC-MS (0.05 % 
formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): tR = 
1.60 min, λ = 220 nm. m.p.: 198 °C. Rf (cHex/EtOAc = 1:1) = 0.17. 
 
(E)-6,6,6-trifluoro-1-phenyl-5-(pyrazin-2-ylamino)hex-1-en-3-one (3j) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with (E)-4-phenylbut-3-en-2-one (99 mg, 
0.68 mmol). After stirring at rt (2 h), aqueous workup and column 
chromatography (chex/EtOAc 3/1 → 1/1) the -amino ketone (92 mg, 
0.29 mmol, 64 %) was obtained as a yellow oil. 1H NMR (400 MHz, DMSO-
d6):  = 8.03 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.99 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 7.80 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.74 – 7.70 (m, 2H, 
H2ph, H6ph), 7.67 (d, JHa,Hb = 16.3 Hz, 1H, Ha), 7.53 (d, JNH,CH = 8.5 Hz, 1H, 
NH), 7.47 – 7.42 (m, 3H, H3ph, H4ph, H5ph,), 6.96 (d, JHb,Ha = 16.3 Hz, 1H, Hb), 
5.48 – 5.31 (m, 1H, CH), 3.32 – 3.24 (m, 1H, CH2), 3.19 (dd, 
JCH2,CH2 = 17.3 Hz, JCH2,CH = 3.6 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, 
DMSO-d6):  = 195.11 (C=O), 154.02 (C2), 143.33 (Ca), 141.45 (C6), 
134.32 (C1ph), 133.18 (C3), 133.05 (C5), 130.88 (C4ph), 129.16 (C3ph, 
C5ph), 128.68 (C2ph, C6ph), 126.31 (q, 1JC,F = 282.8 Hz, CF3) 126.10 (Cb), , 
47.20 (q, 2JC,F = 30.3 Hz, CH) ppm. 19F NMR (376 MHz, DMSO-
d6):  = − 74.50 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HR-ESI-MS (positive, m/z) 
calc. for C16H15F3N3O+ [M+H]+ 322.1162; found 322.1160. Rf (cHex/EtOAc 
= 1:1) = 0.55. 
 
4,4,4-Trifluoro-2-methyl-1-phenyl-3-(pyrazin-2-ylamino)butan-1-one 
(3k) 
Following the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with propiophenone (0.09 mL, 0.68 mmol). After 
stirring at rt (2 h), aqueous workup and column chromatography 
(chex/EtOAc 3/1 → 2/1) the -amino ketone 3k (95 mg, 0.31 mmol, 68 %) 
was obtained as a colorless solid (mixture of diastereomeres). 1H NMR 
(400 MHz, DMSO-d6):  = 8.05 – 7.98 (m, 4H, H6, H3, H2ph, H6ph), 7.80 (d, 
JH5,H6 = 2.8 Hz, 1H, H5), 7.71 – 7.65 (m, 1H, H4ph), 7.60 – 7.53 (m, 3H, H3ph, 
H5ph, NH), 5.36 – 5.23 (m, 1H, CH), 4.17 (dq, JCHCH3,CH = 14.2 Hz, 
JCHCH3,CH3 = 7.0 Hz 1H, CHCH3), 1.25 (dd, JCH3,CHCH3 = 7.0 Hz, JCH3,CF3 = 1.1 Hz 
3H, CH3) ppm. 13C NMR (101 MHz, DMSO-d6):   = 199.81 (C=O), 153.69 
(C2), 141.17 (C6), 135.21 (C1ph), 133.65 (C5), 133.12 (C4ph), 132.96 (C3), 
128.90 (C3ph, C5ph), 128.43 (C2ph, C6ph), 126.13 (q, 1JC,F = 284.3 Hz, CF3), 
52.21 (q, 2JC,F = 28.8 Hz, CH), 26.32 (CHCH3), 14.60 (d, 4JC,F = 1.9 Hz, CH3) 
ppm. 19F NMR (376 MHz, DMSO-d6):  = − 69.65 (dd, JCF3,CH = 8.4 Hz, 
JCF3,CH3 = 1.1 Hz, CF3) ppm. HR-ESI-MS (positive, m/z) calc. for 
C15H15F3N3O+ [M+H]+ 310.1162; found 310.1160. HPLC (0.1 % TFA; 0 min, 
4 % B →  min, 100 % B, flow: 1 mL/min): tR = 15.79 min, 15.97 min, λ = 
214 nm. m.p.: 95 °C. Rf (cHex/EtOAc = 2:1) = 0.37. 
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4,4,4-Trifluoro-2,2-dimethyl-1-phenyl-3-(pyrazin-2-ylamino)butan-1-
one (3l) 
Following the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 2-methyl-1-phenylpropan-1-one (0.1 mL, 
0.68 mmol). After stirring at rt (3 h), aqueous workup and column 
chromatography (chex/EtOAc 3/1 → 2/1) the -amino ketone 3l (32 mg, 
0.10 mmol, 22 %) was obtained as a light yellow solid. 1H NMR (400 MHz, 
DMSO-d6):  = 8.20 (d, JH3,H6 = 1.5 Hz, 1H, H3), 8.00 (dd, JH6,H5 = 2.8 Hz, 
JH6,H3 = 1.5 Hz, 1H, H6), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.75 – 7.68 (m, 1H, 
H4ph), 7.67 – 7.61 (m, 2H, H2ph, H6ph), 7.58 – 7.51 (m, 1H, NH), 7.47 (m, 2H, 
H3ph, H5ph), 6.01 (m, 1H, CH), 1.40 (s, 3H, CH3), 1.27 (s, 3H, CH3) ppm. 
13C NMR (101 MHz, DMSO-d6):   = 206.17 (C=O), 154.05 (C2), 141.02 
(C6), 137.80 (C1ph), 133.52 (C5), 133.14 (C4ph), 131.20 (C3), 128.36 (C3ph, 
C5ph), 127.29 (C2ph, C6ph), 125.73 (q, 1JC,F = 284.7 Hz, CF3), 54.13 (q, 
2JC,F = 27.6 Hz, CH), 49.48 (C(CH3)2), 24.02 (CH3), 20.37 (d, 4JC,F = 1.1 Hz, 
CH3) ppm. 19F NMR (376 MHz, DMSO-d6):  = − 67.66 (d, JCF3,CH = 8.9 Hz, 
CF3) ppm. HR-ESI-MS (positive, m/z) calc. for C16H17F3N3O+ [M+H]+ 
324.1318; found 324.1318. HPLC (0.1 % TFA; 0 min, 4 % B →  min, 
100 % B, flow: 1 mL/min): tR = 15.83 min, λ = 214 nm. m.p.: 130 °C. Rf 
(cHex/EtOAc = 2:1) = 0.29. 
 
2-(2,6-Dichlorophenyl)-4,4,4-trifluoro-3-(pyrazin-2-ylamino)butane-
nitrile (3m) 
Following the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 2,6-dichlorphenylacetonitrile (202 mg, 
1.09 mmol). After stirring at rt (2.5 h), aqueous workup, column 
chromatography (chex/EtOAc 5/1 → 3/1) and washing with toluene the 
-amino ketone 3m (148 mg, 0.41 mmol, 44 %) was obtained as a 
colorless solid (mixture of diastereomeres). 1H NMR (400 MHz, DMSO-
d6):  = 8.33 (d, JH3ar,H4ar = 9.6 Hz, 1H, H3ar), 8.18 (d, JH3,H6 = 1.5 Hz, 1H, H3), 
8.09 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.94 (d, JH5,H6 = 2.7 Hz, 1H, 
H5), 7.65 (s, 2H, NH, H5ar), 7.53 (t, JH4ar,H3ar/H5ar = 8.1 Hz, 1H, H4ar), 
6.22 – 6.07 (m, 1H, CH), 5.51 (d, JCHCN,CH = 10.5 Hz, 1H, CHCN) ppm. 
13C NMR (75 MHz, DMSO-d6):   = 152.60 (C2), 140.63 (C6), 135.21 (C1ph), 
133.83 (C5), 132.89 (C3), 131.79 (C2ph, C6ph), 129.30 (C4ph), 128,21 (q, 
1JC,F = 283.9 Hz, CF3), 126.23 (C3ph, C5ph , .  C≡N , .  q, 
2JC,F = 30.2 Hz, C-CF3), 32.00 (C-CN). 19F NMR (471 MHz, 
DMSO-d6):  = − 71.63 (br s, CF3) ppm. HR-EI-MS (m/z) calc. for 
C14H9Cl2F3N4+ [M]+ 360.0156; found 360.0177. HPLC-MS (0.05 % formic 
acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 mL/min): tR = 1.68 min, 
1.73, λ = 220 nm. 
 
Diethyl 2-(2,2,2-trifluoro-1-(pyrazin-2-ylamino)ethyl)malonate (3n) 
According to the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.42 mL, 
1.42 mmol) and reacted with diethyl malonate (0.16 mL, 1.02 mmol). 
After stirring at rt (2 h) TLC and LC-MS control showed that large amounts 
of starting material remained. The reaction mixture was cooled to −78 °C 
before LHMDS (1.0 M solution in toluene, 0.68 mL, 0.68 mmol) was added. 
Stirring was continued at −  °C (10 min), diethyl malonate (0.1 mL, 
0.68 mmol) was added and the reaction mixture was stirred at 40 °C (2 h). 
Subsequent aqueous workup and column chromatography (chex/EtOAc 
3/1) furnished the desired -amino ketone 3n (134 mg, 0.40 mmol, 40 %) 
as a light yellow oil. 1H NMR (300 MHz, DMSO-d6):  = 8.09 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 8.07 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 
7.87 (d, JH5,H6 = 2.7 Hz, 1H, H5), 7.71 (d, JNH,CH = 9.5 Hz, 1H, NH), 5.73 – 5.59 
(m, 1H, CH), 4.23 – 3.94 (m, 4H, 2 × CH2), 1.16 (t, JCH3,CH2 = 7.1 Hz, 3H, CH3), 
1.01 (t, JCH3,CH2 = 7.1 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-
d6):   = 165.19 (C=O), 164.99 (C=O), 153.23 (C2), 141.06 (C6), 133.57 
(C5), 133.31 (C3), 124.90 (q, 1JC,F = 283.5 Hz, CF3), 61.97 (CH2), 61.70 
(CH2), 51.66 (CH(CO2Et)2), 49.70 (q, 2JC,F = 30.5 Hz, CH), 13.63 (CH3), 13.51 
(CH3) ppm. 19F NMR (282 MHz, DMSO-d6):  = − 72.79 (d, JCF3,CH = 7.9 Hz, 
CF3) ppm. HR-EI-MS (m/z) calc. for C13H16F3N3O4+ [M]+ 335.1093; found 
335.1104. HPLC-MS (0.05 % formic acid; 0 min, 0 % B → .  min, 100 % 
B, flow: 3.3 mL/min): tR = 1.62 min, λ = 220 nm. Rf (cHex/EtOAc 
= 2:1) = 0.31. 
 
Ethyl 4,4,4-trifluoro-3-(pyrazin-2-ylamino)butanoate (3o) 
Following the general procedure, N-(1-ethoxy-2,2,2-
trifluoroethyl)pyrazin-2-amine 1b (90 mg, 0.41 mmol) was dissolved in 
7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.94 mL, 
0.94 mmol) and reacted with ethylacetate (0.06 mL, 0.62 mmol). After 
stirring at rt (1 h), aqueous workup and flash chromatography 
(chex → chex/EtOAc 3/1) the -amino ester 3o (27 mg, 0.10 mmol, 25 %) 
was obtained as a light yellow oil. 1H NMR (400 MHz, DMSO-
d6):  = 8.12 – 7.91 (m, 2H, H6, H3), 7.82 (d, JH5,H6 = 2.3 Hz, 1H, H5), 7.65 
(d, JNH,CH = 8.9 Hz, 1H, NH), 5.40 – 5.18 (m, 1H, CH), 4.03 (m, 2H, OCH2), 
2.92 (dd, JCH2,CH2 = 16.2 Hz, JCH2,CH = 4.2 Hz, 1H, CH2), 2.72 (dd, 
JCH2,CH2 = 16.2 Hz, JCH2,CH = 10.0 Hz, 1H, CH2), 1.06 (t, JCH3,CH2 = 7.1 Hz, 3H, 
CH3) ppm. 13C NMR (101 MHz, DMSO-d6):   = 168.76 (C=O), 153.64 (C2), 
141.15 (C6), 133.11 (C5), 133.06 (C3), 125.57 (q, 1JC,F = 283.2 Hz, CF3), 
60.47 (OCH2), 47.83 (q, 2JC,F = 30.7 Hz, CH), 33.58 (CH2), 13.76 (CH3). 
19F NMR (376 MHz, DMSO-d6):  = − 74.89 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 
HR-EI-MS (m/z) calc. for C10H12F3N3O2+ [M]+ 263.0882; found 263.0898. 
HPLC-MS (0.05 % formic acid; 0 min, 0 % B → .  min, 100 % B, flow: 3.3 
mL/min): tR = 1.43 min, λ = 220 nm. Rf (cHex/EtOAc = 2:1) = 0.15. 
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4. Strategy toward a Stereoselective Synthesis of Trifluoro-
ethylamines 
 
 
 
 
Background 
As soon as a compound exhibits a good profile in preclinical testing and is considered as a potential clinical 
candidate, stereoselective synthesis of the target molecule is typically required in drug discovery. Even though 
being particularly interesting as amide surrogates, the enantioselective preparation of chiral 
trifluoroethylamines has only been scarcely pursued in drug design. Also, the protocols developed in this thesis 
only provided racemic products, thus making attempts toward stereoselective procedures highly desirable.  
To date, two main approaches to control stereochemistry during trifluoroethylamine formation are reported in 
literature: (i) auxiliary-based methods and (ii) the application of chiral ligands.[143, 150-152] Both strategies require 
the presence of (transient) imine species which are subsequently attacked by an appropriate nucleophile. 
Procedures using auxiliary substituents exploit the directing influence of the chiral auxiliary moiety during 
formation of the diastereomeric products. The Ellman´s auxiliary is commonly used in the enantioselective 
synthesis of amines from ketones and aldehydes.[185-186] The resulting N-tert-butanesulfinyl aldimine and 
ketamine are reactive intermediates which can be reacted with a wide range of nucleophiles, including 
organomagnesium and -lithium reagents.[185-187] Regarding the synthesis of enantioenriched 
trifluoroethylamines, N-tert-butanesulfinamide is widely used to introduce a chiral center by formation of a 
trifluoromethylated imine 19, which is subsequently reacted with organolithium or Grignard reagents (see 
Scheme 18). The influence of the auxiliary is predicted to proceed either via a non-chelated or a chelated 
transition state model.[143]  
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Scheme 18. Predicted transition state models for diastereoselectivity.[143] 
Interestingly, organolithium reagents favor addition from the less hindered face indicating a non-chelated 
transition state, whereas most Grignard reagents seem to react via a six-membered chelated transition state, in 
which the oxygen atom of the auxiliary coordinates to magnesium directing the addition of the carbon 
nucleophile preferably to the re-side.[143] 
Even though asymmetric addition reactions using organomagnesium reagents are reported, the majority of 
these synthetic strategies so far are controlled by chiral substrates.[143, 150, 158, 188] However, auxiliary-based 
protocols exclude initial N-functionalization and require additional cleaving steps. While stereocontrolled 
synthesis via application of chiral ligands require only catalytic amounts of the precious ligand to be employed, 
diastereoselective auxiliary-based approaches using stoichiometric amounts are rather expensive. Thus, and 
regarding precedence in the literature, we aimed at developing a stereocontrolled approach toward generation 
of trifluoroethylamines using chiral ligands. In a reported procedure, Lauzon and Charette accessed 
N-phosphinoyl-substituted trifluoroethylamines in a copper-catalyzed addition of dimethyl and diethyl zinc 
using a chiral ligand.[151] We initially focused on modifying our developed protocol toward addition of 
organozinc reagents in a copper-catalyzed reaction to elucidate a possible ligand-based enantioselective 
synthesis of trifluoroethylamines from trifluoromethylated N,O-acetals.  
Results and Discussion 
Initially, we transferred the procedure by Lauzon and Charette to the conversion of N-aryl hemiaminal ethers 
to gain insight into copper-catalyzed reactions. To our delight, reaction of 2-pyridyl N,O-acetal 20 with 
commercially available Et2Zn and catalytic amounts of Cu(OTf)2 proceeded smoothly and furnished the 
corresponding amine 21 in 80% yield without formation of any byproducts (Scheme 19). 
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Scheme 19. Synthesis of N-(1,1,1-trifluorobutan-2-yl)pyridin-2-amine 21. 
To alter stereoselectivity of the carbon-carbon bond formation, MeDuPHOS monoxide (BozPHOS) was 
employed as a chiral ligand and the resulting amine 21 was analyzed via chiral HPLC. In contrast to the reported 
conversion of N-phosphinoyl hemiaminal ethers, the addition of the chiral ligand had no effect on the ratio of 
the two enantiomers as illustrated in the HPLC spectrum of the isolated product in Scheme 20. However, 
screening of further chiral ligands should be pursued in terms of a collaboration to investigate the 
stereoselectivity of this procedure.  
 
 
Scheme 20. Synthesis of amine 21 adding MeDuPHOS monoxide and HPLC spectrum of the isolated product. 
As the procedure reported by Lauzon and Charette is limited to the use of diethyl- and dimethylzinc species, 
we then turned our attention to the transmetallation of previously used organomagnesium reagents into the 
corresponding organocopper species. Thus, we aimed at enhancing the accessibility of a broad scope of 
functionalization patterns of the potentially chiral trifluoroethylamines. Due to their throttled reactivity, 
organocopper reagents are applicable to a large substrate and ligand scope and have been successfully 
employed in stereoselective addition reactions to imines in the presence of chiral ligands.[151, 188-189] Therefore, 
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transmetallation of previously used organomagnesium reagents to less reactive organocopper(I) species was 
pursued.  
In situ conversion of phenylmagnesium chloride (2 equiv) to phenylcopper(I) 22 using CuCN2LiCl and 
subsequent reaction with one equivalent of N,O-acetal 20 furnished the corresponding trifluoroethylamine 23 
in excellent yield (Scheme 21). Interestingly, the basicity of the copper reagent was sufficient to deprotonate 
the hemiaminal ether as no external base was needed for a complete conversion of the starting material. In a 
subsequent experiment the N,O-acetal 20 was deprotonated with one equivalent of lithium 
bis(trimethylsilyl)amide (LiHMDS) before addition of the phenylcopper species (1 equiv). Fortunately, 
employing an external base did not compromise product yield.  
 
Scheme 21. Synthesis of trifluoroethylamine 23. 
With a successful modified synthetic protocol in hand, we investigated the effect of chiral ligands in 
preliminary experiments. Using a variety of ligand classes, we aimed at gaining insight into the structural 
requirements of the ligands directing stereoselectivity. Thus, we screened a first set of chiral ligands (chiral 
amine, oxazoline, phosphate and phospholane ligands depicted in Scheme 22) by adding 0.1 equivalents of a 
chiral ligand to the organocopper reagent. Unfortunately, no stereocontrol was observed in these reactions. 
 
Scheme 22. Synthesis of 23, screening different classes of chiral ligands. 
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Although somehow surprisingly at first sight, the lack of stereocontrol might be attributed to mechanistic 
considerations. As described previously, we expected the addition reaction to proceed via a prochiral aldimine 
intermediate. Formation of an enantioselective transition state by coordination of the aldimine to a copper-
ligand complex might then result in a preferred conformation of the trifluoroethylamine. However, it is also 
possible that the nucleophilic attack proceeds via a SN2-type mechanism resulting in a formal inversion of 
configuration.  
To draw conclusions from the preliminary experiments, the mechanism of the reaction needs to be elucidated 
in the future. Thus, a racemic mixture of the hemiaminal ether should be separated (i.e. via preparative chiral 
HPLC). Subsequently, the enantiopure substrate can be reacted under the stated reaction conditions. 
Stereochemical analysis of the resulting product may then give insight into the transition state of the mechanism 
(Scheme 23). With the profound knowledge of the reaction intermediates regarding the postulated aldimine 
formation, a successful asymmetric synthesis of N-aryl trifluoroethylamines may be developed. Due to time 
constraints and limited resources of chiral ligands this project will be pursued in terms of a collaboration in the 
near future. 
 
Scheme 23. Mechanistic considerations for stereoselective synthesis of trifluoroethylamines. Conversion of enantiopure 
hemiaminal ether could either result in enantiopure formation of the corresponding trifluoroethylamine via deprotonation 
of the substrate or in a mixture of both enantiomers suggesting an in situ formation of an aldimine.  
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5. One-Pot Synthesis of Substituted Trifluoromethylated 
2,3-Dihydro-1H-imidazoles 
A. Deutsch, C. Jessen, C. Deutsch, K. Karaghiosoff and A. Hoffmann-Röder, Org. Lett. 2016, 18 (14), 
34743477. 
 
 
 
 
Declaration of Contribution 
I developed a method to access novel trifluoromethylated 2,3-dihydro-1H-imidazoles in a one-pot reaction 
starting from trifluoromethylated N,O-acetals and aryl Grignard reagents. In the course of his bachelor thesis, 
Christoph Jessen synthesized a set of functionalized imidazole derivatives by variation of the N,O-acetals and 
the arylmagnesium reagents under my supervision.[190] To elucidate the mechanism of this reaction, 
Prof. Dr. K. Karaghiosoff and I performed low temperature NMR experiments. With the knowledge gained 
from these experiments, I extended the methodology to the synthesis of further functionalized fluoroalkylated 
imidazoles by conversion of trifluoroethylamines and N,O-acetals under basic conditions. 
 
Background 
The imidazole motif is present in many major building blocks of living organisms, e.g. the amino acid histidine, 
the purine-based DNA nucleobases, vitamin B12 and histamine. Ever since its discovery in the 19th century, 
the development and potential application of imidazoles has become a flourishing, rapidly growing field of 
interest.[191] The unique structure of the imidazole core, which is highly polar and amphoteric, has multiple 
beneficial binding modes allowing imidazole derivatives to bind with a large number of enzymes and biological 
systems.[192] Due to their high potency imidazole-based research has a prominent role in medicinal 
chemistry.[193-195] For instance, imidazole related compounds can be found in clinical drugs with anticancer, 
antiparasitic, antifungal, antibacterial, antihypertensive and anti-HIV activity.[196-200] A few selected examples 
are depicted in Scheme 24. 
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Scheme 24. Selected examples of imidazole-based drugs. 
Even though numerous examples of biologically active imidazole-based drugs are available, medicinal 
scaffolds containing a fluorinated imidazole core are quite limited.[201-202] Therefore, simple synthetic strategies 
toward novel fluorinated imidazole derivatives, supplementing the positive effects of fluorination (see I.2) and 
the biological potential of imidazole structures, may be highly rewarding.  
In the course of our project on the synthesis of trifluoromethylated amines from N,O-acetals and functionalized 
Grignard reagents, we found by serendipity that the 3-chlorophenyl-substituted N,O-acetal reacts with an 
excess of phenylmagnesium chloride forming a N-aryl trifluoromethylated imidazole derivative bearing an 
additional fluorine in position C-4. Suprisingly, the previously obtained trifluoroethylamine was only isolated 
in a low yield (Scheme 25). These structurally novel and highly functionalized imidazole derivatives aroused 
our interest to further investigate the scope and mechanism of this complex one-pot reaction. After optimization 
of the reaction conditions, we therefore studied the scope of imidazole formation by variation of the N,O-acetals 
and functionalized Grignard reagents employed. In addition, low temperature NMR experiments were 
conducted to elucidate a possible reaction mechanism, which enabled us to extend the method to higher 
substituted fluorinated imidazole derivatives by reacting trifluoromethylated N,O-acetals and 
trifluoroethylamines under basic reaction conditions.[203] 
 
Scheme 25. Synthesis of novel trifluoromethylated imidazoles.[203]
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ABSTRACT: An operationally simple one-pot reaction for the
preparation of a novel class of racemic trifluoromethylated 2,3-
dihydro-1H-imidazoles derived from electron-poor N,O-acetals
and aryl Grignard reagents is described. In addition, access to
highly functionalized 2-trifluoromethyl-2,3-dihydro-1H-imida-
zoles was accomplished by reaction of N-aryl hemiaminal ethers and N-aryl trifluoroethylamines in the presence of an excess of n-
butyllithium.
Owing to their ability to modify important biological andphysicochemical properties, fluorinated substructures are
widely employed in the synthesis of agrochemicals and
pharmaceuticals.1 The rationale for the incorporation of
fluorine substituents mostly relies on their positive effects on
metabolic stability, bioavailability, lipophilicity, and binding
selectivity/affinity of the parent compound.1a Driven by these
potential rewards, research on innovative methods for the
preparation of specifically fluorinated molecules is of
considerable interest. In particular, improved strategies for
efficient and controlled incorporation of CF3 groups are highly
desired.2 Beyond the growing number of approaches toward
late stage fluorinations,3 the use of fluorinated building blocks
for quick and flexible scaffold assembly is still a vital strategy
pursued in medicinal chemistry.4
Despite a large and diverse set of known biologically active
compounds possessing imidazole ring structures,5 the number
of pharmaceuticals and agrochemicals comprising fluorinated
imidazole and benzimidazole analogs is yet surprisingly
limited.6 This is most presumably due to difficulties in quickly
accessing a large number of diverse fluorinated imidazole
derivatives during drug discovery. Similarly, pharmacophores
containing fluorinated or trifluoromethylated imidazolone
derivatives have remained scarce, although 2-imidazolones are
present in numerous biologically active compounds with
intriguing pharmacological activities.7
Recently, we reported the usage of shelf-stable trifluoroace-
taldehyde-derived hemiaminal ether building blocks to
efficiently access functionalized di- and trifluoromethylated N-
aryl amine derivatives.8 In the course of these studies, we also
observed formation of unprecedented pentasubstituted 2,3-
dihydro-1H-imidazoles, bearing a CF3 group at C-2 and an
additional fluorine substituent at C-4 (Figure 1). We now
present a straightforward one-pot protocol to access various
racemic and highly substituted 2-trifluoromethyl-2,3-dihydro-
1H-imidazoles, which may be regarded as novel versatile CF3-
isosteres of 2-imidazolones for potential pharmaceutical
applications.
In our initial study, we found that treating 3-chloro-N-(1-
ethoxy-2,2,2-trifluoroethyl)aniline 1a with an excess of phenyl-
magnesium chloride (PhMgCl, 3 equiv) in tetrahydrofuran
(THF) provided trifluoromethylated imidazole derivate 2a as
the main product instead of targeted trifluoroethylamine 3a,
which was only formed in minor amounts (Scheme 1).
Moreover, by applying the same reaction conditions to
hemiaminal ether 1b, 2-trifluoromethyl-2,3-dihydro-1H-imida-
zole 2b was obtained as the sole reaction product and no traces
of the corresponding trifluoromethylated amine were observed.
Interestingly, this transformation required 2.5 equiv of PhMgCl
to proceed with full conversion, whereas reduced amounts of
Received: June 9, 2016
Published: June 30, 2016
Figure 1. 2-Imidazolone and trifluoromethylated 2,3-dihydro-1H-
imidazole.
Scheme 1. Conversion of Hemiaminal Ether 1a with
PhMgCl
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the Grignard reagent afforded mixtures of hemiaminal ether 1b
and 1H-imidazole 2b. Increasing the reaction temperature of up
to 0 °C failed to improve the yield by promoting formation of
significant amounts of byproducts, again.
However, the rapid and clean formation of product 2b at
−15 °C in THF encouraged us to explore the scope and
generality of this transformation (Figure 2). To our delight,
diverse N-aryl hemiaminal ethers were readily converted into 2-
trifluoromethyl-2,3-dihydro-1H-imidazoles in moderate to high
yields. Thereby, even labile functionalities, such as halides and
ethyl esters, proved compatible with the reaction conditions.
N,O-Acetals derived from electron-poor aminopyridines are a
notable exception, where the substitution pattern strongly
influences the reaction outcome. Thus, complete conversion to
the desired CF3-imidazole derivatives was only observed for 4-
aminopyridyl hemiaminal ether 1b and 3-aminopyridyl hemi-
aminal ether 1d. Contrarily, 2-aminopyridyl derivative 1f
provided the corresponding trifluoroethylamine 3f exclusively,
most presumably due to a stabilizing metal chelate of the
deprotonated aminopyridine unit 4f,9 which prevents further
attack to a second N,O-acetal molecule, as shown in Scheme 2.
After investigating the scope of N,O-acetals, we turned our
attention to the applicability of functionalized aromatic
Grignard reagents for this transformation (Figure 3). Thus, 1-
bromo-2-chlorobenzene was converted into the corresponding
Grignard reagent by treatment with iPrMgCl·LiCl in THF. The
latter was then added to a THF solution of the hemiaminal
ether 1b at −15 °C to provide the desired 2-trifluoromethyl-
2,3-dihydro-1H-imidazole 2g in quantitative yield. Similarly,
Grignard reagents prepared from 4- and 2-bromobenzonitrile
afforded the functionalized imidazole derivatives 2h and 2i in
high yields. As summarized in Figure 3, the reaction is general
for Grignard reagents having electron-deficient aryl and
heteroaryl groups. It should be noted, however, that reaction
of pyrid-2-ylmagnesium chloride with N,O-acetal 1b again
provided significant amounts of trifluoroethylamine 3k as a
byproduct, most presumably again due to complexation
phenomena. Finally, also vinylmagnesium chloride was less
effective as a substrate by furnishing increased amounts of
trifluoroethylamine 3o, whereas simple alkyl Grignard reagents
failed in this reaction.
A plausible reaction mechanism for the 2-trifluoromethyl-2,3-
dihydro-1H-imidazole formation is proposed in Scheme 3.
Thereby the reaction is initiated by deprotonation of the N,O-
acetal 1b. The resulting anionic species 5b then undergoes a
nucleophilic substitution reaction with PhMgCl to form the
deprotonated trifluoroethylamine 4b. Subsequent nucleophilic
attack at a second N,O-acetal 5b affords intermediate 6b, which
after transformation into difluoroenamine 7b cyclizes under
fluoride elimination to the desired reaction product 2b.
To verify the proposed reaction mechanism, we initially
performed low temperature NMR studies, which unfortunately
did not disclose any intermediates owing to the high reaction
rate. We therefore decided to examine the reaction in a
stepwise manner and subjected hemiaminal ether 1b to
deprotonation with 1 equiv of nBuLi. Recorded NMR spectra
Figure 2. Scope of the reaction of hemiaminal ether 1 with PhMgCl.
Scheme 2. Presumed Chelation of Metalated Intermediate 4f
Figure 3. Scope of the reaction of hemiaminal ether 1 with aryl
Grignard reagents.
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of the reaction mixture proved formation of two deprotonated
species, which after treatment with iodomethane yielded the
corresponding N-methylated products. Alternatively, formation
of a transient imine species could be postulated, which however
was not observed under these conditions.10 In principle, the
reaction could then proceed further, either via substitution
product 6b (pathway 2) or involvement of an enamine species
9b (pathway 1), resulting from 4b by HF elimination. To
distinguish between these two possible routes, we aimed at
preparation of gem-difluoroenamine 9b, which however was not
feasible by treatment of N-(2,2,2-trifluoro-1-phenylethyl)-
pyridine-4-amine 3b with PhMgCl. In contrast, using more
basic nBuLi and 3b furnished 9b, which was proven by
characteristic resonance signals at −100/−107 ppm in the
corresponding 19F NMR spectra (see Supporting Information
(SI)).11 Interestingly, upon increasing the temperature above
−30 °C, compound 9b undergoes exchange of one of the
vinylic fluorine atoms by a butyl group (see SI). Since this
transformation was not observed under the reaction conditions
leading to formation of 1H-imidazoles (i.e., in the presence of
Grignard reagents), the direct nucleophilic attack of 4b at N,O-
acetal 5b to generate 6b was considered more likely, although
formation of intermediate 9b cannot be fully excluded. Next,
generation of intermediate 6b was attempted by combining a
solution of hemiaminal ether 1b and 1 equiv of nBuLi with a
solution of trifluoroethylamine 3b and 1 equiv of PhMgCl at
−60 °C. Aqueous workup then provided both substrates and
the desired trifluoromethylated 1H-imidazole 2b in a 1:1:1.7
ratio as determined by 19F NMR spectroscopy (see SI).
The possibility of conducting the initial deprotonation step
separately led us to investigate the synthesis of 2-trifluor-
omethyl-2,3-dihydro-1H-imidazole derivatives bearing two
different N-aryl substitution patterns (Figure 4). Therefore,
equimolar amounts of ethyl 4-((1-ethoxy-2,2,2-trifluoroethyl)-
amino)benzoate 1e and trifluoroethylamine 3b were deproto-
nated separately with nBuLi/PhMgCl and merged, to furnish
the desired imidazole derivative 2p in 62% isolated yield. To
our delight, a comparable yield of 2p was also obtained by a
one-pot protocol, in which a solution of both substrates in THF
was treated with 2.5 equiv of nBuLi. For instance, subjecting
trifluoroethylamine 3b and N-(1-ethoxy-2,2,2-trifluoroethyl)-4-
(trifluoromethyl)aniline 1q to these conditions provided the
corresponding trifluoromethylated imidazole 2q in 65% isolated
yield. Interestingly, reversal of the substitution pattern reaction,
i.e., by reaction of N,O-acetal 1b and N-(2,2,2-trifluoro-1-
phenylethyl)-4-(trifluoromethyl)aniline 3r, resulted in a
diminished isolated yield of 26% of the desired product 2r
and large amounts of unreacted substrate. Moreover, the
protocol allows preparation of 1H-imidazole derivatives bearing
N-2-pyridyl substituents, which were previously difficult to
access. However, this transformation is limited to reactions of
2-pyridyl-substituted hemiaminal ethers such as 1f, whereas
trifluoroethylamines bearing the 2-pyridyl substituent are not
compatible. Finally, the product portfolio was also extended
toward hitherto unknown 2-difluoromethyl-2,3-dihydro-1H-
imidazole derivatives, e.g. 2t, which was efficiently prepared
from N-(1-ethoxy-2,2-difluoroethyl)pyridin-2-amine 1t and 3b.
In summary, we have devised a rapid and practical method
for the synthesis of racemic 2-trifluoromethyl-2,3-dihydro-1H-
imidazoles. The latter belong to a novel class of fluorinated
imidazole derivatives of high pharmaceutical potential, which
are accessible by condensation of N-aryl hemiaminal ethers
with aryl Grignard reagents or N-aryl trifluoroethylamines.
Crossover and control experiments have provided the first
Scheme 3. Proposed Mechanisms for the Formation of
Trifluoromethylated 2,3-Dihydro-1H-imidazole 2b
Figure 4. Synthesis of further functionalized 2-CF3-2,3-dihydro-1H-
imidazole derivatives.
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insights into the reaction mechanism. The operational
simplicity of the protocol and the ready availability of the
starting materials make this a very convenient approach for the
synthesis of novel structurally diverse imidazole building blocks.
With regard to their complex substitution patterns, the
synthesis of reported 2-trifluoromethyl-2,3-dihydro-1H-imida-
zoles might be of particular interest for future pharmacological
applications. Hence, their use for targeted synthesis is currently
under investigation in our laboratory.
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Hoffmann-Röder, A. Eur. J. Org. Chem. 2016, 2016, 930−945.
(9) Ortu, F.; Moxey, G. J.; Blake, A. J.; Lewis, W.; Kays, D. L. Inorg.
Chem. 2013, 52, 12429−12439.
(10) Formation of imine species were only observed during
preparation of electron-rich hemiaminal ethers under acidic con-
ditions; for an experimental procedure, see: Gong, Y.; Kato, K. J.
Fluorine Chem. 2004, 125, 767−773.
(11) Kirij, N. V.; Babadzhanova, L. A.; Movchun, V. N.; Yagupolskii,
Y. L.; Tyrra, W.; Naumann, D.; Fischer, H. T. M.; Scherer, H. J.
Fluorine Chem. 2008, 129, 14−21.
Organic Letters Letter
DOI: 10.1021/acs.orglett.6b01672
Org. Lett. 2016, 18, 3474−3477
3477
III. RESULTS AND DISSCUSION   
 
82 
 
6. Strategy toward ψ[CH(CF3)NH]-Gly Dipeptide Building 
Blocks for Peptide Synthesis 
 
 
 
Background 
The remarkable therapeutic potential of peptides is mainly limited by their inadequate oral bioavailability, 
membrane permeability, metabolic stability and their physicochemical properties. The development of 
appropriate peptidomimetics to avoid these restrictions and to take advantage of the high biological activity of 
this structural motif is therefore highly rewarding. Substitution of one or multiple peptide bonds by 
enzymatically stable mimics is a promising approach, but has not gained much attention for 
trifluoroethylamines in medicinal research up to now.[123-125, 204-207]  
One of the first synthetic strategies to access short peptides containing trifluoroethylamine building blocks was 
reported by Zanda and co-workers (Scheme 22).[205] Their protocol toward ψ[CH(CF3)NH]-Gly peptides relies 
on the use of trifluoro-1-nitropropene 24 to incorporate the trifluoromethyl group. Substrate 24 can be prepared 
by a Henry reaction of TFAE and nitromethane, followed by subsequent dehydration of the intermediate 
nitroaldol product 25 using P2O5. The key step of this route comprises an aza-Michael reaction between the 
trifluoromethylated nitroalkene 24 and the corresponding hydrochloric salts of α-amino acid esters 26 to 
provide the desired trifluoromethylated -nitro-α-amino esters 27 and 28. The stereochemistry of this 
aza-Michael reaction is strongly influenced by the solvent, the base and the substitution pattern of the starting 
amino acid ester 26. The best diastereoselectivity is observed using 1.1 equivalents of 
N,N-diisopropylethylamine (DIPEA) as a base in toluene, whereas use of NaHCO3 or 
2,2,6,6-tetramethylpiperidine (TMP) resulted in reduced yields of compounds 27 and 28.[205] 
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Scheme 26. Synthesis of the trifluoromethylated nitroalkene 24 and subsequent aza-Michael reaction.[205] 
Subsequent hydrogenation of the nitro group using Pearlmans catalyst provides trifluoromethylated dipeptide 
building block 29, which can be further condensed to α-amino acids using standard coupling conditions to 
furnish the corresponding pseudo-tripeptides (Scheme 27).[205]  
 
Scheme 27. Synthesis of ψ[CH(CF3)NH]-Gly tripeptide.[205] 
Regarding our previous work on the synthesis of N-aryl trifluoroethylamines, we sought to apply this method 
to access ψ[CH(CF3)NH]-Gly dipeptide building blocks. Whereas the approach by Zanda and co-workers 
requires coupling of a second amino acid in an early stage of the synthetic route and has found little application 
in peptide synthesis, we aimed at a more convenient strategy toward ψ[CH(CF3)NH]-Gly building blocks for 
the synthesis of larger peptides by late-stage coupling of a second amino acid substrate to provide a large 
number of diverse trifluoromethylated dipeptides.  
Results and Discussion 
Retrosynthetic analysis to access ψ[CH(CF3)NH]-Gly dipeptide building blocks 30 disclosed two principle 
strategies (Scheme 28). On the one hand, the amino acid building block could be inserted by reaction of 
trifluoroethylamine 31 with an amino acid precursor 32 featuring a leaving group (LG) (Strategy A). 
Alternatively, protected amino acid 33 could function as the nucleophile to attack the trifluoromethylated 
building block 34 (Strategy B). In the course of her master thesis, Elen Baumann investigated the synthesis of 
the pseudo-peptide building blocks following strategy A.[208] The major challenge of strategy A was the hitherto 
unreported coupling of a trifluoroethylamine building block 31 with a suitable amino acid precursor 32 due to 
the electron-withdrawing effect of the trifluoromethyl moiety adjacent to the amine. Additionally to the steric 
hindrance, this resulted in a diminished nucleophilicity of the amino group and prohibited the reaction with an 
electrophile. Furthermore, this procedure requires synthesis of amino acid precursors by introducing an 
appropriate leaving group to allow nucleophilic attack of the trifluoroethylamine 31. In contrast, strategy B 
relies on coupling of readily available C-terminal protected building blocks. Furthermore, the electron-
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withdrawing effect of the trifluoromethyl moiety should facilitate the attack of a nucleophile. Thus, strategy B 
was pursued in the following, even though a more elegant approach featuring a trifluoromethylated acetal is 
conceivable.  
 
Scheme 28. Retrosynthetic strategies A and B toward ψ[CH(CF3)NH]-Gly dipeptide building block 30. 
Initially, the preparation of trifluoromethylated N,O-acetal 35 was accomplished with para-anisidine, TFAE 
and catalytic amounts of para-toluenesulfonic acid (pTSA) in good yield following a procedure reported by 
Gong et al. (Scheme 29).[153] Implementing para-methoxyphenyl (PMP) as a protecting group for the amino 
group allows its selective deprotection in the presence of a further Fmoc protecting group, which is commonly 
used in SPPS protocols. A subsequent Strecker-type reaction of 35 with TMSCN in the presence of catalytic 
amounts of BF3Et2O provided the nitrile 36 as a racemic mixture in excellent yield.[209]  
 
Scheme 29. Synthesis of trifluoromethylated nitrile 36.  
Nitrile 36 was subsequently reduced using lithiumaluminium hydride (LAH), providing 37 with a free amino 
group in 73% yield. With compound 37 in hand, diamine 31 was accessible within two synthetic steps (Scheme 
30). In the first step, the unprotected amino group of 37 was treated with Fmoc N-hydroxysuccinimide ester 
using standard conditions furnishing compound 38 after recrystallization from dichloromethane in 67% yield. 
Next, deprotection of the PMP group was addressed, which however turned out to be rather challenging. Thus, 
different oxidation strategies had to be tested to identify a suitable protocol. Following a mild protocol by 
Verkade et al. using trichloroisocyanuric acid (TCCA) as an oxidizing agent did not result in the deprotection 
of PMP moiety. Similarly, procedures using 2-iodoxybenzoic acid (IBX) or bis(acetoxy)iodobenzene (BAIB) 
and 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) did not provide the desired product 31 in satisfying yield. 
Finally, compound 31 was obtained in good yield of 81% by treatment of 38 with an excess of ceric ammonium 
nitrate (CAN). Interestingly, rapid conversion of the starting material to the corresponding imine intermediate 
took place, whereas the subsequent hydrolysis proceeded sluggishly and required more than 16 hours for 
complete conversion.  
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Scheme 30. Synthesis of trifluoromethylated diamine 31.  
Next, the unprotected amine moiety (31) needed to be converted into an appropriate leaving group to allow the 
nucleophilic attack by the amino acid building block. Thus, different approaches to obtain the 
ψ[CH(CF3)NH]-Gly-Val dipeptide 39 were investigated, including the conversion of the amino group into a 
chloride (compound 40) and hydroxyl moiety (compound 41) for subsequent condensation. Compound 40 was 
obtained by diazotization of 31 using NaNO2 and 6 M hydrochloric acid in moderate yield (Scheme 31). 
Analogously, amine 31 was converted into the corresponding hydroxyl compound 41 upon treatment with 
NaNO2 and acetic acid. 
 
Scheme 31. Synthesis of compounds 40 and 41. 
With compounds 40, 41 and a benzyl-protected L-valine derivative in hand, formation of ψ[CH(CF3)NH]-Gly-
Val dipeptide 39 was studied by screening different reaction conditions. Initially, the chloride 40 and the valine 
derivative were refluxed in CH2Cl2 using triethylamine or DIPEA as base (Table 3). As no reaction between 
the substrates occurred under these conditions, the solvent was replaced with dimethylformamid (DMF) to 
enable heating of the reaction to 100 °C. This however resulted in a partial deprotection of the Fmoc-protecting 
group without displaying any formation of the dipeptide building block 39. 
Table 3. Reaction condition for coupling of chloride 40 with benzyl-protected L-valine 
 
 
 
 
 
Alternatively, reacting compound 41 under Appel conditions (via compound 42) and subsequent addition of 
the benzyl-protected amino acid did not result in formation the desired dipeptide 39 (Table 4). However, 
Substrate Temperature Base Solvent Observation 
40 40 °C NEt3 CH2Cl2 no reaction 
40 40 °C DIPEA CH2Cl2 no reaction 
40 100 °C NEt3 DMF decomposition 
40 100 °C DIPEA DMF decomposition 
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protection of 41 using triflate anhydride (via compound 43) and subsequent reaction with the amino acid 
resulted in formation of traces of the desired ψ[CH(CF3)NH]-Gly-Val dipeptide 39. Due to the poor conversion 
rate, compound 39 could not be isolated after work-up. Interestingly, significant amounts of substrate 41 were 
re-isolated, indicating a presumable lack of reactivity as a result of the sterically demanding trifluoromethyl 
moiety. In addition, deactivation of the hydroxyl group by to the strong electron-withdrawing character of the 
trifluoromethyl moiety might hamper its nucleophilicity toward triflate anhydride and triphenylphosphine. 
Table 4. Reaction condition for coupling of substrates 41 with benzyl-protected L-valine 
 
 
 
 
To further optimize and develop of a more elegant synthetic strategy, e.g. by using a trifluoromethylated acetal 
precursor for subsequent incorporation into peptide model systems, further synthetic studies are currently 
pursued in the group. Moreover, using acetals may also enable access toward novel ψ[CH(CF3)O]-pepsipeptide 
building blocks (Figure 24). The successfully prepared amine building block 31 could also be implemented in 
the preparation of retro-invers ψ[CH(CF3)NH]-Gly peptides.   
 
Figure 24. Structures of ψ[CH(CF3)O]-pepsipeptides and retro-invers ψ[CH(CF3)NH]-Gly peptide building blocks. 
 
Substrate Reagents Temperature Solvent Observation 
41 CBr4, PPh3 r.t. → 40 °C CH2Cl2 no reaction 
41 TfO2, 2,6-lutidine -78 °C → 0 °C CH2Cl2 traces of 39 
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IV. CONCLUSION AND OUTLOOK 
In summary, several strategies toward novel trifluoromethylated amine scaffolds for application in lead 
structure research have been developed and executed. A selection of these fluoroalkylated compounds is 
depicted in Scheme 32. 
 
Scheme 32. Selected examples of synthesized fluoroalkylated compounds. 
Focusing on the synthesis of trifluoroethylamines as bioisosteric replacements for amide moieties, a range of 
highly functionalized derivatives were successfully synthesized. These novel trifluoromethylated scaffolds 
might be of particular interest for pharmaceutical applications. Initially, N-aryl substituted hemiaminal ethers 
were reacted with simple alkyl-, alkenyl, and phenylmagnesium reagents to furnish trifluoroethylamines in 
good to excellent yields. Moreover, to access hemiaminal ethers with N-heteroaryl and electron-poor N-aryl 
substituents, an improved method using microwave assisted reaction conditions was established. Subsequently, 
the strategy toward trifluoroethylamines was successfully extended to the use of functionalized Grignard 
reagents, enabling the synthesis of rather complex target molecules (Scheme 33).  
 
Scheme 33. Synthesis of functionalized N-aryl trifluoromethylated amines. 
The sublime applicability of our methodology in more complex building blocks was proven by preparation of 
bioisosteric analogs of the androgen receptor antagonist DIMN and 1,2-dihydroquinazolin-4-(1H)-thione in 
good yield (Figure 25a and b). 
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Figure 25 Synthesized trifluoroethylamine bioisosteres of a) nicotinamide DIMN and b) 1,2-dihydroquinazolin-4(1H)-
thione. 
In addition, the newly developed method effectively furnished novel functionalized difluoroethylamines. This 
structural motif exhibits promising properties as the difluoromethyl moiety can alter the pKa value of adjacent 
amines but is still a weak hydrogen-bond donor in contrast to the trifluoromethyl group.  
Besides the synthesis of fluoromethylated amines using organometallic reagents, novel synthetic approaches 
were investigated to access further complex trifluoromethylated scaffolds by conversion of N-aryl hemiaminal 
ethers with heteroatom nucleophiles as well as C-nucleophiles (Scheme 34). Thus, amines, benzamidines, 
O- and S-nucleophiles were successfully reacted with an appropriate hemiaminal ether under basic conditions 
furnishing the desired trifluoromethylated compounds in good to excellent yields. Additionally, an efficient 
one-pot procedure for the synthesis of fluorinated -amino carbonyl compounds was accomplished under 
Mannich-type reaction conditions. These were applied to a large variety of hemiaminal ethers as well as 
C-nucleophiles. 
 
Scheme 34. Conversion of N-aryl hemiaminal ethers with C-, N-, O- and S-nucleophiles.  
In terms of future work, synthesis of additional trifluoromethylated structures and biological evaluation of these 
bioisosteres in comparison to their parent structures could be beneficial to elucidate the influence of this 
bioisosteric replacement on binding affinity, ADME and pharmacokinetic parameters. In this context, the 
synthesized novel N-aryl tri- and difluoroethylamines should be evaluated regarding their biological activity 
and pharmacological properties. Furthermore, trifluoromethylated -amino carbonyl compounds could be 
deployed as precursors of -trifluoromethyl -amino acids and subsequently be incorporated into peptide 
mimetics.  
Regarding the stereoselectivity of the conversions, first attempts toward an enantioselective conversion of the 
hemiaminal ethers with nucleophiles have been made. Initially, the synthesis was successfully transferred to 
the use of organocopper reagents. Preliminary experiments aiming at an asymmetric formation of 
trifluoroethylamines via chiral ligands were performed. Although these efforts remained unsuccessful, the 
extension of the procedure to organocopper reagents facilitates access to a broad scope of substrates and 
ligands. In the future, the mechanism of the reaction should be elucidated and additional chiral ligands should 
be screening within scientific collaborations. 
IV. SUMMARY AND OUTLOOK    
89 
 
During investigations on the scope trifluoroethylamines accessible via our procedure, formation of a hitherto 
unknown class of fluorinated imidazole derivatives was observed. Thus, trifluoromethylated 2,3-dihydro-1H-
imidazoles were obtained from trifluoromethylated N,O-hemiaminal ethers featuring electron-withdrawing 
substituents and aryl Grignard reagents in an one-pot reaction (Scheme 35).  
 
Scheme 35. One-pot synthesis of trifluoromethylated 2,3-dihydro-1H-imidazoles. 
The mechanism of this formation was studied via low-temperature NMR experiments by disassembling two 
proposed pathways in separate experiments (Scheme 36). Deprotonating the hemiaminal ether with nBuLi 
at -60 °C revealed formation of two deprotonated species, whereas aldimine formation could not be detected 
under the stated reaction conditions. Moreover, formation of a difluoroenamine species was observed treating 
an appropriate trifluoroethylamine with nBuLi, which however was not feasible using PhMgCl. 
 
Scheme 36. Proposed mechanistic pathways of 2-CF3-2,3-dihydro-1H-imidazole formation. 
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These experiments suggested a mechanism according to pathway 2, which was confirmed in further 
experiments and finally led to the development of a modified protocol providing access to various highly 
functionalized fluoromethylated imidazoles from trifluoroethylamines and hemiaminal ethers (Scheme 37).  
 
Scheme 37. Synthesis of further functionalized 2-CF3-2,3-dihydro-1H-imidazole derivatives. 
Due to the significance of peptide mimetics in drug discovery and our experience in synthetic approaches 
toward trifluoroethylamines, a strategy toward ψ[CH(CF3)NH]-Gly dipeptide building blocks was developed. 
The key diamino intermediate was obtained in six synthetic steps starting from the PMP-protected N,O-acetal 
(Scheme 38). Furthermore, first studies toward finding an appropriate leaving group for the subsequent 
coupling with a second amino acid were undertaken. Prospective optimization of this approach and the 
following incorporation in a model peptide sequence may give an insight into the influence of the bioisosteric 
replacement in terms of stability and structure. 
 
Scheme 38. Strategy toward ψ[CH(CF3)NH]-Gly dipeptide building blocks. 
As summarized above, synthetic approaches toward functionalized fluoroalkylated scaffolds for medicinal 
chemistry research have been established. The conversion of fluorinated N,O-acetals with various nucleophiles, 
including carbon and heteroatom nucleophiles, allow efficient synthesis of a broad range of fluoroalkylated 
compounds. These functionalized fluoroalkylated compounds are particularly interesting as potential building 
blocks for drug development and biomedical applications. 
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V. EXPERIMENTAL PROCEDURES 
1. Material and Methods 
 
All reactions were carried out under argon atmosphere in flame-dried glassware. Syringes which were used to 
transfer anhydrous solvents or reagents were purged with argon prior to use. Dry THF was freshly distilled 
from sodium and benzophenone under argon. Commercially available reagents and solvents were used without 
further purification. Grignard reagents were purchased from Aldrich or synthesized with the described 
procedure. All microwave irradiation experiments were carried out in a CEM ExplorerTM microwave apparatus, 
operating at a frequency of 2.45 GHz with continuous irradiation power from 0 to 200 W utilizing the standard 
absorbance level of 300 W maximum power. The reactions were carried out in 10 mL Pyrex vessels sealed 
with CEM plastic crimp tops equipped with magnetic stirrers. The temperature was measured with an infrared 
sensor on the outer surface of the process vial. After the irradiation period, the reaction vessel was cooled 
rapidly (1−2 min) to ambient temperature using a nitrogen jet. 
Reactions were monitored by TLC with pre-coated silica gel 60 F254 aluminium plates (Merck KGaA, 
Darmstadt) using UV light as the visualizing agent. The crude products were purified by standard flash 
chromatography or MPLC with a CombiFlash Rf Teledyne ISCO or by standard flash chromatography using 
silica gel (35–70 µm) from Acros Organics. Analytical RP-HPLC was measured on a JASCO system with a 
Phenomenex Luna C18 column (5 µm, 250 × 4.6 mm). ESI- and HR-ESI-mass spectra were recorded on a 
Thermo Finnigan LTQ FT or on a Bruker maxis equipped with a Waters Acquity UPLC using a Kinetex C18 
column (2.6 µ, 100 A) at 40 °C. HPLC-MS was performed on Agilent 1100 and Agilent 1200 systems using 
Chromolith Speed ROD RP-18e columns. In all cases, mixtures of water (eluent A) and acetonitrile (eluent B) 
were used as solvents. if required, 0.05% formic acid or 0.1% TFA were added. 1 H, 13C, and 19F NMR spectra 
were recorded on a Varian 300 MHz and 600 MHz spectrometer or on a Bruker Avance II 400 MHz 
spectrometer in DMSO-d6 or CDCl3. The chemical shifts are reported in ppm relative to the signal of the 
deuterated solvent. Multiplicities are given as: s (singlet), br s (broad singlet), d (doublet), t (triplet), and m 
(multiplet). Melting points were measured on a Melting Point B-540 Büchi. IR spectra were measured on a 
Perkin-Elmer FT-IR Spektrum BXII spectrometer with a Smiths Dura SampIIR II ATR. 
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2. Experimental Procedures and Analytical Data: Synthesisof 
functionalized α-trifluoroethyl amine scaffolds via Grignard 
addition to N-aryl hemiaminal ethers 
 
The complete supporting information including the experimental procedures and NMR spectra of all 
compounds is available on the RSC Advances website (DOI: 10.1039/c3ra47708h) and on the CD in the book 
cover of this thesis. The compounds are numbered according to the publication. 
2.1 General procedure for the synthesis of trifluoroethylamines 
A dry Schlenk flask was flushed with argon, equipped with a magnetic stirrer and a septum and charged with 
N-aryl hemiaminal ether in dry THF (ca. 0.05 M). The solution was cooled to 15 °C, the Grignard reagent 
(2 equiv) was added drop wise, and the solution was stirred at 15 °C until complete consumption of the 
starting material (ca. 1 h, TLC and LC-MS control). Then, the solution was quenched with 1:1 THF/H2O 
(12 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic phases were dried over Na2SO4, 
and the solvent was evaporated in vacuo. Purification by flash chromatography furnished the desired amines 
2a-j, 3a-h, 5 and 6.  
2.2 Experimental data 
3-Chloro-N-(2,2,2-trifluoro-1-methylethyl)aniline 2a 
According to the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (152 mg, 0.60 mmol) 
was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 0.86 mL, 1.20 mmol) in dry THF (12 mL). The crude 
product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 80:20) to give the 
desired amine 2a (116 mg, 87%) as a light yellow oil.  
1H NMR (400 MHz, DMSO-d6): δ = 7.09 (t, J = 8.1 Hz, 1 H, H5), 6.78 (t, J = 2.1 Hz, 
1 H, H2), 6.68 (dd, J = 8.2 Hz, 2.0 Hz, 1 H, H6), 6.60 (ddd, J = 7.8 Hz, 1.9 Hz, 0.7 Hz, 
1 H, H4), 6.26 (d, J = 9.0 Hz, 1 H, NH), 4.45 – 4.30 (m, 1 H, CH), 1.28 (d, J = 6.8 Hz, 
3 H, CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 75.76 (d, JCF3,CH = 7.0 Hz, CF3) ppm. 13C NMR 
(101 MHz, DMSO-d6): δ = 148.64 (C1), 133.59 (C3), 130.33 (C5), 126.77 (q, JC,F = 284.0 Hz, CF3), 116.29 
(C4), 111.94 (C2), 111.32 (C6), 49.07 (q, JC,F = 29.5 Hz, CCF3), 14.28 (CH3) ppm. FT-IR (ATR): ῦ = 3420 
(br, vw), 1598 (s), 1510 (m), 1482 (m), 1252 (m), 1133 (vs), 1022 (s), 990 (m), 841 (w), 764 (m), 680 (m) cm -1. 
HPLC-MS (0.1% TFA. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.52 min, λ = 220 nm. 
HRMS (ESI+): m/z calcd. for C9H10ClF3N+ [M+H]+ 224.0448, found 224.0448.  
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N-(2,2,2-Trifluoro-1-methylethyl)aniline 2b[[139]] 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1b[139] (200 mg, 0.91 mmol) was 
reacted with MeMgBr (1.4 M in toluene/THF 3:1, 1.30 mL, 1.82 mmol) in dry THF (12 mL). The crude product 
was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 80:20) to give the desired 
amine 2b (109 mg, 63%) as a light yellow liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.15 – 7.01 (m, 2 H, H3. H5), 6.71 (d, J = 7.8 Hz, 2 H, 
H2, H6), 6.59 (tt, J = 7.4 Hz, 1.0, 1 H, H4), 5.88 (d, J = 8.9 Hz, 1 H, NH), 4.38 – 4.20 (m, 
1 H, CH), 1.29 (d, J = 6.8 Hz, 3 H, CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 75.70 
(d, JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 147.00 (Cq), 128.84 (CHar), 126.90 (q, 
JC,F = 284.2 Hz, CF3), 116.85 (CHar), 112.58 (CHar), 49.31 (q, JC,F = 29.4 Hz, CCF3), 14.35 (CH3) ppm. FT-
IR (ATR): ῦ = 3406 (br, vw), 3026 (vw), 1603 (m), 1511 (m), 1497 (m), 1387 (w), 1250 (s), 1166 (m) 1127 
(vs), 1018 (s), 946 (w), 747 (s), 691 (s) cm-1. HPLC-MS (0.1% TFA. 0 min: 4% B → 2.8 min: 100% B, flow: 
2.4 mL/min): tR = 2.19 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C9H11ClF3N+ [M+H]+ 190.0838, found 
190.0838. 
 
N-(2,2,2-Trifluoro-1-methylethyl)aminopyridine 2c 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1c (196 mg, 0.89 mmol) was 
reacted with MeMgBr (1.4 M in toluene/THF 3:1, 1.27 mL, 1.78 mmol) in dry THF (12 mL). The crude product 
was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 80:20) to give the desired 
amine 2c (137 mg, 81%) as a white solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.07 (dd, J = 4.8 Hz, 1.5 Hz, 2 H, H3. H5), 6.81 (d, 
J = 9.0 Hz, 1 H, NH), 6.66 (dd, J = 4.9 Hz, 1.5 Hz, 2 H, H2. H4), 4.56 – 4.41 (m, 1 H, CH), 
1.30 (d, J = 6.8 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, DMSO-d6): δ = 75.82 (d, 
JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 152.50 (C1), 149.54 (CHar), 126.56 (q, 
JC,F = 284.0 Hz, CF3), 107.71 (CHar), 48.13 (q, JC,F = 29.9 Hz, CCF3), 14.06 (CH3) ppm. FT-IR (ATR): 
ῦ = 3234 (w), 2994 (br, w), 1602 (s), 1533 (m), 1325 (w), 1267 (m), 1220 (s), 1162 (s), 1138 (vs), 1020 (s), 
992 (s), 812 (s), 673 (m) cm-1. HPLC-MS (0.1% TFA. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): 
tR = 1.07 min, λ = 220 nm. mp 148 °C. HRMS (ESI+): m/z calcd. for C8H10F3N2+ [M+H]+ 191.0791, found 
191.0798. 
 
4-Methoxy-N-(2,2,2-trifluoro-1-methylethyl)aniline 2d[[210]] 
According to the general procedure, 4-methoxy-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1d[[211]] (190 mg, 
0.76 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 1.09 mL, 1.52 mmol) in dry THF (12 mL). 
The crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 60:40) 
to give the desired amine 2d (67 mg, 40%) as a light yellow liquid.  
V. EXPERIMENTAL PROCEDURES   
 
95 
 
1H NMR (400 MHz, DMSO-d6): δ = 6.75 – 6.65 (m, 4H, 4 × Har), 5.46 (d, J = 9.0 Hz, 
1 H, NH), 4.24 – 4.09 (m, 1 H, CH), 3.64 (s, 3 H, OCH3), 1.26 (d, J = 6.8 Hz, 3 H, 
CH3) ppm. 19F NMR (376 MHz, DMSO-d6): δ = 75.65 (d, JCF3,CH = 7.3 Hz, 
CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 151.34 (Cq), 141.07 (Cq), 127.01 (q, JC,F = 284.3 Hz, CF3), 
114.44 (CHar), 113.91 (CHar), 55.25 (OCH3), 50.36 (q, JC,F = 29.0 Hz, CCF3), 14.44 (CH3) ppm. FT-IR (ATR): 
ῦ = 3386 (br, vw), 2942 (br, vw), 1511 (vs), 1457 (w), 1273 (w), 1232 (s), 1130 (vs), 1018 (s), 946 (w), 819 
(s), 666 (m) cm-1. HPLC-MS (0.05% formic acid. 0 min, 4% B → 2.8 min, 100% B, flow: 2.4 mL/min): 
tR = 2.25 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C10H13F3NO+ [M+H]+ 220.0944, found 220.0941. 
 
Ethyl-N-(2,2,2-trifluoro-1-methylethyl)4-aminobenzoate 2e 
Following the general procedure, ethyl-N-(1-ethoxy-2,2,2-trifluoroethyl)-4-aminobenzoate 1e (220 mg, 
0.76 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 1.08 mL, 1.51 mmol) in dry THF (12 mL). 
The desired amine 2e (186 mg, 94%) was isolated after workup as a yellow solid without further purification.  
1H NMR (400 MHz, DMSO-d6): δ = 7.72 (d, J = 8.8 Hz, 2 H, 2 × Har), 6.79 (m, 3 H, 
NH . 2 × Har), 4.58 – 4.40 (m, 1 H, CH), 4.22 (q, J = 7.1 Hz, 2 H, CH2CH3), 1.32 (d, 
J = 6.7 Hz, 3 H, CHCH3), 1.27 (t, J = 7.1 Hz, 3 H, CH2CH3) ppm. 19F NMR (376 
MHz, DMSO-d6): δ = 75.76 (d, JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 165.63 
(COOEt), 151.29 (C1), 130.75 (C3. C5), 124.07 (q, JC,F = 284.8 Hz, CF3), 117.68 (C4), 111.74 (C2. C6), 59.65 
(CH2), 48.78 (q, JC,F = 29.7 Hz, CCF3), 14.25 (CH3), 14.17 (CH3) ppm. FT-IR (ATR): ῦ = 2251 (m), 2976 (br, 
vw), 1684 (s), 1601 (s), 1265 (w), 1286 (s), 1251 (vs), 1148 (vs), 1124 (s), 1097 (s), 1015 (s), 847 (m), 769 
(vs), 700 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): 
tR = 2.35 min, λ = 220 nm. mp 86 °C. HRMS (ESI+): m/z calcd. for C12H15F3NO2+ [M+H]+ 262.1049, found 
262.1049. 
 
2-(3-Morpholinopropoxy)-5-(trifluoromethyl)-N-(2,2,2-trifluoro-1-methylethyl)aniline 2f  
According to the general procedure, 2-(3-morpholinopropoxy)-5-(trifluoromethyl)-N-(1-ethoxy-2,2,2-
trifluoroethyl)aniline 1f (184 mg, 0.43 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 1.08 mL, 
0.86 mmol) in dry THF (12 mL). The crude product was purified by flash chromatography 
(SiO2, CH2Cl2 → CH2Cl2/MeOH 85:15) to give the desired amine 2f (97 mg, 57%) as a yellow 
liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.08 (s, 1 H, H2), 7.04 – 6.95 (m, 2 H, H4. H5), 5.05 (d, 
J = 9.5 Hz, 1 H, NH), 4.66 – 4.53 (m, 1 H, CH), 4.15 – 4.10 (m, 2 H, CH2), 3.58 – 3.55 (m, 
4 H, 2 × CH2), 2.42 (t, J = 7.1 Hz, 2 H, CH2), 2.39 – 2.32 (m, 4H, 2 × CH2), 1.97 – 1.87 (m, 
2 H, CH2), 1.36 (d, J = 6.7 Hz, 3 H, CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 59.89 
(CF3), 75.75 (d, JCF3,CH = 7.3 Hz, CHCF3) ppm. 13C NMR (101 MHz, DMSO-d6): 
δ = 148.25 (Cq), 136.56 (Cq), 126.73 (CF3), 124.68 (CF3), 121.48 (CHar), 114.44 (CCF3), 111.03 (CHar), 
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107.02 (CHar), 66.77 (CH2), 66.13 (CH2), 54.71 (CH2), 53.31 (CH2), 49.24 (CHCF3), 25.47 (CH2CH2CH2), 
14.44 (CH3) ppm. FT-IR (ATR): ῦ = 3420 (br, vw), 2956 (br, vw), 1606 (w), 1532 (w), 1447 (m), 1328 (w), 
1256 (m), 1109 (vs), 960 (w), 861 (m), 874 (w) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 
100% B, flow: 2.4 mL/min): tR = 1.73 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C17H23F6N2O2+ [M+H]+ 
401.1658, found 401.1657. 
 
(6-Chloro-1-methyl-1H-benzoimidazol-2-yl)-(2,2,2-trifluoro-1-methylethyl)amine 2g 
According to the general procedure, (6-chloro-1-methyl-1H-benzoimidazol-2-yl)-(1-ethoxy-2,2,2-
trifluoroethyl)amine 1g (32 mg, 0.07 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 0.10 mL, 
0.15 mmol) in dry THF (5 mL). The crude product was purified by flash chromatography (SiO2, cyclohexane 
→ cyclohexane/CH2Cl2 70:30) to give the desired amine 2g (14 mg, 69%) as a light yellow liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.32 (d, J = 2.0 Hz, 1 H, Har), 7.20 (dd, 
J = 8.4 Hz, 2.6 Hz, 2 H, NH. Har), 6.99 (dd, J = 8.3 Hz, 2.1 Hz, 1 H, Har), 4.86 (dp, 
J = 15.1 Hz, 7.5 Hz, 1 H, CH), 3.55 (s, 3 H, NCH3), 1.41 (d, J = 7.0 Hz, 3 H, 
CH3) ppm. 19F NMR (376 MHz, DMSO-d6): δ = 75.96 (d, JCF3,CH = 7.9 Hz, 1 H, 
CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 154.61 (Cq), 140.54 (Cq), 136.22 (Cq), 126.16 (q, 
JC,F = 282.4 Hz, CF3), 124.75 (Cq), 120.44 (CHar), 116.19 (CHar), 107.99 (CHar), 49.66 (q, JC,F = 30.8, CCF3), 
28.63 (NCH3), 13.88 (CH3) ppm. FT-IR (ATR): ῦ = 3064 (br, w), 1707 (w), 1597 (m), 1563 (m), 1453 (m), 
1265 (s), 1135 (vs), 1058 (m), 916 (w), 807 (m), 670 (w) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B 
→ 2.8 min: 100% B, flow: 2.4 mL/min): tR = 1.47 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for 
C11H12ClF3N3 [M+H]+ 278.0666, found 278.0668. 
 
2-(1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-N-(2,2,2-trifluoro-1-methylethyl)aniline 2h 
According to the general procedure, 2-(1,2,3-triazol-1-yl)-5-(trifluoromethyl)-N-(1-ethoxy-2,2,2-
trifluoroethyl)aniline 1h (175 mg, 0.49 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 0.71 mL, 
0.99 mmol) in dry THF (12 mL). The desired amine 2h (154 mg, 96%) was isolated after workup as a yellow 
solid without further purification.  
1H NMR (400 MHz, DMSO-d6): δ = 8.61 (d, J = 1.1 Hz, 1 H, Htriazole), 8.05 (d, J = 1.1 Hz, 
1 H, Htriazole), 7.62 – 7.56 (m, 1 H, H3), 7.52 (s, 1 H, H6), 7.18 (dd, J = 8.3 Hz, 1.3 Hz, 1 H, 
H2), 6.24 (d, J = 9.3 Hz, 1 H, NH), 4.85 – 4.74 (m, 1 H, CH), 1.32 (d, J = 6.7 Hz, 3 H, CH3). 
19F NMR (376 MHz, DMSO-d6): δ = -61.41 (CF3), -75.85(d, JCF3,CH = 7.0 Hz, CHCF3) ppm. 
13C NMR (101 MHz, DMSO-d6): δ = 140.77 (Cq), 133.97 (CHar), 130.59 (q, JC,F = 32.0 Hz, 
CCF3), 126.45 (CHar), 126.41 (q, JC,F = 283.6 Hz, HCCF3), 126.27 (CHar), 125.41 (Cq), 
123.78 (q, JC,F = 272.6 Hz, CF3), 113.96 (CHar), 110.63 (CHar), 49.21 (q, JC,F = 29.7 Hz, HCCF3), 14.15 
(CH3) ppm. FT-IR (ATR): ῦ = 3282 (br, vw), 3155 (vw), 1620 (w), 1597 (w), 1448 (m), 1345 (m), 1285 (m), 
1166 (m), 1125 (vs), 1092 (vs), 979 (s), 858 (m), 815 (s), 781 (m), 668 (m) cm-1. HPLC-MS (0.05% formic 
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acid. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.40 min, λ = 220 nm. mp 83 °C. HRMS 
(ESI+): m/z calcd. for C12H11F6N4+ [M+H]+ 325.0882, found 325.0886. 
 
N-(2,2,2-Trifluoro-1-methylethyl)aminopyrazine 2i 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyrazine 1i (50 mg, 0.23 mmol) was 
reacted with MeMgBr (1.4 M in toluene/THF 3:1, 0.32 mL, 0.45 mmol) in dry THF (5 mL). The crude product 
was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 4:1) to give the desired amine 2i 
(35 mg, 80%) as a white solid.  
1H NMR (400 MHz, CDCl3): δ = 8.02 (dd, J = 2.7 Hz, 1.5 Hz, 1 H, H5), 7.96 (d, J = 1.4 Hz, 
1 H, H2), 7.90 (d, J = 2.7 Hz, 1 H, H4), 4.88 (m, 1 H, CH), 4.57 (d, J = 8.9 Hz, 1 H, NH), 
1.42 (dd, J = 6.9 Hz, 0.6 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = 77.67 (d, 
JCF3,CH = 7.3 Hz, CHCF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 152.86 (C1), 141.60 (C5), 134.27 (C4), 
132.72 (C2), 125.80 (q, JC,F = 281.9 Hz, CF3), 47.46 (q, JC,F = 31.2 Hz, CCF3), 14.76 (CH3) ppm. FT-
IR (ATR): ῦ = 3256 (w), 3057 (w), 1601 (m), 1521 (s), 1457 (m), 1398 (m), 1268 (s), 1163 (s), 1135 (vs), 1096 
(s), 1023 (s), 1000 (m), 825 (s) cm-1. HPLC (0.1% TFA, 0 min: 4% B → 15 min: 100% B, flow: 1 mL/min): 
tR = 10.95 min, λ = 214 nm. mp 81 °C. HRMS (ESI+): m/z calcd. for C7H9F3N3+ [M+H]+ 192.0743, found 
192.0742. 
 
5-(tert-Butyl)-N-(2,2,2-trifluoro-1-methylethyl)isoxazol-3-amine 2j 
According to the general procedure, 5-(tert-butyl)-N-(1-ethoxy-2,2,2-trifluoroethyl)isoxazol-3-amine 1j 
(100 mg, 0.38 mmol) was reacted with MeMgBr (1.4 M in toluene/THF 3:1, 0.54 mL, 0.76 mmol) in dry THF 
(6 mL). The crude product was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 4:1) to give 
the desired amine 2j (66 mg, 74%) as a white solid. 
1H NMR (300 MHz, CDCl3): δ = 5.48 (s, 1 H, Har), 4.19 (m, 1 H, CHCH3), 3.90 (s, 
1 H, NH), 1.40 (d, J = 6.9 Hz, 3 H, CHCH3), 1.30 (s, 9 H, 3 × CH3) ppm. 19F NMR 
(282 MHz, CDCl3): δ = 78.10 (d, JCF3,CH = 6.9 Hz, CF3) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 181.24 (-HCCO-), 162.87 (-HCCN-), 125.67 (d, JC,F = 280.7 Hz, CF3), 89.75 (-CCHC-), 51.34 (q, 
JC,F = 31.1 Hz, CCF3), 32.77 ((CH3)3C), 28.60 (3 × CH3), 14.92 (CH3) ppm. FT-IR (ATR): ῦ = 3297 (br, w), 
2970 (w), 1612 (m), 1551 (m), 1459 (m), 1265 (m), 1183 (m), 1135 (vs), 1016 (m), 981 (m), 781 (m) cm-1. 
HPLC (0.1% TFA, 0 min: 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 14.63 min, λ = 214 nm. mp 98 °C. 
HRMS (ESI+): m/z calcd. for C10H16F3N2O+ [M+H]+ 237.1209, found 237.1208. 
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3-Chloro-N-(2,2,2-trifluoro-1-isopropylethyl)aniline 3a 
Reaction with iPrMgCl: 
Following the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (200 mg, 0.79 mmol) 
was reacted with iPrMgCl (1.0 M in THF, 1.58 mL, 1.58 mmol) in dry THF (12 mL). The crude product was 
purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 20:1) to give the desired amine 
3a (139 mg, 70%) as a light yellow liquid together with the side product 3-chloro-N-2,2,2-trifluoroethyl)aniline 
4 (26 mg, 16%, light yellow liquid).  
Reaction with iPrMgCl·LiCl: 
According to the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (165 mg, 0.65 mmol) 
was reacted with iPrMgCl·LiCl (1.1 M in THF, 1.18 mL, 1.30 mmol) in dry THF (8 mL). The crude product 
was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/ethyl acetate 40:1) to give the 
desired amine 3a (112 mg, 68%) as a light yellow liquid together with the side product 3-chloro-N-2,2,2-
trifluoroethyl)aniline 4 (40 mg, 30%, light yellow liquid).   
1H NMR (400 MHz, DMSO-d6): δ = 7.07 (t, J = 8.1 Hz, 1 H, H5), 6.88 (t, J = 2.1 Hz, 
1 H, H2), 6.76 (dd, J = 8.1 Hz, 2.0 Hz, 1 H, H6), 6.58 (ddd, J = 7.8 Hz, 1.9 Hz, 
0.7 Hz, 1 H, H4), 6.08 (d, J = 10.1 Hz, 1 H, NH), 4.29 – 4.09 (m, 1 H, NHCH), 2.16 
– 2.00 (m, 1 H, CH), 0.98 (t, J = 6.1 Hz, 6 H, 2 × CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 70.57 (d, 
JCF3,CH = 8.4 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 149.82 (C1), 133.60 (C3), 130.29 (C5), 
126.59 (q, JC,F = 285.6 Hz, CF3), 116.05 (C4), 111.92 (C2), 111.12 (C6), 57.63 (q, JC,F = 26.9 Hz, CCF3), 
28.15 (CH), 19.40 (CH3), 17.48 (CH3) ppm. FT-IR (ATR): ῦ = 3429 (br, vw), 2969 (w), 1597 (s), 1509 (m), 
1483 (m), 1261 (m), 1135 (vs), 1079 (s), 990 (m), 842 (br,m), 763 (m), 679 (s) cm-1. HPLC-MS (0.05% formic 
acid. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.70 min, λ = 220 nm. HRMS (ESI+): m/z 
calcd. for C11H14ClF3N+ [M+H]+ 252.0761, found 252.0761. 
3-Chloro-N-(2,2,2-trifluoroethyl)aniline 4  
1H NMR (400 MHz, DMSO-d6): δ = 7.10 (t, J = 8.1 Hz, 1 H, H5), 6.78 (t, J = 2.1 Hz, 
1 H, H2), 6.68 (dd, J = 8.1 Hz, 2.0 Hz, 1 H, H6), 6.62 (ddd, J = 7.8 Hz, 2.0 Hz, 0.8 Hz, 
1 H, H4), 6.49 (t, J = 6.9 Hz, 1 H, NH), 3.95 (qd, J = 9.7 Hz, 7.0 Hz, 2 H, CH2) ppm. 
19F NMR (377 MHz, DMSO-d6): δ = 70.61 (t, JCF3,CH = 9.5 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): 
δ = 149.06 (C1), 133.62 (C3), 130.37 (C5), 125.71 (q, JC,F = 281.1 Hz, CF3), 116.46 (C4), 111.69 (C2), 
111.13 (C6), 43.65 (q, JC,F = 32.3 , CCF3) ppm. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 
100% B, flow: 2.4 mL/min): tR = 2.24 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C8H8ClF3N+ [M+H]+ 
210.0292, found 210.0291. 
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3-Chloro-N-(2,2,2-trifluoro-1-butylethyl)aniline 3b  
According to the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (200 mg, 0.79 mmol) 
was reacted with nBuMgBr (2.0 M in Et2O, 0.79 mL, 1.58 mmol) in dry THF (12 mL). The desired amine 3b 
(197 mg, 94%) was isolated after workup without further purification as a light yellow liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.08 (t, J = 8.1 Hz, 1 H, H5), 6.80 (t, 
J = 2.1 Hz, 1 H, H2), 6.70 (dd, J = 8.3 Hz, 1.8 Hz, 1 H, H6), 6.59 (ddd, 
J = 7.8 Hz, 1.9 Hz, 0.7 Hz, 1 H, H4), 6.20 (d, J = 9.1 Hz, 1 H, NH), 4.26 – 4.12 
(m, 1 H, CH), 1.76 – 1.64 (m, 1 H, CH2), 1.62 – 1.49 (m, 1 H, CH2), 1.47 – 1.21 (m, 4 H, 2 × CH2), 0.85 (t, 
J = 7.1 Hz, 3 H, CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 74.78 (d, JCF3,CH = 7.4 Hz, CF3) ppm. 
13C NMR (101 MHz, DMSO-d6): δ = 149.48 (C1), 133.61 (C3), 130.35 (C5), 126.63 (q, JC,F = 284.4 Hz, CF3), 
116.08 (C4), 111.67 (C2), 111.04 (C6), 53.40 (q, JC,F = 28.4 Hz, CCF3), 27.80 (CH2), 26.99 (CH2), 21.70 
(CH2), 13.70 (CH3) ppm. FT-IR (ATR): ῦ = 3420 (br, vw), 2959 (w), 2932 (w), 1598 (s), 1509 (m), 1483 (m), 
1250 (m), 1167 (m), 1130 (vs), 1088 (s), 990 (m), 764 (m), 679 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 
4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.87 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for 
C12H16ClF3N+ [M+H]+ 266.0918, found 266.0918. 
 
3-Chloro-N-(2,2,2-trifluoro-1-tert-butylethyl)aniline 3c 
Following the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (200 mg, 0.79 mmol) 
was reacted with tert-BuMgBr (2.0 M in Et2O, 0.79 mL, 1.58 mmol) in dry THF (12 mL). The reaction time 
was 3 h. The crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 
20:1) to give the desired amine 3c (120 mg, 57%) as a light yellow liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.07 (t, J = 8.1 Hz, 1 H, H5), 6.94 (t, J = 2.1 Hz, 
1 H, H2), 6.82 (dd, J = 8.3 Hz, 1.8 Hz, 1 H, H6), 6.57 (ddd, J = 7.8 Hz, 1.9 Hz, 0.7 Hz, 
1 H, H4), 6.07 (d, J = 10.7 Hz, 1 H, NH), 4.22 – 4.04 (m, 1 H, CH), 1.05 (s, 9H, 
3 × CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 66.68 (d, JCF3,CH = 8.6 Hz, CF3) ppm. 13C NMR 
(101 MHz, DMSO-d6): δ = 150.02 (C1), 133.60 (C3), 130.28 (C5), 126.94 (q, JC,F = 286.8 Hz, CF3) 115.98 
(C4), 111.94 (C2), 111.18 (C6), 60.37 (q, JC,F = 25.7 Hz, CCF3), 34.41 (Cq), 26.74 (3 × CH3) ppm. FT-
IR (ATR): ῦ = 3433 (br, vw), 2967 (w), 1698 (br, w), 1599 (s), 1510 (m), 1481 (m), 1251 (m), 1156 (s), 1106 
(vs), 990 (m), 762 (m), 679 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 100% B, flow: 
2.4 mL/min): tR = 2.63 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C12H16ClF3N+ [M+H]+ 266.0918, found 
266.0912. 
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3-Chloro-N-(2,2,2-trifluoro-1-cyclohexylethyl)aniline 3d 
Following the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (177 mg, 0.70 mmol) 
was reacted with cyclohexylmagnesium bromide (1.0 M in THF, 1.40 mL, 1.40 mmol) in dry THF (12 mL). 
The crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 20:1) to 
give the desired amine 3d (159 mg, 78%) as a light yellow oil.  
1H NMR (400 MHz, DMSO-d6): δ = 7.06 (t, J  = 8.1 Hz, 1 H, H5), 6.84 (t, 
J = 2.1 Hz, 1 H, H2), 6.73 (dd, J = 8.3 Hz, 1.8 Hz, 1 H, H6), 6.57 (ddd, J = 7.9 Hz, 
1.9 Hz, 0.7 Hz, 1 H, H4), 6.08 (d, J = 10.1 Hz, 1 H, NH), 4.19 – 4.05 (m, 1 H, CH), 
1.81 – 1.55 (m, 6 H, 3 × CH2), 1.25 – 1.04 (m, 5 H, CH. 2 × CH2) ppm. 19F NMR 
(376 MHz, DMSO-d6): δ = 70.05 (d, JCF3,CH = 8.4 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): 
δ = 149.79 (C1), 133.60 (C3), 130.33 (C5), 126.54 (q, JC,F = 285.6 Hz, CF3), 116.03 (C4), 111.84 (C2), 111.03 
(C6), 57.45 (q, JC,F = 27.0 Hz, CCF3), 37.89 (CH), 28.96 (CH2), 27.19 (CH2), 25.50 (CH2), 25.45 (CH2), 25.36 
(CH2) ppm. FT-IR (ATR): ῦ = 3425 (br, w), 2923 (m), 2855 (w), 1597 (vs), 1510 (m), 1264 (m), 1238 (s), 
1146 (vs), 1119 (vs), 1093 (m), 990 (m), 835 (m), 761 (s), 679 (vs) cm-1. HPLC-MS (0.05% formic acid. 
0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.96 min, λ = 220 nm. HRMS (ESI+): m/z calcd. 
for C14H18ClF3N+ [M+H]+ 292.1074, found 292.1071. 
 
3-Chloro-N-(2,2,2-trifluoro-1-methylcyclohexylethyl)aniline 3e 
Following the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (200 mg, 0.79 mmol) 
was reacted with cyclohexylmethylmagnesium bromide (0.5 M in Et2O, 3.16 mL, 1.58 mmol) in dry THF 
(12 mL). The crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 
3:2) to give the desired amine 3e (62 mg, 26%) as a colorless oil together with the side product 3-chloro-N-
2,2,2-trifluoroethyl)aniline 4 (32 mg, 19%, light yellow liquid).   
 1H NMR (400 MHz, DMSO-d6): δ = 7.08 (t, J = 8.1 Hz, 1 H, H5), 6.81 (t, 
J = 2.1 Hz, 1 H, H2), 6.71 (dd, J = 8.2 Hz, 1.8 Hz, 1 H, H6), 6.58 (ddd, J = 7.8 Hz, 
1.9 Hz, 0.7 Hz, 1 H, H4), 6.21 (d, J = 9.0 Hz, 1 H, NH), 4.33 – 4.19 (m, 1 H, NHCH), 
1.74 – 1.34 (m, 8 H, 4 × CH2), 1.26 – 0.93 (m, 4 H, 2 × CH2), 0.92 – 0.78 (m, 1 H, 
CH) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 74.91 (d, JCF3,CH = 9.0 Hz, 
CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 149.26 (C1), 133.62 (C3), 130.40 (C5), 126.84 (q, 
JC,F = 284.6 Hz, CF3), 116.08 (C4), 111.61 (C2), 110.90 (C6), 51.12 (q, JC,F = 28.4 Hz, CCF3), 35.29 (CH2), 
33.32 (CH2), 32.95 (CH), 31.35 (CH2), 25.87 (CH2), 25.70 (CH2), 25.39 (CH2) ppm. FT-IR (ATR): ῦ = 3421 
(br, vw), 2922 (m), 2852 (w), 1598 (vs), 1509 (m), 1449 (m), 1254 (s), 1150 (s), 1122 (vs), 1091 (s), 990 (m), 
844 (br,m), 763 (m), 679 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 100% B, flow: 
2.4 mL/min): tR = 2.83 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C15H20ClF3N+ [M+H]+ 306.1231, found 
306.1228. 
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3-Chloro-N-(2,2,2-trifluoro-1-vinylethyl)aniline 3f 
Following the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (229 mg, 0.90 mmol) 
was reacted with vinylmagnesium bromide (1.0 M in THF, 1.81 mL, 1.81 mmol) in dry THF (12 mL). The 
crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 4:1) to give 
the desired amine 3f (131 mg, 62%) as a colorless oil.  
1H NMR (400 MHz, DMSO-d6): δ = 7.11 (t, J = 8.1 Hz, 1 H, H5), 6.87 (t, J = 2.1 Hz, 
1 H, H2), 6.77 (dd, J = 8.0 Hz, 2.0 Hz, 1 H, H6), 6.64 (ddd, J = 7.8 Hz, 2.0 Hz, 0.8 Hz, 
1 H, H4), 6.48 (d, J = 9.7 Hz, 1 H, NH), 5.86 (ddd, J = 16.8 Hz, 10.4 Hz, 6.2 Hz, 1 H, 
CH2=CH), 5.56 (d, J = 17.1 Hz, 1 H, HCHtrans=CH), 5.43 (d, J = 10.4 Hz, 1 H, HCHcis=CH), 5.10 – 4.97 (m, 
1 H, CH) ppm. 19F NMR (377 MHz, DMSO-d6): δ = 73.77 (d, JCF3,CH = 7.7 Hz, CF3) ppm. 13C NMR 
(101 MHz, DMSO-d6): δ = 148.36 (C1), 133.62(C3), 130.36 (C5), 129.80 (CH2=CH), 125.52 (q, 
JC,F = 283.4 Hz, CF3), 120.83 (CH2=CH), 116.70 (C4), 112.31 (C2), 111.71 (C6), 55.83 (q, JC,F = 29.4 Hz, 
CCF3) ppm. FT-IR (ATR): ῦ = 3417 (br, vw), 3029 (br, vw), 1597 (s), 1482 (m), 1250 (m), 1156 (s), 1114 
(vs), 991 (m), 941 (m), 847 (m), 764 (s), 679 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 2.8 min: 
100% B, flow: 2.4 mL/min): tR = 2.53 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C10H10ClF3N+ [M+H]+ 
236.0448, found 236.0452. 
 
3-Chloro-N-(2,2,2-trifluoro-1-allylethyl)aniline 3g 
According to the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (230 mg, 0.91 mmol) 
was reacted with allylmagnesium bromide (1.0 M in MeTHF, 1.81 mL, 1.81 mmol) in dry THF (12 mL). The 
crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 4:1) to give 
the desired amine 3g (191 mg, 84%) as a colorless oil.  
1H NMR (400 MHz, DMSO-d6): δ = 7.07 (t, J = 8.1 Hz, 1 H, H5), 6.79 (t, J = 2.1 Hz, 
1 H, H2), 6.69 (dd, J = 8.2 Hz, 1.8 Hz, 1 H, H6), 6.61 – 6.57 (d, J = 8.0 Hz, 1, H4), 
6.26 (d, J = 9.3 Hz, 1 H, NH), 5.77 (ddt, J = 17.0 Hz, 10.2 Hz, 6.8 Hz, 1 H, 
H2C=CHCH2), 5.17 (dd, J = 17.2 Hz, 1.7 Hz, 1 H, HCHtrans=CH), 5.09 – 5.04 (dd, 
J = 10.2 Hz, 1.7 Hz, 1 H, HCHcis=CH), 4.35 (tqd, J = 11.0 Hz, 7.4 Hz, 3.9 Hz, 1 H, CH), 2.55 – 2.45 (m, 1 H, 
CH2) 2.40 – 2.28 (m, 1 H, CH2) ppm. 19F NMR (376 MHz, DMSO-d6): δ = 74.47 (d, JCF3,CH = 7.3 Hz, 
CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 149.14 (C1), 133.60 (H2C=CH), 132.95 (C3), 130.35 (C5), 
126.33 (q, JC,F = 284.7 Hz, CF3), 118.24 (H2C=CH), 116.26 (C4), 111.81 (C2), 111.19 (C6), 53.17 (q, 
JC,F = 28.4 Hz, CCF3), 32.53 (CH2) ppm. FT-IR (ATR): ῦ = 3417 (br, vw), 1597 (vs), 1509 (m), 1482 (m), 
1322 (w), 1275 (m), 1246 (s), 1122 (vs), 1093 (s), 991 (m), 844 (m), 764 (s), 679 (s) cm-1. HPLC-MS (0.05% 
formic acid. 0 min: 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.65 min, λ = 220 nm. HRMS (ESI+): 
m/z calcd. for C12H14ClF3N+ [M+H]+ 250.0605, found 250.0604. 
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3-Chloro-N-(2,2,2-trifluoro-1-dimethylvinylethyl)aniline 3h 
According to the general procedure, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (180 mg, 0.71 mmol) 
was reacted with 2-methyl-1-propenylmagnesium bromide (0.5 M in THF, 2.84 mL, 1.42 mmol) in dry THF 
(12 mL). The crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/CH2Cl2 
4:1) to give the desired amine 3h (159 mg, 85%) as a light yellow liquid.  
1H NMR (400 MHz, DMSO-d6): δ = 7.09 (t, J = 8.05 Hz, 1 H, H5), 6.87 (t, J = 2.1 Hz, 
1 H, C2), 6.75 (dd, J = 8.2 Hz, 1.9 Hz, 1 H, H6), 6.61 (ddd, J = 5.6 Hz, 2.8 Hz, 2.2 Hz, 
1 H, H4), 6.31 (d, J = 8.6 Hz, 1 H, NH), 5.16 (d, J = 8.6 Hz, 1 H, HC=C(CH)3), 4.98 
– 4.87 (m, 1 H, CH), 1.75 (d, J = 0.8 Hz, 3 H, CH3), 1.73 (d, J = 0.7 Hz, 3 H, CH3). 
19F NMR (376 MHz, DMSO-d6): δ = 74.16 (d, JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-
d6): δ = 148.46 (C1), 139.75 ((CH3)2C=CH), 133.59 (C3), 130.30 (C5), 126.22 (q, JC,F = 284.8 Hz, CF3), 116.91 
(C4 / (CH3)2C=CH), 116.42 (C4 / (CH3)2C=CH), 112.13 (C2), 111.43 (C6), 52.37 (q, JC,F = 29.8 Hz, CCF3), 
25.39 (CH3), 18.57 (CH3) ppm. FT-IR (ATR): ῦ = 3417 (br, vw), 3029 (br, w), 1598 (m), 1482 (m), 1379 (w), 
1164 (s), 1114 (vs), 990 (m), 866 (w), 764 (w), 680 (s) cm-1. HPLC-MS (0.05% formic acid. 0 min: 4% B → 
2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.74 min, λ = 220 nm. HRMS (ESI+): m/z calcd. for C12H14ClF3N+ 
[M+H]+ 264.0761, found 264.0763. 
 
N-(2,2,2-Trifluoro-1-phenylethyl)aminopyrazine 5 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyrazine 1i (200 mg, 0.90 mmol) 
was reacted with PhMgBr (1.5 M in THF, 1.18 mL, 1.81 mmol) in dry THF (12 mL). The crude product was 
purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 10:1) to give the desired amine 5 (174 mg, 
76%) as yellow oil.  
1H NMR (599 MHz, CDCl3): δ = 8.04 – 8.02 (m, 1 H, H5), 8.01 (s, 1 H, H2), 7.91 (d, 
J = 2.6 Hz, 1 H, H4), 7.49 – 7.45 (m, 2 H, 2 × Hphenyl), 7.43 – 7.38 (m, 3 H, 3 × Hphenyl), 
5.89 (p, J = 7.9 Hz, 1 H, CH), 5.26 (d, J = 9.0 Hz, 1 H, NH) ppm. 19F NMR (376 MHz, 
CDCl3): δ = 73.81 (d, JCF3,CH = 7.8 Hz, CF3) ppm. 13C NMR (151 MHz, CDCl3): δ = 152.48 (C1), 141.61 
(C5), 134.65 (C4), 133.53 (C1phenyl), 132.95 (C2), 129.20 (CHphenyl), 128.94 (CHphenyl), 127.86 (CHphenyl), 
127.85 (CHphenyl), 124.91 (q, JC,F = 282.0 Hz, CF3), 55.64 (q, JC,F = 30.9 Hz, CCF3) ppm. FT-IR (ATR): 
ῦ = 3258 (br, w), 3036 (w), 1594 (m), 1515 (s), 1396 (m), 1250 (s), 1168 (s), 1147 (s), 1114 (vs), 1003 (s), 825 
(m), 696 (s) cm-1. HPLC (0.1% TFA, 0 min: 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 13.48 min, 
λ = 214 nm. HRMS (ESI+): m/z calcd. for C12H11F3N3+ [M+H]+ 254.0900, found 254.0899. 
 
5-(tert-Butyl)-N-(2,2,2-trifluoro-1-phenylethyl)isoxazol-3-amine 6 
Following the general procedure, 5-(tert-butyl)-N-(1-ethoxy-2,2,2-trifluoroethyl)isoxazol-3-amine 1j (200 mg, 
0.88 mmol) was reacted with PhMgBr (1.5 M in THF, 1.15 mL, 1.77 mmol) in dry THF (12 mL). The crude 
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product was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 10/1) to give the desired amine 
6 (189 mg, 72%) as a white solid.  
1H NMR (300 MHz, CDCl3): δ = 7.50 – 7.33 (m, 5 H, 5 × Hphenyl), 5.49 (s, 1 H, 
Hisoxazole), 5.25 – 5.09 (m, 1 H, CH), 4.52 (d, J = 6.3 Hz, 1 H, NH), 1.27 (d, J = 0.4 Hz, 
9 H, 3 × CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = 74.37 (d, JCF3,CH = 7.6 Hz, 
CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 181.34 (-HCCO-), 162.55 (-HCCN-), 133.62 (C1phenyl), 129.19 
(CHphenyl), 128.87 (CHphenyl), 127.78 (CHphenyl), 127.77 (CHphenyl), 124.71 (d, JC,F = 281.8 Hz, CF3), 89.95 
(-CCHC-), 59.44 (q, JC,F = 31.0 Hz, CCF3), 32.77 ((CH3)3C), 28.63 (CH3), 28.58 (2 × CH3) ppm. FT-
IR (ATR): ῦ = 3261 (br, w), 2971 (w), 1611 (m), 1549 (m), 1402 (w), 1254 (m), 1170 (s), 1119 (vs), 977 (w), 
910 (w), 695 (s) cm-1. HPLC (0.1% TFA, 0 min: 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 15.83 min, 
λ = 214 nm. mp 78°C. HRMS (ESI+): m/z calcd. for C15H18F3N2O+ [M+H]+ 299.1366, found 299.1365. 
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3. Experimental Procedures and Analytical Data: Convenient 
Access to Di- and Trifluoroethylamines for Lead Structure 
Research  
 
The complete supporting information including the NMR spectra of all compounds is available on the 
European Journal of Organic Chemistry website (DOI: 10.1002/ejoc.201501576) and on the CD in the book 
cover of this thesis. The compounds are numbered according to the publication. 
3.1  Typical Procedures 
Typical Procedure for the microwave synthesis of the hemiaminal ethers (TP1) 
A dry microwave tube equipped with a magnetic stirrer was charged with an arylamine (1 equiv) and 
pTSA·H2O (0.05 equiv). The starting material was solved in toluene and TFAE/ difluoroacetaldehyde ethyl 
hemiacetal (1.2 equiv) was added. The microwave tube was sealed and the mixture was reacted at 180 °C for 
30 minutes (max. 200 W).  
The solvent was evaporated and the crude product was purified by flash chromatography (SiO2). 
Typical Procedure for the synthesis of the hemiaminal ether (TP2) 
A roundbottom flask equipped with a magnetic stirrer was charged with an arylamine (1 equiv) and pTSA·H2O 
(0.05 equiv). The starting material was solved in ethanol and TFAE/ difluoroacetaldehyde ethyl hemiacetal 
(1.2 equiv) was added. The mixture was refluxed at 90 °C until the reaction showed no further conversion.  
The solvent was evaporated and the product was purified by flash chromatography (SiO2). 
Typical Procedure for the magnesium insertion (TP3)[212] 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirrer and a septum, was charged with 
iPrMgCl·LiCl (1.25 M in THF, 1.1 equiv). The neat aryl bromide (1 equiv) was added at the appropriate 
temperature. The reaction mixture was stirred at the stated temperature, while the completion of the Br/Mg 
exchange was monitored by GC-analysis. 
Typical Procedure for the addition of the functionalized Grignard reagent to the hemiaminal ether (TP4) 
The hemiaminal ether (0.045 mmol, 1 equiv) was solved in freshly distilled THF (5 mL) in a dry and argon 
flushed 10 mL flask, equipped with a magnetic stirrer and a septum and cooled to -78 °C. NaHMDS or 
LiHMDS (1 M in THF, 0.045 mmol, 1 equiv) was added and the reaction was stirred for 15 min until the 
deprotonation was complete. The Grignard reagent was added dropwise with a syringe and the solution was 
allowed to warm up to the appropriate temperature. The reaction was stirred until GC-analysis showed the 
complete conversion. After the reaction was completed sat. NH4Cl solution was added and the mixture was 
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extracted three times with Et2O. The solvent was evaporated and the product was purified by flash 
chromatography (SiO2). 
Typical procedure for the synthesis of CF2H-amines with RMgX (TP5) 
In a dry, argon-flushed Schlenk-flask a hemiaminal ether (1 equiv) was dissolved in dry THF. The solution 
was cooled to 0 °C, RMgX (2 eq) was added dropwise, and the solution was stirred at 0 °C until complete 
consumption of the starting material (ca. 2 h, TLC control). Then the solution was quenched with saturated 
NH4Cl-solution (10 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic phases were 
dried with MgSO4, filtered and the solvent was evaporated in vacuo. Purification by flash chromatography 
(SiO2) furnished the desired amines.  
3.2 Experimental data 
N-(1-Ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine (1a)  
The hemiaminal ether 1a was prepared according to TP1. 2-Aminopyridine (100 mg, 1.06 mmol), pTSA·H2O 
(10 mg, 0.05 mmol) and TFAE (0.15 mL, 1.28 mmol) were reacted in a CEM microwave reactor in toluene 
(2 mL). Flash column chromatography (cyclohexane/ethyl acetate/NEt3 8:1:0.1) furnished 1a as a white solid 
(196 mg, 82%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. mp 84 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.13 (ddd, JH6,H5 = 5.0 Hz, JH6,H4 = 1.9 Hz, J = 0.9 Hz, 1 H, H6), 7.48 (ddd, 
JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.73 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 
= 5.1 Hz, JH5,H3 = 1.0 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.3 Hz, J = 5.1 Hz, 1 H, H3), 6.01 (dq, JCH,NH = 10.2 Hz, 
JCH,CF3 = 5.1 Hz, 1 H, CH), 4.89 (d, JNH,CH = 10.4 Hz, 1 H, NH), 3.86 – 3.66 (m, 2 H, CH2), 1.22 (t, JCH3,CH2 = 
7.0 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3) δ = -80.66 (d, JCF3,CH = 5.0 Hz, CF3) ppm. 13C NMR 
(75 MHz, CDCl3) δ = 156.19 (C2), 148.06 (C6), 138.13 (C4), 123.27 (q, JC,F = 282.2 Hz, CF3), 115.66 (C5), 
109.24 (C3), 78.50 (q, JC,F = 33.9 Hz, CHCF3), 65.35 (CH2), 15.30 (CH3) ppm. HRMS (ESI+): m/z calcd. for 
C9H12ON2F3+ [M+H]+ 221.0902, found 221.0898. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 
1 mL/min): tR = 9.21 min, λ = 214 nm. 
 
N-(1-Ethoxy-2,2-difluoroethyl)pyridine-2-amine (1b) 
Following TP1, 2-aminopyridine (100 mg, 1.06 mmol), pTSA·H2O (10 mg, 0.05 mmol) and 
difluoroacetaldehyde ethyl hemiacetal (0.15 mL, 1.28 mmol) were reacted in a CEM microwave reactor in 
toluene (2.5 mL). Flash column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 100:1:1 
→ 10:2:0.1) furnished 1b (84 mg, 39%) as a white solid. 
Rf (cyclohexane/ethyl acetate 1:1) = 0.74. mp <40 °C. 1H NMR (400 MHz, CDCl3): δ = 
8.11 (ddd, JH6,H5 = 5.0 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.45 (ddd, JH4,H3 = 
8.4 Hz, JH4,H5 = 7.3 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.70 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, 
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JH5,H3 = 0.9 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.3 Hz, JH3,H6 = JH3,H5 = 0.9 Hz, 1 H, H3), 5.86 (ddd, JH,F = 55.1 Hz, 
JH,F = 53.3 Hz, JCHF2,CH = 2.3 Hz, 1 H, CHF2), 5.74 – 5.70 (m, 1 H, CH), 4.94 (d, JNH,CH = 10.0 Hz, 1 H, NH), 
3.71 (ddq, JCH2,CH = 44.3 Hz, JCH2,CH2 = 9.6 Hz, JCH2,CH3 = 7.0 Hz, 1 H, CH2), 1.21 (t, JCH3,CH2 = 7.0 Hz, 3 H, 
CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = -129.66 (ddd, JF,F = 286.6 Hz, JF,H = 54.7 Hz, JF,CH = 8.2 Hz, 
CHF2), -133.95 (ddt, JF,F = 286.7 Hz, JF,H = 55.8 Hz, JF,CH = 12.4 Hz, CHF2) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 156.84 (C2), 148.00 (C6), 137.89 (C4), 115.09 (C5), 113.74 (dd, JC,F = 246.4 Hz, JC,F = 244.7 Hz, 
CHF2), 108.90 (C3), 79.35 (dd, JC,F = 26.8 Hz, JC,F = 22.7 Hz, CH), 64.36 (CH2), 15.31 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C9H13F2N2O+ [M+H]+ 203.0990, found 203.0991. HPLC (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 7.41 min, λ = 214 nm.  
 
N-(1-Ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine (1c) 
The hemiaminal ether 1c was prepared according to TP1. Aminopyrazine (100 mg, 1.05 mmol), pTSA·H2O 
(10 mg, 0.05 mmol) and TFAE (0.17 mL, 1.26 mmol) were reacted in a CEM microwave reactor in toluene 
(2 mL). Flash column chromatography (cyclohexane/ethyl acetate/NEt3 3:1:0.1) furnished 1c as a white solid 
(181 mg, 78%). 
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.55. mp 110 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.05 (ddd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, JH6,NH = 0.4 Hz, 1 H, H6), 8.03 (dd, 
JH3,H6 = 1.5 Hz, JH3,H5 = 0.4 Hz, 1 H, H3), 7.99 (dd, JH5,H6 = 2.8 Hz, JH5,H3 = 0.4 Hz, 1 H, 
H5), 5.94 (dq, JCH,NH = 10.0 Hz, JCH,CF3 = 5.0 Hz, 1 H, CH), 5.26 (d, JNH,CH = 10.1 Hz, 1 H, NH), 3.93 – 3.64 
(m, 2 H, CH2), 1.23 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3) δ = -80.71 (d, JCF3,CH 
= 5.1 Hz, CHCF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 152.56 (C2), 141.73 (C6), 135.68 (C5), 133.17 
(C3), 122.87 (q, JC,F = 282.2 Hz, CF3), 78.01 (q, JC,F = 34.3 Hz, CHCF3), 65.69 (CH2), 15.11 (CH3) ppm. 
HRMS (ESI+): m/z calcd. for C9H12F3N3O+ [M+H]+ 222.0849, found 222.0848. HPLC (0.1% TFA. 0 min: 
4% B → 15 min: 100% B, flow: 1 mL/min): tR = 13.99 min, λ = 214 nm. 
 
N-(1-Ethoxy-2,2-difluoroethyl)pyrazin-2-amine (1d) 
Following TP1, aminopyrazine (100 mg, 1.05 mmol), pTSA·H2O (10 mg, 0.05 mmol) and 
difluoroacetaldehyde ethyl hemiacetal (0.15 mL, 1.28 mmol) were reacted in a CEM microwave reactor in 
toluene (2.5 mL). Flash column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 100:2:1 
→ 10:2:0.1) furnished 1d (95 mg, 44%) as a white solid. 
Rf (cyclohexane/ethyl acetate 1:1) = 0.55. mp 64-65 °C. 1H NMR (600 MHz, CDCl3): δ = 
8.03 – 8.01 (m, 2 H, H3, H6), 7.95 (dd, JH5,H6 = 2.7 Hz, JH5,H3 = 1.0 Hz, 1 H, H5), 5.87 
(dddd, JH,F = 55.7 Hz, JH,F = 54.8 Hz, JCHF2,CH = 2.2 Hz, JCHF2,NH = 1.3 Hz, 1 H, CHF2), 5.75 
– 5.68 (m, 1 H, CH), 5.26 (d, JNH,CH = 9.9 Hz, 1 H, NH), 3.78 – 3.62 (m, 1 H, CH2), 1.21 (td, JCH3,CH2 = 7.0 Hz, 
JCH3,CH = 1.2 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -129.03 (ddd, JF,F = 288.0 Hz, JF,H = 
55.0 Hz, JCHF2,CH = 7.9 Hz, CHF2), -134.70 (ddt, JF,F = 287.9 Hz, JF,H = 55.7 Hz, JCHF2,CH = 12.1 Hz, CHF2) ppm. 
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13C NMR (101 MHz, CDCl3): δ = 153.27 (C2), 141.73 (C6), 135.17 (C5), 133.10 (C3), 113.41 (t, JC,F = 
245.7 Hz, CHF2), 78.94 (dd, JC,F = 27.6 Hz, JC,F = 22.5 Hz, CH), 64.73 (CH2), 15.20 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C8H12F2N3O+ [M+H]+ 204.0943, found 204.0943. HPLC (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 11.43 min, λ = 214 nm.  
 
N-(1-Ethoxy-2,2,2-trifluoroethyl)-6-methylpyridin-2-amine (1e) 
The hemiaminal ether 1e was prepared according to TP1. 6-Methylpyridinamine (300 mg, 2.77 mmol), 
pTSA·H2O (26 mg, 0.14 mmol) and TFAE (0.43 mL, 3.32 mmol) were reacted in a CEM microwave reactor 
in toluene (4 mL). Flash column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 20μ1μ0.1 → 
10:1:0.1) furnished 1e as a colorless oil (350 mg, 54%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40. 1H NMR (300 MHz, CDCl3): δ = 
7.36 (dd, JH4,H3 = 8.1 Hz, JH4,H5 = 7.4 Hz, 1 H, H4), 6.59 (dq, JH5,H4 = 7.3 Hz, JH5,CH3 = 
0.6 Hz, 1 H, H5), 6.31 (dt, JH3,H4 = 8.2 Hz, J = 0.6 Hz, 1 H, H3), 5.99 (dq, JCH,NH = 
10.3 Hz, JCH,CF3 = 5.1 Hz, 1 H, CH), 4.84 (d, JNH,CH = 10.4 Hz, 1 H, NH), 3.90 – 3.62 (m, 2 H, CH2), 2.39 (s, 
3 H, CH3), 1.22 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH2CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -80.49 (d, JCF3,CH 
= 4.8 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 157.53 (C6), 155.96 (C2), 138.69 (C4), 123.72 (q, JC,F 
= 282.3 Hz, CF3), 115.18 (C5), 106.04 (C3), 78.88 (q, JC,F = 33.7 Hz, CHCF3), 65.57 (CH2CH3), 24.89 (CCH3), 
15.61 (CH2CH3) ppm. HRMS (ESI+): m/z calcd. for C10H14F3N2O+ [M+H]+ 235.1053, found 235.1054. HPLC 
(0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 9.79 min, λ = 214 nm. 
 
N-(1-Ethoxy-2,2-difluoroethyl)-3,5-bis(trifluoromethyl)aniline (1f) 
According to TP2, 3,5-bis(trifluoromethyl)aniline (0.50 g, 2.18 mmol), difluoroacetaldehyde ethyl hemiacetal 
(0.32 mL, 2.62 mmol) and pTSA·H2O (21 mg, 0.11 mmol) were dissolved in EtOH (15 mL) and the reaction 
mixture was refluxed for 18 h. After removal of the solvent, flash column chromatography (SiO2, gradient: 
cyclohexane/ethyl acetate/NEt3 100:1:1 → 100μ2μ1) furnished 1f (485 mg, 66%) as a white solid. 
Rf (cyclohexane/ethyl acetate 4:1) = 0.66. mp 50-52 °C. 1H NMR (400 MHz, 
CDCl3): δ = 7.32 (s, 1 H, H4), 7.14 (s, 2 H, H2, H6), 5.87 (ddd, JH,F = 55.5 Hz, JH,F = 
54.7 Hz, JCHF2,CH = 2.5 Hz, 1 H, CHF2), 5.00 – 4.88 (m, 1 H, CH), 4.69 (d, JNH,CH = 
9.3 Hz, 1 H, NH), 3.70 (ddq, JCH2,CH2 = 41.2 Hz, JCH2,CH = 9.2 Hz, JCH2,CH3 = 7.0 Hz, 
2 H, CH2), 1.24 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = 63.27 (2 × CF3), -
128.05 (dd, JF,F = 289.6 Hz, JF,H = 54.7 Hz, CHF2), -133.54 (ddd, JF,F = 289.6 Hz, JF,H = 55.6 Hz, JCHF2,CH = 
10.7 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 146.30 (C1), 132.96 (q, JC,F = 33.1 Hz, C3, C5), 
123.40 (q, JC,F = 272.7 Hz, 2 × CF3), 113.81 (C2, C6), 113.34 (t, JC,F = 246.9 Hz, CHF2), 113.14 – 112.94 (m, 
C4), 82.68 (dd, JC,F = 27.8 Hz, JC,F = 23.3 Hz, CH), 64.21 (CH2), 15.21 (CH3) ppm. HRMS (ESI-): m/z calcd. 
for C12H11F8NO- [M-H]- 336.0640, found 336.0646. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, 
flow: 1 mL/min): tR = 20.02 min, λ = 214 nm.  
V. EXPERIMENTAL PROCEDURES   
 
108 
 
N-(1-Ethoxy-2,2-difluoroethyl)-2,3,4,5,6-pentafluoroaniline (1g) 
According to TP2, 2,3,4,5,6-pentafluoroaniline (1.00 g, 5.45 mmol), difluoroacetaldehyde ethyl hemiacetal 
(0.77 mL, 6.56 mmol) and pTSA·H2O (52 mg, 0.27 mmol) were solved in EtOH (15 mL) and the reaction 
mixture was refluxed for 18 h. After removal of the solvent, flash column chromatography (SiO2, gradient: 
cyclohexane/NEt3 100:1 → cyclohexane/ethyl acetate/NEt3 100:3:1) furnished 1g (574 mg, 36%) as a colorless 
oil. 
Rf (cyclohexane/ethyl acetate 7:1) = 0.73. 1H NMR (400 MHz, CDCl3): δ = 5.81 (ddd, 
JH,F = 55.6 Hz, JH,F = 54.6 Hz, JCHF2,CH = 2.2 Hz, 1 H, CHF2), 4.99 – 4.87 (m, 1 H, CH), 
4.13 (d, JNH,CH = 11.1 Hz, 1 H, NH), 3.73 (ddq, JCH2,CH = 67.9 Hz, JCH2,CH2 = 9.4 Hz, 
JCH2,CH3 = 7.0 Hz, 1 H, CH2), 1.22 (t, JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR 
(377 MHz, CDCl3): δ = -129.19 (ddd, JF,F = 289.8 Hz, JF,H = 54.8 Hz, JF,H = 7.1 Hz, CHF2), -135.38 (ddt, JF,F 
= 289.2 Hz, JF,H = 55.3 Hz, JCHF2,CH = 9.9 Hz, CHF2), -156.49 – -156.63 (m, 2 F, F2. F6), -163.13 (td, JF5,F4 = 
JF5,F6 = JF3,F2 = JF3,F4 = 22.1 Hz, JF5,F3 = JF3,F5 = 4.8 Hz, 2 F, F3, F5), -167.38 (tt, JF4,F3 = JF4,F5 = 21.9 Hz, JF4,F2 
= JF4,F6 = 4.7 Hz, F4) ppm. 13C NMR (101 MHz, CDCl3): δ = 140.33 – 137.45 (m), 139.84 – 137.00 (m), 
136.89 –133.89 (m), 121.01 – 120.55 (m), 113.49 (t, JC,F = 246.4 Hz, CHF2), 84.43 (ddt, JC,F = 27.1 Hz, JC,F = 
23.1 Hz, JC,F = 3.9 Hz, CH), 65.07 (CH2), 15.16 (CH3) ppm. HRMS (ESI-): m/z calcd. for C10H7F7NO- [M-H]- 
290.0421, found 290.0422. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
18.81 min, λ = 214 nm.  
 
N-(2,2,2-Trifluoro-1-ethoxyethyl)aminopyridine (1h) 
Following TP1, 4-aminopyridine (200 mg, 2.12 mmol), pTSA·H2O (20 mg, 0.11 mmol) and TFAE (0.33 mL, 
2.55 mmol) were reacted in a CEM microwave reactor in toluene (2.5 mL). Flash column chromatography 
(SiO2, gradient: ethyl acetate → ethyl acetate/MeOH 10:1) furnished 1h as a white solid (258 mg, 55%). 
Rf = 0.11 (cyclohexane/ethyl acetate/NEt3 1:1:0.01). mp 84 °C. 1H NMR (400 MHz, DMSO-d6): δ = 8.24 – 
8.05 (m, 2 H, H2, H6), 7.37 (d, JNH,CH = 10.0 Hz, 1 H, NH), 6.97 – 6.80 (m, 2 H, H3, H5), 
5.70 (dq, JCH,NH = 10.3 Hz, JCH,CF3 = 5.2 Hz, 1 H, CH), 3.82 – 3.47 (m, 2 H, CH2), 1.13 (t, 
JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (377 MHz, DMSO-d6): δ = -78.80 (d, JCF3,CH 
= 5.8 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 151.94 (C4), 149.84 (C2, C6), 123.06 (q, JC,F = 
283.8 Hz, CF3), 108.31 (C3, C5), 78.89 (q, JC,F = 33.3 Hz, CHCF3), 63.52 (CH2), 14.86 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C9H12F3N2O+ [M+H]+ 221.0896, found 221.0898. HPLC-MS (0.1% formic acid. 0 min: 
4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 1.18 min, λ = 220 nm.  
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2-(2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl)benzonitrile (2a) 
(2-Cyanophenyl)magnesium chloride was prepared according to TP3 from 2-bromobenzonitrile (91 mg, 
0.50 mmol) in 1 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2a as a light yellow oil (94 mg, 75%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. 1H NMR (300 MHz, CDCl3): δ = 
8.44 (ddd, JH6′,H5′ = 4.9 Hz, JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 8.04 (s, 2 H, NH, 
H3′), 7.85 – 7.75 (m, 2 H, H4, H4′), 7.71 – 7.52 (m, 3 H, H3, H5, H6), 7.11 (ddd, JH5′,H4′ 
= 7.3 Hz, JH5′,H6′ = 4.9 Hz, JH5′,H3′ = 1.0 Hz, 1 H, H5′), 6.5λ – 6.46 (m, 1 H, CH) ppm. 
19F NMR (282 MHz, CDCl3): δ = -73.06 (dd, JCF3,CH = 5.7 Hz, JCF3,NH = 1.2 Hz, CF3) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 152.50 (C2′), 148.23 (C6′), 138.11 (C4′), 134.87 (d, JC,F = 1.5 Hz, CF3), 133.78 (C1), 
132.16 (C6), 130.23 (C5), 130.21 – 118.74 (m, CF3), 124.49 (d, JC,F = 1.9 Hz, C3), 122.84 (C4), 120.17 (C5′), 
117.66 (CN), 61.67 (q, JC,F = 32.7 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H10F3N3+ [M+H]+ 
278.0905, found 278.0899. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
9.83 min,  = 214 nm. 
 
3-(2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl)benzonitrile (2b) 
(3-Cyanophenyl)magnesium chloride was prepared according to TP3 from 3-bromobenzonitrile (91 mg, 
0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2b as a light yellow oil (89 mg, 71%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. 1H NMR (300 MHz, CDCl3): δ 
= 8.09 (ddd, JH6′,H5′ = 5.1 Hz, JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 7.80 (td, 
JH6,H2 = JH6,H4 = 1.4 Hz, JH6,H3 = 0.6 Hz, 1 H, H6), 7.74 (dtt, JH4,H3 = 7.9 Hz, JH4,H2 
= JH4,H6 = 1.3 Hz, JH4,CH = JH4,NH = 0.7 Hz, 1 H, H4), 7.65 (dt, JH2,H3 = 7.9 Hz, JH2,H4 
= JH2,H6 = 1.4 Hz, 1 H, H2), 7.50 (t, JH3,H2 = JH3,H4 = 7.5 Hz, 1 H, H3), 7.45 (ddd, JH4′,H3′ = 8.3 Hz, JH4′,H5′ = 
7.1 Hz, JH4′,H6′ = 1.8 Hz, 1 H, H4′), 6.6λ (dddd, JH5′,H4′ = 7.2 Hz, JH5′,H6′ = 5.0 Hz, JH6′,H5′ = 0.9 Hz, JH6′,NH = 
0.3 Hz, 1 H, H5′), 6.53 (ddd, JH3′,H4′ = 8.4 Hz, JH3′,H5′ = JH3′,NH = 0.7 Hz, 1 H, H3′), 6.01 (p, JCH,CF3 = JCH,NH = 
8.0 Hz, 1 H, CH), 5.04 (d, JNH,CH = 8.7 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -73.60 (d, JCF3,CH 
= 7.9 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 155.77 (C2′), 148.11 (C6′), 138.02 (C4′), 136.57 (d, JC,F 
= 1.1 Hz, C5), 132.77 (C4), 132.68 (C2), 132.05 – 131.64 (m, C6), 129.83 (C3), 124.98 (q, JC,F = 281.7 Hz, 
CF3), 118.56 (CN), 115.38 (C5′), 113.31 (C1), 10λ.22 (C3′), 55.λ2 (q, JC,F = 30.6 Hz, CH) ppm. HRMS (ESI+): 
m/z calcd. for C14H11N3F3+ [M+H]+ 278.0905, found 278.0898. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 
100% B, flow: 1 mL/min): tR = 10.30 min,  = 214 nm. 
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4-(2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl)benzonitrile (2c) 
(4-Cyanophenyl)magnesium chloride was prepared according to TP3 from 4-bromobenzonitrile (91 mg, 
0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2c as a light yellow oil (85 mg, 68%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. 1H NMR (300 MHz, CDCl3): δ 
= 8.08 (ddd, JH6′,H5′ = 5.0 Hz, JH6′,H4′ = 1.9 Hz, JH6′,H3′ = 0.9 Hz, 1 H, H6′), 7.72 – 
7.65 (m, 2 H, H2, H6), 7.64 – 7.59 (m, 2 H, H3, H5), 7.44 (ddd, JH4′,H3′ = 8.3 Hz, 
JH4′,H5′ = 7.2 Hz, JH4′,H6′ = 1.9 Hz, 1 H, H4′), 6.68 (ddd, JH5′,H4′ = 7.2 Hz, JH5′,H6′ = 5.0 Hz, JH6′,H5′ = 0.9 Hz, 1 H, 
H5′), 6.51 (dt, JH3′,H4′ = 8.3 Hz, J = 0.9 Hz, 1 H, H3′), 6.01 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.06 (d, 
JNH,CH = 8.9 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -73.38 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 
13C NMR (75 MHz, CDCl3): δ = 155.81 (C2′), 148.0λ (C6′), 140.02 (d, JC,F = 0.9 Hz, C4), 138.01 (C4′), 12λ.07 
(q, JC,F = 1.2 Hz, C3, C5), 128.17 (C2, C6), 124.96 (q, JC,F = 281.8 Hz, CF3), 118.50 (CN), 115.36 (C5′), 113.13 
(C1), 10λ.15 (C3′), 56.23 (q, JC,F = 30.6 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N3F3+ [M+H]+ 
278.0905, found 278.0897. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
7.28 min, λ = 214 nm. 
 
N-(1-(3-Chlorophenyl)-2,2,2-trifluoroethyl)pyridin-2-amine (2d) 
(3-Chlorophenyl)magnesium chloride was prepared according to TP3 from 1-bromo-3-chlorobenzene (96 mg, 
0.50 mmol) in 3 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 3 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2d as a light yellow oil (97 mg, 75%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40. 1H NMR (400 MHz, CDCl3): δ 
= 8.11 (dddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, JH6,NH = 0.3 Hz, 1 H, 
H6), 7.48 (ddt, JH2′,H6′/H4′ = 1.9 Hz, JH2′,H6′/H4′ = 1.3 Hz, JH2′,H5′ = JH2′,CH = 0.7 Hz, 1 H, 
H2′), 7.44 (ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.39 – 7.36 (m, 1 H, H6′), 7.36 – 
7.29 (m, 2 H, H4′, H5′), 6.68 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, JH6,H5 = 0.9 Hz, 1 H, H5), 6.49 (dt, JH3,H4 = 
8.3 Hz, JH3,H5 = JH3,NH = 0.9 Hz, 1 H, H3), 5.95 – 5.85 (m, 1 H, CH), 5.00 (d, JNH,CH = 9.4 Hz, 1 H, NH) ppm. 
19F NMR (282 MHz, CDCl3): δ = -80.36 (d, JCF3,CH = 4.6 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 
156.19 (C2), 148.25 (C6), 138.05 (C4), 136.57 (d, JC,F = 1.0 Hz, C1′), 135.05 (C3′), 130.3λ (C5′), 12λ.47 (C4′), 
128.45 (q, JC,F = 1.2 Hz, C2′), 126.56 (q, JC,F = 1.2 Hz, C6′), 12λ.5λ – 120.84 (CF3), 115.24 (C5), 109.04 (C3), 
56.13 (q, JC,F = 30.7 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N3F3+ [M+H]+ 287.0557, found 
287.0557. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 11.35 min,  = 214 nm. 
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N-(1-(4-Chlorophenyl)-2,2,2-trifluoroethyl)pyridin-2-amine (2e) 
(4-Chlorophenyl)magnesium chloride was prepared according to TP3 from 1-bromo-4-chlorobenzene (96 mg, 
0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2e as a light yellow oil (85 mg, 66%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40. 1H NMR (300 MHz, CDCl3): δ 
= 8.10 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47 – 7.38 
(m, 3 H, H4, H2′, H6′), 7.38 – 7.33 (m, 2 H, H3′, H5′), 6.67 (dddd, JH5,H4 = 7.2 Hz, 
JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, JH5,NH = 0.3 Hz, 1 H, H5), 6.47 (dt, JH3,H4 = 8.3 Hz, 
J = 0.9 Hz, 1 H, H3), 5.87 (dq, JCH,NH = 8.7 Hz, JCH,CF3 = 7.9 Hz, 1 H, CH), 4.99 (d, JNH,CH = 9.0 Hz, 1 H, 
NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -73.88 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 156.20 (C2), 148.16 (C6), 137.93 (C4), 135.16 (C4′), 133.35 – 133.04 (m, C1′), 12λ.55 (q, JC,F = 
1.2 Hz, C2′, C6′), 12λ.26 (C3′, C5′), 125.22 (q, JC,F = 281.8 Hz, CF3), 115.10 (C5), 108.88 (C3), 56.04 (q, JC,F 
= 30.6 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C13H11ClN2F3+ [M+H]+ 287.0563, found 287.0557. 
HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 11.43 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)pyridin-2-amine (2f)  
(4-(Trifluoromethyl)phenyl)magnesium chloride was prepared according to TP3 from 1-bromo-4-
(trifluoromethyl)benzene (113 mg, 0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2f as a light yellow oil (105 mg, 73%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.50. 1H NMR (300 MHz, CDCl3): δ = 8.10 (d, JH6,H5 = 4.0 Hz, 
1 H, H6), 7.66 (d, JH3′,H2′ = JH5′,H6′ = 8.9 Hz, 2 H, H3′, H5′), 7.61 (d, JH2′,H3′ = JH6′,H5′ 
= 8.8 Hz, 2 H, H2′, H6′), 7.44 (ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 
1 H, H4), 6.68 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.50 
(dt, JH3,H4 = 8.3 Hz, J = 0.9 Hz, 1 H, H3), 6.00 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, 
CH), 5.04 (d, JNH,CH = 8.9 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3) δ = -62.84 (s, CCF3), -73.60 (d, 
JCF3,CH = 7.9 Hz, CHCF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.03 (C2), 148.14 (C6), 138.6λ (C1′), 
138.00 (C4), 131.38 (q, JC,F = 32.3 Hz, C4′), 128.68 (q, JC,F = 1.2 Hz, C2′, C6′), 126.00 (q, JC,F = 3.8 Hz, C3′, 
C5′), 125.13 (q, JC,F = 282.3 Hz, CHCF3), 124.09 (q, JC,F = 272.2 Hz, CCF3), 115.26 (C5), 109.02 (C3), 56.21 
(q, JC,F = 30.6 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N2F3+ [M+H]+ 321.0826, found 
321.0820. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 11.98 min, λ = 214 nm. 
N-(2,2,2-Trifluoro-1-(pyridin-2-yl)ethyl)pyridin-2-amine (2g)  
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Pyridin-2-ylmagnesium chloride was prepared according to TP3 from 2-bromopyridine (50 L, 0.55 mmol) in 
2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2g as a light yellow oil (71 mg, 62%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.35. 1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, JH6′,H5′ = 
4.9 Hz, JH6′,H4′ = 1.8 Hz, J = 1.0 Hz, 1 H, H6′), 8.12 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, 
J = 0.9 Hz, 1 H, H6), 7.78 – 7.67 (m, 1 H, H4′), 7.48 – 7.39 (m, 2 H, H3′, H4), 7.30 (ddd, 
JH5′,H4′ = 7.6 Hz, JH5′,H6′ = 4.9 Hz, JH5′,H3′ = 1.2 Hz, 1 H, H5′), 6.67 – 6.59 (m, 2 H, H3, 
H5), 6.17 (d, JNH,CH = 8.5 Hz, 1 H, NH), 6.08 (p, JCH,NH = JCH,CF3 = 7.4 Hz, 1 H, CH) ppm. 
19F NMR (282 MHz, CDCl3): δ = -74.10 (d, JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 
156.75 (C2), 152.26 (C2′), 14λ.4λ (C6′), 147.76 (C6), 137.5λ (C4), 136.8λ (C4′), 125.08 (q, JC,F = 281.8 Hz, 
CF3), 124.3λ (C3′), 124.00 (C5′), 114.56 (C5), 10λ.77 (C3), 55.83 (q, JC,F = 31.0 Hz, CHCF3) ppm. HRMS 
(ESI+): m/z calcd. for C12H11F3N3+ [M+H]+ 254.0900, found 254.0899. HPLC (0.1% TFA, 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 9.13 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(pyridin-3-yl)ethyl) pyridin-2-amine (2h)  
Pyridin-3-ylmagnesium chloride was prepared according to TP3 from 3-bromopyridine (50 L, 0.55 mmol) in 
2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2h as a light yellow oil (79 mg, 69%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.50. 1H NMR (600 MHz, CDCl3): δ = 8.75 (d, JH2′,H4′ = 2.2 Hz, 
1 H, H2′), 8.60 (dd, JH6′,H5′ = 4.8 Hz, JH6′,H4′ = 1.6 Hz, 1 H, H6′), 8.10 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, 
JH6,H3 = 0.9 Hz, 1 H, H6), 7.81 (dt, JH4′,H5′ = 8.2 Hz, JH4′,H2′ = JH4′,H6′ = 1.8 Hz, 1 H, H4′), 
7.43 (ddd, JH4,H3 = 8.8 Hz, JH4,H5 = 7.3 Hz, JH4,H6 = 1.8 Hz, 1 H, H4), 7.32 (ddd, JH5′,H4′ 
= 8.0 Hz, JH5′,H6′ = 4.8 Hz, JH5′,H2′ = 1.0 Hz, 1 H, H5′), 6.68 (ddd, JH5,H4 = 7.1 Hz, JH5,H6 
= 5.1 Hz, JH5,H3 = 1.0 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.4 Hz, J = 1.0 Hz, 1 H, H3), 6.02 (p, JCH,CF3 = JCH,NH = 
8.2 Hz, 1 H, CH), 5.14 (d, JNH,CH = 9.0 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -74.63 (q, J = 
8.0 Hz, CF3) ppm. 13C NMR (151 MHz, CDCl3): δ = 155.74 (C2), 150.14 (C6′), 14λ.5λ (C2′), 147.85 (C6), 
137.76 (C4), 135.41 (C4′), 130.51 (C3′), 124.λ4 (q, JC,F = 281.8 Hz, CF3), 123.62 (C5′), 115.02 (C5), 108.λ1 
(C3), 54.37 (q, JC,F = 31.0 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C12H11N3F3+ [M+H]+ 254.0905, 
found 254.0899. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 10.33 min, λ = 
214 nm.  
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N-(1-(6-Chloropyridin-3-yl)-2,2,2-trifluoroethyl)-6-methylpyridin-2-amine (2i) 
(6-Chloropyridin-3-yl)magnesium chloride was prepared according to TP3 from 5-bromo-3-chloropyridine 
(218 mg, 1.13 mmol) in 1 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)-6-
methylpyridin-2-amine (100 mg, 0.43 mmol) at 0 °C in 5 h. Flash column chromatography (SiO2, 
cyclohexane/ethyl acetate/NEt3, 20:1:0.1) furnished 2i as a white solid (84 mg, 65%). 
Rf  (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40. mp 74 °C. 1H NMR 
(600 MHz, CDCl3): δ = 8.53 (s, 1 H, H2′), 7.77 (dd, JH4′,H5′ = 8.4 Hz, JH4′,CH = 
2.4 Hz, 1 H, H4′), 7.35 (d, JH5′,H4′ = 8.0 Hz, 1 H, H5′), 7.32 (d, JH5,H4 = 8.2 Hz, 
1 H, H4), 6.60 – 6.47 (d, JH5,H4 = 7.0 Hz, 1 H, H5), 6.29 (d, JH5,H4 = 8.2 Hz, 1 H, 
H3), 5.95 (p, JCH,CF = JCH,NH = 8.1 Hz, 1 H, CH), 4.92 (d, JNH,CH = 8.7 Hz, 1 H, NH), 2.35 (s, 3 H, CH3) ppm. 
19F NMR (282 MHz, CDCl3): δ = -73.59 (d, JCF3,CH = 8.1 Hz, CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 
157.18 (C6), 154.λ6 (C2), 152.05 (C6′), 14λ.85 (C2′), 138.23 (C4, C4′), 12λ.λ2 (C3′), 124.88 (q, JC,F = 
281.3 Hz, CF3), 124.52 (C5′), 114.56 (C5), 105.54 (C3), 54.22 (q, JC,F = 31.2 Hz, CHCF3), 24.40 (CH3) ppm. 
HRMS (ESI+): m/z calcd. for C13H12ClF3N3+ [M+H]+ 302.0666, found 302.0664. HPLC (0.1% TFA, 0 min: 
4% B → 15 min: 100% B, flow: 1 mL/min): tR = 10.50 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(perfluorophenyl)ethyl)pyridin-2-amine (2j) 
(Perfluorophenyl)magnesium chloride was prepared from 1-bromo-2,3,4,5,6-pentafluorobenzene (60 L, 
0.50 mmol) solved in THF (0.50 mL). iPrMgCl (1.25 M, 0.44 mL, 0.55 mL) was added dropwise at -78 °C and 
the reaction was stirred for 45 min.  
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -78 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2j as a light yellow oil (131 mg, 85%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. 1H NMR (400 MHz, CDCl3): δ 
= 8.13 (ddd, JH6,H5 = 5.2 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47 (ddd, 
JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH3,H6 = 1.9 Hz, 1 H, H4), 6.72 (ddd, JH5,H4 = 7.2 Hz, 
JH5,H6 = 5.2 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.72 – 6.63 (m, 1 H, CH), 6.55 (dt, JH3,H4 
= 8.3 Hz, J = 0.9 Hz, 1 H, H3), 5.21 (d, JNH,CH = 10.6 Hz, 1 H, NH) ppm. 19F NMR (376 MHz, CDCl3): δ = -
74.63 (q, J = 7.9 Hz, CF3), -141.2λ (s, F2′, F6′), -152.01 (tt, JF4′,F3′ = JF4′,F5′ = 20.9 Hz, JF4′,F2′ = JF4′,F6′ = 2.7 Hz, 
F4′), -160.80 (td, JF5′,F4′ = JF5′,F6′ = JF3′,F2′ = JF3′,F4′ = 22.0 Hz, JF5′,F3′ = JF3′,F5′ = 7.8 Hz, F5′, F3′) ppm. 13C NMR 
(101 MHz, CDCl3): δ = 155.30 (C2), 148.07 (C6), 147.54 – 144.58 (m, C2′, C6′), 143.52 – 140.32 (m, C3′, 
C5′), 138.12 (C4), 13λ.48 – 136.17 (m, C4′), 124.44 (q, JC,F = 282.9 Hz, CF3), 115.66 (C5), 109.47 (C3), 109.21 
– 108.71 (m, C1′), 48.11 (q, JC,F = 34.3 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C13H7N2F8+ [M+H]+ 
343.0481, found 343.0474. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
14.56 min, λ = 214 nm. 
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N-(2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)ethyl)pyridin-2-amine (2k) 
(4-Methylnaphthalen-1-yl)magnesium chloride was prepared according to TP3 from 
1-bromo-4-methylnaphthalen (158 mg, 0.50 mmol) in 18 h at 25 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at 25 °C in 18 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2k as a light yellow oil (83 mg, 58%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. 1H NMR (400 MHz, CDCl3): δ 
= 8.29 – 8.22 (m, 1 H, H8′), 8.17 (dddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 
0.9 Hz, JH6,NH = 0.3 Hz, 1 H, H6), 8.09 – 8.03 (m, 1 H, H5′), 7.64 (dd, JH2′,H3′ = 
7.3 Hz, JH2′,CH = 1.2 Hz, 1 H, H2′), 7.62 – 7.54 (m, 2 H, H6′, H7′), 7.3λ (ddd, JH4,H3 
= 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.35 (dd, JH3′,H2′ = 7.4 Hz, JH3′,CH3 = 0.9 Hz, 1 H, H3′), 6.81 
(p, JCH,CF3 = JCH,NH = 7.7 Hz, 1 H, CH), 6.66 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 
6.41 (dt, JH3,H4 = 8.3 Hz, J = 0.9 Hz, 1 H, H3), 5.04 (d, JNH,CH = 8.8 Hz, 1 H, NH), 2.71 (d, JCH3,C3′ = 0.9 Hz, 
3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -80.38 (d, JCF3,CH = 4.7 Hz, CHCF3) ppm. 13C NMR 
(101 MHz, CDCl3): δ = 156.56 (C2), 148.34 (C6), 137.λ5 (C4), 136.25 (C8′a), 133.31 (C4′a), 132.02 (C4′), 
129.29 (d, JC,F = 1.0 Hz, C1′), 126.λ3 (C7′), 126.3λ (C3′), 126.23 (C6′), 126.11 (q, JC,F = 282.9 Hz, CF3), 125.31 
(C5′), 124.88 (q, JC,F = 1.8 Hz, C2′), 123.λ4 (d, JC,F = 0.9 Hz, C8′), 114.88 (C5), 108.70 (C3), 51.67 (q, JC,F = 
30.6 Hz, CH), 20.04 (CH3) ppm. HRMS (ESI+): m/z calcd. for C18H16F3N2+ [M+H]+ 317.1260, found 
317.1262. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 12.09 min, λ = 214 nm. 
 
N-(1-(2,4-Dimethoxypyrimidin-5-yl)-2,2,2-trifluoroethyl)pyridin-2-amine (2l) 
(2,4-Dimethoxypyrimidin-5-yl)magnesium chloride was prepared according to TP3 from 5-bromo-2,4-
dimethoxypyrimidine (110 mg, 0.50 mmol) in 1 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2l as a light yellow oil (120 mg, 85%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40.1H NMR (400 MHz, 
CDCl3): δ = 8.30 (s, 1 H, H6′), 8.11 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.8 Hz, JH6,H3 
= 0.8 Hz, 1 H, H6), 7.43 (ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 
1 H, H4), 6.66 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 
6.49 (dt, JH3,H4 = 8.3 Hz, J = 0.9 Hz, 1 H, H3), 6.07 (dqd, JCH,NH = 9.7 Hz, JCH,CF3 = 8.0 Hz, JCH,H5 = 0.5 Hz, H, 
CH), 5.34 (d, JNH,CH = 9.6 Hz, 1 H, NH), 4.07 (s, 3 H, OCH3), 3.99 (s, 3 H, OCH3) ppm. 19F NMR (282 MHz, 
CDCl3): δ = -74.27 (d, JCF3,CH = 8.0 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 16λ.61 (C4′), 165.72 
(C2′), 15λ.12 (q, JC,F = 1.1 Hz, C6′), 156.22 (C2), 148.20 (C6), 137.λλ (C4), 125.29 (q, JC,F = 282.6 Hz, CF3), 
115.08 (C5), 109.07 (C3), 108.68 (d, JC,F = 1.2 Hz, C5′), 55.2λ (OCH3), 54.82 (OCH3), 50.95 (q, JC,F = 32.4 Hz, 
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CHCF3) ppm. HRMS (ESI+): m/z calcd. for C14H11N3F3+ [M+H]+ 315.1063, found 315.1064. HPLC (0.1% 
TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 9.46 min,  = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(thiophen-2-yl)ethyl)pyridin-2-amine (2m)  
Thiophen-2-ylmagnesium chloride was prepared according to TP3 from 2-bromothiophene (0.05 mL, 
0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2m as a colorless oil (84 mg, 72%). 
Rf (cyclohexane/ethyl acetate 10:1) = 0.60. 1H NMR (400 MHz, CDCl3): δ = 8.15 
(dddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.8 Hz, JH6,H3 = 0.8 Hz, JH6,NH = 0.3 Hz, 1 H, H6), 7.45 
(ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.30 (dd, JH5′,H4′ = 5.1, 
JH5′,H3′ = 1.2 Hz, 1 H, H5′), 7.21 (ddt, JH3′,H4′ = 3.6 Hz, JH3′,H5′ = 1.3 Hz, JH3′,CH = 0.7 Hz, 1 H, H3′), 7.02 (dd, 
JH4′,H5′ = 5.1 Hz, JH4′,H3′ = 3.6 Hz, 1 H, H4′), 6.70 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, 
H5), 6.51 (dt, JH3,H4 = 8.3 Hz, J = 0.9 Hz, 1 H, H3), 6.30 (dqd, JCH,NH = 9.5 Hz, JCH,CF3 = 7.6 Hz, J = 0.8 Hz, 
1 H, CH), 4.87 (d, JNH,CH = 9.5 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -74.72 (d, JCF3,CH = 
7.7 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): δ = 156.04 (C2), 148.07 (C6), 137.98 (C4), 137.13 – 137.08 
(m, C2′), 127.43 (C4′), 127.21 (q, JC,F = 1.3 Hz, C3′), 126.15 (C5′), 124.λ5 (q, JC,F = 281.9 Hz, CF3), 115.22 
(C5), 109.07 (C3), 52.28 (q, JC,F = 32.2 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M+H]+ 
259.0517, found 259.05113. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
10.10 min, λ = 214 nm. 
 
N-(1-(Benz[b]thiophen-3-yl)-2,2,2-trifluoroethyl)pyridin-2-amine (2n) 
Benzo[b]thiophen-3-ylmagnesium chloride was prepared according to TP3 from 3-bromobenz[b]thiophene 
(107 mg, 0.50 mmol) in 3 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 3 h. Flash column chromatography (SiO2, gradient: cyclohexane/ethyl 
acetate/NEt3 50μ1μ0.1 → 15μ1μ0.1) furnished 2n as a yellow oil (115 mg, 83%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.40. 1H NMR (300 MHz, CDCl3): δ 
= 8.22 (ddd, JH6,H5 = 5.0 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.86 (dddd, 
JH4′,H5′ = JH7′,H6′ = 6.8 Hz, JH4′,H6′ = JH7′,H5′ = 5.4 Hz, JH4′,H7′ = JH7′,H4′ = 3.3 Hz, JH4′,H2′ 
= JH7′,H2′ = 0.7 Hz, 2 H, H4′, H7′), 7.62 (dd, JH2′,CH = 1.5 Hz, JH2′,H4′ = JH2′,H7′ = 
0.7 Hz, 1 H, H2′), 7.43 (ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 7.40 – 7.35 (m, 2 H, 
H5′, H6′), 6.71 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.44 (dt, JH3,H4 = 8.3 Hz, J = 
0.9 Hz, 1 H, H3), 6.54 (dqd, JCH,NH = 9.9 Hz, JCH,CF3 = 7.6 Hz, JCH,H2′ = 0.8 Hz, 1 H, CH), 4.79 (d, JNH,CH = 
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9.3 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -73.10 (d, JCF3,CH = 7.6 Hz, JCF3,NH = 1.1 Hz, 
CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.0λ (C2), 147.85 (C6), 13λ.λ7 (C7′a), 137.λ0 (C3′a), 137.6λ 
(C4), 129.24 (d, JC,F = 1.1 Hz, C3′), 125.43 (q, JC,F = 282.6 Hz, CF3), 124.λ4 (C2′), 124.8λ (C5′), 124.61 (C6′), 
122.77 (C4′), 121.λ4 (C7′), 114.73 (C5), 108.62 (C3), 50.20 (q, JC,F = 31.8 Hz, CHCF3) ppm. HRMS (ESI+): 
m/z calcd. for C15H12F3N3S+ [M+H]+ 309.0668, found 309.0667. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 
100% B, flow: 1 mL/min): tR = 11.71 min,  = 214 nm. 
 
N-(1-Cyclopropyl-2,2,2-trifluoroethyl)pyridin-2-amine (2o) 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(100 mg, 0.45 mmol) and cyclopropylmagnesium bromide (1.0 M, 0.55 mL, 0.55 mmol) at 0 °C in 2 h. Flash 
column chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 50μ1μ0.1 → 10μ1μ0.1) furnished 2o as 
a white solid (83 mg, 85%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.45. mp 77 °C, 1H NMR (300 MHz, 
CDCl3): δ = 8.07 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.42 
(ddd, JH4,H3 = 8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.63 (ddd, JH5,H4 = 7.2 Hz, 
JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.44 (dt, JH3,H4 = 8.4 Hz, JH3,H5 = JH3,H6 = 0.9 Hz, 1 H, H3), 4.47 (d, 
JNH,CH = 9.5 Hz, 1 H, NH), 4.36 – 4.17 (m, 1 H, CH), 1.17 – 1.04 (m, 1 H, CH(CH2)2), 0.76 – 0.63 (m, 1 H, 
CH2), 0.61 – 0.49 (m, 2 H, CH2), 0.46 – 0.32 (m, 1 H, CH2) ppm. 19F NMR (282 MHz, CDCl3): δ = -75.58 (d, 
JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 157.26 (C2), 147.98 (C6), 137.81 (C4), 126.26 
(q, JC,F = 283 Hz, CF3), 114.47 (C5), 108.50 (C3), 55.82 (q, JC,F = 29.3 Hz, CHCF3), 10.86 (q, JC,F = 2.3 Hz, 
CH(CH2)2), 3.82 (d, JC,F = 0.9 Hz, CH2), 1.91 (CH2) ppm. HRMS (ESI+): m/z calcd. for C10H12F3N2+ [M+H]+ 
217.0953, found 217.0946. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
9.14 min,  = 214 nm.  
 
4-(2,2,2-Trifluoro-1-(pyrazin-2-ylamino)ethyl)benzonitrile (2p) 
(4-Cyanophenyl)magnesium chloride was prepared according to TP3 from 4-bromobenzonitrile (91 mg, 
0.50 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluorethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, gradient: cyclohexane/ethyl 
acetate 10:1 → 3:1) furnished 2p as a light yellow oil (70 mg, 56%). 
Rf (cyclohexane/ethyl acetate 1:1) = 0.37. 1H NMR (600 MHz, CDCl3): δ = 8.07 
(d, JH3′,H6′ = 1.5 Hz, 1 H, H3′), 8.00 (dd, JH6′,H5′ = 2.7 Hz, JH6′,H3′ = 1.5 Hz, 1 H, H6′), 
7.93 (d, JH5′,H6′ = 2.7 Hz, 1 H, H5′), 7.72 – 7.67 (m, 2 H, H3, H5), 7.61 (d, J = 8.1 Hz, 
2 H, H2, H6), 5.97 (p, JCH,CF3 = JCH,NH = 8.0 Hz, 1 H, CH), 5.48 (d, JNH,CH = 8.8 Hz, 
1 H, NH) ppm. 19F NMR (280 MHz, CDCl3): δ = -73.33 (d, JCF3,CH = 7.7 Hz, CF3) ppm. 13C NMR (150 MHz, 
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CDCl3): δ = 152.18 (C2′), 141.71 (C6′), 13λ.01 (C1), 135.1λ (C5′), 133.32 (C3′), 132.77 (C3, C5), 128.λ8 (C2, 
C6), 124.41 (q, JC,F = 281.8 Hz, CF3), 118.27 (CN), 113.32 (C4) , 55.48 (q, JC,F = 31.0 Hz, CHCF3) ppm. 
HRMS (ESI+): m/z calcd. for C13H10F3N4+ [M+H]+ 279.0852, found 279.0852. HPLC (0.1% TFA, 0 min: 4% 
B → 15 min: 100% B, flow: 1 mL/min): tR = 13.16 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(pyridin-2-yl)ethyl)pyrazin-2-amine (2q)  
Pyridin-2-ylmagnesium chloride was prepared according to TP3 from 2-bromopyridine (50 L, 0.55 mmol) in 
2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2q as a light yellow oil (65 mg, 56%). 
Rf (cyclohexane/ethyl acetate 1:1) = 0.48. 1H NMR (300 MHz, CDCl3): δ = 8.68 – 8.62 
(m, 1 H, H6′), 8.13 – 8.10 (m, 1 H, H3), 8.03 (ddd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, J = 
0.5 Hz, 1 H, H6), 7.89 (dt, JH5,H6 = 2.7 Hz, J = 0.5 Hz, 1 H, H5), 7.75 (tdd, JH4′,H3′ = 
JH4′,H5′ = 7.7 Hz, J = 1.8 Hz, J = 0.5 Hz, 1 H, H4′), 7.46 (dd, JH3′,H4′ = 8.1 Hz, JH3′,H5′ = 
1.3 Hz, 1 H, H3′), 7.3λ – 7.31 (m, 1 H, H5′), 6.51 (d, JNH,CH = 8.2 Hz, 1 H, NH), 6.00 (m, 1 H, CH) ppm. 
19F NMR (280 MHz, CDCl3): δ = -74.15 (d, JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 
153.08 (C2), 151.21 (C2′), 14λ.52 (C6′), 141.53 (C6), 137.08 (C4′), 134.46 (C5), 134.03 (C3), 124.78 (q, JC,F 
= 283.3 Hz, CF3), 124.33 (C3′/C5′), 124.2λ (C3′/C5′), 55.16 (q, JC,F = 31.1 Hz, CHCF3) ppm. HRMS (ESI+): 
m/z calcd. for C11H10F3N4+ [M+H]+ 255.0852, found 255.0852. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 
100% B, flow: 1 mL/min): tR = 10.98 min, λ = 214 nm. 
 
N-(1-(2,4-Dimethoxypyrimidin-5-yl)-2,2,2-trifluoroethyl)pyrazine-2-amine (2r) 
(2,4-Dimethoxypyrimidin-5-yl)magnesium chloride was prepared according to TP3 from 5-bromo-2,4-
dimethoxypyrimidine (77 mg, 0.35 mmol) in 1 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 
(66 mg, 0.3 mmol) at -30 °C in 2 h. Flash column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 
8:1:0.1) furnished 2r as a light yellow oil (75 mg, 79%). 
Rf (cyclohexane/ethyl acetate/NEt3 6:4:0.1) = 0.24. 1H NMR (400 MHz, 
CDCl3): δ = 8.30 (s, 1 H, H6′), 8.05 – 8.00 (m, 2 H, H3, H5), 7.92 (d, JH6,H5 = 
2.6 Hz, 1 H, H6), 6.04 (dq, JCH,NH = 9.6 Hz, JCH,CF3 = 7.9 Hz, 1 H, CH), 5.60 (d, 
JNH,CH = 9.6 Hz, 1 H, NH), 4.09 (s, 3 H, OCH3), 4.00 (s, 3 H, OCH3) ppm. 
19F NMR (376 MHz, CDCl3): δ = -74.21 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (100 MHz, CDCl3): δ = 
169.38 (C4′), 165.71 (C2′), 159.08 (C6′), 152.39 (C2), 141.69 (C6), 134.94 (C5), 133.29 (C3), 124.84 (q, JC,F 
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= 282.6 Hz, CF3), 107.71 (C5′), 55.28 (OCH3), 54.74 (OCH3), 50.41 (q, JC,F = 33.0 Hz, CHCF3) ppm. HRMS 
(ESI+): m/z calcd. for C12H13F3N5O2+ [M+H]+ 316.1016, found 316.1014. 
 
N-(2,2,2-Trifluoro-1-(thiophen-2-yl)ethyl)pyrazin-2-amine (2s): 
Thiophen-2-ylmagnesium chloride was prepared according to TP3 from 2-bromothiophene (0.07 mL, 
0.70 mmol) in 2 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazine-2-
amine (100 mg, 0.45 mmol) at -30 °C in 8 h. Flash column chromatography (SiO2, cyclohexane/ethyl 
acetate/NEt3 8:1:0.1) furnished 2s as a light red oil (64 mg, 55%). 
Rf (cyclohexane/ethyl acetate/NEt3 4:2:0.1) = 0.38. 1H NMR (400 MHz, CDCl3): δ = 
8.06 (ddd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, J = 0.4 Hz, 1 H, H6), 8.03 (dd, JH3,H6 = 1.5 Hz, 
J = 0.4 Hz, 1 H, H3), 7.95 (dd, JH5,H6 = 2.8 Hz, J = 0.4 Hz, 1 H, H5), 7.33 (dd, JH5′,H4′ = 
5.1 Hz, JH5′,H3′ = 1.2 Hz, 1 H, H5′), 7.22 (ddt, JH3′,H4′ = 3.6 Hz, JH3′,H5′ = 1.3 Hz, JH3′,CH = 
0.7 Hz, 1 H, H3′), 7.04 (dd, JH4′,H5′ = 5.1 Hz, JH4′,H3′ = 3.6 Hz, 1 H, H4′), 6.27 (dqd, JCH,NH = 9.4 Hz, JCH,CF3 = 
7.4 Hz, JCH,H3′ = 0.8 Hz, 1 H, CH), 5.11 (d, JNH,CH = 9.4 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = 
-74.67 (d, JCF3,CH = 7.6 Hz, CF3) ppm. 13C NMR (100 MHz, CDCl3): δ = 152.28 (C2), 141.73 (C6), 135.84 
(C2′), 135.12 (C5), 133.21 (C3), 127.51 (q, JC,F = 1.3 Hz, C3′), 127.45 (C4′), 126.44 (C5′), 124.58 (q, JC,F = 
281.9 Hz, CF3), 51.60 (q, JC,F = 32.7 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M+H]+ 
260.0464, found 260.0463. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
13.50 min, λ = 214 nm. 
 
N-(1-(Benz[b]thiophen-3-yl)-2,2,2-trifluoroethyl)pyrazine-2-amine (2t) 
Benzo[b]thiophen-3-ylmagnesium chloride was prepared according to TP3 from 3-bromobenz[b]thiophene 
(192 mg, 0.90 mmol) in 3 h at 0 °C. 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) at 0 °C in 6 h. Flash column chromatography (SiO2, gradient: cyclohexane/ethyl 
acetate/NEt3 20μ1μ0.1 → 8μ1μ0.1) furnished 2t as a yellow oil (120 mg, 86%). 
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.38. 1H NMR (300 MHz, CDCl3): δ = 
8.13 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1 H, H6), 7.96 (d, JH5,H6 = 2.8 Hz, 2 H, H3, H5), 
7.92 – 7.85 (m, 1 H, H5′), 7.82 – 7.75 (m, 1 H, H8′), 7.67 – 7.62 (m, 1 H, H2′), 7.46 – 7.32 
(m, 2 H, H6′, H7′), 6.5λ – 6.42 (m, 1 H, CH), 5.02 (d, JNH,CH = 9.1 Hz, 1 H, NH) ppm. 
19F NMR (282 MHz, CDCl3): δ = -73.06 (dd, JCF3,CH = 7.5 Hz, JCF3,NH = 1.2 Hz, CF3) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 152.58 (C2), 141.76 (C6), 140.14 (C4′, Cλ′), 137.84 (C3′), 134.λ4 (C5), 133.13 (C3), 
125.53 (C2′), 125.32 (q, JC,F = 282.5 Hz, CF3), 125.24 (C6′/C7′), 124.λ3 (C6′/C7′), 123.07 (C5′), 121.76, 4λ.6λ 
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(q, JC,F = 32.3 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M+H]+ 310.0620, found 
310.0619, HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 15.13 min, λ = 214 nm. 
 
N-(1,1,1-Trifluoro-but-3-yn-2-yl)pyrazin-2-amine (2u) 
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) and ethynylmagnesium bromide (0.5 M, 1.4 mL, 0.67 mmol) at -78 °C in 2 h. Flash 
column chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 10:1:0.1) furnished 2u as a light yellow oil 
(88 mg, 96%). 
Rf (cyclohexane/ethyl acetate/NEt3 8:1:0.1) = 0.46. 1H NMR (300 MHz, CDCl3): δ 
= 8.07 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1 H, H6), 8.04 (d, JH3,H6 = 1.5 Hz, 1 H, 
H3), 7.99 (d, JH5,H6 = 2.7 Hz, 1 H, H5), 5.82 (dqd, JCH,NH = 9.1 Hz, JCH,CF3 = 6.6 Hz, 
JCH,C≡CH = 2.5 Hz, 1 H, CH), 4.93 (d, JNH,CH = 9.2 Hz, 1 H, NH), 2.46 (d, JC≡CH,CH = 
2.5 Hz, 1 H, C≡CH) ppm. 19F NMR (282 MHz, CDCl3): δ = -76.14 (d, JCF3,CH = 6.5 Hz, CF3) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 151.74 (C2), 141.62 (C6), 135.60 (C5), 133.34 (C3), 123.36 (q, JC,F = 281.8 Hz, CF3), 
75.30 (C≡CH), 74.45 (C≡CH), 44.83 (q, JC,F = 35.8 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for 
C8H7F3N3+ [M+H]+ 202.0587, found 202.0586. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 
1 mL/min): tR = 11.99 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-(perfluorophenyl)ethyl)pyrazin-2-amine (2v) 
(Perfluorophenyl)magnesium chloride was prepared from 1-bromo-2,3,4,5,6-pentafluorobenzene (λ0 L, 0.70 
mmol) solved in THF (0.50 mL). iPrMgCl (2 M, 0.39 mL, 0.77 mL) was added dropwise at -78 °C and the 
reaction was stirred for 45 min.  
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) at -78 °C in 5 h. Flash column chromatography (SiO2, gradient: cyclohexane/ethyl 
acetate 30μ1 → 8μ1) furnished 2v as a colorless oil (143 mg, 92%). 
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.58. 1H NMR (300 MHz, CDCl3): δ 
= 8.09 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 8.06 (dd, JH6,H5 = 2.8, JH6,H3 = 1.5 Hz, 1 H, H6), 
7.99 (d, JH5,H6 = 2.7 Hz, 1 H, H5), 6.56 (dq, JCH,NH = 10.2 Hz, JCH,CF3 = 7.8 Hz, 1 H, 
CH), 5.48 (d, JNH,CH = 10.4 Hz, 1 H, NH) ppm. 19F NMR (282 MHz, CDCl3): δ = -
74.56 (d, JCF3,CH = 7.8 Hz, CF3), -141.10 (s, F2′, F6′), -151.01 (tt, JF4′,F3′ = JF4′,F5′ = 20.9 Hz, JF4′,F2′ = JF4′,F6′ = 
2.9 Hz, F4′), -159.73 – -160.77 (m, F5′, F3′) ppm. 13C NMR (75 MHz, CDCl3): δ = 151.71 (C2), 147.95 – 
144.10 (m, C2′, C6′) , 143.95 – 140.22 (m, C3′, C5′), 141.66 (C6), 139.91 – 135.96 (m, C4′), 135.71 (C5), 
133.45 (C3), 124.04 (q, JC,F = 281.9 Hz, CF3), 108.30 – 107.72 (m, C1′), 47.60 (q, JC,F = 34.3 Hz, CHCF3) ppm. 
HRMS (ESI+): m/z calcd. for C11H10N2F3+ [M+H]+ 344.0428, found 344.0427. HPLC (0.1% TFA, 0 min: 4% 
B → 15 min: 100% B, flow: 1 mL/min): tR = 15.72 min, λ = 214 nm. 
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N-(4-Cyclopropyl-1,1,1-trifluorobut-3-yn-2-yl)pyrazin-2-amine (2w) 
(Cyclopropylethynyl)magnesium chloride was prepared from ethynylcyclopropane (45 L, 0.54 mmol) in THF 
(1 mL), which was reacted with nBuMgBr (2.0 M in Et2O, 0.27 mL, 0.54 mmol) for 2 h at 0 °C.  
The addition reaction was performed according to TP4 with N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 
(100 mg, 0.45 mmol) and (cyclopropylethynyl)magnesium chloride at -20 °C in 2 h. Flash column 
chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 10:1:0.1 → 4μ1μ0.05) furnished 2w as a 
colorless oil (87 mg, 80%). 
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.38. 1H NMR (400 MHz, CDCl3): δ 
= 8.05 (ddd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, J = 0.4 Hz, 1 H, H6), 8.00 (dd, JH3,H6 = 
1.5 Hz, J = 0.4 Hz, 1 H, H3), 7.95 (dd, JH5,H6 = 2.8 Hz, J = 0.4 Hz, 1 H, H5), 5.74 – 
5.62 (m, 1 H, NHCH), 4.81 (d, JNH,CH = 9.2 Hz, 1 H, NH), 1.32 – 1.20 (m, 1 H, CH), 
0.85 – 0.77 (m, 2 H, CH2), 0.75 – 0.69 (m, 2 H, CH2) ppm. 19F NMR (282 MHz, 
CDCl3): δ = -76.45 (d, JCF3,CH = 6.6 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 152.04 (C2), 141.65 (C6), 
135.10 (C5), 133.20 (C3), 123.66 (q, JC,F = 281.7 Hz, CF3), λ0.12 (C≡C-CH(CH2)2), 66.43 (C≡C-CH(CH2)2), 
45.15 (q, JC,F = 35.4 Hz, CHCF3) , 8.42 (2 × CH2), -0.58 (C≡C-CH(CH2)2) ppm. HRMS (ESI+): m/z calcd. for 
C11H11F3N3+ [M+H]+ 242.0900, found 242.0898. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 
1 mL/min): tR = 13.83 min, λ = 214 nm. 
 
N-(1,1-Difluoropropan-2-yl)pyridine-2-amine (3a)  
Following TP5, the hemiaminal ether 1b (100 mg, 0.50 mmol) was reacted with MeMgBr (1.4 M in 
toluene/THF 3:1, 0.78 mL, 1.09 mmol) in dry THF (5 mL) for 2 h at 0 °C. The crude product was purified by 
flash chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 100:10:1) to give the desired amine 3a (61 mg, 
72%) as an orange, amorphous solid.  
Rf (cyclohexane/ethyl acetate 1:1) = 0.70. 1H NMR (300 MHz, CDCl3): δ = 8.09 (ddd, 
JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.41 (ddd, JH4,H3 = 8.3 Hz, JH4,H5 
= 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.61 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 
0.9 Hz, 1 H, H5), 6.42 (dt, JH3,H4 = 8.4 Hz, JH3,H6 = JH3,H5 = 0.9 Hz, 1 H, H3), 5.90 (ddd, JF,H = 57.7 Hz, JF,H = 
55.7 Hz, JCHF2,CH = 2.0 Hz, 1 H, CHF2), 4.54 – 4.36 (m, 1 H, CH), 4.32 (s, br, 1 H, NH), 1.30 (dt, JCH3,CH = 
6.7 Hz, J = 1.0 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -125.78 (ddd, JF,F = 280.1 Hz, JF,H = 
55.6 Hz, JCHF2,CH = 6.8 Hz, CHF2), -134.19 (ddt, JF,F = 280.2 Hz, JF,H = 57.9 Hz, JCHF2,CH = 20.4 Hz, CHF2) ppm. 
13C NMR (101 MHz, CDCl3): δ = 157.28 (C2), 148.10 (C6), 137.57 (C4), 115.65 (dd, JC,F = 245.4 Hz, JC,F = 
244.2 Hz, CHF2), 113.92 (C5) 108.47 (C3), 48.23 (dd, JC,F = 26.1 Hz, JC,F = 21.7 Hz, CH), 12.79 (CH3) ppm. 
HRMS (ESI+): m/z calcd. for C8H11F2N2+ [M+H]+ 173.0885, found 173.0885. HPLC (0.1% TFA. 0 min: 4% 
B → 15 min: 100% B, flow: 1 mL/min): tR = 3.55 min, λ = 214 nm.  
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N-(1,1-difluoropropan-2-yl)pyrazin-2-amine (3b) 
Following TP5, the hemiaminal ether 1d (100 mg, 0.49 mmol) was reacted with MeMgBr (1.4 M in 
toluene/THF 3:1, 0.77 mL, 1.08 mmol) in dry THF (5 mL) for 1.5 h at 0 °C. The crude product was purified 
by preparative HPLC (0.1% TFA. 0 minμ 4% MeCN (B) → 15 min: 100% B, flow: 20 mL/min, tR = 16.51 min) 
to give the desired amine 3b (80 mg, 94%) as colorless oil. 
Rf (cyclohexane/ethyl acetate 1:1) = 0.36. 1H NMR (400 MHz, CDCl3): δ = 8.01 – 7.91 
(m, 2 H, H3, H6), 7.85 (d, JH5,H6 = 2.8 Hz, 1 H, H5), 5.89 (ddd, JH,F = 57.4 Hz, JH,F = 
55.4 Hz, JCHF2,CH = 2.0 Hz, 1 H, CHF2), 4.61 (s, br, 1 H, NH), 4.55 – 4.39 (m, 1 H, CH), 
1.32 (d, JCH3,CH2 = 6.9 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = -126.59 (ddd, JF,F = 281.4 Hz, 
JF,H = 55.4 Hz, JCHF2,CH = 7.8 Hz, CHF2), -133.24 (ddd, JF,F = 281.5 Hz, JF,H = 57.4 Hz, JCHF2,CH = 19.3 Hz, 
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 153.52 (C2), 141.78 (C6), 133.82 (C5), 133.13 (C3), 115.17 (t, 
JC,F = 244.8 Hz, CHF2), 47.83 (dd, JC,F = 26.2 Hz, JC,F = 21.8 Hz, CH), 12.84 (dd, JC,F = 5.7 Hz, JC,F = 2.1 Hz, 
CH3) ppm. HRMS (ESI+): m/z calcd. for C7H10F2N3+ [M+H]+ 174.0837, found 174.0837. HPLC (0.1% TFA. 
0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 10.16 min, λ = 214 nm.  
 
N-(1,1-Difluoropropan-2-yl)-3,5-bis(trifluoromethyl)aniline (3c)  
Following TP5, the hemiaminal ether 1f (101 mg, 0.30 mmol) was reacted with MeMgBr (1.4 M in 
toluene/THF 3:1, 0.47 mL, 0.69 mmol) in dry THF (5 mL) for 3 h at 0 °C. The crude product was purified by 
flash chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 100:5:1) to give the desired amine 3c (65 mg, 
71%) as a colorless oil.  
Rf (cyclohexane/ethyl acetate 5:1) = 0.64. 1H NMR (400 MHz, CDCl3): δ = 7.21 (s, 
1 H, H4), 7.00 (s, 2 H, H2, H6), 5.79 (ddd, JH,F = 56.2 Hz, JH,F = 55.5 Hz, JCHF2,CH = 
2.6 Hz, 1 H, CHF2), 4.06 (d, JNH,CH = 9.0 Hz, 1 H, NH), 3.98 – 3.79 (m, 1 H, CH), 
1.34 (dt, JCH3,CH2 = 6.7 Hz, JCH3,CH = 1.1 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, 
CDCl3): δ = 63.30 (2 × CF3), -127.08 (ddd, JF,F = 282.9 Hz, JF,H = 55.6 Hz, JCHF2,CH = 9.9 Hz, CHF2), -128.03 
(ddd, JF,F = 282.9 Hz, JF,H = 56.2 Hz, JCHF2,CH = 14.0 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 147.31 
(C1), 132.87 (q, JC,F = 33.0 Hz, C3, C5), 123.53 (q, JC,F = 272.7 Hz, 2 × CF3), 115.69 (t, JC,F = 245.8 Hz, CHF2), 
112.62 (m, C2, C6), 111.57 (dq, J= 3.9 Hz, C4), 50.63 (dd, JC,F = 24.0 Hz, JC,F = 22.6 Hz, CH), 13.81 
(CH3) ppm. HRMS (ESI+): m/z calcd. for C11H8F8N- [M-H]- 306.0534, found 306.0538. HPLC (0.1% TFA. 
0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 19.89 min, λ = 214 nm.  
 
N-(1,1-Difluorohexan-2-yl)-2,3,4,5,6-pentafluoroaniline (3d) 
According TP5, the hemiaminal ether 1g (113 mg, 0.39 mmol) was reacted with nBuMgBr (2.0 M in Et2O, 
0.43 mL, 0.85 mmol) in dry THF (5 mL) for 1.5 h at 0 °C. The desired amine 3d (108 mg, 92%) was isolated 
after workup as a yellow liquid without further purification.  
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Rf (cyclohexane/ethyl acetate 7:1) = 0.80. 1H NMR (400 MHz, CDCl3): δ = 5.79 
(td, JH,F = 55.7 Hz, JCHF2,CH = 2.1 Hz, 1 H, CHF2), 3.88 – 3.70 (m, 1 H, CH), 3.46 
(d, JNH,CH = 10.7 Hz, 1 H, NH), 1.82 – 1.68 (m, 1 H, CH2), 1.60 – 1.45 (m, 2 H, 
CH2), 1.42 – 1.33 (m, 2 H, CH2), 0.93 (t, JCH3,CH2 = 7.2 Hz, 3 H, CH3) ppm. 
19F NMR (376 MHz, CDCl3): δ = -127.32 (ddd, JF,F = 282.6 Hz, JF,H = 55.8 Hz, 
JCHF2,CH = 13.0 Hz, CHF2), -129.96 (ddt, JF,F = 282.6 Hz, JF,H = 55.6 Hz, JCHF2,CH = 13.0 Hz, CHF2), -158.23 (d, 
JF2,F3 = JF6,F5 = 21.8 Hz, F2, F6), -163.86 (td, JF5,F4 = JF5,F6 = JF3,F2 = JF3,F4 = 21.8 Hz, JF5,F3 = JF3,F5 = 6.4 Hz, F3, 
F5), -169.88 (td, JF4,F3 = JF4,F5 = 21.9 Hz, J = 6.0 Hz, F4) ppm. 13C NMR (101 MHz, CDCl3): δ = 140.07 – 
137.12 (m), 136.10 – 132.99 (m), 123.47 – 122.92 (m), 116.28 (t, JC,F = 245.1 Hz, CHF2), 57.35 (ddt, JC,F = 
24.0 Hz, JC,F = 20.4 Hz, JC,F = 3.6 Hz, CH), 29.21 (CH2), 27.79 (CH2), 22.55 (CH2), 13.99 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C12H11F7N- [M-H]- 302.0785, found 302.0787. HPLC (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 21.58 min, λ = 214 nm.  
 
N-(1,1-Difluorohexan-2-yl)pyridine-2-amine (3e) 
According TP5, the hemiaminal ether 1b (100 mg, 0.50 mmol) was reacted with nBuMgBr (2.0 M in Et2O, 
0.54 mL, 1.08 mmol) in dry THF (5 mL) for 2.5 h at 0 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 100:10:1) to give the desired amine 3e (72 mg, 68%) 
as a white solid.  
Rf (cyclohexane/ethyl acetate 1:1) = 0.88. mp 30 °C. 1H NMR (400 MHz, CDCl3): δ 
= 8.07 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.40 (ddd, 
JH4,H3 = 8.4 Hz, JH4,H5 = 7.1 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.60 (ddd, JH5,H4 = 7.1 Hz, 
JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.43 (dt, JH3,H4 = 8.4 Hz, JH3,H6 = JH3,H5 = 1.0 Hz, 1 H, H3), 5.87 (ddd, 
JH,F = 57.3 Hz, JH,F = 55.9 Hz, JCHF2,CH = 1.9 Hz, 1 H, CHF2), 4.42 – 4.19 (m, 2 H, CH, NH), 1.92 – 1.75 (m, 
1 H, CH2), 1.58 – 1.40 (m, 2 H, CH2), 1.42 – 1.28 (m, 3 H, CH2), 0.89 (t, JCH3,CH = 7.2 Hz, 3 H, CH3) ppm. 
19F NMR (376 MHz, CDCl3): δ = -126.07 (ddd, JF,F = 279.8 Hz, JF,H = 55.6 Hz, JCHF2,CH = 8.6 Hz, CHF2), -
131.59 (ddt, JF,F = 280.0 Hz, JF,H = 57.2 Hz, JCHF2,CH = 18.4 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ 
= 157.87 (C2), 148.07 (C6), 137.58 (C4), 115.86 (t, JC,F = 244.6 Hz, CHF2), 113.74 (C5) 108.16 (C3), 52.45 
(dd, JC,F = 24.4 Hz, JC,F = 21.1 Hz, CH), 27.91 (CH2), 27.48 (CH2), 22.70 (CH2), 14.02 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C11H17F2N2+ [M+H]+ 215.1354, found 215.1354. HPLC (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 9.96 min, λ = 214 nm.  
 
N-(1,1-Difluorohexan-2-yl)pyrazin-2-amine (3f)  
According TP5, the hemiaminal ether 1d (100 mg, 0.49 mmol) was reacted with nBuMgBr (2.0 M in Et2O, 
0.54 mL, 1.08 mmol) in dry THF (5 mL) for 1.5 h at 0 °C. The crude product was purified by flash 
chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 100μ10μ1 → 100μ15μ1) to give the desired 
amine 3f (112 mg, quant.) as a yellow oil.  
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Rf (cyclohexane/ethyl acetate 1:1) = 0.61. 1H NMR (400 MHz, CDCl3): δ = 7.97 
(dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1 H, H6), 7.94 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 
7.84 (d, JH5,H6 = 2.8 Hz, 1 H, H5), 5.86 (ddd, JH,F = 56.9 Hz, JH,F = 55.6 Hz, JCHF2,CH 
= 2.0 Hz, JCHF2,NH = 1.3 Hz, 1 H, CHF2), 4.56 (d, JNH,CH = 8.9 Hz, 1 H, NH), 4.48 – 
4.30 (m, 1 H, CH), 1.90 – 1.77 (m, 2 H, CH2), 1.62 – 1.24 (m, 4 H, 2 × CH2), 0.89 (t, JCH3,CH2 = 7.1 Hz, 3 H, 
CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -126.96 (ddd, JF,F = 281.2 Hz, JF,H = 55.6 Hz, JCHF2,CH = 10.6 Hz, 
CHF2), -130.63 (ddt, JF,F = 281.1 Hz, JF,H = 56.9 Hz, JCHF2,CH = 17.4 Hz, CHF2) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 154.14 (C2), 141.78 (C6), 133.69 (C5), 132.93 (C3), 115.43 (t, JC,F = 244.8 Hz, CHF2), 51.93 (dd, 
JC,F = 24.1 Hz, JC,F = 21.0 Hz, CH), 27.82 (CH2), 27.45 (CH2), 22.59 (CH2), 13.97 (CH3) ppm. HRMS (ESI+): 
m/z calcd. for C10H16F2N3+ [M+H]+ 216.1307, found 216.1307. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 
100% B, flow: 1 mL/min): tR = 14.57 min, λ = 214 nm.  
 
N-(1,1-Difluorohexan-2-yl)-3,5-bis(trifluoromethyl)aniline (3g) 
According TP5, the hemiaminal ether 1f (100 mg, 0.30 mmol) was reacted with nBuMgBr (2.0 M in Et2O, 
0.33 mL, 0.65 mmol) in dry THF (5 mL) for 2 h at 0 °C. The desired amine 3g (100 mg, 96%) was isolated 
after workup as an orange liquid without further purification.  
1H NMR (600 MHz, CDCl3): δ = 7.20 (s, 1 H, H4), 7.00 (s, 2 H, H2, H6), 5.79 (td, JH,F = 55.7 Hz, JCHF2,CH = 
2.5 Hz, 1 H, CHF2), 3.99 (d, JNH,CH = 9.3 Hz, 1 H, NH), 3.78 – 3.66 (m, 1 H, 
CH), 1.86 – 1.77 (m, 1 H, CH2), 1.58 – 1.46 (m, 2 H, CH2), 1.43 – 1.30 (m, 
3 H, CH2), 0.96 – 0.89 (m, 3 H, CH3) ppm. 19F NMR (376 MHz, CDCl3): δ 
= -63.33 (2 × CF3), -126.33 (ddd, JF,F = 282.7 Hz, JF,H = 55.8 Hz, JCHF2,CH = 12.3 Hz, CHF2), -128.03 (ddd, JF,F 
= 282.7 Hz, JF,H = 55.7 Hz, JCHF2,CH = 12.3 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 148.08 (C1), 
132.83 (q, JC,F = 32.9 Hz, C3, C5), 123.56 (q, JC,F = 272.6 Hz, 2 × CF3), 115.80 (t, JC,F = 245.7 Hz, CHF2), 
112.40 (m, C2, C6), 111.35 (C4), 55.12 (t, JC,F = 21.8 Hz, CH), 28.76 (CH2), 27.86 (CH2), 22.65 (CH2), 13.94 
(CH3) ppm. HRMS (ESI+): m/z calcd. for C14H14F8N- [M-H]- 348.1004, found 348.1010. HPLC (0.1% TFA. 
0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 21.70 min, λ = 214 nm.  
 
N-(1,1-Difluoro-1-phenylethyl)-2,3,4,5,6-pentafluoroaniline (3h) 
According to TP5, the hemiaminal ether 1g (91 mg, 0.31 mmol) was reacted with PhMgBr (3 M in Et2O, 
0.23 mL, 0.69 mmol) in dry THF (5 mL) for 4 h at 0 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/NEt3 100:1) to give the desired amine 3h (51 mg, 50%) as a yellow oil. 
Rf (cyclohexane/ethyl acetate 7:1) = 0.56. 1H NMR (400 MHz, CDCl3): δ = 7.42 – 7.31 (m, 5 H, 5 × HPhenyl), 
6.07 (ddd, JH,F = 55.8 Hz, JH,F = 55.0 Hz, JCHF2,CH = 2.3 Hz, 1 H, CHF2), 4.96 (tdd, JCH,F = 13.5 Hz, JCH,NH = 
10.6 Hz, JCH,CHF2 = 2.2 Hz, 1 H, CH), 4.33 (d, JNH,CH = 10.5 Hz, 1 H, NH) ppm. 19F NMR (376 MHz, CDCl3): 
δ = -125.23 (ddd, JF,F = 282.4 Hz, JF,H = 55.9 Hz, JCHF2,CH = 14.0 Hz, CHF2), -129.32 (ddt, JF,F = 282.2 Hz, JF,H 
= 55.0 Hz, JCHF2,CH = 13.6 Hz, CHF2), -157.21 (dd, JF2,F3 = JF6,F5 = 21.0 Hz, JF2,F4 = JF6,F4 = 4.0 Hz F2, F6), -
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163.40 (td, JF5,F4 = JF5,F6 = JF3,F2 = JF3,F4 = 21.6 Hz, JF5,F3 = JF3,F5 = 4.4 Hz, 2 F, F3, F5), 
-168.14 (td, JF4,F3 = JF4,F5 = 21.9 Hz, J = 4.8 Hz, F4) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 140.06 – 137.38 (m), 139.48 – 136.64 (m), 136.26 – 133.48 (m), 134.41 
(C1Phenyl), 129.08 (CPhenyl), 129.02 (CPhenyl), 127.48 (CPhenyl), 121.68 – 121.40 (m, 
CPhenyl), 115.22 (dd, JC,F = 248.1 Hz, JC,F = 246.1 Hz CHF2), 61.17 (tt, JC,F = 21.5 Hz, JC,F = 4.1 Hz, CH) ppm. 
HRMS (ESI-): m/z calcd. for C14H7F7N- [M-H]- 322.0472, found 322.0474. HPLC (0.1% TFA. 0 min: 4% B 
→ 15 min: 100% B, flow: 1 mL/min): tR = 19.82 min, λ = 214 nm.  
 
N-(1,1-Difluoro-1-phenylethyl)pyridine-2-amine (3i) 
According to the TP5, the hemiaminal ether 1b (100 mg, 0.49 mmol) was reacted with PhMgBr (3 M in Et2O, 
0.36 mL, 1.07 mmol) in dry THF (5 mL) for 2 h at 0 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate/NEt3 100:10:1) to give the desired amine 3i (118 mg, quant.) 
as a colorless oil. 
Rf (cyclohexane/ethyl acetate 1:1) = 0.83. 1H NMR (400 MHz, CDCl3): δ = 8.10 (ddd, JH6,H5 = 5.0 Hz, JH6,H4 
= 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.47 – 7.43 (m, 2 H, 2 × HPhenyl), 7.43 – 7.32 (m, 4 H, 
3 × HPhenyl, H4), 6.63 (ddd, JH5,H4 = 7.1 Hz, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.43 
(dt, JH3,H4 = 8.4 Hz, JH3,H6 = JH3,H5 = 1.0 Hz, 1 H, H3), 6.12 (td, JH,F = 55.9 Hz, JCHF2,CH = 
2.4 Hz, 1 H, CHF2), 5.48 – 5.33 (m, 1 H, CH), 5.07 (d, JNH,CH = 7.9 Hz, 1 H, NH) ppm. 19F NMR (376 MHz, 
CDCl3): δ = -126.42 (ddd, JF,H = 56.0 Hz, JF,H = 33.8 Hz, JCHF2,CH = 14.7 Hz, CHF2) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 157.13 (C2), 148.17 (C6), 137.66 (C4), 135.43 (C1Phenyl), 128.91 (CPhenyl), 128.61 (CPhenyl), 128.06 
(CPhenyl), 115.51 (t, JC,F = 246.6 Hz, CHF2), 114.34 (C5) 108.43 (C3), 57.15 (t, JC,F = 22.1 Hz, CH) ppm. HRMS 
(ESI+): m/z calcd. for C13H13F2N2+ [M+H]+ 235.1041, found 235.1041. HPLC (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 8.77 min, λ = 214 nm.  
 
N-(1,1-difluoro-1-phenylethyl)pyrazin-2-amine (3j)  
According to TP5, hemiaminal ether 1d (100 mg, 0.49 mmol) was reacted with PhMgBr (3 M in Et2O, 
0.39 mL, 1.08 mmol) in dry THF (5 mL) for 1.5 h at 0 °C. The crude product was purified by flash 
chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 100μ6μ1 → 100μ25μ1) to give the desired 
slightly unpurified amine 3j (145 mg, quant.). A fraction of the product was further purified by preparative 
HPLC (0.1% TFA. 0 minμ 4% MeCN (B) → 30 min: 100% B, flow: 20 mL/min, tR = 19.37 min) to give the 
desired amine as a colorless oil. 
Rf (cyclohexane/ethyl acetate 1:1) = 0.55. 1H NMR (400 MHz, CDCl3): δ = 7.99 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 
1.5 Hz, 1 H, H6), 7.98 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.86 (d, JH5,H6 = 2.7 Hz, 1 H, H5), 7.45 
– 7.33 (m, 5 H, 5 × HPhenyl), 6.11 (ddd, JH,F = 56.0 Hz, JH,F = 55.2 Hz, JCHF2,CH = 2.3 Hz, 
1 H, CHF2), 5.52 – 5.42 (m, 1 H, CH), 5.35 (d, JNH,CH = 8.2 Hz, 1 H, NH) ppm. 19F NMR 
(282 MHz, CDCl3): δ = -125.38 (ddd, JF,F = 280.3 Hz, JF,H = 56.1 Hz, JCHF2,CH = 15.3 Hz, CHF2), -127.47 (ddd, 
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JF,F = 280.3 Hz, JF,H = 55.2 Hz, JCHF2,CH = 13.7 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 153.21 (C2), 
141.73 (C6), 134.68 (C1Phenyl) 134.12 (C5), 132.90 (C3), 128.90 (CPhenyl), 128.72 (CPhenyl), 127.80 (CPhenyl), 
115.08 (t, JC,F = 246.2 Hz, CHF2), 56.35 (dd, JC,F = 22.6 Hz, JC,F = 21.3 Hz, CH) ppm. HRMS (ESI+): m/z 
calcd. for C12H12F2N3+ [M+H]+ 236.0994, found 236.0994. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% 
B, flow: 1 mL/min): tR = 13.59 min, λ = 214 nm. 
 
4-(2,2-Difluoro-1-(pyridin-2-ylamino)ethyl)benzonitrile (3k) 
(4-Cyanophenyl)magnesium chloride was prepared from 4-bromobenzonitrile (82 mg, 0.45 mmol) and 
iPrMgCl·LiCl (1.25 M in THF, 0.36 mL, 0.45 mmol) according to TP3 within 3 h at 0 °C. 
Following TP4, a solution of N-(1-ethoxy-2,2-difluoroethyl)pyridine-2-amine 1b (76 mg, 0.38 mmol) in dry 
THF (5 mL) was treated with LiHMDS (1 M in THF, 0.38 mL, 0.38 mmol) at -78 °C. The Grignard reagent 
was added after 15 min and the solution was stirred at -30 °C for 4 h. After workup and flash chromatography 
(SiO2, gradient: cyclohexane/ethyl acetate 20:1 → 5:1) the desired amine 3k (60 mg, 56%) was furnished as a 
light yellow oil. 
Rf (cyclohexane/ethyl acetate 2:1) = 0.47. 1H NMR (400 MHz, CDCl3): δ = 8.06 (d, JH6ꞌ,H5ꞌ = 5.1 Hz, 1 H, H6ꞌ), 
7.74 – 7.63 (d, JH3,H2 = JH5,H6 = 8.4 Hz, 2 H, H3, H5), 7.58 (d, JH2,H3 = JH6,H5 = 
7.9 Hz, 2 H, H2, H6), 7.48 – 7.38 (t, JH4ꞌ,H3ꞌ = JH4ꞌ,H5ꞌ = 7.7 Hz, 1 H, H4ꞌ), 6.66 (dd, 
JH5ꞌ,H4ꞌ = 7.2 Hz, JH5ꞌ,H6ꞌ = 5.2 Hz, 1 H, H5ꞌ), 6.48 (d, JH3ꞌ,H4ꞌ = 8.3 Hz, 1 H, H3ꞌ), 6.12 
(td, JH,F = 55.7 Hz, JCHF2,CH = 2.4 Hz, 1 H, CHF2), 5.67 – 5.48 (m, 1 H, CH), 5.11 (d, JNH,CH = 8.2 Hz, 1 H, 
NH) ppm. 19F NMR (376 MHz, CDCl3): δ = -124.67 (ddd, JF,F = 282.9 Hz, JF,H = 55.1 Hz, JCHF2,CH = 11.2 Hz, 
CHF2), -127.41 (ddd, JF,F = 282.8 Hz, JF,H = 56.2 Hz, JCHF2,CH = 18.2 Hz, CHF2) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 156.3λ (C2ꞌ), 148.05 (C6ꞌ), 140.λ7 (C1), 137.85 (C4ꞌ), 132.54 (C3, C5), 12λ.00 (C2, C6), 118.60 
(CN), 114.96 (t, JC,F = 247.0 Hz, CHF2), 114.85 (C5ꞌ), 112.51 (C4), 108.86 (C3ꞌ), 56.61 (dd, JC,F = 23.7 Hz, 
JC,F = 21.1 Hz, CH) ppm. HRMS (ESI+): m/z calcd. for C14H12F2N3+ [M+H]+ 260.0994, found 260.0996. 
HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 9.56 min, λ = 214 nm.  
 
N-(2,2-Difluoro-1-(pyridin-2-yl)ethyl)pyridin-2-amine (3l) 
Pyridin-2-ylmagnesium chloride was prepared from 2-bromopyridine (43 L, 0.45 mmol) and iPrMgCl·LiCl 
(1.25 M in THF, 0.36 mL, 0.45 mmol) according to TP3 within 2 h at 0 °C. 
Following TP4, a solution of N-(1-ethoxy-2,2-difluoroethyl)pyridine-2-amine 1b (76 mg, 0.38 mmol) in dry 
THF (5 mL) was treated with LiHMDS (1 M in THF, 0.38 mL, 0.38 mmol) at -78 °C. The Grignard reagent 
was added after 15 min and the solution was stirred at -30 °C for 4 h. After workup and flash chromatography 
(SiO2, gradient: cyclohexane/ethyl acetate 10:1 → 5:1) the desired amine 3l (39 mg, 44%) was furnished as a 
light yellow oil. 
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Rf (cyclohexane/ethyl acetate 3:1) = 0.26. 1H NMR (400 MHz, CDCl3): δ = 8.56 (d, 
JH6ꞌ,H5ꞌ = 4.7 Hz, 1 H, H6ꞌ), 8.04 (d, JH6,H5 = 4.9 Hz, 1 H, H6), 7.63 (td, JH4ꞌ,H3ꞌ = JH4ꞌ,H5ꞌ = 
7.7 Hz, JH4ꞌ,H6ꞌ = 1.7 Hz, 1 H, H4ꞌ), 7.35 (m, 2 H, H4, H3ꞌ), 7.24 – 7.19 (m, 1 H, H5ꞌ), 
6.56 (dd, JH5,H4 = 7.1 Hz, JH5,H6 = 5.1 Hz, 1 H, H5), 6.51 (d, JH3,H4 = 8.3 Hz, 1 H, H3), 6.34 – 6.00 (m, 1 H, 
CHF2), 5.96 (d, JNH,CH = 7.3 Hz, 1 H, NH), 5.61 – 5.48 (m, 1 H, CH) ppm. 19F NMR (376 MHz, CDCl3): δ = -
124.85 (ddd, JF,F = 278.5 Hz, JF,H = 55.5 Hz, JCHF2,CH = 9.6 Hz, CHF2), -129.09 (ddd, JF,F = 278.6 Hz, JF,H = 
56.6 Hz, JCHF2,CH = 17.3 Hz, CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 157.24 (C2), 153.85 (C2ꞌ), 14λ.31 
(C6ꞌ), 147.λ6 (C6), 137.54 (C4), 136.76 (C4ꞌ), 123.86 (C3ꞌ), 123.41 (C5ꞌ), 115.43 (t, JC,F = 246.8 Hz, CHF2), 
114.03 (C5), 109.28 (C3) , 56.93 (dd, JC,F = 24.1 Hz, JC,F = 22.7 Hz, CH) ppm. HRMS (ESI+): m/z calcd. for 
C12H12F2N3+ [M+H]+ 236.0994, found 236.0997. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 
1 mL/min): tR = 7.48 min, λ = 214 nm.  
 
N-(1-(2,4-Dimethoxypyrimidin-5-yl)-2,2-difluoroethyl)pyridin-2-amine (3m) 
(2,4-Dimethoxypyrimidin-5-yl)magnesium chloride was prepared from 5-bromo-2,4-dimethoxypyrimidine 
(99 mg, 0.45 mmol) and iPrMgCl·LiCl (1.25 M in THF, 0.36 mL, 0.45 mmol) according to TP3 within 3 h at 
0 °C. 
Following TP4, a solution of N-(1-ethoxy-2,2-difluoroethyl)pyridine-2-amine 1b (76 mg, 0.38 mmol) in dry 
THF (5 mL) was treated with LiHMDS (1 M in THF, 0.38 mL, 0.38 mmol) at -78 °C. The Grignard reagent 
was added after 15 min and the solution was stirred at -30 °C for 4 h. After workup and flash chromatography 
(SiO2, gradient: cyclohexane/ethyl acetate 10:1 → 5:1) the desired amine 3m (85 mg, 75%) was furnished as 
a light yellow oil. 
Rf (cyclohexane/ethyl acetate 2:1) = 0.36. 1H NMR (400 MHz, CDCl3): δ = 8.26 
(s, 1 H, H6ꞌ), 8.11 – 8.03 (d, JH6,H5 = 4.0 Hz, 1 H, H6), 7.39 (ddd, JH4,H3 = 8.6 Hz, 
JH4,H5 = 7.2 Hz, J = 1.9 Hz, 1 H, H4), 6.61 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, J 
= 0.9 Hz, 1 H, H5), 6.46 (dt, JH3,H4 = 8.3 Hz, J = 1.0 Hz, 1 H, H3), 6.09 (td, JH,F = 
56.1 Hz, JCHF2,CH = 3.1 Hz, 1 H, CHF2), 5.68 – 5.52 (m, 1 H, CH), 5.26 (d, JNH,CH = 9.1 Hz, 1 H, NH), 4.04 (s, 
3 H. OCH3), 3.96 (s, 3 H, OCH3) ppm. 19F NMR (376 MHz, CDCl3): δ = -125.00 (ddd, JF,F = 279.0 Hz, JF,H = 
56.1 Hz, JCHF2,CH = 13.8 Hz, CHF2), -126.88 (ddd, JF,F = 279.0 Hz, JF,H = 56.0 Hz, JCHF2,CH = 13.8 Hz, 
CHF2) ppm. 13C NMR (101 MHz, CDCl3): δ = 16λ.13 (C4ꞌ), 165.33(C2ꞌ), 158.45 (C6ꞌ), 156.70 (C2), 148.01 
(C6), 137.65 (C4), 114.47 (t, JC,F = 246.0 Hz, CHF2), 114.40 (C5), 10λ.28 (C5ꞌ), 108.63 (C3), 55.02 (OCH3), 
54.42 (OCH3), 51.16 (t, JC,F = 23.6 Hz, CH) ppm. HRMS (ESI+): m/z calcd. for C13H15F2N4O2+ [M+H]+ 
297.1158, found 297.1160. HPLC (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
8.61 min, λ = 214 nm.  
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N-Butyl-2,2,2-trifluoro-N'-phenylethan-1,1-diamine (4a) 
In a dry, argon-flushed Schlenk-flask n-BuLi (2.48 M in hexane, 0.36 mL, 0.90 mmol) was slowly added to a 
solution of n-butylamine (0.10 mL, 0.90 mmol) in dry n-hexane (3 mL) at 0 °C. The suspension was stirred at 
0 °C for 30 min. A solution of N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine 1a (100 mg, 0.45 mmol) in 
dry THF (3 mL) was added to the reaction mixture. After stirring the reaction mixture for 2 h, the solution was 
quenched with sat. NH4Cl-solution (10 mL) and extracted with diethyl ether (3 × 20 mL). The combined 
organic phases were dried with MgSO4, filtered and the solvent was evaporated in vacuo. Purification by flash 
chromatography (SiO2, gradient: cyclohexane/ethyl acetate/NEt3 100μ20μ1 → 100μ50μ1) furnished the desired 
diamine 4a (84 mg, 75%) as a light yellow oil.  
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.56. 1H NMR (600 MHz, 
CDCl3): δ = 8.13 – 8.08 (d, JH6,H5 = 5.0 Hz, 1 H, H6), 7.45 (dddd, JH4,H3 = 8.2 Hz, 
JH4,H5 = 7.2 Hz, J = 1.9 Hz, J = 1.0 Hz, 1 H, H4), 6.68 (ddt, JH5,H4 = 7.0 Hz, JH5,H6 
= 4.9 Hz, J = 0.9 Hz, 1 H, H5), 6.47 (dt, JH3,H4 = 8.4 Hz, J = 1.0 Hz, 1 H, H3), 5.49 (m, 1 H, CH), 4.57 (d, 
JNH,CH = 9.4 Hz, 1 H, NH), 2.72 (m, 2 H, CH2), 1.53 – 1.40 (m, 2 H, CH2), 1.37 – 1.24 (m, 2 H, CH2), 0.88 (td, 
JCH3,CH2 = 7.3 Hz, J = 1.1 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ = -78.80 (d, JCF3,CH = 6.1 Hz, 
CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 156.90 (C2), 148.04 (C6), 137.81 (C4), 124.61 (q, JC,F = 
282.6 Hz, CF3), 114.76 (C5), 108.54 (C3), 65.57 (q, JC,F = 31.4 Hz, CHCF3), 45.29 (CH2), 32.21 (CH2), 20.33 
(CH2), 14.00 (CH3) ppm. HRMS (ESI+): m/z calcd. for C11H18F3N3+ [M+H]+ 248.1369, found 248.1368. 
HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 3.82 min, λ = 214 nm. 
 
2,2,2-Trifluoro-N-(4-methylbenzyl)-N'-(pyridin-4-yl)ethane-1,1-diamine (4b) 
In a dry, argon-flushed Schlenk-flask n-BuLi (1.7 M in hexane, 0.53 mL, 0.90 mmol) was slowly added to a 
solution of 4-methylbenzylamine (0.12 mL, 0.90 mmol) in dry n-hexane (4 mL) at 0 °C. The white suspension 
was stirred at 0 °C for 3 h. A solution of N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-4-amine 1h (100 mg, 
0.45 mmol) in dry THF (2 mL) was added to the reaction mixture. After stirring the reaction mixture for 2 h at 
0 °C, the solution was quenched with sat. NH4Cl-solution (10 mL) and extracted with diethyl ether 
(3 × 20 mL). The combined organic phases were dried with MgSO4, filtered and the solvent was evaporated in 
vacuo. Purification by flash chromatography (SiO2, gradient: cyclohexane/ethyl acetate 10μ1 → 5μ1) furnished 
the desired diamine 4b (116 mg, 87%) as a light yellow oil.  
Rf (ethyl acetate/MeOH 10:1) = 0.12. 1H NMR (400 MHz, CDCl3) δ = 8.24 (d, 
JH2,H3 = JH6,H5 = 5.5 Hz, 2 H, H2, H6), 7.13 (m, 4 H, H2ꞌ, H3ꞌ, H5ꞌ, H6ꞌ), 6.47 – 
6.39 (m, 2 H, H3, H5), 4.67 (dq, JCH,NH = 10.0 Hz, JCH,CF3 = 5.1 Hz, 1 H, CH), 
4.29 (d, JNH,CH = 9.3 Hz, 1 H, NH), 3.98 – 3.78 (m, 2 H, CH2), 2.35 (s, 3 H, 
CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = -78.91 (d, JCF3,CH = 5.1 Hz, CF3) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 151.3λ (C4), 150.37 (C2, C6), 137.48 (C4ꞌ), 134.λ7 (C1ꞌ), 12λ.40 (C3ꞌ, C5ꞌ), 128.1λ (C2ꞌ, C6ꞌ), 
108.40 (C3, C5), 66.22 (q, JC,F = 32.1 Hz, CHCF3), 48.92 (CH2), 21.11 (CH3) ppm. HRMS (ESI+): m/z calcd. 
for C15H17F3N3+ [M+H]+ 296.1369, found 296.13696.
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N-(2,2,2-Trifluoro-1-(pyridin-2-ylamino)ethyl)benzimidamide (4c) 
A dry microwave vial equipped with a magnetic stirrer was charged with N-(1-ethoxy-2,2,2-
trifluoroethyl)pyridine-2-amine 1a (50 mg, 0.23 mmol) and benzamidine (27 mg, 0.23 mmol) in toluene 
(2 mL). The reaction mixture was stirred at 160 °C in a CEM microwave reactor operating at 200 W (maximum 
power) for 1 h. After removal of the solvent using rotary evaporation, purification by flash column 
chromatography (SiO2, cyclohexane/ethyl acetate 4μ1 → 1μ1) afforded the desired product 4c (58 mg, 86%) as 
a white solid. 
Rf (cyclohexane/ethyl acetate 4:1) = 0.18. mp 99 – 105 °C. 1H NMR (400 MHz, CDCl3) δ = 8.09 (dd, JH6ꞌ,H5ꞌ 
= 5.2 Hz, JH6ꞌ,H4ꞌ = 1.8 Hz, 1 H, H6ꞌ), 7.75 (d, JH2,H3 = JH6,H5 = 7.4 Hz. 2 H, H2, H6), 
7.48-7.31 (m, 4 H, H4ꞌ, H3, H4, H5), 6.68 (ddd, JH5ꞌ,H4ꞌ = 7.2 Hz, JH5ꞌ,H6ꞌ = 5.1 Hz, 
JH5ꞌ,H3ꞌ = 1.0 Hz, 1 H, H5ꞌ), 6.49 (d, JH3ꞌ,H4ꞌ = 8.3 Hz, 1 H, H3ꞌ), 6.20 (s, 2 H, NH) 
6.12 (dq, JCH,NH = 10.0 Hz, JCH,CF3 = 6.2 Hz, 1 H, CH), 5.05 (d, JNH,CH = 10.0 Hz, 1 H, NH) ppm. 19F NMR 
(376 MHz, CDCl3) δ = -79.59 (d, JCF3,CH = 6.2 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3) δ = 160.68 
(C=NH), 156.73 (C2ꞌ), 147.24 (C6ꞌ), 138.28 (C4ꞌ), 136.54 (C1), 130.69 (C4), 128.59 (C3, C5), 127.07 (C2, 
C6), 124.79 (q, JC,F = 280.8 Hz, CF3), 114.64 (C5ꞌ), 110.06 (C3ꞌ), 63.82 (q, JC,F = 31.9 Hz, CHCF3) ppm. 
HRMS (ESI+): m/z calcd. for C14H14F3N4+ [M+H]+ 295.1165, found 295.11646. HPLC (0.1% TFA, 0 min: 
4% B → 15 min: 100% B, flow: 1 mL/min): tR = 9.78 min, λ = 214 nm. 
 
N-(2,2,2-Trifluoro-1-methoxyethyl)pyridin-2-amine (4d) 
In a dry, argon-flushed Schlenk-flask n-BuLi (2.48 M in hexane, 2.00 mL, 5.00 mmol) was slowly added to a 
solution of MeOH (0.20 mL, 5.00 mmol) in dry n-hexane (5 mL) at 0 °C. The suspension was stirred at 0 °C 
for 1 h. N-(1-Ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine 1a (220 mg, 1.00 mmol) was added and the 
reaction mixture was allowed to warm up to room temperature. After stirring the reaction mixture for 48 h the 
solvent was evaporated in vacuo. Purification by flash chromatography (SiO2, gradient: cyclohexane/ethyl 
acetate 10μ1 → 2μ1) furnished the desired hemiaminal ether 4d (100 mg, 49%) as a yellow solid.  
Rf (cyclohexane/ethyl acetate/NEt3 2:1:0.05) = 0.51. mp 63-64 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.16 (d, JH6,H5 = 5.1 Hz, 1 H, H6), 7.55 – 7.46 (m, 1 H, H4), 6.76 (ddd, JH5,H4 
= 7.3 Hz, JH5,H6 = 5.1 Hz, J = 0.9 Hz, 1 H, H5), 6.59 – 6.51 (m, 1 H, H3), 5.87 (dq, JCH,NH 
= 10.1 Hz, JCH,CF3 = 5.0 Hz, 1 H, CH), 5.08 (d, JNH,CH = 7.6 Hz, 1 H, NH), 3.52 (s, 3 H, OCH3) ppm. 19F NMR 
(282 MHz, CDCl3): δ = -80.37 (d, JCF3,CH = 5.0 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.14 (C2), 
147.91 (C6), 138.34 (C4), 123.06 (q, JC,F = 282.5 Hz, CF3), 115.76 (C5), 109.18 (C3), 79.97 (q, JC,F = 33.9 Hz, 
CHCF3), 56.85 (OCH3) ppm. HRMS (ESI+): m/z calcd. for C8H9F3N2O* [M*] 206.0667, found 206.0661. 
HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 8.25 min, λ = 214 nm. 
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N-(1-(Ethylthio)-2,2,2-trifluoroethyl)pyridin-2-amine (4e) 
In a dry, argon-flushed Schlenk-flask n-BuLi (1.7 M in hexane, 1.32 mL, 2.25 mmol) was slowly added to a 
solution of EtSH (0.17 mL, 2.25 mmol) in dry n-hexane (6 mL) at 0 °C. The white suspension was stirred at 
0 °C for 1 h. N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine 1a (100 mg, 0.45 mmol) was added to the 
reaction mixture and the reaction was allowed to warm up to room temperature. After stirring for 3 d, the 
solution was quenched with sat. NH4Cl-solution (10 mL) and extracted with ethyl acetate (3 × 20 mL). The 
combined organic phases were dried with MgSO4, filtered and the solvent was evaporated in vacuo. The desired 
product 4e (160 mg, quant.) was obtained as a light yellow solid without further purification.  
Rf (cyclohexane/ethyl acetate 3:1) = 0.60. mp 54 °C. 1H NMR (300 MHz, CDCl3) δ = 
8.15 (ddd, JH6,H5 = 5.0 Hz, JH6,H4 = 1.9 Hz, J = 0.9 Hz, 1 H, H6), 7.47 (ddd, JH4,H3 = 
8.3 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, H4), 6.72 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 
5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.51 (dt, JH3,H4 = 8.3 Hz, J = 0.9 Hz, 1 H, H3), 6.03 (dq, JCH,NH = 10.3 Hz, 
JCH,CF3 = 7.4 Hz, 1 H, CH), 4.63 (d, JNH,CH = 10.4 Hz, 1 H, NH), 2.74 (tdd, JCH2,CH3 = 7.7 Hz, JCH2,CH3 = 6.9 , J 
= 1.7 Hz, 2 H, CH2), 1.29 (t, JCH3,CH2 = 7.4 Hz, 3 H, CH3) ppm. 19F NMR (282 MHz, CDCl3) δ = -74.24 (d, 
JCF3,CH = 7.5 Hz, CF3) ppm. 13C NMR (75 MHz, CDCl3) δ = 155.62 (C2), 148.04 (C6), 137.94 (C4), 115.37 
(C5), 109.22 (C3), 56.55 (q, JC,F = 33.0 Hz, CHCF3), 25.38 (CH2), 14.97 (CH3) ppm. HRMS (ESI+): m/z calcd. 
for C9H12F3N2S+ [M+H]+ 237.0668, found 237.06672. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, 
flow: 1 mL/min): tR = 10.33 min, λ = 214 nm. 
 
N-(1-(6-(3,4-Dihydroisoquinolin-2(1H)-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-6-methylpyridin-2-amine 
(5) 
N-(1-(6-Chloropyridin-3-yl)-2,2,2-trifluoroethyl)-6-methylpyridin-2-amine 2i (1.01 g, 3.35 mmol) and 
tetrahydroisoquinolin (1.76 g, 13.2 mol) were refluxed in 2-propanol (40 mL) for 48 h. After removal of the 
solvent the crude product was purified by preparative HPLC (0 minμ 4% MeCN (B) → 30 min: 100% B, flow: 
20 mL/min, tR = 26.28 min) to give the desired DIMN bioisostere 5 (438 mg, 33%) as colorless oil. 
Rf (cyclohexane/ethyl acetate/NEt3 4:1:0.1) = 0.35. 1H NMR (600 MHz, 
CDCl3): δ = 8.29 (d, JH2ꞌꞌ,H4ꞌꞌ = 2.4 Hz, 1 H, H2ꞌꞌ ), 7.59 (dd, JH4ꞌꞌ,H5ꞌꞌ = 
8.9 Hz, JH4ꞌꞌ,H2ꞌꞌ = 2.3 Hz, 1 H, H4ꞌꞌ), 7.31 (t, JH4, H3,H5 = 7.7 Hz, 1 H, H4), 
7.22 – 7.14 (m, 4 H, H5ꞌ, H6ꞌ, H7ꞌ, H8ꞌ), 6.66 (d, JH5ꞌꞌ,H4ꞌꞌ = 8.9 Hz, 1 H, 
H5ꞌꞌ), 6.52 (d, JH5,H4 = 7.3 Hz, 1 H, H5), 6.25 (d, JH3,H4 = 8.3 Hz, 1 H, 
H3), 5.59 (p, JCH,CF3 = JCH,NH = 8.1 Hz, 1 H, CH), 5.12 (s, 1 H, NH), 4.70 (s, 2 H. 2 × H1ꞌ), 3.84 (t, JH3ꞌ,H4ꞌ = 
5.9 Hz, 2 H, 2 × H3ꞌ), 2.96 (t, JH4ꞌ,H3ꞌ = 6.0 Hz, 2 H, 2 × H4ꞌ), 2.38 (s, 3 H, CH3) ppm. 19F NMR (282 MHz, 
CDCl3): δ = -74.15 (d, JCF3,CH = 8.0 Hz, CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 158.82 (C6ꞌꞌ), 157.02 
(C6), 155.82 (C2), 148.12 (C2ꞌꞌ), 138.26 (C4), 136.71 (C4ꞌꞌ), 135.43 (C5aꞌ/C8aꞌ), 134.21 (C5aꞌ/C8aꞌ), 128.48 
(C5ꞌ/C6ꞌ/C7ꞌ/C8ꞌ), 126.66 (C5ꞌ/C6ꞌ/C7ꞌ/C8ꞌ), 126.41 (C5ꞌ/C6ꞌ/C7ꞌ/C8ꞌ), 125.37 (q, JC,F = 281.6 Hz, CF3), 118.23 
(H3ꞌꞌ), 114.06 (H5), 106.4λ (H5ꞌꞌ), 104.85 (H3), 54.83 (q, JC,F = 30.9 Hz, CHCF3), 47.15 (C1ꞌ), 42.5λ (C3ꞌ), 
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2λ.10 (C4ꞌ), 24.30 (CH3) ppm. HRMS (ESI+): m/z calcd. for C22H22F3N4+ [M+H]+ 399.1791, found 399.1787. 
HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 10.06 min, λ = 214 nm. 
 
2-((1-Ethoxy-2,2,2-trifluoroethyl)amino)benzonitrile (1i) 
According to TP2, 2-aminobenzonitril (2.00 g, 17.0 mmol), TFAE (2.58 mL, 22.0 mmol) and pTSA·H2O 
(160 mg, 0.86 mmol) were solved in EtOH (20 mL) and the reaction mixture was refluxed for 6 h until no 
further conversion was observed. After removal of the solvent using rotary evaporation, flash column 
chromatography (SiO2, cyclohexane/ethyl acetate 20:1) furnished the hemiaminal ether 1i (1.46 g, 35%) as a 
colorless oil. 
Rf (cyclohexane/ethyl acetate 10:1) = 0.29. mp 31 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.52 – 7.43 (m, 2 H, H4, H6), 6.90 (m, 2 H, H3, H6), 5.16 – 5.06 (m, 1 H, CH), 4.99 (d, 
JNH,CH = 9.5 Hz, 1 H, NH), 3.85 – 3.59 (m, 2 H, CH2), 1.25 (t, JCH3,CH2 = 7.0 Hz, 3 H, 
CH3) ppm. 19F NMR (376 MHz, CDCl3): δ = -80.14 (d, JCF3,CH = 4.2 Hz, CF3) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 147.13 (C2), 134.53 (C4), 133.25 (C6), 122.60 (q, JC,F = 283.7 Hz, CF3), 120.01 (C5), 116.90 
(C≡N), 112.λ3 (C3), λ8.68 (C1), 81.76 (q, JC,F = 34.4 Hz, CHCF3), 64.93 (CH2), 15.03 (CH3) ppm. HRMS 
(ESI-): m/z calcd. for C11H10F3N2O- [M-H]- 243.0751, found 243.07511. HPLC (0.1% TFA, 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 17.69 min, λ = 214 nm. 
 
2-((1-Ethoxy-2,2,2-trifluoroethyl)amino)benzothioamide (8) 
Following a literature procedure,[213] 2-((1-ethoxy-2,2,2-trifluoroethyl)amino)benzonitrile 1i (448 mg, 
2.00 mmol), MgCl2 (190 mg, 2.00 mmol) and NaHS·H2O (296 mg, 4.00 mmol) were solved in dry DMF 
(8 mL). The reaction mixture was stirred at room temperature for 1.5 h. After complete conversion, the reaction 
was quenched with distilled water and extracted with ethyl acetate (3 × 30 mL). The aqueous phase was 
acidified (pH 6.5) with an aqueous solution of HCl (1 N) and extracted with ethyl acetate (3 × 30 mL) again. 
The combined organic phases were dried over MgSO4. After filtration and removal of the solvent the desired 
thioamid 8 (570 mg, quant.) was obtained as a yellow oil without further purification. 
Rf (cyclohexane/ethyl acetate 3:1) = 0.34. 1H NMR (400 MHz, DMSO-d6): δ = 9.83 (d, J = 
158.6 Hz, 2 H, NH2), 7.71 (d, JNH,CH = 10.1 Hz, 1 H, NH), 7.30 (t, JH4,H3 = JH4,H5 = 7.8 Hz, 
1 H, H4), 7.24 (d, JH6,H5 = 7.7 Hz, 1 H, H6), 7.10 (d, JH3,H4 = 8.3 Hz, 1 H, H3), 6.80 (t, JH5,H4 
= JH5,H6 = 7.5 Hz, 1 H, H5), 5.73 (dq, JCH,NH = 10.0 Hz, JCH,CF3 = 4.8 Hz, 1 H, CH), 3.78 – 
3.55 (m, 2 H, CH2), 1.11 (t, JCH2,CH3 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, DMSO-
d6): δ = -79.31 (d, JCF3,CH = 4.8 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 199.51 (C=S), 143.21 
(C2), 131.09 (C4), 127.12 (C6), 126.49 (C1), 123.38 (q, JC,F = 283.8 Hz, CF3), 118.20 (C5), 113.59 (C3), 80.12 
(q, JC,F = 32.3 Hz, CHCF3), 63.51 (CH2), 15.08 (CH3) ppm. HRMS (ESI-): m/z calcd. for C11H12F3N2OS- [M-
H]- 277.0628, found 277.06283. HPLC (0.1% TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 
16.29 min, λ = 214 nm. 
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2-(Trifluoromethyl)-2,3-dihydroquinazoline-4(1H)-thione (7) 
2-((1-Ethoxy-2,2,2-trifluoroethyl)amino)benzothioamide 8 (40 mg, 0.14 mmol) was solved in dry THF (2 mL) 
with molecular sieve (4 Å) and cooled to 0 °C. KOtBu (16 mg, 0.14 mmol) was added and the reaction was 
stirred at room temperature for 48 h. After complete conversion of the starting material, the reaction was 
quenched with distilled water, extracted with diethyl ether (3 × 20 mL) and dried with MgSO4. After filtration 
and removal of the solvent the desired dihydroquinalzoline thione 7 (28 mg, 86%) was furnished by 
crystallization from CH2Cl2/cyclcohexane as yellow crystals.  
1H NMR (400 MHz, DMSO-d6): δ = 10.67 (d, JNH,CH = 5.0 Hz, 1 H, NH), 8.07 (dd, JH5,H6 
= 8.1 Hz, JH5,H7 = 1.6 Hz, 1 H, H5), 7.81 (d, JNH,CH = 4.0 Hz, 1 H, NH), 7.33 (ddd, JH7,H8 = 
8.5 Hz, JH7,H6 = 7.2 Hz, JH7,H5 = 1.6 Hz, 1 H, H7), 6.82 (dd, JH8,H7 = 8.2 Hz, JH8,H6 = 1.1 Hz, 
1 H, H8), 6.73 (ddd, JH6,H5 = 8.1 Hz, JH6,H7 = 7.2 Hz, JH6,H8 = 1.1 Hz, 1 H, H6), 5.43 (dt, 
JCH,CF3 = 6.7 Hz, JCH,NH = 4.7 Hz, 1 H, CH) ppm. 19F NMR (376 MHz, DMSO-d6): δ = -80.74 (d, JCF3,CH = 
6.6 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 190.73 (C=S), 141.12 (C8a), 134.53 (C7), 131.24 
(C5), 123.33 (q, JC,F = 291.7 Hz, CF3), 118.77 (C4a), 118.02 (C6), 114.51 (C8), 61.55 (q, JC,F = 33.4 Hz, 
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C9H8F3N2S+ [M+H]+ 233.0355, found 233.03556. HPLC (0.1% 
TFA, 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 14.43 min, λ = 214 nm. 
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4. Experimental Procedures and Analytical Data: One-Pot 
Synthesis of Functionalized -Fluoroalkylated Mannich-Type 
Products from N-Aryl N,O-Acetals 
 
The complete supporting information including the NMR spectra of all compounds is available on the Synthesis 
website (DOI: 10.1055/s-0035-1561324) and on the CD in the book cover of this thesis. The compounds are 
numbered according to the publication. 
4.1 General procedure for the addition of ketones to N-aryl N,O-acetals 1a-i 
N-aryl hemiaminal ether 1 was placed in a dry Schlenk flask equipped with a magnetic stirrer and a septum, 
and dissolved in dry CH2Cl2 (ca. 0.06 M). The solution was flushed with argon and cooled to −78 °C before 
lithium bis(trimethylsilylamide) (LiHMDS, 1.0 M solution in toluene, 2.0−3.3 equiv) was added dropwise. 
Stirring was continued at −78 °C for 10 min, the ketone (1.5−2.5 equiv) was added, the reaction mixture was 
allowed to warm up to room temperature and stirred for 1−2 h (TLC and LC-MS control). After complete 
consumption of the starting material the solution was quenched with H2O (10 mL) and extracted with CH2Cl2 
(3 × 20 mL). The combined organic phases were dried over Na2SO4 and the solvent was removed under 
reduced pressure. Purification by flash- or column chromatography and optional subsequent crystallization 
from cyclohexane/ethyl acetate furnished the desired -amino -fluoroalkylated carbonyl compounds 2a−2i 
and 3a−3o. 
4.2  Experimental data 
3-((3-Chlorophenyl)amino)-4,4,4-trifluoro-1-phenylbutan-1-one (2a) 
According to the general procedure, 3-Chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (150 mg, 
0.59 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.18 mL, 
1.18 mmol) and reacted with acetophenone (0.10 mL, 0.89 mmol). After stirring at rt (2 h), aqueous workup, 
flash chromatography (cyclohexane → cyclohexane/ethyl acetate 9:1) and recrystallization (cyclohexane) the 
-amino ketone 2a (138 mg, 0.42 mmol, 71%) was obtained as a colorless crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.07 – 7.93 (m, 2H, H2ph, H6ph), 7.73 – 7.62 (m, 
1H, H4ph), 7.55 (m, 2H, H3ph, H5ph), 7.11 (t, JH5,H4/H6 = 8.1 Hz, 1H, H5), 6.77 (br s, 1H, 
H2), 6.65 (m, 2H, H4, H6), 6.30 (d, JNH,CH = 8.4 Hz, 1H, NH), 4.87 – 4.76 (m, 1H, CH), 
3.62 (dd, JCH2,CH2 = 17.8 Hz, JCH2,CH = 10.0 Hz, 1H, CH2), 3.44 (dd, JCH2,CH2 = 17.8 Hz, 
JCH2,CH = 2.5 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 194.97 (C=O), 
148.96 (C1), 136.13(C1ph), 133.55 (C3), 133.52 (C4ph) 130.34 (C5), 128.73 (C3ph, C5ph), 128.09 (C2ph, C6ph), 
126.58 (q, 1JC,F = 283.8 Hz, CF3), 116.47 (C4), 111.93 (C2), 111.35 (C6), 50.16 (q, 2JC,F = 29.7 Hz, CH), 37.54 
(CH2) ppm. 19F NMR (376 MHz, DMSO-d6): δ = − 74.25 (d, JCF3,CH = 7.4 Hz, CF3) ppm. HRMS (EI): m/z 
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calcd. for C16H13ClF3NO+ [M]+ 327.0638; found 327.0641. HPLC-MS (0.05% formic acid; 0 min, 0% B → 
2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.98 min, λ = 220 nm. mp 98 °C. Rf (cyclohexane/ethyl 
acetate 2:1) = 0.61. 
 
4,4,4-Trifluoro-1-phenyl-3-(pyrazin-2-ylamino)butan-1-one (2b) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with acetophenone (0.08 mL, 0.68 mmol). After stirring at rt (1h), aqueous workup, 
flash chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane) the 
-amino ketone 2b (123 mg, 0.42 mmol, 92%) was obtained as a colorless crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.04 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 
8.01 – 7.94 (m, 3H, H3, H2ph, H6ph), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.70 – 7.63 (m, 
1H, H4ph), 7.58 – 7.51 (m, 2H, H3ph, H5ph), 7.48 (d, JNH,CH = 8.2 Hz, 1H, NH), 5.50 – 5.38 
(m, 1H, CH), 3.65 (dd, JCH2,CH2 = 17.8 Hz, JCH2,CH = 9.8 Hz, 1H, CH2), 3.52 (dd, 
JCH2,CH2 = 17.8 Hz, JCH2,CH = 3.3 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 195.03 (C=O), 
153.90 (C2), 141.26 (C6), 136.08 (C1ph), 133.55 (C5), 133.02 (C4ph), 132.91 (C3), 128.74 (C3ph, C5ph), 128.07 
(C2ph, C6ph), 126.22 (q, 1JC,F = 282.8 Hz, CF3) 47.17 (q, 2JC,F = 30.5 Hz, CH), 37.12 (CH2) ppm. 19F NMR 
(376 MHz, DMSO-d6): δ = − 74.37 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (EI): m/z calcd. for C14H12F3N3O+ 
[M]+ 295.0932; found 295.0931. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 
mL/min): tR = 1.59 min, λ = 220 nm. mp 128 °C. Rf (hex/ethyl acetate 2:1) = 0.20. 
 
4,4,4-Trifluoro-3-(4-methylpyrimidin-2-ylamino)-1-phenylbutan-1-one (2c) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-methylpyrimidin-2-amine 1c (100 mg, 
0.43 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.98 mL, 
0.98 mmol) and reacted with acetophenone (0.08 mL, 0.64 mmol). After stirring at rt (2 h), aqueous workup, 
flash chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane) the 
-amino ketone 2c (97 mg, 0.31 mmol, 72%) was obtained as a colorless crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.19 (br s, 1H, H6), 8.00 – 7.91 (m, 2H, H2ph, H6ph), 
7.65 (tt, JH4ph,H3ph/H5ph = 7.4 Hz, JH4ph,H2ph/H6ph = 1.1 Hz, H4ph), 7.53 (m, 3H, NH, H3ph, 
H5ph), 6.60 (d, JH5,H6 = 5.0 Hz, 1H, H5), 5.54 – 5.39 (m, 1H), 3.74 (dd, JCH2,CH2 = 17.7 Hz, 
JCH2,CH = 10.3 Hz, 1H, CH2), 3.39 (dd, JCH2,CH2 = 17.6 Hz, JCH2,CH = 2.9 Hz, 1H, CH2), 
2.25 (s, 3H, CH3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 195.89 (C=O), 167.89 
(C4), 162.05 (C2), 157.85 (C6), 136.70 (C1ph), 134.02 (C4ph), 129.24 (C2ph, C6ph), 128.19 (C3ph, C5ph), 126.78 
(q, 1JC,F = 283.1 Hz, CF3), 111.53 (C5), 48.51 (q, 2JC,F = 30.2 Hz, CH), 37.21 (CH2), 24.00 (CH3) ppm. 
19F NMR (376 MHz, DMSO-d6): δ = − 74.48 (br s, CF3) ppm. HRMS (ESI+): m/z calcd. for C15H15F3N3O+ 
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[M+H]+ 310.1162; found 310.1162. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 1 mL/min): 
tR = 13.93 min, λ = 214 nm. mp 109 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.35. 
 
4,4,4-Trifluoro-1-phenyl-3-(quinolin-8-ylamino)butan-1-one (2d) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)quinolin-8-amine 1d (100 mg, 
0.37 mmol) was dissolved in 5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.85 mL, 
0.85 mmol) and reacted with acetophenone (0.65 mL, 0.56 mmol). After stirring at rt (20 min), aqueous 
workup and flash chromatography (cyclohexane → cyclohexane/ethyl acetate 9:1) the -amino ketone 2d 
(117 mg, 0.34 mmol, 92%) was obtained as a light yellow oil. 
 1H NMR (400 MHz, CDCl3): δ = 8.68 (dd, JH2,H3 = 4.2 Hz, JH2,H4 = 1.7 Hz, 1H, H2), 
8.06 (dd, JH4,H3 = 8.2 Hz, JH4,H2 = 1.7 Hz, 1H, H4), 7.99 – 7.93 (m, 2H, H2ph, H6ph), 
7.62 – 7.54 (m, 1H, H4ph), 7.51 – 7.40 (m, 3H, H6, H3ph, H5ph), 7.36 (dd, JH3,H4 = 8.2 Hz, 
JH3,H2 = 4.2 Hz, 1H, H3), 7.16 (dd, JH5,H6 = 8.2 Hz, JH5,H7 = 1.1 Hz, 1H, H5), 7.07 (d, 
JH7,H6 = 7.6 Hz, 1H, H7), 6.44 (d, JNH,CH = 9.9 Hz, 1H, NH), 5.10 (dtd, JCH,NH = 9.9 Hz, 
JCH,CF3 = 7.2 Hz, JCH,CH2 = 4.7 Hz, 1H, CH), 3.63 – 3.49 (m, 2H, CH2) ppm. 13C NMR (101 MHz, 
CDCl3):  δ = 195.05 (C=O), 147.32 (C2), 142.75 (C4a), 138.16 (C8a), 136.42 (C1ph), 136.20 (C4), 133.82 
(C4ph), 128.91 (C3ph, C5ph), 128.73 (C8), 128.34 (C2ph, C6ph), 127.71 (C6), 126.40 (q, J C,F = 283.3 Hz, CF3), 
121.61 (C3), 116.12 (C5), 106.54 (C7), 51.40 (q, JC,F = 30.5 Hz, CCF3), 39.06 (CH2) ppm. 19F NMR 
(376 MHz, CDCl3): δ = − 75.63 (d, JCF3,CH = 7.1 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C19H16F3N2O+ 
[M+H]+ 345.1209; found 345.1210. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 1 mL/min): 
tR = 18.93 min, λ = 214 nm. Rf (cyclohexane/ethyl acetate 3:1) = 0.50.  
 
4,4,4-Trifluoro-1-phenyl-3-((4-(trifluoromethyl)phenyl)amino)butan-1-one (2e) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-(trifluoromethyl)aniline 1e (50 mg, 
0.17 mmol) was dissolved in 5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.40 mL, 
0.40 mmol) and reacted with acetophenone (0.03 mL, 0.26 mmol). After stirring at rt (1 h), aqueous workup 
and flash chromatography (cyclohexane → cyclohexane/ethyl acetate 5:1) the -amino ketone 2e (33 mg, 
0.09 mmol, 52%) was obtained as a light brown solid. 
1H NMR (400 MHz, CDCl3): δ = 7.98 – 7.92 (m, 2H, H2ph, H6ph), 7.65 – 7.59 (m, 1H, H4ph), 7.50 (dd, 
J = 8.3 Hz, J = 7.1 Hz, 2H, H3ph, H5ph), 7.44 (d, JH3,H2 = JH5,H6 = 8.5 Hz, 2H, H3, 
H5), 6.79 (d, JH2,H3 = JH6,H5 = 8.4 Hz, 2H, H2, H6), 4.87 (dtd, JCH,NH = 9.6 Hz, 
JCH,CF3 = 7.2 Hz, JCH,CH2 = 4.3 Hz, 1H, CH), 4.14 (d, JNH,CH = 9.9 Hz, 1H, NH), 
3.45 – 3.37 (m, 2H, CH2) ppm. 13C NMR (101 MHz, CDCl3): δ = 194.90 (C=O), 148.67 (C1), 136.16 (C1ph), 
134.14 (C4ph), 129.05 (C3ph, C5ph), 128.31 (C2ph, C6ph), 126.92 (q, JC,F = 3.8 Hz, C3, C5), 125.97 (q, 
J C,F = 283.2 Hz, CF3), 124.77 (d, JC,F = 270.6 Hz, CF3), 121.15 (q, JC,F = 32.8 Hz, C4), 113.19 (C2, C6), 51.80 
(q, 2JC,F = 30.7 Hz, CCF3), 38.34 (CH2) ppm. 19F NMR (376 MHz, CDCl3): δ = − 61.40 (CF3), − 75.66 (d, 
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JCF3,CH = 7.1 Hz, CF3) ppm. HRMS (ESI-): m/z calcd. for C17H12F6NO− [M−H]− 360.0828; found 360.0835. 
HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 1 mL/min): tR = 19.85 min, λ = 214 nm. mp 127 °C. 
Rf (cyclohexane/ethyl acetate 3:1) = 0.46.  
 
4,4,4-Trifluoro-3-((4-methoxyphenyl)amino)-1-phenylbutan-1-one (2f) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-methoxyaniline 1f (170 mg, 0.68 mmol) 
was dissolved in 10 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 1.56 mmol) 
and reacted with acetophenone (0.12 mL, 1.02 mmol). After stirring at rt (2 h), aqueous workup and flash 
chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane) the -
amino ketone 2f (140 mg, 0.43 mmol, 64%) was obtained as a colorless crystalline solid.  
1H NMR (600 MHz, CDCl3): δ = 7.95 (m, 1H, H2ph/H6ph), 7.94 (m, 1H, 
H2ph/H6ph), 7.60 (m, 1H, H4ph), 7.51 – 7.46 (m, 2H, H3ph, H5ph), 6.80 – 6.76 (m, 
2H, H2, H6), 6.76 – 6.72 (m, 2H, H3, H5), 4.69 (m, 1H, CH), 3.74 (s, 3H, OMe), 
3.40 – 3.29 (m, 2H, CH2) ppm. 13C NMR (151 MHz, CDCl3): δ = 195.53 (C=O), 
153.58 (C4), 139.93 (C1), 136.48 (C1ph), 133.85 (C4ph), 129.94 (C2ph, C6ph), 128.29 (C3ph, C5ph), 126.34 (q, 
J C,F = 283.5 Hz, CF3), 116.13 (C3ph, C5ph), 114.98 (C2ph, C1ph), 55.79 (OMe), 53.97 (q, 2JC,F = 29.5 Hz, CCF3), 
38.47 (CH2) ppm. 19F NMR (376 MHz, CDCl3): δ = − 75.48 (CF3) ppm. HRMS (ESI+): m/z calcd. for 
C17H17F3NO2+ [M+H]+ 324.1206; found 324.1210. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 
1 mL/min): tR = 18.43 min, λ = 214 nm. mp 90 °C. Rf (cyclohexane/ethyl acetate 4:1) = 0.53.  
 
4,4,4-Trifluoro-1-phenyl-3-(pyridin-2-ylamino)butan-1-one (2g) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-2-amine 1g (100 mg, 0.45 mmol) 
was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 1.04 mmol) and 
reacted with acetophenone (0.08 mL, 0.68 mmol). After stirring at rt (1 h), aqueous workup, flash 
chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane) the -
amino ketone 2g (104 mg, 0.35 mmol, 78%) was obtained as a colorless crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.02 (dd, JH6,H5 = 5.0 Hz, JH6,H4 = 1.2 Hz, 1H, H6), 
8.00 – 7.95 (m, 2H, H2ph, H6ph), 7.69 – 7.63 (m, 1H, H4ph), 7.56 – 7.51 (m, 2H, H3ph, 
H5ph), 7.41 (ddd, JH4,H3 = 8.8 Hz, JH4,H5 = 7.1 Hz, JH4,H6 = 1.9 Hz, 1H, H4), 6.94 (d, 
JNH,CH = 8.4 Hz, 1H, NH), 6.59 (ddd, JH5,H4 = 7.0 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.8 Hz, 
1 H, H5), 6.51 (d, JH3,H4 = 8.4 Hz, 1H, H3), 5.60 – 5.44 (m, 1H, CH), 3.60 (dd, JCH2,CH2 = 17.5 Hz, 
JCH2,CH = 9.6 Hz, 1H, CH2), 3.43 (dd, JCH2,CH2 = 17.5 Hz, JCH2,CH = 3.5 Hz, 1H, CH2) ppm. 13C NMR 
(101 MHz, DMSO-d6):  δ = 195.50 (C=O), 157.47 (C1), 147.33 (C6), 137.18 (C4), 136.34 (C1ph), 133.67 
(C4ph), 128.92 (C3ph, C5ph), 128.21 (C2ph, C6ph), 126.59 (q, JC,F = 283.8 Hz, CF3), 113.32 (C5), 108.74 (C3), 
47.56 (q, JC,F = 30.0 Hz, CH), 37.55 (CH2) ppm. 19F NMR (376 MHz, DMSO-d6): δ = − 74.34 (d, 
JCF3,CH = 8.0 Hz, CF3) ppm. HRMS (EI): m/z calcd. for C15H13F3N2O+ [M]+ 294.0980; found 294.0977. HPLC-
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MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.25 min, λ = 220 nm. mp 
124 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.46. 
 
4,4-Difluoro-1-phenyl-3-(pyridin-2-ylamino)butan-1-one (2h) 
According to the general procedure, N-(1-ethoxy-2,2-difluoroethyl)pyridin-2-amine 1h (100 mg, 0.49 mmol) 
was dissolved in 5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.13 mL, 1.13 mmol) and 
reacted with acetophenone (0.09 mL, 0.74 mmol). After stirring at rt (2 h), aqueous workup and flash 
chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) the -amino ketone 2h (136 mg, 0.49 mmol, 
quant.) was obtained as a light brown solid.  
1H NMR (400 MHz, CDCl3): δ = 8.07 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, 
JH6,H3 = 0.9 Hz, 1H, H6), 8.00 – 7.92 (m, 2H, H2ph, H6ph), 7.65 – 7.54 (m, 1H, H4ph), 
7.53 – 7.44 (m, 2H, H3ph, H5ph), 7.40 (ddd, JH4,H3 = 8.4 Hz, JH4,H5 = 7.1 Hz, 
JH4,H6 = 1.9 Hz, 1H, H4), 6.62 (ddd, JH5,H4 = 7.1 Hz, JH5,H6 = 5.1 Hz, JH5,H3 = 0.9 Hz, 1H, 
H5), 6.48 (dt, JH3,H4 = 8.3 Hz, JH3,H5 = 0.9 Hz, 1H, H3), 6.20 (td, JCHF2,CHF2 = 56.7 Hz, JCHF2,CH = 3.1 Hz, 1H, 
CHF2), 5.08 – 4.91 (m, 1H, CH), 4.89 (d, JNH,CH = 9.0 Hz, 1H, NH), 3.46 – 3.38 (m, 2H, CH2) ppm. 13C NMR 
(101 MHz, CDCl3):  δ = 197.85 (C=O), 157.16 (C2), 147.97 (C6) , 137.61 (C4), 136.58 (C1ph), 133.76 (C4ph), 
128.89 (C3ph, C5ph), 128.34 (C2ph, C6ph), 115.45 (t, JCHF2,CHF2 = 244.9 Hz, CHF2), 113.02 (C5), 108.87 (C3), 
49.94 (dd, JCH,CHF2 = 24.5 Hz, JCH,CHF2 = 22.8 Hz, CH), 36.73 (CH2) ppm. 19F NMR (376 MHz, 
CDCl3): δ = − 125.78 (ddd, JCHF2,CHF2 = 281.1 Hz, JCHF2,CHF2 = 56.4 Hz, JCHF2,CH = 10.4 Hz, CHF2), − 128.96 
(ddd, JCHF2,CHF2 = 281.1 Hz, JCHF2,CHF2 = 56.9 Hz, JCHF2,CH = 16.0 Hz, CHF2) ppm. HRMS (ESI+): m/z calcd. 
for C15H15F2N2O+ [M+H]+ 277.1147; found 277.1146. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, 
flow: 1 mL/min): tR = 10.23 min, λ = 214 nm. mp 115 °C. Rf (cyclohexane/ethyl acetate 3:1) = 0.24.  
 
4,4,5,5,5-Pentafluoro-1-phenyl-3-(pyrazin-2-ylamino)pentan-1-one (2i) 
Following the general procedure, N-(1-ethoxy-2,2,3,3,3-pentafluoropropyl)pyrazin-2-amine 1i (100 mg, 
0.37 mmol) was dissolved in 5 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.85 mL, 
0.85 mmol) and reacted with acetophenone (0.07 mL, 0.55 mmol). After stirring at rt (1 h), aqueous workup 
and flash chromatography (cyclohexane → cyclohexane/ethyl acetate 2:1) the -amino ketone 2i (130 mg, 
0.37 mmol, quant.) was obtained as a light yellow solid.  
1H NMR (400 MHz, CDCl3): δ = 8.01 (dd, JH6,H5 = 2.8  Hz, JH6,H3 = 1.5 Hz, 1 H, H6), 
7.99 (d, JH3,H6 = 1.5 Hz, 1 H, H3), 7.95 – 7.91 (m, 2 H, H2ph; H6ph), 7.90 (m, 1 H, H5), 
7.60 (m, 1 H, H4ph), 7.48 (m, 2 H, H3ph; H5ph), 5.73 (m, 1 H, CH), 5.06 (d, 
JNH,CH = 10.0 Hz, 1 H, NH), 3.51 – 3.46 (m, 2 H, CH2) ppm. 13C NMR (101 MHz, 
CDCl3):  δ = 195.68 (C=O), 152.61 (C2), 141.68 (C6), 136.31 (C1ph), 134.84 (C5), 134.01 (C4ph), 132.96 (C3), 
129.01 (C3ph; C5ph), 128.27 (C2ph; C6ph), 46.94 (dd, 2JCH,CF2 = 27.1 Hz, 2JCH,CF2 = 21.4 Hz, CH), 37.07 
(CH2) ppm. 19F NMR (376 MHz, CDCl3): δ = − 81.84 (CF3), − 118.54 (dd, JCF2,CF2 = 273.6 Hz, 
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JCF2,CF3 = 7.3 Hz, CF2), − 124.82 (dd, JCF2,CF2 = 273.6 Hz, JCF2,CF3 = 19.8 Hz, CF2) ppm. HRMS (ESI+): m/z 
calcd. for C15H13F5N3O+ [M+H]+ 346.0973; found 346.0973. . HPLC (0.1% TFA; 0 min, 4% B → 15 min, 
100% B, flow: 1 mL/min): tR = 16.28 min, λ = 214 nm.  mp 105 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.23.  
 
1-(4-Bromophenyl)-4,4,4-trifluoro-3-(pyrazin-2-ylamino)butan-1-one (3a) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (150 mg, 
0.68 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 4-bromoacetophenone (203 mg, 1.02 mmol). After stirring at 40 °C (2 h), 
aqueous workup, flash chromatography (cyclohexane/ethyl acetate 3:1 → 2:1) and recrystallization 
(cyclohexane/ethyl acetate 9:1) the -amino ketone 3a (157 mg, 0.42 mmol, 62%) was obtained as a colorless 
crystalline solid.  
1H NMR (500 MHz, DMSO-d6): δ = 8.04 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.4 Hz, 
1H, H6), 7.96 (d, JH3,H6 = 1.4 Hz, 1H, H3), 7.94 – 7.89 (m, 2H, H2ph, H6ph), 7.82 
(d, JH5,H6 = 2.7 Hz, 1H, H5), 7.78 – 7.73 (m, 2H, H3ph, H5ph), 7.46 (d, 
JNH,CH = 8.2 Hz, 1H, NH), 5.48 – 5.35 (m, 1H, CH), 3.62 (dd, JCH2,CH2 = 17.8 Hz, 
JCH2,CH = 9.8 Hz, 1H, CH2), 3.52 (dd, JCH2,CH2 = 17.8 Hz, JCH2,CH = 3.3 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 194.57 (C=O), 154.01 (C2), 141.46 (C6), 135.19 (C1), 
133.13 (C3), 133.09 (C5), 131.98 (C3ph, C5ph), 130.26 (C2ph, C6ph), 127.87 (C-Br), 126.29 (q, JC,F = 282.8 Hz, 
CF3), 47.26 (q, JC,F = 30.3 Hz, CH), 37.28 (CH2) ppm. 19F NMR (471 MHz, DMSO-d6): δ = − 74.37 (d, 
JCF3,CH = 7.6 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C14H12BrF3N3O+ [M+H]+ 374.0110; found 
374.0112. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.74 min, 
λ = 220 nm. mp 112 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.24. 
 
4,4,4-Trifluoro-1-(4-methoxyphenyl)-3-(pyrazin-2-ylamino)butan-1-one (3b) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (150 mg, 
0.68 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 4-methoxyacetophenone (153 mg, 1.02 mmol). After stirring at rt (2 h), aqueous 
workup, flash chromatography (cyclohexane/ethyl acetate 3:1 → 2:1) and recrystallization (cyclohexane/ethyl 
acetate 9:1) the -amino ketone 3b (199 mg, 0.61 mmol, 90%) was obtained as a colorless crystalline solid.  
1H NMR (500 MHz, DMSO-d6): δ = 8.03 (dd, JH6,H5 = 2.6 Hz, 
JH6,H3 = 1.4 Hz, 1H, H6), 7.99 – 7.93 (m, 3H, H3, H2ph, H6ph), 7.81 (d, 
JH5,H6 = 2.8 Hz, 1H, H5), 7.47 (d, JNH,CH = 8.3 Hz, 1H, NH), 7.05 (m, 2H, 
H3ph, H5ph), 5.52 – 5.34 (m, 1H, CH), 3.85 (s, 3H, OMe), 3.57 (dd, 
JCH2,CH2 = 17.5 Hz, JCH2,CH = 9.9 Hz, 1H, CH2), 3.42 (dd, JCH2,CH2 = 17.5 Hz, 
JCH2,CH = 3.2 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 193.51 (C=O), 163.59 (C-OMe), 
154.04 (C2), 141.47 (C6), 133.10 (C3), 133.01 (C5), 130.64 (C2ph, C6ph), 129.17 (C1ph), 126.40 (q, 
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1JC,F = 283.0 Hz, CF3), 114.11 (C3ph, C5ph), 55.73 (OMe), 47.36 (q, 2JC,F = 30.3 Hz, CH), 36.84 (CH2) ppm. 
19F NMR (376 MHz, DMSO-d6): δ = − 74.34 (d, JCF3,CH = 7.8 Hz, CF3) ppm. HRMS (EI): m/z calcd. for 
C15H14F3N3O2+ [M]+ 325.1038; found 325.1043. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 
100% B, flow: 3.3 mL/min): tR = 1.60 min, λ = 220 nm. mp 135 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.11. 
 
4,4,4-Trifluoro-1-(2-methoxyphenyl)-3-(pyrazin-2-ylamino)butan-1-one (3c) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (150 mg, 
0.68 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 
1.56 mmol) and reacted with 2-methoxyacetophenone (0.14 mL, 1.02 mmol). After stirring at rt (2 h), aqueous 
workup, flash chromatography (cyclohexane/ethyl acetate 3:1 → 2:1) and recrystallization (cyclohexane/ethyl 
acetate 9:1) the -amino ketone 3c (194 mg, 0.59 mmol, 88%) was obtained as a colorless crystalline solid. 
1H NMR (500 MHz, DMSO-d6): δ = 7.97 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, 
H6), 7.95 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.79 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.60 – 7.49 
(m, 3H, H2ph, H4ph, H5ph), 7.20 (d, JNH,CH = 8.2 Hz, 1H, NH), 7.03 – 6.97 (m, 1H, 
H3ph), 5.47 – 5.37 (m, 1H, CH), 3.91 (s, 3H, OMe), 3.46 (dd, JCH2,CH2 = 17.4 Hz, 
JCH2,CH = 4.2 Hz, 1H, CH2), 3.40 (dd, JCH2,CH2 = 17.4 Hz, JCH2,CH = 9.2 Hz, 1H, CH2) 
ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 196.16 (C=O), 158.68 (C-OMe), 153.95 (C2), 141.39 (C6), 134.64 
(C4ph), 133.16 (C3), 132.95 (C5), 129.99 (C2ph), 126.51 (C1ph), 126.30 (q, 1JC,F = 282.9 Hz, CF3) 120.71 (C3ph), 
112.68 (C5ph), 55.97 (OMe), 47.31 (q, 2JC,F = 30.1 Hz, CH), 42.49 (CH2) ppm.  19F NMR (471 MHz, DMSO-
d6): δ = − 74.52 (d, JCF3,CH = 7.7 Hz, CF3) ppm. HRMS (EI): m/z calcd. for C15H14F3N3O2+ [M]+ 325.1038; 
found 325.1044. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): 
tR = 1.62 min, λ = 220 nm. mp 134 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.14. 
 
Methyl 4-(4,4,4-trifluoro-3-(pyrazin-2-ylamino)butanoyl)benzoate (3d) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with methyl-4-acetylbenzoate (120 mg, 0.68 mmol). After stirring at rt (2.5 h), 
aqueous workup, flash chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization 
(cyclohexane) the desired -amino ketone 3d (130 mg, 0.37 mmol, 82%) was obtained as a colorless crystalline 
solid. 
 1H NMR (400 MHz, DMSO-d6): δ = 8.10 (d, JH2ph,H3ph = JH5ph,H6ph = 2.1 Hz, 
4H, H2ph, H3ph, H5ph, H6ph), 8.04 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, 
H6), 7.96 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.46 
(d, JNH,CH = 8.2 Hz, 1H, NH), 5.49 – 5.36 (m, 1H, CH), 3.69 (dd, 
JCH2,CH2 = 17.9 Hz, JCH2,CH = 9.7 Hz, 1H, CH2), 3.59 (dd, JCH2,CH2 = 17.5 Hz, 
JCH2,CH = 3.1 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 194.84 (C=O), 165.46 (COOMe), 
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153.85 (C2), 141.22 (C6), 139.39 (C1ph), 133.47 (C5), 133.00 (C4ph), 132.96 (C3), 129.42 (C3ph, C5ph), 128.38 
(C2ph, C6ph), 52.47 (CH3), 47.12 (q, 2JC,F = 30.5 Hz, CH), 37.50 (CH2) ppm.* 19F NMR (376 MHz, DMSO-
d6): δ = − 74.38 (d, JCF3,CH = 8.0 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C16H15F3N3O3+ [M+H]+ 
354.1060; found 354.1061. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 
mL/min): tR = 1.62 min, λ = 220 nm. mp 121 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.17. 
* Due to low intensity the signal of CF3 could not be observed. 
 
4,4,4-Trifluoro-1-(4-nitrophenyl)-3-(pyrazin-2-ylamino)butan-1-one (3e) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 4'-nitroacetophenone (111 mg, 0.68 mmol). After stirring at rt (1 h) followed by 
stirring at 40 °C (2 h) TLC and LC-MS control showed that large amounts of starting material remained. The 
reaction mixture was cooled to −78 °C before LHMDS (1.0 M solution in toluene, 0.45 mL, 0.45 mmol) was 
added. Stirring was continued at −78 °C for 10 min, 4'-nitroacetophenone (75 mg, 0.45 mmol) was added and 
the reaction mixture was stirred at 40 °C (20 h). Subsequent aqueous workup, flash chromatography 
(cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane/ethyl acetate 9:1) furnished 
the -amino ketone 3e (115 mg, 0.34 mmol, 75%) as a yellow crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.41 – 8.30 (m, 2H, H3ph, H5ph), 
8.26 – 8.18 (m, 2H, H2ph, H6ph), 8.04 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, 
H6), 7.96 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.83 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.47 
(d, JNH,CH = 8.1 Hz, 1H, NH), 5.52 – 5.33 (m, 1H, CH), 3.77 – 3.60 (m, 2H, 
2 × CH2) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 194.63 (C=O), 154.01 
(C2), 150.24 (C-NO2), 141.46 (C6), 140.72 (C3), 133.17 (C5), 129.70 (C2ph, C6ph), 126.23 (q, 1JC,F = 282.8 Hz, 
CF3) 123.98 (C3ph, C5ph), 47.25 (q, 2JC,F = 30.5 Hz, CH), 37.90 (CH2) ppm. 19F NMR (376 MHz, DMSO-
d6): δ = − 74.47 (d, JCF3,CH = 7.8 Hz, CF3) HRMS (ESI+): m/z calcd. for C14H12F3N4O3+ [M+H]+ 341.0856; 
found 341.0859. HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): 
tR = 1.62 min, λ = 220 nm. mp 163 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.14. 
 
4-(4,4,4-Trifluoro-3-(pyrazin-2-ylamino)butanoyl)benzonitrile (3f) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 4'-cyanoacetophenone (99 mg, 0.68 mmol). After stirring at rt (1 h) followed by 
stirring at 40 °C (1h) TLC and LC-MS control showed that large amounts of starting material remained. The 
reaction mixture was cooled to −78 °C before LHMDS (1.0 M solution in toluene, 0.45 mL, 0.45 mmol) was 
added. Stirring was continued at −78 °C (10 min), 4'-cyanoacetophenone (65 mg, 0.45 mmol) was added and 
the reaction mixture was stirred at 40 °C (1 h). Subsequent aqueous workup, flash chromatography 
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(cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization (cyclohexane) furnished the -amino 
ketone 3f (131 mg, 0.41 mmol, 91%) as a colorless crystalline solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.18 – 8.09 (m, 2H, H3ph, H5ph), 
8.05 – 8.02 (m, 2H, H2ph, H6ph), 8.01 (m, 1H, H6), 7.96 (d, JH3,H6 = 1.4 Hz, 1H, 
H3), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.46 (d, JNH,CH = 8.1 Hz, 1H, NH), 
5.53 – 5.28 (m, 1H, CH), 3.68 (dd, JCH2,CH2 = 18.1 Hz, JCH2,CH = 9.3 Hz, 1H, 
CH2), 3.61 (dd, JCH2,CH2 = 18.0 Hz, JCH2,CH = 3.9 Hz, 1H, CH2) ppm. 13C NMR 
(101 MHz, DMSO-d6): δ = 194.84 (C=O), 154.01 (C2), 141.45 (C6), 139.30 (C1ph), 133.16 (C3), 133.15 (C5), 
132.94 (C2ph, C6ph), 128.88 (C3ph, C5ph), 126.24 (q, 1JC,F = 282.7 Hz, CF3), 118.22 (C≡N), 115.61 (C-CN), 
47.24 (q, 2JC,F = 30.5 Hz, CH), 37.69 (CH2) ppm. 19F NMR (376 MHz, DMSO-d6): δ = − 74.37 (d, 
JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C15H12F3N4O+ [M+H]+ 321.0958; found 321.0959. 
HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.56 min, λ = 220 
nm. mp 185 °C. Rf (cyclohexane/ethyl acetate 1:1) = 0.37. 
 
4,4,4-Trifluoro-1-(perfluorophenyl)-3-(pyrazin-2-ylamino)butan-1-one (3g) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 2',3',4',5',6'-pentafluoroacetophenone (0.10 mL, 0.68 mmol). After  stirring at rt 
(1 h) followed by stirring at 40 °C (2 h) TLC and LC-MS control showed that large amounts of starting material 
remained. The reaction mixture was cooled to −78 °C before LHMDS (1.0 M solution in toluene, 0.45 mL, 
0.45 mmol) was added. Stirring was continued at −78 °C (10 min), 2',3',4',5',6'-pentafluoroacetophenone 
(0.07 mL, 0.45 mmol) was added and the reaction mixture was stirred at 40 °C (20 h). Subsequent aqueous 
workup, flash chromatography (cyclohexane → cyclohexane/ethyl acetate 4:1) and recrystallization 
(cyclohexane/ethyl acetate 9:1) furnished the -amino ketone 3g (61 mg, 0.16 mmol, 35%) as a light yellow 
solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.03 – 7.97 (m, 2H, H6, H3), 7.84 (d, 
JH5,H6 = 2.3 Hz, 1H, H5), 7.70 (d, JNH,CH = 8.8 Hz, 1H, NH), 5.51 – 5.37 (m, 1H, CH), 
3.55 (dd, JCH2,CH2 = 17.7 Hz, JCH2,CH = 4.0 Hz, 1H, CH2), 3.40 (dd, JCH2,CH2 = 17.7 Hz, 
JCH2,CH = 9.7 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 189.83 
(C=O), 153.88 (C2), 146.07 – 145.78 (m, C-F), 144.42 – 144.10 (m, C-F), 143.55 - 143.31 (m, C-F), 141.56 
(C6), 139.00 - 138.65 (m, C-F), 136.52 - 136.16 (m, C-F), 133.64 (C5), 133.49 (C3), 126.01 (q, 
1JC,F = 283.0 Hz, CF3), 113.99 - 113.63 (m, C-F), 47.15 (q, 2JC,F = 30.8 Hz, CH), 43.49 (CH2) ppm. 19F NMR 
(376 MHz, DMSO-d6): δ = − 74.68 (d, JCF3,CH = 7.8 Hz, CF3), − 140.87 – −141.17 (m, F2, F6), − 149.30 (tt, 
JF4,F3 = JF4,F5 = 22.2 Hz, JF4,F2 = JF4,F6 = 4.4 Hz, F4), − 160.93 – −161.21 (m, F3, F5) ppm. HRMS (ESI+): m/z 
calcd. for C14H8F8N3O+ [M+H]+ 386.0534; found 386.0534. HPLC-MS (0.05% formic acid; 0 min, 0% B → 
2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.74 min, λ = 220 nm. mp 115 °C. Rf (cyclohexane/ethyl 
acetate 2:1) = 0.30. 
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4,4,4-Trifluoro-1-(furan-2-yl)-3-(pyrazin-2-ylamino)butan-1-one (3h) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMSD (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 2-acetylfuran (75 mg, 0.68 mmol). After stirring at rt (2 h), aqueous workup and 
column chromatography (cyclohexane/ethyl acetate 5:1 → 1:1) the -amino ketone 3h (75 mg, 0.26 mmol, 
58%) was obtained as a light yellow oil.  
1H NMR (800 MHz, DMSO-d6): δ = 8.02 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, 
H6), 8.00 (dd, JH5furan,H4furan = 1.7 Hz, JH5furan,H3furan = 0.7 Hz, 1H, H5furan), 7.95 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 7.80 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.57 (d, JNH,CH = 8.5 Hz, 
1H, NH), 7.52 (dd, JH3furan,H4furan = 3.6 Hz, JH3furan,H5furan = 0.7 Hz 1H, H3furan), 6.73 (dd, 
JH4furan,H3furan = 3.6 Hz, JH4furan,H5furan = 1.7 Hz, 1H, H4furan), 5.47 – 5.29 (m, 1H, CH), 
3.43 – 3.37 (m, 1H, CH2), 3.31 (dd, JCH2,CH2 = 17.1 Hz, JCH2,CH = 3.8 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, 
DMSO-d6): δ = 183.44 (C=O), 153.91 (C2), 151.57 (C2furan), 148.36 (C5furan), 141.45 (C6), 133.15 (C3, C5), 
129.19 (q, 1JC,F = 282.8 Hz, CF3), 119.42 (C3furan), 112.92 (C4furan), 47.02 (q, 2JC,F = 30.5 Hz, CH), 36.95 (CH2) 
ppm. 19F NMR (376 MHz, DMSO-d6): δ = − 74.52 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. 
for C12H11F3N3O2+ [M+H]+ 286.0798; found 286.0797 HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, 
flow: 1 mL/min): tR = 12.68 min, λ = 214 nm. Rf (cyclohexane/ethyl acetate 1:1) = 0.32. 
 
4,4,4-Trifluoro-1-(1-methyl-1H-indol-3-yl)-3-(pyrazin-2-ylamino)butan-1-one (3i) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with 1-(1-methyl-1H-indol-3-yl)ethan-1-one (117 mg, 0.68 mmol). After stirring at rt 
(2 h), aqueous workup, flash chromatography (CH2Cl2 → CH2Cl2/MeOH 10:1) and recrystallization 
(cyclohexane) the -amino ketone (105 mg, 0.30 mmol, 67%) was obtained as a colorless solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.46 (s, 1H, H2in), 8.12 (d, 
JH7in,H6in = 7.6 Hz, 1H, H7in), 8.03 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 
7.98 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.79 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.54 (m, 2H, 
NH, H4in), 7.32 – 7.25 (m, 1H, H5in), 7.21 (td, JH6in,H7in/H5in = 7.6 Hz, 
JH6in,H4in = 1.0 Hz, 1H, H6in), 5.59 – 5.41 (m, 1H, CH), 3.89 (s, 3H, NCH3), 3.45 
(dd, JCH2,CH2 = 16.5 Hz, JCH2,CH = 9.8 Hz, 1H, CH2), 3.26 (dd, JCH2,CH2 = 16.5 Hz, 
JCH2,CH = 3.5 Hz, 1H, CH2) ppm. 13C NMR (101 MHz, CDCl3):  δ = 188.98 (C=O), 154.06 (C2), 141.51 (C6), 
138.37 (C2in), 137.39 (Cquart-N), 133.11 (C3), 132.92 (C5), 126.53 (q, 1JC,F = 283.0 Hz, CF3) 125.75 (C3in), 
123.21 (C5in), 122.46 (C6in), 121.47 (C7in), 115.00 (Cquart), 110.81 (C4in), 47.42 (q, 2JC,F = 30.1 Hz, CH), 37.64 
(CH2), 33.35 (CH3) ppm. 19F NMR (376 MHz, DMSO-d6): δ = − 74.34 (d, JCF3,CH = 8.0 Hz, CF3) ppm. HRMS 
(ESI+): m/z calcd. for C17H16F3N4O+ [M+H]+ 349.1271; found 349.1273. HPLC-MS (0.05% formic acid; 
0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.60 min, λ = 220 nm. mp 198 °C. Rf 
(cyclohexane/ethyl acetate 1:1) = 0.17. 
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(E)-6,6,6-trifluoro-1-phenyl-5-(pyrazin-2-ylamino)hex-1-en-3-one (3j) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 
0.45 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 
1.04 mmol) and reacted with (E)-4-phenylbut-3-en-2-one (99 mg, 0.68 mmol). After stirring at rt (2 h), 
aqueous workup and column chromatography (cyclohexane/ethyl acetate 3:1 → 1:1) the -amino ketone 
(92 mg, 0.29 mmol, 64%) was obtained as a yellow oil.  
1H NMR (400 MHz, DMSO-d6): δ = 8.03 (dd, JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, 
H6), 7.99 (d, JH3,H6 = 1.5 Hz, 1H, H3), 7.80 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.74 – 7.70 
(m, 2H, H2ph, H6ph), 7.67 (d, JHa,Hb = 16.3 Hz, 1H, Ha), 7.53 (d, JNH,CH = 8.5 Hz, 1H, 
NH), 7.47 – 7.42 (m, 3H, H3ph, H4ph, H5ph,), 6.96 (d, JHb,Ha = 16.3 Hz, 1H, Hb), 
5.48 – 5.31 (m, 1H, CH), 3.32 – 3.24 (m, 1H, CH2), 3.19 (dd, JCH2,CH2 = 17.3 Hz, JCH2,CH = 3.6 Hz, 1H, 
CH2) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 195.11 (C=O), 154.02 (C2), 143.33 (Ca), 141.45 (C6), 134.32 
(C1ph), 133.18 (C3), 133.05 (C5), 130.88 (C4ph), 129.16 (C3ph, C5ph), 128.68 (C2ph, C6ph), 126.31 (q, 
1JC,F = 282.8 Hz, CF3) 126.10 (Cb), , 47.20 (q, 2JC,F = 30.3 Hz, CH) ppm. 19F NMR (376 MHz, DMSO-
d6): δ = − 74.50 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C16H15F3N3O+ [M+H]+ 
322.1162; found 322.1160. Rf (cyclohexane/ethyl acetate 1:1) = 0.55. 
 
4,4,4-Trifluoro-2-methyl-1-phenyl-3-(pyrazin-2-ylamino)butan-1-one (3k) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) 
was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 1.04 mmol) and 
reacted with propiophenone (0.09 mL, 0.68 mmol). After stirring at rt (2 h), aqueous workup and column 
chromatography (cyclohexane/ethyl acetate 3:1 → 2:1) the -amino ketone 3k (95 mg, 0.31 mmol, 68%) was 
obtained as a colorless solid (mixture of diastereomeres).  
1H NMR (400 MHz, DMSO-d6): δ = 8.05 – 7.98 (m, 4H, H6, H3, H2ph, H6ph), 7.80 (d, 
JH5,H6 = 2.8 Hz, 1H, H5), 7.71 – 7.65 (m, 1H, H4ph), 7.60 – 7.53 (m, 3H, H3ph, H5ph, NH), 
5.36 – 5.23 (m, 1H, CH), 4.17 (dq, JCHCH3,CH = 14.2 Hz, JCHCH3,CH3 = 7.0 Hz 1H, 
CHCH3), 1.25 (dd, JCH3,CHCH3 = 7.0 Hz, JCH3,CF3 = 1.1 Hz 3H, CH3) ppm. 13C NMR 
(101 MHz, DMSO-d6):  δ = 199.81 (C=O), 153.69 (C2), 141.17 (C6), 135.21 (C1ph), 133.65 (C5), 133.12 
(C4ph), 132.96 (C3), 128.90 (C3ph, C5ph), 128.43 (C2ph, C6ph), 126.13 (q, 1JC,F = 284.3 Hz, CF3), 52.21 (q, 
2JC,F = 28.8 Hz, CH), 26.32 (CHCH3), 14.60 (d, 4JC,F = 1.9 Hz, CH3) ppm. 19F NMR (376 MHz, DMSO-
d6): δ = − 69.65 (dd, JCF3,CH = 8.4 Hz, JCF3,CH3 = 1.1 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for 
C15H15F3N3O+ [M+H]+ 310.1162; found 310.1160. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 
1 mL/min): tR = 15.79 min, 15.97 min, λ = 214 nm. mp 95 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.37. 
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4,4,4-Trifluoro-2,2-dimethyl-1-phenyl-3-(pyrazin-2-ylamino)butan-1-one (3l) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (100 mg, 0.45 mmol) 
was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.04 mL, 1.04 mmol) and 
reacted with 2-methyl-1-phenylpropan-1-one (0.1 mL, 0.68 mmol). After stirring at rt (3 h), aqueous workup 
and column chromatography (cyclohexane/ethyl acetate 3:1 → 2:1) the -amino ketone 3l (32 mg, 0.10 mmol, 
22%) was obtained as a light yellow solid.  
1H NMR (400 MHz, DMSO-d6): δ = 8.20 (d, JH3,H6 = 1.5 Hz, 1H, H3), 8.00 (dd, 
JH6,H5 = 2.8 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.82 (d, JH5,H6 = 2.8 Hz, 1H, H5), 7.75 – 7.68 
(m, 1H, H4ph), 7.67 – 7.61 (m, 2H, H2ph, H6ph), 7.58 – 7.51 (m, 1H, NH), 7.47 (m, 2H, 
H3ph, H5ph), 6.01 (m, 1H, CH), 1.40 (s, 3H, CH3), 1.27 (s, 3H, CH3) ppm. 13C NMR 
(101 MHz, DMSO-d6):  δ = 206.17 (C=O), 154.05 (C2), 141.02 (C6), 137.80 (C1ph), 133.52 (C5), 133.14 
(C4ph), 131.20 (C3), 128.36 (C3ph, C5ph), 127.29 (C2ph, C6ph), 125.73 (q, 1JC,F = 284.7 Hz, CF3), 54.13 (q, 
2JC,F = 27.6 Hz, CH), 49.48 (C(CH3)2), 24.02 (CH3), 20.37 (d, 4JC,F = 1.1 Hz, CH3) ppm. 19F NMR (376 MHz, 
DMSO-d6): δ = − 67.66 (d, JCF3,CH = 8.9 Hz, CF3) ppm. HRMS (ESI+): m/z calcd. for C16H17F3N3O+ [M+H]+ 
324.1318; found 324.1318. HPLC (0.1% TFA; 0 min, 4% B → 15 min, 100% B, flow: 1 mL/min): 
tR = 15.83 min, λ = 214 nm. mp 130 °C. Rf (cyclohexane/ethyl acetate 2:1) = 0.29. 
 
2-(2,6-Dichlorophenyl)-4,4,4-trifluoro-3-(pyrazin-2-ylamino)butane-nitrile (3m) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (150 mg, 0.68 mmol) 
was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.56 mL, 1.56 mmol) and 
reacted with 2,6-dichlorphenylacetonitrile (202 mg, 1.09 mmol). After stirring at rt (2.5 h), aqueous workup, 
column chromatography (cyclohexane/ethyl acetate 5:1 → 3:1) and washing with toluene the -amino ketone 
3m (148 mg, 0.41 mmol, 60%) was obtained as a colorless solid (mixture of diastereomeres).  
1H NMR (400 MHz, DMSO-d6): δ = 8.33 (d, JH3ar,H4ar = 9.6 Hz, 1H, H3ar), 8.18 (d, 
JH3,H6 = 1.5 Hz, 1H, H3), 8.09 (dd, JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.94 (d, 
JH5,H6 = 2.7 Hz, 1H, H5), 7.65 (s, 2H, NH, H5ar), 7.53 (t, JH4ar,H3ar/H5ar = 8.1 Hz, 1H, 
H4ar), 6.22 – 6.07 (m, 1H, CH), 5.51 (d, JCHCN,CH = 10.5 Hz, 1H, CHCN) ppm. 
13C NMR (75 MHz, DMSO-d6):  δ = 152.60 (C2), 140.63 (C6), 135.21 (C1ph), 133.83 
(C5), 132.89 (C3), 131.79 (C2ph, C6ph), 129.30 (C4ph), 128,21 (q, 1JC,F = 283.9 Hz, CF3), 126.23 (C3ph, C5ph), 
114.λ8 (C≡N), 50.71 (q, 2JC,F = 30.2 Hz, C-CF3), 32.00 (C-CN). 19F NMR (471 MHz, DMSO-d6): δ = − 71.63 
(br s, CF3) ppm. HRMS (EI): m/z calcd. for C14H9Cl2F3N4+ [M]+ 360.0156; found 360.0177. HPLC-MS 
(0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.68 min, 1.73, λ = 220 nm. 
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Diethyl 2-(2,2,2-trifluoro-1-(pyrazin-2-ylamino)ethyl)malonate (3n) 
According to the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (150 mg, 
0.68 mmol) was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 1.42 mL, 
1.42 mmol) and reacted with diethyl malonate (0.16 mL, 1.02 mmol). After stirring at rt (2 h) TLC and LC-
MS control showed that large amounts of starting material remained. The reaction mixture was cooled to 
−78 °C before LHMDS (1.0 M solution in toluene, 0.68 mL, 0.68 mmol) was added. Stirring was continued at 
−78 °C (10 min), diethyl malonate (0.1 mL, 0.68 mmol) was added and the reaction mixture was stirred at 
40 °C (2 h). Subsequent aqueous workup and column chromatography (cyclohexane/ethyl acetate 3:1) 
furnished the desired -amino ketone 3n (134 mg, 0.40 mmol, 59%) as a light yellow oil.  
1H NMR (300 MHz, DMSO-d6): δ = 8.09 (d, JH3,H6 = 1.5 Hz, 1H, H3), 8.07 (dd, 
JH6,H5 = 2.7 Hz, JH6,H3 = 1.5 Hz, 1H, H6), 7.87 (d, JH5,H6 = 2.7 Hz, 1H, H5), 7.71 (d, 
JNH,CH = 9.5 Hz, 1H, NH), 5.73 – 5.59 (m, 1H, CH), 4.23 – 3.94 (m, 4H, 2 × CH2), 
1.16 (t, JCH3,CH2 = 7.1 Hz, 3H, CH3), 1.01 (t, JCH3,CH2 = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (75 MHz, DMSO-d6):  δ = 165.19 (C=O), 164.99 (C=O), 153.23 (C2), 141.06 (C6), 133.57 (C5), 
133.31 (C3), 124.90 (q, 1JC,F = 283.5 Hz, CF3), 61.97 (CH2), 61.70 (CH2), 51.66 (CH(CO2Et)2), 49.70 (q, 
2JC,F = 30.5 Hz, CH), 13.63 (CH3), 13.51 (CH3) ppm. 19F NMR (282 MHz, DMSO-d6): δ = − 72.79 (d, 
JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (EI): m/z calcd. for C13H16F3N3O4+ [M]+ 335.1093; found 335.1104. 
HPLC-MS (0.05% formic acid; 0 min, 0% B → 2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.62 min, λ = 220 
nm. Rf (cyclohexane/ethyl acetate 2:1) = 0.31. 
 
Ethyl 4,4,4-trifluoro-3-(pyrazin-2-ylamino)butanoate (3o) 
Following the general procedure, N-(1-ethoxy-2,2,2-trifluoroethyl)pyrazin-2-amine 1b (90 mg, 0.41 mmol) 
was dissolved in 7 mL dry CH2Cl2, treated with LHMDS (1.0 M solution in toluene, 0.94 mL, 0.94 mmol) and 
reacted with ethylacetate (0.06 mL, 0.62 mmol). After stirring at rt (1 h), aqueous workup and flash 
chromatography (cyclohexane → cyclohexane/ethyl acetate 3:1) the -amino ester 3o (27 mg, 0.10 mmol, 
25%) was obtained as a light yellow oil.  
1H NMR (400 MHz, DMSO-d6): δ = 8.12 – 7.91 (m, 2H, H6, H3), 7.82 (d, 
JH5,H6 = 2.3 Hz, 1H, H5), 7.65 (d, JNH,CH = 8.9 Hz, 1H, NH), 5.40 – 5.18 (m, 1H, CH), 
4.03 (m, 2H, OCH2), 2.92 (dd, JCH2,CH2 = 16.2 Hz, JCH2,CH = 4.2 Hz, 1H, CH2), 2.72 
(dd, JCH2,CH2 = 16.2 Hz, JCH2,CH = 10.0 Hz, 1H, CH2), 1.06 (t, JCH3,CH2 = 7.1 Hz, 3H, 
CH3) ppm. 13C NMR (101 MHz, DMSO-d6):  δ = 168.76 (C=O), 153.64 (C2), 141.15 (C6), 133.11 (C5), 
133.06 (C3), 125.57 (q, 1JC,F = 283.2 Hz, CF3), 60.47 (OCH2), 47.83 (q, 2JC,F = 30.7 Hz, CH), 33.58 (CH2), 
13.76 (CH3). 19F NMR (376 MHz, DMSO-d6): δ = − 74.89 (d, JCF3,CH = 7.9 Hz, CF3) ppm. HRMS (EI): m/z 
calcd. for C10H12F3N3O2+ [M]+ 263.0882; found 263.0898. HPLC-MS (0.05% formic acid; 0 min, 0% B → 
2.0 min, 100% B, flow: 3.3 mL/min): tR = 1.43 min, λ = 220 nm. Rf (cyclohexane/ethyl acetate 2:1) = 0.15. 
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5. Experimental Procedures and Analytical Data: Strategy toward 
a Stereoselective Synthesis of Trifluoroethylamines 
 
5.1 General procedures 
Typical procedure for the conversion of hemiaminal ethers with RMgCl, Typical Procedure TPI 
The hemiaminal ether 20 (1 equiv) was solved in freshly distilled THF in a dry and argon flushed Schlenk-
flask, equipped with a magnetic stirrer and a septum and cooled to 15 °C. The Grignard reagent (2 equiv) 
was added dropwise with a syringe and the solution was stirred until TLC-analysis showed complete 
conversion. Subsequently, sat. NH4Cl solution was added and the mixture was extracted three times with Et2O. 
The organic solvent was dried with MgSO4, filtrated and evaporated and the crude product was purified by 
flash chromatography (SiO2). 
Typical procedure for the conversion of hemiaminal ethers with Et2Zn and Cu(OTf)2, Typical procedure 
TPII 
A suspension of Cu(OTf)2 (0.1 equiv) and MeDuPHOS monooxide (0.1 equiv) in dry toluene (5 mL) was 
stirred at r.t. for 1 h. Et2Zn (3 equiv) was added dropwise and the reaction mixture was stirred further for 20 min 
and then cooled to 0 °C. The hemiaminal ether 20 (1 equiv) was then added and the reaction was stirred for 
18 h at 0 °C. Subsequently, sat. NH4Cl solution was added and the mixture was extracted three times with 
Et2O. The organic solvent was dried with MgSO4, filtrated and evaporated and the crude product was purified 
by flash chromatography (SiO2). 
Typical procedure for the preparation of CuCN2LiCl solution, Typical procedure TPIII 
CuCN2LiCl solution (1.00 M) was prepared by drying CuCN (20.0 mmol, 1.80 g) and LiCl (40 mmol, 1.70 g) 
in a Schlenk-flask under vacuum at 140 °C for 5 h. After cooling, 20 mL dry THF were added and stirring was 
continued until the salts were dissolved.  
Typical procedure for the conversion of hemiaminal ethers with organocopper reagents, Typical procedure 
TPIV 
A solution of a Grignard reagent (2.5 equiv) in dry THF (5 mL) was cooled to -30 °C and a solution of 
CuCN2LiCl (1.00 M, 3.1 equiv) was added dropwise. After stirring the reaction mixture for 30 min, the chiral 
ligand (0.1 equiv) added. The mixture was stirred for 1 h, before the hemiaminal ether 20 (1 equiv) was added 
and the reaction was stirred for 18 h at 0 °C. Subsequently, sat. NH4Cl solution was added and the mixture was 
extracted three times with Et2O. The organic solvent was dried with MgSO4, filtrated and evaporated and the 
crude product was purified by flash chromatography (SiO2). 
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5.2 Experimental data 
N-(1,1,1-Trifluorbutan-2-yl)pyridin-2-amine 21  
Reaction conditions without addition of a chiral ligand: 
Following TPII, hemiaminal ether 20 (100 mg, 0.45 mmol) was reacted with Et2Zn (1.0 M, 1.35 mL, 
1.35 mmol) and Cu(OTf)2 (17.0 mg, 0.05 mmol) in toluene (5 mL) at 0 °C for 16 h. Subsequently, sat. NH4Cl 
solution was added and the mixture was extracted three times with Et2O. The organic solvent was dried with 
MgSO4, filtrated and evaporated. The crude product was purified by flash chromatography (SiO2, 
cyclocyclohexaneane/ethyl acetate/NEt3 8:1:0.1) to give the desired amine 21 (74 mg, 80%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, 
JH6,H3 = 0.9 Hz, 1 H, H6), 7.43 (ddd, JH4,H3 = 8.4 Hz, JH4,H5 = 7.2 Hz, JH4,H6 = 1.9 Hz, 1 H, 
H4), 6.64 (ddd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.0 Hz, JH5,H3 = 0.9 Hz, 1 H, H5), 6.46 (dt, 
JH3,H4 = 8.4 Hz, JH3,H5.NH = 0.9 Hz, 1 H, H3), 4.74 – 4.54 (m, 1 H, CH), 4.35 (d, JNH,CH = 9.6 Hz, 1 H, NH), 1.95 
(dtq, JCH2,CH2 = 18.8 Hz, JCH2,CH3 = 7.5 Hz, JCH2,CF3 = 3.9 Hz, 1 H, CH2), 1.58 (ddq, JCH2,CH2 = 14.6 Hz, 
JCH2,CF3 = 10.0 Hz, JCH2,CH3 = 7.4 Hz, 1 H, CH2), 1.03 (td, JCH3,CH2 = 7.6 Hz, JCH3,CH = 0.9 Hz, 3 H, CH3) ppm. 
19F NMR (282 MHz, CDCl3): δ = -76.12 (d, JCF3,CH = 7.4 Hz, CF3) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 157.83 (C2), 148.21 (C6), 137.94 (d, JC,F = 0.8 Hz, C4), 126.41 (q, JC,F = 282.8 Hz, CF3), 114.49 
(C5), 108.20 (C3), 53.87 (q, JC,F = 29.4 Hz, CH), 22.85 (q, JC,F = 1.7 Hz, CH2), 10.24 (CH3) ppm. HRMS 
(EI+): m/z calcd. for C13H11N2F3+ [M+] 204.0869, found 204.0881. HPLC (0.1% TFA, 0 min: 4% B → 15 min: 
100% B, flow: 1 mL/min): tR = 8.68 min,  = 214 nm. 
Reaction conditions under addition of a chiral ligand: 
Following TPII, hemiaminal ether 20 (100 mg, 0.45 mmol) was reacted with Et2Zn (1.0 M, 1.35 mL, 
1.35 mmol), Cu(OTf)2 (17.0 mg, 0.05 mmol) and MeDuPHOS monoxide (16.0 mg, 0.05 mmol) in toluene 
(5 mL) at 0 °C for 16 h. Subsequently, sat. NH4Cl solution was added and the mixture was extracted three 
times with Et2O. The organic solvent was dried with MgSO4, filtrated and evaporated. The crude product was 
purified by flash chromatography (SiO2, cyclocyclohexaneane/ethyl acetate/NEt3 8:1:0.1) to give the desired 
amine 21 (74 mg, 80%) as a colorless oil.  
The product was analyzed via chiral HPLC to determine the ratio of enantiomers.  
 
N-(2,2,2-Trifluoro-1-phenylethyl)pyridin-2-amine 23 
Synthesis of 23 using PhMgCl: 
According to TPI, N-(1-Ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine 20 (100 mg, 0.45 mmol) was reacted 
with PhMgCl (3.0 M in Et2O, 0.45 mL, 1.36 mmol) in dry THF (6 mL). The crude product was purified by 
flash chromatography (SiO2, cyclohexane /ethyl acetate 10:1) to give the desired amine 23 (115 mg, quant.) as 
colorless oil.  
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1H NMR (300 MHz, CDCl3): δ = 8.12 (ddd, JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, 
JH6,H3 = 0.9 Hz, 1 H, H6), 7.52 – 7.34 (m, 6 H, H4, H2', H3', H4', H5', H6'), 6.66 (dd, 
JH5,H4 = 7.2 Hz, JH5,H6 = 5.1 Hz, 1 H, H5), 6.47 (dt, JH3,H4 = 8.3 Hz, JH3,H4 = 0.9 Hz, 1 H, H3), 
5.86 (p, JCH,NH = JCH,CF3 = 8.1 Hz, 1 H, CHCF3), 5.04 (d, JNH,CH = 9.1 Hz, 1 H, NH) ppm. 19F NMR (280 MHz, 
CDCl3): δ = -73.88 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (150 MHz, CDCl3): δ = 156.42 (C2), 148.08 
(C6), 137.77 (C4), 134.49 (q, J(C,F) = 1.0 Hz, C1'), 129.06 (C3', C5'), 128.96 (C4'), 128.07 (C2', C6'), 125.35 
(q, JC,F = 281.9 Hz, CF3), 114.79 (C5), 108.62 (C3), 56.52 (q, JC,F = 30.5 Hz, CHCF3) ppm. HRMS (ESI+): 
m/z calcd. for C13H12F3N2+ [M+H]+ 253.0953, found 253.0945. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 
100% B, flow: 1 mL/min): tR = 6.28 min, λ = 214 nm. 
Synthesis of 23 using organocopper reagents: 
Following TPIV, PhMgCl (3.0 M, 0.38 mL, 1.13 mmol) and CuCN2LiCl (1.0 M, 1.13 mL, 1.13 mmol) were 
reacted in dry THF (6 mL) for 20 min. Then, the hemiaminal ether 20 (100 mg, 0.45 mmol) was added to the 
reaction mixture, which was stirred for further 8 h. Subsequently, sat. NH4Cl solution was added and the 
mixture was extracted three times with Et2O. The organic solvent was dried with MgSO4, filtrated and 
evaporated.  The crude product was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 10:1) 
to give the desired amine 23 (102 mg, 90%) as colorless oil.  
Synthesis of 23 using an external base and organocopper reagents: 
Similar to TPIV, PhMgCl (3.0 M, 0.38 mL, 1.13 mmol) and CuCN2LiCl (1.0 M, 1.13 mL, 1.13 mmol) were 
reacted in dry THF (6 mL) for 20 min. In a second Schlenk-flask, the hemiaminal ether 20 (100 mg, 0.45 mmol) 
was solved in dry THF (3 mL). After the solution was cooled to -78 °C, LiHMDS (1.0 M, 0.45 mL, 0.45 mmol) 
was added dropwise and the reaction mixture was stirred for 15 min. The phenylcopper(I)-solution was added 
to the reaction mixture and the reaction mixture was allowed to warm up to -20 °C and was stirred at this 
temperature for 8 h. Subsequently, sat. NH4Cl solution was added and the mixture was extracted three times 
with Et2O. The organic solvent was dried with MgSO4, filtrated and evaporated.  The crude product was 
purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 10:1) to give the desired amine 23 (100 mg, 
88%) as colorless oil.  
Synthesis of 23 using organocopper reagents and chiral ligands: 
Following TPIII, PhMgCl (3.0 M, 0.38 mL, 1.13 mmol) and CuCN2LiCl (1.0 M, 1.13 mL, 1.13 mmol) were 
reacted in dry THF (6 mL) for 20 min before the chiral ligand (0.05 mmol) was added. After stirring the 
reaction mixture for 1 h, the hemiaminal ether 20 (100 mg, 0.45 mmol) was added to the reaction mixture, 
which was stirred for further 8 h. Subsequently, sat. NH4Cl solution was added and the mixture was extracted 
three times with Et2O. The organic solvent was dried with MgSO4, filtrated and evaporated.  The crude product 
was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 10:1) to give the desired amine 23 as 
colorless oil.  
The product was analyzed via chiral HPLC to determine the ratio of enantiomers.  
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HPLC spectra and added chiral ligands 
(+)-Bis[(R)-1-phenylethyl]amine (ChiPros): 
 
 
(S)-4-tert-Butyl-2-(2-pyridyl)oxazoline: 
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1,2-Bis[(2R,5R)-2,5-dimethylphospholano]benzene monooxide: 
 
(R,R-MeBozPhos)(R)-3,3'-Bis[3,5-bis(trifluoromethyl)phenyl]-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate: 
 
 
 
V. EXPERIMENTAL PROCEDURES   
 
150 
 
6. Experimenal procedures and analytical data: Novel One-Pot 
Synthesis of Highly Substituted Trifluoromethylated Imidazoles 
 
The complete supporting information including the experimental procedures and NMR spectra of all 
compounds is available on the Organic Letters website (DOI: 10.1021/acs.orglett.6b01672) and on the CD in 
the book cover of this thesis. The synthesized compounds are numbered according to the publication. 
6.1 Typical Procedures 
Typical procedure for the synthesis of CF3-imidazole derivatives 2, Typical Procedure TPI 
The hemiaminal ether 1 (1 equiv) was solved in freshly distilled THF in a dry and argon flushed Schlenk-flask, 
equipped with a magnetic stirrer and a septum and cooled to 15 °C. The Grignard reagent (3 equiv) was added 
dropwise with a syringe and the solution was stirred until TLC-analysis showed complete conversion. 
Subsequently, sat. NH4Cl solution was added and the mixture was extracted three times with Et2O. The organic 
solvent was dried with MgSO4, filtrated and evaporated and the crude product was purified by flash 
chromatography (SiO2). 
Typical Procedure for the magnesium insertion, Typical procedure TPII 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirrer and a septum, was charged with 
iPrMgCl·LiCl (1.25 M in THF, 1.1 equiv). The neat aryl bromide (1 equiv) was added at the appropriate 
temperature. The reaction mixture was stirred at the stated temperature, while the completion of the Br/Mg 
exchange was monitored by GC-analysis. 
Typical procedure for the synthesis of CF3-imidazole derivatives 2 with nBuLi, Typical Procedure TPIII 
The hemiaminal ether 1 (1 equiv) and trifluoroethylamine 3 (1 equiv) were solved in freshly distilled THF in 
a dry and argon flushed Schlenk-flask, equipped with a magnetic stirrer and a septum and cooled to 60 °C. 
nBuLi (3 equiv) was added dropwise with a syringe, the solution was stirred at 60 °C for 30 min, warmed up 
to 30 °C and stirred until no further conversion was observed. Subsequently, sat. NH4Cl solution was added 
and the mixture was extracted three times with Et2O. The organic solvent was dried with MgSO4, filtrated and 
evaporated and the crude product was purified by flash chromatography (SiO2).
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6.2 Synthesis of CF3-imidazole derivatives 
1,3-bis(3-Chlorophenyl)-4-fluoro-5-phenyl-2-(trifluoromethyl)-2,3-dihydro-1H-imidazole 2a and 
3-chloro-N-(2,2,2-trifluoro-1-phenylethyl)aniline 3a 
According to the TPI, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (200 mg, 0.79 mmol) was reacted 
with PhMgCl (1.0 M in MeTHF, 2.37 mL, 2.37 mmol) in dry THF (12 mL) for 3 h at 0 °C. The crude product 
was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/DCM 20μ1) to give the desired 
imidazole derivative 2a (125 mg, 70%) as a yellow solid and 3-chloro-N-(2,2,2-trifluoro-1-phenylethyl)aniline 
3a (36 mg, 16%) as a light yellow liquid. 
 
1,3-bis(3-Chlorophenyl)-4-fluoro-5-phenyl-2-(trifluoromethyl)-2,3-dihydro-1H-imidazole 2a 
Rf (cyclohexane/ethyl acetate 10:1) = 0.60. 1H NMR (400 MHz, 
CDCl3): δ = 7.51 – 7.46 (m, 2 H, H2ꞌꞌ, H6ꞌꞌ), 7.38 – 7.33 (m, 2 H, H3ꞌꞌ, H5ꞌꞌ), 
7.31 – 7.24 (m, 2 H, H4ꞌꞌ, H5ꞌ), 7.15 (tdd, JH2ꞌ,H4ꞌ = JH2ꞌ,H6ꞌ = 1.9 Hz, 
JH2ꞌ,H5ꞌ = JH2ꞌ,CH = 0.4 Hz, 1 H, H2ꞌ), 7.12 (ddd, JH4ꞌ,H5ꞌ = 8.0 Hz, 
JH4ꞌ,H2ꞌ = 1.9 Hz, JH4ꞌ,H6ꞌ = 0.9 Hz, 1 H, H4ꞌ), 7.12 (ddd, JH5,H6 = 8.1 Hz, JH5,H4 = 7.7 Hz, JH5,H2 = 0.7 Hz, 1 H, 
H5), 7.05 (dtd, JH6ꞌ,H5ꞌ = 8.1 Hz, JH6ꞌ,H2ꞌ = 2.3 Hz, JH6ꞌ,H4ꞌ = 0.9 Hz, 1 H, H6ꞌ), 7.03 – 6.99 (m, 2 H, H2, H4), 6.88 
(ddd, JH6,H5 = 8.1 Hz, JH6,H2 = 2.2 Hz, JH6,H4 = 1.1 Hz, 1 H, H6), 5.11 – 5.03 (m, 1 H, CH) ppm. 19F NMR 
(282 MHz, CDCl3): δ = 83.32 (d, JCF3,CH = 4.9 Hz, CF3), 135.19 (dt, JCF,CH = 4.5 Hz, J = 2.2 Hz, CF) ppm. 
13C NMR (101 MHz, CDCl3): δ = 149.11 (d, JC,F = 1.5 Hz, C1), 147.25 (d, JC,F =  277.5 Hz, CF), 145.46 (d, 
JC,F = 6.0 Hz, C1ꞌ), 135.81 (C3ꞌ), 135.46 (C3), 131.11 (C5ꞌ), 130.71 (C5), 12λ.16 (d, JC,F = 0.9 Hz, C3ꞌꞌ, C5ꞌꞌ), 
128.67 (d, JC,F = 7.0 Hz, C1ꞌꞌ), 128.12 (d, JC,F = 2.0 Hz, C4ꞌꞌ), 126.51 (d, JC,F = 5.1 Hz, C2ꞌꞌ, C6ꞌꞌ), 125.37 (C4ꞌ), 
124.91 (C4), 122.69 (q, JC,F = 282.9 Hz, CF3), 121.46 (C2), 120.08 (d, JC,F = 2.4 Hz, C2ꞌ), 11λ.30 (C6), 117.87 
(d, JC,F = 1.9 Hz, C6ꞌ), 110.52 (d, JC,F = 21.8 Hz, FCCN), 85.10 (qd, JC,F = 34.7 Hz, JC,F = 5.4 Hz, CH) ppm. 
HRMS (EI): m/z calcd. for C22H14Cl2F4N2· [M·] 452.0470, found 452.0467. HPLC (0.1% TFA, 0 min: 4% B 
→ 15 minμ 100% B, flowμ 1 mL/min): tR = 17.20 min, λ = 214 nm. mp 93 °C. 
 
3-Chloro-N-(2,2,2-trifluoro-1-phenylethyl)aniline 3a 
1H NMR (300 MHz, CDCl3): δ = 7.48 – 7.36 (m, 5 H, 5 × Hphenyl), 7.07 (t, 
JH5,H4 = JH5,H6 = 8.1 Hz, 1 H, H5), 6.75 (ddd, JH4,H5 = 7.9 Hz, JH4,H2 = 1.9 Hz, JH4,H6 = 0.9 Hz, 
1 H, H4), 6.65 (t, JH2,H4 = JH2,H6 = 2.1 Hz, 1 H, H2), 6.51 (ddd, JH6,H5 = 8.2 Hz, 
JH6,H2 = 2.3 Hz, JH6,H4 = 0.8 Hz, 1 H, H6), 4.89 (q, JCH,CF3 = 7.2 Hz, 1 H, CH), 4.40 (s, 1 H, 
NH) ppm. 19F NMR (280 MHz, CDCl3): δ = -74.02 (d, JCF3,CH = 7.2 Hz, CF3) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 146.62 (C1), 135.08 (C3), 133.48 (C1phenyl), 130.32 (C5), 129.31 (C4phenyl), 129.01 (C3phenyl, 
C5phenyl), 127.80 (C2phenyl, C6phenyl), 124.84 (q, JC,F = 282.1 Hz, CF3), 119.24 (C4), 113.81 (C2), 112.05 (C6), 
60.34 (q, JC,F = 30.1 Hz, CCF3) ppm. HRMS (ESI+): m/z calcd. for C14H13ClF3N+ [M+H]+ 286.0605, found 
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286.0608. HPLC-MS (0.1% TFA, 0 minμ 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.52 min, 
λ = 220 nm.  
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-phenyl-2,3-dihydro-1H-imidazole 2b 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (200 mg, 0.91 mmol) was reacted 
with PhMgCl (1.0 M in MeTHF, 2.72 mL, 2.72 mmol) in dry THF (12 mL) for 1.5 h at 15 °C. The crude 
product was purified by flash chromatography (SiO2, DCM → DCM/MeOH 20μ1) to give the desired imidazole 
derivative 2b (163 mg, 93%) as a light yellow solid.  
Rf (ethyl acetate/MeOH 10:1) = 0.19. 1H NMR (400 MHz, DMSO-d6): δ = 8.50 
(d, JH2,H3 = JH6,H5 = 6.5 Hz, 2 H, H2, H6), 8.34 (d, JH2',H3' = JH6',H5' = 6.5 Hz, 2 H, 
H2', H6'), 7.50 – 7.42 (m, 4 H, H2'', H3'', H5'', H6''), 7.37 (tt, 
JH4'',H3'' = JH4'',H5'' = 6.7 Hz, JH4'',H2'' = JH4'',H6'' = 2.1 Hz, 1 H, H4''), 7.25 (d, 
JH3,H2 = JH5,H6 = 4.7 Hz, 2 H, H3, H5), 6.87 (d, JH3',H2' = JH5',H6' = 6.4 Hz, 2 H, H3', H5'), 6.68 (q, 
JCH,CF3 = 4.9 Hz, 1 H, CH) ppm. 19F NMR (380 MHz, DMSO-d6): δ = 82.32 (d, JCF3,CH = 4.9 Hz, CF3), 
133.83 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 152.42 (C4'), 150.79 (C2, C6), 150.22 (C2', C6'), 
148.85 (d, JC,F = 6.2 Hz, C4), 146.59 (d, JC,F = 279.7 Hz, CF), 129.27 (C3'', C5''), 128.48 (C4''), 127.57 (d, 
JC,F = 6.7 Hz, C1''), 125.71 (C2'', C6''), 122.74 (q, JC,F = 284.6 Hz, CF3), 114.06 (C3', C5'), 111.85 (C3, C5), 
110.08 (d, JC,F = 24.0 Hz, FCCN), 79.20 (q, JC,F = 35.1 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for 
C20H15F4N4+ [M+H]+ 387.1233, found 387.1233. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 
1 mL/min): tR = 9.16 min, λ = 214 nm. mp 159 °C. 
 
N,N'-1,3-(3-Trifluoromethylphenyl)-2-(trifluoromethyl)-4-fluoro-5-phenyl-2,3-dihydro-1H-imidazole 
2c 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)-3-(trifluoromethyl)aniline 1c (200 mg, 0.69 mmol) 
was reacted with PhMgBr (3.0 M in THF, 0.69 mL, 2.06 mmol) in dry THF (10 mL) for 4 h at 15 °C. The 
crude product was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 100:1) to give the desired 
imidazole derivative 2c (100 mg, 56%) as a colorless oil. 
Rf (ethyl acetate/MeOH 10:1) = 0.48. 1H NMR (400 MHz, DMSO-d6): 
δ = 8.77 (d, JH3,H2 = JH5,H6 = 6.4 Hz, 2 H, H3, H5), 8.62 (d, 
JH3',H2' = JH5',H6' = 6.5 Hz, 2 H, H3', H5'), 7.65 (m, 2 H, H2, H6), 7.58 – 
7.55 (m, 3 H, H4'', H5'', H6''), 7.38 – 7.33 (m, 2 H, CHCF3, H2''), 7.18 (d, 
JH2',H3' = JH6',H5' = 7.2 Hz, 2 H, H2', H6') ppm. 19F NMR (380 MHz, DMSO-d6): δ = 81.14 (d, 
JCF3,CH = 4.2 Hz, CF3), 130.91 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 156.66 (C1'), 152.09 (d, 
JC,F = 5.9 Hz, C1), 147.28 (d, JC,F = 284.4 Hz, CF), 144.33 (C3, C5), 142.93 (C3', C5'), 134.30 (C3''), 131.60 
(C5''), 129.24 (C4''), 128.20 (d, JC,F = 6.4 Hz, C1''), 125.41 (C6''), 124.42 (C2''), 114.01 (C2', C6'), 112.43 (C2, 
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C6), 109.17 (d, JC,F = 26.0 Hz, FCCN), 77.16 (q, JC,F = 35.1 Hz, CHCF3) ppm. HRMS (ESI-): m/z calcd. for 
C25H14F10N2O2- [M+HCOO-]- 564.0901, found 565.0980. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% 
B, flow: 1 mL/min): tR = 19.25 min, λ = 214 nm. 
 
N,N'-1,3-(Pyridin-3-yl)-2-(trifluoromethyl)-4-fluoro-5-phenyl-2,3-dihydro-1H-imidazole 2d 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-3-amine 1d (200 mg, 0.91 mmol) was reacted 
with PhMgBr (3.0 M in THF, 0.76 mL, 2.28 mmol) in dry THF (10 mL) for 3 h at 15 °C. The crude product 
was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 1μ2→ ethyl acetate/MeOH 100μ1) to 
give the desired imidazole derivative 2d (158 mg, 90%) as a light yellow solid. 
Rf (ethyl acetate/MeOH 10:1) = 0.32. 1H NMR (400 MHz, DMSO-d6): δ = 8.56 (t, 
JH2,H4 = JH2,H6 = 2.2 Hz, 1 H, H2), 8.39 (dd, JH4,H5 = 4.7 Hz, JH4,H6 = 1.4 Hz, 1 H, 
H4), 8.35 (dd, JH2',H6' = 2.8 Hz, JH2',H4' = 0.7 Hz, 1 H, H2'), 8.26 (dd, JH4',H5' = 4.7 Hz, 
JH4',H6' = 1.4 Hz, 1 H, H4'), 7.71 (ddd, JH6,H5 = 8.3 Hz, JH6,H2 = 2.5 Hz, 
JH6,H4 = 1.4 Hz, 1 H, H6), 7.50 – 7.40 (m, 5 H, H6', H5, H2'', H4'', H6''), 7.34 – 7.25 (m, 2 H, H3'', H5''), 7.28 
(m, 3 H, H5', H3'', H5''), 6.40 (q, JCH,CF3 = 5.3 Hz, 1 H, CHCF3) ppm. 19F NMR (380 MHz, DMSO-d6): 
δ = 82.81 (d, JCF3,CH = 5.4 Hz, CF3), 136.81 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 146.66 (d, 
JC,F = 280.2 Hz, CF), 145.88 (C4), 145.32 (C4'), 143.29 (C2'), 142.60 (C1'), 141.60 (C2), 139.60 (d, 
JC,F = 5.9 Hz, C1), 129.04 (C4''), 128.69 (C6'), 128.04 (C3'', C5''), 127.75 (d, JC,F = 6.8 Hz, C1''), 127.30 (C6), 
126.05 (C2'', C6''), 124.25 (C5), 123.80 (C5'), 122.78 (q, JC,F = 283.1 Hz, CF3), 109.68 (d, JC,F = 22.5 Hz, 
FCCN), 81.28 (q, JC,F = 33.9 Hz, JC,F = 5.1 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C20H15F4N4+ 
[M+H]+ 387.1233, found 387.1233. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): 
tR = 10.33 min, λ = 214 nm. mp 160 °C. 
 
N,N'-1,3-(4-(Ethoxycarbonyl)phenyl)-2-(trifluoromethyl)-4-fluoro-5-phenyl-2,3-dihydro-1H-imidazole 
2e 
According to the TPI, ethyl-N-(1-ethoxy-2,2,2-trifluoroethyl)-4-aminobenzoate 1e (200 mg, 0.69 mmol) was 
reacted with PhMgBr (3.0 M in THF, 0.69 mL, 2.06 mmol) in dry THF (10 mL) for 4 h at 15 °C. The crude 
product was purified by flash chromatography (SiO2, cyclohexane/ethyl acetate 100μ1→ 30μ1) to give the 
desired imidazole derivative 2e (115 mg, 63%) as a yellow solid.  
Rf (cyclohexane/ethyl acetate 7:3) = 0.42. 1H NMR (600 MHz, 
DMSO-d6): δ = 7.96 (d, JH3,H4 = JH5,H6 = 8.9 Hz, 2 H, H3, H5), 
7.80 (d, JH3',H4' = JH5',H6' = 8.9 Hz, 2 H, H3', H5'), 7.47 – 7.41 (m, 
4 H, H2'', H3'', H5'', H6''), 7.36 (d, JH2,H3 = JH6,H5 = 8.9 Hz, 2 H, 
H2, H6), 7.35 – 7.31 (m, 1 H, H4'') 7.08 (d, JH2',H3' = JH6',H5' = 8.8 Hz, 2 H, H2', H6'), 6.43 (q, JCH,CF3 = 5.1 Hz, 
1 H, CHCF3), 4.28 (q, JCH2,CH3 = 7.1 Hz, 2 H, CH2), 4.22 (q, JCH2,CH3 = 7.0 Hz, 2 H, CH2), 1.28 (t, 
JCH3,CH2 = 7.1 Hz, 3 H, CH3), 1.23 (t, JCH3,CH2 = 7.1 Hz, 3 H, CH3) ppm. 19F NMR (280 MHz, DMSO-d6): 
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δ = 82.40 (d, JCF3,CH = 5.1 Hz, CF3), 134.39 (s, CF) ppm. 13C NMR (150 MHz, DMSO-d6): δ = 165.01 
(2×COOEt), 150.27 (C1'), 146.89 (d, JC,F = 5.6 Hz, C1), 146.87 (d, JC,F = 277.6 Hz, CF), 130.80 (C3, C5), 
130.31 (C3', C5'), 129.11 (C3'', C5''), 128.15 (C4''), 127.90 (d, JC,F = 6.7 Hz, C1''), 125.78 (C2'', C6''), 125.45 
(C4), 125.20 (C4'), 122.82 (q, JC,F = 283.5 Hz, CF3), 120.27 (C2', C6'), 118.26 (C2, C6), 110.41 (d, 
JC,F = 22.9 Hz, FCCN), 81.32 (q, JC,F = 34.3 Hz, CHCF3), 60.67 (CH2), 60.51 (CH2), 14.16 (CH3), 14.13 
(CH3) ppm. HRMS (EI): m/z calcd. for C28H24F4N2O4· [M·] 528.1672, found 528.1676. HPLC (0.1% TFA, 
0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 20.30 min, λ = 214 nm. mp 67 – 74 °C. 
 
N-(2,2,2-Trifluoro-1-phenylethyl)pyridin-2-amine 3f 
According to TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)pyridine-2-amine 1f (100 mg, 0.45 mmol) was reacted with 
PhMgBr (3.0 M in Et2O, 0.45 mL, 1.36 mmol) in dry THF (6 mL). The crude product was purified by flash 
chromatography (SiO2, cyclohexane /ethyl acetate 10:1) to give the amine 3f (115 mg, quant.) as yellow oil.  
Rf (cyclohexane/ethyl acetate 19:1) = 0.14. 1H NMR (300 MHz, CDCl3): δ = 8.12 (ddd, 
JH6,H5 = 5.1 Hz, JH6,H4 = 1.9 Hz, JH6,H3 = 0.9 Hz, 1 H, H6), 7.52 – 7.34 (m, 6 H, H4, H2', H3', 
H4', H5', H6'), 6.66 (dd, JH5,H4 = 7.2 Hz, JH5,H6 = 5.1 Hz, 1 H, H5), 6.47 (dt, JH3,H4 = 8.3 Hz, 
JH3,H4 = 0.9 Hz, 1 H, H3), 5.86 (p, JCH,NH = JCH,CF3 = 8.1 Hz, 1 H, CHCF3), 5.04 (d, JNH,CH = 9.1 Hz, 1 H, 
NH) ppm. 19F NMR (280 MHz, CDCl3): δ = -73.88 (d, JCF3,CH = 7.9 Hz, CF3) ppm. 13C NMR (150 MHz, 
CDCl3): δ = 156.42 (C2), 148.08 (C6), 137.77 (C4), 134.49 (q, J(C,F) = 1.0 Hz, C1'), 129.06 (C3', C5'), 128.96 
(C4'), 128.07 (C2', C6'), 125.35 (q, J(C,F) = 281.9 Hz, CF3), 114.79 (C5), 108.62 (C3), 56.52 (q, 
J(C,F) = 30.5 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C13H12F3N2+ [M+H]+ 253.0953, found 
253.0945. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B. Flowμ 1 mL/min): tR = 6.28 min, λ = 214 nm. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(3-chlorophenyl)-2,3-dihydro-1H-imidazole 2g 
The magnesium reagent was prepared from 3-bromo-1-chlorobenzene (0.16 mL, 1.36 mmol) and 
iPrMgCl·LiCl (1.2 M in THF, 1.14 mL, 1.40 mmol) according to TPII within 3.5 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (100 mg, 0.45 mmol) was reacted 
with the Grignard reagent in dry THF (5 mL) for 3 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 50μ1 → 25μ1) to give the desired imidazole derivative 2g (102 mg, 
quant.) as a yellow solid. 
Rf (ethyl acetate/MeOH 10:1) = 0.19. 1H NMR (400 MHz, DMSO-d6): δ = 8.77 
(d, JH2,H3 = JH6,H5 = 6.4 Hz, 2 H, H2, H6), 8.62 (d, JH2',H3' = JH6',H5' = 6.5 Hz, 2 H, 
H2', H6'), 7.65 (d, JH3,H2 = JH5,H6 = 5.8 Hz, 2 H, H3, H5), 7.58 – 7.55 (m, 3 H, H4'', 
H5'', H6''), 7.38 – 7.33 (m, 2 H, CHCF3, H2''), 7.18 (d, JH3',H2' = JH5',H6' = 7.2 Hz, 
2 H, H3', H5') ppm. 19F NMR (380 MHz, DMSO-d6): δ = 81.14 (d, 
JCF3,CH = 4.2 Hz, CF3), 130.91 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): 
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δ = 156.66 (C4'), 152.09 (d, JC,F = 5.9 Hz, C4), 147.28 (d, JC,F = 284.4 Hz, CF), 144.33 (C2, C6), 142.93 (C2', 
C6'), 134.30 (C3''), 131.60 (C5''), 129.24 (C4''), 128.20 (d, JC,F = 6.4 Hz, C1''), 125.41 (C6''), 124.42 (C2''), 
114.01 (C3', C5'), 112.43 (C3, C5), 109.17 (d, JC,F = 26.0 Hz, FCCN), 77.16 (q, JC,F = 35.1 Hz, CHCF3) ppm. 
HRMS (ESI+): m/z calcd. for C20H14ClF4N4+ [M+H]+ 421.0843, found 421.0836. HPLC (0.1% TFA, 0 min: 
4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 9.49 min, λ = 214 nm. mp 179 °C.  
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(4-cyanophenyl)-2,3-dihydro-1H-imidazole 2h 
The magnesium reagent was prepared from 4-bromobenzonitrile (373 mg, 2.05 mmol) and iPrMgCl·LiCl 
(1.20 M in THF, 1.90 mL, 2.25 mmol) according to TPII within 1.5 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (135 mg, 0.61 mmol) was reacted 
with the Grignard reagent in dry THF (7 mL) for 2 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 100μ1 → 10μ1) to give the desired imidazole derivative 2h (95 mg, 
76%) as a yellow oil. 
Rf (ethyl acetate/MeOH 10:1) = 0.17 1H NMR (400 MHz, DMSO-d6): δ = 8.77 (d, 
JH2,H3 = JH6,H5 = 6.5 Hz, 2 H, H2, H6), 8.63 (d, JH2',H3' = JH6',H5' = 6.0 Hz, 2 H, H2', 
H6'), 8.00 (d, JH3'',H2'' = JH5'',H6'' = 8.4 Hz, 1 H, H3'', H5''), 7.75 – 7.63 (m, 2 H, H3, 
H5), 7.61 (d, JH6'',H5'' = JH2'',H3'' = 8.4 Hz, 2 H, H2'', H6''), 7.46 – 7.31 (m, 1 H, 
CHCF3), 7.21 – 7.12 (m, 2 H, H3', H5') ppm. 19F NMR (380 MHz, DMSO-d6): 
δ = 81.13 (m, CF3), 128.03 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 156.53 (C4'), 151.56 (C4), 
148.43 (d, JC,F = 287.0 Hz, CF), 144.72 (C2, C6), 143.20 (C2', C6'), 133.47 (C3'', C5''), 130.73 (C1''), 126.39 
(C4'', C6''), 122.46 (q, JC,F = 286.4 Hz, CF3), 118.37 (CN), 112.56 (C3', C5'), 111.18 (C3, C5), 108.79 (d, 
JC,F = 25.4 Hz, FCCN), 77.19 (qd, JC,F = 36.1 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C21H14F4N5+ 
[M+H]+ 412.1185, found 412.1181. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): 
tR = 9.02 min, λ = 214 nm. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(2-cyanophenyl)-2,3-dihydro-1H- imidazole 2i 
The magnesium reagent was prepared from 2-bromobenzonitrile (491 mg, 2.70 mmol) and iPrMgCl·LiCl 
(1.20 M in THF, 2.50 mL, 3.00 mmol) according to TPII within 3 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (200 mg, 0.91 mmol) was reacted 
with the Grignard reagent in dry THF (7 mL) for 3 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 100μ1 → 10μ1) to give the desired imidazole derivative 2i (151 mg, 
81%) as a yellow solid. 
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Rf (ethyl acetate/MeOH 10:1) = 0.18. 1H NMR (600 MHz, DMSO-d6): δ = 8.56 
(d, JH2,H3 = JH6,H5 = 6.6 Hz, 2 H, H2, H6), 8.38 (d, JH2',H3' = JH6',H5' = 6.5 Hz, 2 H, 
H2', H6'), 7.84 (d, JH3'',H4'' = 7.8 Hz, 1 H, H3''), 7.62 (td, JH5'',H4'' = JH5'',H6'' = 7.7 Hz, 
JH5'',H3'' = 1.4 Hz, 1 H, H5''), 7.55 (d, JH6'',H5'' = 7.8 Hz, 1 H, H6''), 7.50 (t, 
JH4'',H3'' = 7.6, JH4'',H5'' = 7.6 Hz, 1 H, H4''), 7.11 – 7.06 (m, 2 H, H3, H5), 6.74 (d, 
JH3',H2' = JH5',H6' = 6.5 Hz, 2 H, H3', H5'), 5.45 (q, JCH,CF3 = 4.6 Hz, 1 H, CHCF3) ppm. 19F NMR (380 MHz, 
DMSO-d6): δ = 82.57 (d, JCF3,CH = 4.6 Hz, CF3), 125.75 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): 
δ = 152.95 (C4'), 151.41 (C2, C6), 151.06 (C2', C6'), 149.52 (d, JC,F = 5.9 Hz, C4), 147.72 (d, JC,F = 282.6 Hz, 
CF), 134.30 (C3''), 133.57 (C5''), 131.27 (d, JC,F = 6.2 Hz, C1''), 129.61 (C4''), 128.40 (C6''), 122.27 (q, 
JC,F = 283.9 Hz, CF3), 117.39 (CN), 113.57 (C3', C5'), 112.33 (C3, C5), 111.31 (C2''), 107.63 (d, 
JC,F = 25.2 Hz, FCCN), 82.34 (qd, JC,F = 36.3 Hz, JC,F = 3.8 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for 
C21H14F4N5+ [M+H]+ 412.1185, found 412.1177. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 
1 mL/min): tR = 8.82 min, λ = 214 nm. mp 94 °C. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(thiophen-2-yl)-2,3-dihydro-1H-imidazole 2j 
The magnesium reagent was prepared from 2-bromothiophene (259 mg, 1.59 mmol) and iPrMgCl·LiCl 
(1.25 M in THF, 1.40 mL, 1.70 mmol) according to TPII within 3.5 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (100 mg, 0.45 mmol) was reacted 
with the Grignard reagent in dry THF (5 mL) for 3 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 25:1) to give the desired imidazole derivative 2j (95 mg, quant.) 
as a yellow oil. 
Rf (ethyl acetate/MeOH 10:1) = 0.17. 1H NMR (400 MHz, DMSO-d6): δ = 8.51 – 
8.47 (m, 2 H, H2, H6), 8.41 – 8.36 (m, 2 H, H2', H6'), 7.67 (dd, JH3'',H4'' = 5.1 Hz, 
JH3'',H5'' = 1.2 Hz, 1 H, H3''), 7.24 – 7.20 (m, 2 H, H3, H5), 7.19 (dd, 
JH5'',H4'' = 3.7 Hz, JH5'',H3'' = 1.2 Hz, 1 H, H3''), 7.15 (dd, JH4'',H3'' = 5.0 Hz, 
JH4'',H5'' = 3.7 Hz, 1 H, H4''), 6.99 – 6.93 (m, 2 H, H3', H5'), 6.65 (q, 
JCH,CF3 = 4.9 Hz, 1 H, CHCF3) ppm. 19F NMR (280 MHz, DMSO-d6): δ = 82.32 (d, JCF3,CH = 4.8 Hz, CF3), 
132.78 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 152.47 (C4'), 150.82 (C2, C6), 150.31 (C2', C6'), 
148.79 (d, JC,F = 6.4 Hz, C4), 145.38 (d, JC,F = 279.5 Hz, CF), 129.18 (d, JC,F = 8.5 Hz, C1''), 128.20 (C4''), 
127.49 (C3''), 126.04 (C5''), 122.60 (q, JC,F = 284.2 Hz, CF3), 114.39 (C3', C5'), 111.83 (C3, C5), 106.21 (d, 
JC,F = 26.4 Hz, FCCN), 79.53 (q, JC,F = 34.4 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C18H13F4N4S+ 
[M+H]+ 393.0797, found 393.0786. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): 
tR = 9.02 min, λ = 214 nm. 
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N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(pyridin-2-yl)-2,3-dihydro-1H-imidazole 2k 
The magnesium reagent was prepared from 2-bromopyridine (130 L, 1.36 mmol) and iPrMgCl·LiCl (1.25 M 
in THF, 1.14 mL, 1.40 mmol) according to TPII within 3 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (100 mg, 0.45 mmol) was reacted 
with the Grignard reagent in dry THF (5 mL) for 2 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 50μ1 → 10μ1) to give the desired imidazole derivative 2k (37 mg, 
42%) as a yellow oil and N-(2,2,2-trifluoro-1-(pyridin-2-yl)ethyl)pyridin-4-amine 3k (44 mg, 39%) as a yellow 
oil. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(pyridin-2-yl)-2,3-dihydro-1H-imidazole 2k 
Rf (ethyl acetate/MeOH 10:1) = 0.18. 1H NMR (400 MHz, DMSO-d6): δ = 8.62 
(dd, JH3'',H4'' = 4.7 Hz, J = 2.7 Hz, 1 H, H3''), 8.52 - 8.48 (m, 2 H, H2, H6), 8.36 – 
8.33 (m, 2 H, H2', H6'), 7.86 (td, JH5'',H4'' = JH5'',H6'' = 7.8 Hz, J = 1.9 Hz, 1 H, H5''), 
7.40 (d, JH6'',H5'' = 7.9 Hz, 1 H, H6''), 7.33 (ddd, JH4'',H5'' = 7.6 Hz, JH4'',H3'' = 4.8 Hz, 
J = 1.1 Hz, 1 H, H4''), 7.28 – 7.22 (m, 2 H, H3, H5), 6.86 – 6-82 (m, 2 H, H3', H5'), 
6.72 (q, JCH,CF3 = 4.6 Hz, 1 H, CHCF3) ppm. 19F NMR (380 MHz, DMSO-d6): δ = 82.05 (d, JCF3,CH = 4.8 Hz, 
CF3), 128.03 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 152.65 (C4'), 150.85 (C2, C6), 150.10 (C2', 
C6'), 149.95 (C3''), 148.10 (d, JC,F = 6.0 Hz, C4), 147.27 (d, JC,F = 7.8 Hz, C2''), 146.03 (d, JC,F = 272.5 Hz, 
CF), 137.26 (C5''), 122.74 (C4''), 122.73 (q, JC,F = 285.2 Hz, CF3), 121.25 (C6''), 113.98 (C3', C5'), 111.89 (C3, 
C5), 109.56 (d, JC,F = 20.3 Hz, FCCN), 78.97 (q, JC,F = 35.1 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for 
C19H14F4N5+ [M+H]+ 388.1185, found 388.1175. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 
1 mL/min): tR = 7.77 min, λ = 214 nm. 
 
N-(2,2,2-Trifluor-1-(pyridin-2-yl)ethyl)pyridin-4-amine 3k 
Rf (ethyl acetate/MeOH 10:1) = 0.10. 1H NMR (600 MHz, DMSO-d6): δ = 8.65 
(ddd, JH3',H4' =4.8 Hz, JH3',H5' = 1.8 Hz, JH3',H6' = 0.9 Hz, 1 H, H3'), 8.09 (d, 
JH2,H3 = JH6,H5 = 6.6 Hz, 2 H, H2/H6), 7.90 (td, JH5',H4' = JH5',H6' = 7.7 Hz, 
JH5',H3' = 1.8 Hz, 1 H, H5'), 7.67 (d, JH6',H5' = 7.9 Hz, 1 H, H6'), 7.47 – 7.43 (m, 2 H, 
H4', NH), 6.88 (d, JH3,H2 = JH5,H6 = 6.5 Hz, 2 H, H3, H5), 5.83 (dq, JCH,NH = 9.6 Hz, JCH,CF3 = 7.6 Hz, 1 H, 
CHCF3) ppm. 19F NMR (380 MHz, DMSO-d6): δ = 71.76 (d, JCF3,CH = 7.6 Hz, CF3) ppm. 13C NMR 
(100 MHz, DMSO-d6): δ = 152.47 – 152.46 (m, C1'), 152.33 (C4), 149.51 (C2, C6), 149.37 (C3'), 137.38 
(C5'), 125.12 (q, JC,F = 283.9 Hz, CF3), 124.28 (C4'), 123.79 (C6'), 108.33 (C3, C5), 57.18 (q, JC,F = 29.4 Hz, 
CHCF3) ppm. HRMS (ESI+): m/z calcd. for C12H11F3N3+ [M+H]+ 254.0905, found 254.0897. HPLC (0.1% 
TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 8.78 min, λ = 214 nm. 
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N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(pyridin-3-yl)-2,3-dihydro-1H-imidazole 2l 
The magnesium reagent was prepared from 3-bromopyridine (0.26 mL, 2.70 mmol) and iPrMgCl·LiCl (1.20 M 
in THF, 2.50 mL, 3.00 mmol) according to TPII within 2 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (200 mg, 0.91 mmol) was reacted 
with the Grignard reagent in dry THF (7 mL) for 2 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 100μ1 → 10μ1) to give the desired imidazole derivative 2l (171 mg, 
97%) as a yellow solid. 
Rf (ethyl acetate/MeOH 10:1) = 0.10. 1H NMR (400 MHz, DMSO-d6): δ = 8.70 – 
8.66 (m, 1 H, H2''), 8.55 (dd, JH6'',H5'' = 4.8 Hz, JH6'',H4'' = 1.6 Hz, 1 H, H6''), 8.54 – 
8.50 (m, 2 H, H2, H6), 8.40 – 8.33 (m, 2 H, H2', H6'), 7.76 (ddd, JH4'',H5'' = 8.0 Hz, 
JH4'',H2'' = 2.5 Hz, JH4'',H6'' = 1.7 Hz, 1 H, H4''), 7.47 (ddd, JH5'',H4'' = 8.0 Hz, 
JH5'',H6'' = 4.8 Hz, JH5'',H2'' = 0.9 Hz , 1 H, H5''), 7.30 – 7.24 (m, 2 H, H3, H5), 6.92 – 
6.88 (m, 2 H, H3', H5'), 6.73 (q, JCH,CF3 = 4.9 Hz, 1 H, CHCF3) ppm. 19F NMR (380 MHz, DMSO-d6): 
δ = 82.40 (d, JCF3,CH = 4.9 Hz, CF3), 131.84 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 152.43 
(C4'), 150.41 (C2, C6), 149.71 (C2', C6'), 149.34 (C6''), 148.59 (d, JC,F = 6.1 Hz, C4), 147.62 (d, 
JC,F = 281.2 Hz, CF), 146.47 (d, JC,F = 5.4 Hz, C2''), 132.91 (C4''), 124.22 (C5''), 123.91 – 123.84 (m, C3''), 
122.64 (q, JC,F = 284.4 Hz, CF3), 114.24 (C3', C5'), 112.06 (C3, C5), 107.18 (d, JC,F = 25.0 Hz, FCCN), 79.11 
(q, JC,F = 35.3 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C19H14F4N5+ [M+H]+ 388.1185, found 
388.1180. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 7.31 min, λ = 214 nm. 
mp 95 – 98 °C. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(2,4-dimethoxypyrimidin-5-yl)-2,3-di-
hydro-1H-imidazole 2m 
The magnesium reagent was prepared from 5-bromo-2,4-dimethoxypyrimidine (449 mg, 2.05 mmol) and 
iPrMgCl·LiCl (1.20 M in THF, 1.90 mL, 2.25 mmol) according to TPII within 1 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (150 mg, 0.68 mmol) was reacted 
with the Grignard reagent in dry THF (7 mL) for 2 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 100μ1 → 10μ1) to give the desired imidazole derivative 2m 
(120 mg, 79%) as a yellow solid. 
Rf (ethyl acetate/MeOH 10:1) = 0.17. 1H NMR (400 MHz, DMSO-d6): δ = 8.50 
(d, JH2,H3 = JH6,H5 = 4.4 Hz, 2 H, H2, H6), 8.32 (d, JH2',H3' = JH6',H5' = 4.5 Hz, 2 H, 
H2', H6'), 8.31 (s, 1 H, H6''), 7.18 (d, JH3,H2 = JH5,H6 = 4.5 Hz, 2 H, H3, H5), 6.83 
(d, JH3',H2' = JH5',H6' = 4.3 Hz, 2 H, H3', H5'), 6.68 (q, JCH,CF3 = 4.8 Hz, 1 H, 
CHCF3), 4.02 (s, 3 H, OCH3), 3.93 (s, 3 H, OCH3) ppm. 19F NMR (280 MHz, 
DMSO-d6: δ = 82.11 (d, JCF3,CH = 4.9 Hz, CF3), 130.90 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): 
δ = 167.51 (COCH3), 165.40 (COCH3), 157.97 (C6''), 152.30 (C4'), 151.26 (C2, C6), 150.82 (C2', C6'), 149.39 
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(d, JC,F = 6.0 Hz, C4), 146.48 (d, JC,F = 277.2 Hz, CF), 123.11 (d, JC,F = 277.2 Hz, CF3), 113.72 (C3', C5'), 
112.18 (C3, C5), 103.69 (d, JC,F = 27.3 Hz, FCCN), 103.64 (d, JC,F = 6.0 Hz, C1''), 79.13 (q, JC,F = 30.4 Hz, 
CHCF3), 55.37 (OCH3), 55.11 (OCH3) ppm. HRMS (ESI+): m/z calcd. for C20H17F4N6O2+ [M+H]+ 449.1349, 
found 449.1338. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 8.28 min, 
λ = 214 nm. mp 154 °C. 
 
N,N'-1,3-(Pyridin-4-yl)-2-(trifluoromethyl)-4-fluoro-5-(6-chloropyridin-3-yl)-2,3-dihydro-1H-imidazole 
2n 
The magnesium reagent was prepared from 3-bromo-2-chloropyridine (520 mg, 2.70 mmol) and iPrMgCl·LiCl 
(1.20 M in THF, 2.50 mL, 3.00 mmol) according to TPII within 1 h at 0 °C. 
According to the TPI, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (200 mg, 0.91 mmol) was reacted 
with the Grignard reagent in dry THF (7 mL) for 4 h at 15 °C. The crude product was purified by flash 
chromatography (SiO2, ethyl acetate/MeOH 100μ1 → 10μ1) to give the desired imidazole derivative 2n 
(130 mg, 69%) as a yellow solid. 
Rf (ethyl acetate/MeOH 10:1) = 0.25. 1H NMR (400 MHz, DMSO-d6): δ = 8.53 
– 8.50 (m, 2 H, H2, H6), 8.50 – 8.49 (m, 1 H, H2''), 8.42 – 8.36 (m, 2 H, H2', H6'), 
7.79 (dd, JH4'',H5'' = 8.4 Hz, JH4'',H2'' = 2.5 Hz, 1 H, H4''), 7.62 (dd, JH5'',H4'' = 8.4 Hz, 
JH5'',H3'' = 0.7 Hz, 1 H, H5''), 7.32 – 7.22 (m, 2 H, H3, H5), 6.95 – 6.88 (m, 2 H, 
H3', H5'), 6.74 (q, JCH,CF3 = 4.9 Hz, 1 H, CHCF3) ppm. 19F NMR (380 MHz, 
DMSO-d6): δ = 82.39 (d, JCF3,CH = 4.9 Hz, CF3), 130.50 (s, CF) ppm. 13C NMR (100 MHz, DMSO-d6): 
δ = 151.87 (C4'), 150.83 (C2, C6), 150.45 (C2', C6'), 149.34 (C6''), 148.24 (d, JC,F = 6.1 Hz, C4), 146.58 (d, 
JC,F = 5.8 Hz, C3'', C2''), 136.19 (C4''), 122.52 (d, JC,F = 7.2 Hz, C5''), 122.62 (q, JC,F = 284.5 Hz, CF3), 114.33 
(C3', C5'), 112.11 (C3, C5), 106.12 (d, JC,F = 24.6 Hz, FCCN), 79.27 (q, JC,F = 34.8 Hz, CHCF3) ppm. HRMS 
(ESI+): m/z calcd. for C19H13ClF4N5+ [M+H]+ 422.0790, found 422.0790. HPLC (0.1% TFA, 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 7.76 min, λ = 214 nm. mp 63 – 73 °C 
 
N,N'-1,3-(3-Chlorophenyl)-2-(trifluoromethyl)-4-fluoro-5-vinyl-2,3-dihydro-1H-imidazole 2o 
According to the TPI, 3-chloro-N-(1-ethoxy-2,2,2-trifluoroethyl)aniline 1a (230 mg, 0.90 mmol) was reacted 
with vinyl magnesium chloride (1 M in THF, 1.81 mL, 1.81 mmol) in dry THF (12 mL) for 1 h at 15 °C. The 
crude product was purified by flash chromatography (SiO2, cyclohexane → cyclohexane/DCM 20:1) to give 
the desired imidazole derivative 2o (30 mg, 17%) as a blue liquid and 3-chloro-N-(1,1,1-trifluorobut-3-en-2-
yl)aniline 3o (131 mg, 62%) as a colorless liquid. 
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N,N'-1,3-(3-Chlorophenyl)-2-(trifluoromethyl)-4-fluoro-5-vinyl-2,3-dihydro-1H-imidazole 2o 
1H NMR (400 MHz, DMSO-d6): δ =7.40 (t, JH5,H4 = JH5,H6 = 8.1 Hz, 1 H, 
H5), 7.34 (t, JH5,H4 = JH5,H6 = 8.1 Hz, 1 H, H5), 7.21 (ddd, JH6,H5 = 8.0 Hz, 
JH6,H5 = 2.0 Hz, J = 0.9 Hz, 1 H, H6), 7.18 – 7.10 (m, 3 H, H4, 2  H2), 7.08 
(t, JH2,H4 = JH2,H6 = 2.1 Hz, 1 H, H4), 7.04 (ddd, JH6,H5 = 8.1 Hz, 
JH6,H5 = 2.3 Hz, J = 0.9 Hz, 1 H, H6), 6.63 – 6.46 (m, 1 H, CH2=CH), 6.22 (q, JCH,CF3 = 5.2 Hz, 1 H, CH), 5.20 
(dt, JCH=CHcis,CH=CH2 = 11.2 Hz, J = 1.6 Hz, 1 H, HCHcis=CH), 4.89 (dt, JCH=CHtrans,CH=CH2 = 17.4 Hz, J = 1.4 Hz, 
1 H, HCHtrans=CH) ppm.19F NMR (380 MHz, DMSO-d6): δ = -82.55 (d, JCF3,CH = 5.9 Hz, CF3), -136.94 (s, 
CF) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 147.64, 143.85, 133.98, 133.40, 131.22, 130.61, 124.86, 
124.52, 124.20, 121.50, 121.43, 121.00, 119.64, 119.22, 117.66, 117.63, 115.52, 115.47, 112.15, 109.86 (d, 
JC,F = 24.5 Hz) ppm. HRMS (ESI+): m/z calcd. for C18H13Cl2F4N2+ [M+H]+ 403.0386, found 403.0389. 
HPLC-MS (0.05% formic acid, 0 minμ 4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 3.19 min, λ = 220 
nm.  
 
3-Chloro-N-(2,2,2-trifluoro-1-vinylethyl)aniline 3o 
1H NMR (400 MHz, DMSO-d6): δ = 7.11 (t, JH5,H4 = JH5,H6 = 8.1 Hz, 1 H, H5), 6.87 (t, 
JH2,H4 = JH2,H6 = 2.1 Hz, 1 H, H2), 6.77 (dd, JH6,H5 = 8.0 Hz, JH6,H2 = 2.0 Hz, 1 H, H6), 6.64 
(ddd, JH4,H5 = 7.8 Hz, JH4,H2 = 2.0 Hz, JH4,H6 = 0.8 Hz, 1 H, H4), 6.48 (d, JNH,CH = 9.7 Hz, 
1 H, NH), 5.86 (ddd, JCH=CH2,CH=CHtrans = 16.8 Hz, JCH=CH2,CH=CHcis = 10.4 Hz, 
JCH=CH2,CH = 6.2 Hz, 1 H, CH2=CH), 5.56 (d, JCH=CHtrans,CH=CH2 = 17.1 Hz, 1 H, HCHtrans=CH), 5.43 (d, 
JCH=CHcis,CH=CH2 = 10.4 Hz, 1 H, HCHcis=CH), 5.10 – 4.97 (m, 1 H, CH) ppm. 19F NMR (377 MHz, DMSO-d6): 
δ = 73.77 (d, JCF3,CH = 7.7 Hz, CF3) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 148.36 (C1), 133.62(C3), 
130.36 (C5), 129.80 (CH2=CH), 125.52 (q, JC,F = 283.4 Hz, CF3), 120.83 (CH2=CH), 116.70 (C4), 112.31 
(C2), 111.71 (C6), 55.83 (q, JC,F = 29.4 Hz, CCF3) ppm. HRMS (ESI+): m/z calcd. for C10H10ClF3N+ [M+H]+ 
236.0448, found 236.0452. HPLC-MS (0.05% formic acid, 0 minμ 4% B → 2.8 min: 100% B, flow: 
2.4 mL/min): tR = 2.53 min, λ = 220 nm.  
 
Ethyl 4-(5-fluoro-4-phenyl-3-(pyridin-4-yl)-2-(trifluoromethyl)-2,3-dihydro-1H-imidazol-1-yl)benzoate 
2p 
According to the TPIII, ethyl 4-((1-ethoxy-2,2,2-trifluoroethyl)amino)benzoate 1e (60 mg, 0.20 mmol) and N-
(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (52 mg, 0.20 mmol) were reacted with nBuLi (1.6 M in 
hexane, 0.38 mL, 0.60 mmol) in dry THF (6 mL) for 4 h at 30 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate 2:1 → ethyl acetate) to give desired imidazole derivative 2p 
(57 mg, 62%) as a yellow oil, ethyl 4-((1-ethoxy-2,2,2-trifluoroethyl)amino)benzoate 1e (25 mg, 37%) and N-
(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (17 mg, 34%). 
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Rf (cyclohexane/ethyl acetate 3:1) = 0.50. 1H NMR (400 MHz, 
CDCl3): δ =8.33 (d, JH2',H3' = JH6',H5' = 5.5 Hz, 2 H, H2ꞌ, H6ꞌ), 8.06 – 
8.00 (m, 2 H, H3, H5), 7.48 (d, JH2'',H3'' = JH6'',H5'' = 7.3 Hz, 2 H, H2ꞌꞌ, 
H6ꞌꞌ), 7.40 (t, JH3'',H4'' = JH5'',H4'' = JH3'',H2'' = JH5'',H6'' = 7.6 Hz, 2 H, H3ꞌꞌ, 
H5ꞌꞌ), 7.33 (d, J = 7.3 Hz, 1 H, H4ꞌꞌ), 7.17 (dd, JH2,H3 = JH6,H5 = 8.8 Hz, J = 2.4 Hz, 2 H, H2, H6), 6.77 (d, 
JH3',H2' = JH5',H6' = 6.0 Hz, 2 H, H3ꞌ, H5ꞌ), 5.34 (dq, JCH,CF3 = 4.8 Hz, 1 H, CH), 4.35 (q, JCH2,CH3 = 7.1 Hz, 2 H, 
CH2), 1.36 (t, JCH3,CH2 = 7.1 Hz, 3 H, CH3) ppm. 19F NMR (380 MHz, CDCl3): δ = 82.76 (d, JCF3,CH = 4.9 Hz, 
CF3), 131.73 (s, CF) ppm. 13C NMR (100 MHz, CDCl3): δ = 165.79 (COOEt), 154.01 (C4ꞌ), 150.69 (C2', 
C6'), 147.42 (d, JC,F = 277.8 Hz, CF), 147.19 (d, JC,F = 6.0 Hz, C1), 131.57 (C3, C5), 129.18 (C3'', C5''), 128.35 
(C4ꞌꞌ), 128.09 (d, JC,F = 6.8 Hz, C1ꞌꞌ), 126.93, 126.13 (d, JC,F = 4.8 Hz, C2'', C6''), 122.45 (q, JC,F = 283.6 Hz, 
CF3), 118.24 (C2, C6), 113.84 (C3', C5'), 109.91 (d, JC,F = 23.9 Hz, FCCN), 83.65 (qd, JC,F = 35.7 Hz, 
JC,F = 4.6 Hz, CHCF3), 61.18 (CH2), 14.44 (CH3) ppm. HRMS (EI): m/z calcd. for C24H20F4N3O2+ [M+H]+ 
458.1486, found 458.14895. 
 
4-(4-Fluoro-5-phenyl-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazol-1-
yl)pyridine 2q 
According to the TPIII, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-(trifluoromethyl)aniline 1q (57 mg, 0.20 mmol) 
and N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (50 mg, 0.20 mmol) were reacted with nBuLi (2.5 M 
in hexane, 0.18 mL, 0.44 mmol) in dry THF (6 mL) for 4 h at 30 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate 5:1 → ethyl acetate) to give desired imidazole derivative 2q 
(59 mg, 65%) as a yellow oil, N-(1-ethoxy-2,2,2-trifluoroethyl)-4-(trifluoromethyl)aniline 1q (14 mg, 25%) 
and N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (17 mg, 34%). 
Rf (cyclohexane/ethyl acetate 5:1) = 0.27. 1H NMR (400 MHz, CDCl3): δ = 
8.34 (dd, JH2,H3 = JH6,H5 = 4.9 Hz, J = 1.4 Hz, 2 H, H2, H6), 7.62 (d, 
JH3',H2' = JH5',H6' = 8.5 Hz, 2 H, H3ꞌ, H5ꞌ), 7.50 – 7.46 (m, 2 H, H2ꞌꞌ, H6ꞌꞌ), 7.41 
(t, JH3'',H4'',H5'' = JH5'',H4'',H3'' = 7.4 Hz, 2 H, H3ꞌꞌ, H5ꞌꞌ), 7.36 – 7.30 (m, 1 H, 
H4ꞌꞌ), 7.24 (dd, JH2',H3' = JH6',H5' = 8.6 Hz, J = 2.0 Hz, 2 H, H2ꞌ, H6ꞌ), 6.78 (dd, JH3,H2 = JH5,H6 = 4.7 Hz, 
J = 1.6 Hz, 2 H, H3, H5), 5.29 (dq, JCH,CF3 = 4.8 Hz, 1 H, CH) ppm. 19F NMR (380 MHz, CDCl3): δ = 62.36 
(CF3), -82.91 (d, JCF3,CH = 4.8 Hz, CF3), 134.36 (s, CF) ppm. 13C NMR (100 MHz, CDCl3): δ = 153.99 (d, 
JC,F = 1.4 Hz, C4), 150.80 (C2, C6), 147.28 (d, JC,F = 277.7 Hz, CF), 146.39 (d, JC,F = 6.2 Hz, C1ꞌ), 129.22 (d, 
JC,F = 0.8 Hz, C3'', C5''), 128.44 (d, JC,F = 1.8 Hz, C4''), 128.04 (d, JC,F = 6.8 Hz, C1''), 127.29 (q, JC,F = 3.8 Hz, 
C4'), 127.04 (C3', C5'), 126.17 (d, JC,F = 4.8 Hz, C2'', C6''), 123.94 (d, JC,F = 271.8 Hz, CF3), 122.43 (q, 
JC,F = 283.2 Hz, CF3), 119.20 – 118.90 (m, C2', C6'), 113.86 (C3, C5), 110.02 (d, JC,F = 23.7 Hz, FCCN), 83.80 
(qd, JC,F = 35.8 Hz, JC,F = 4.8 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C22H15F4N3+ [M+H]+ 454.1149, 
found 454.1146. HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 16.43 min, 
λ = 214 nm. 
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4-(5-Fluoro-4-phenyl-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-imidazol-1-
yl)pyridine 2r 
According to the TPIII, N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-4-amine 1b (59 mg, 0.26 mmol) and 
N-(2,2,2-trifluoro-1-phenylethyl)-4-(trifluoromethyl)aniline 3r (127 mg, 0.4 mmol) were reacted with nBuLi 
(2.5 M in hexane, 0.31 mL, 0.78 mmol) in dry THF (6 mL) for 4 h at 30 °C. The crude product was purified 
by flash chromatography (SiO2, cyclohexane/ethyl acetate 5:1 → ethyl acetate) to give desired imidazole 
derivative 2r (31 mg, 26%) as a yellow oil, N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-4-amine 1b (43 mg, 61%) 
and N-(2,2,2-trifluoro-1-phenylethyl)-4-(trifluoromethyl)aniline 3r (30 mg, 63%). 
Rf (ethyl acetate) = 0.44. 1H NMR (400 MHz, CDCl3): δ = 8.50 (d, 
JH2,H3 = JH6,H5 = 5.6 Hz, 2 H, H2, H6), 7.47 (m, 4 H, H3ꞌ, H5ꞌ, H2ꞌꞌ, H6ꞌꞌ), 7.43 
– 7.35 (m, 2 H, H3ꞌꞌ, H5ꞌꞌ), 7.35 – 7.28 (m, 1 H, H4ꞌꞌ), 7.06 (d, 
JH2',H3' = JH6',H5' = 8.5 Hz, 2 H, H2ꞌ, H6ꞌ), 7.00 (dt, JH3,H2 = JH5,H6 = 4.5 Hz, 
J = 2.1 Hz, 2 H, H3, H5), 5.30 (dq, JCH,CF3 = 4.8 Hz, 1 H, CH) ppm. 19F NMR (380 MHz, CDCl3): δ = 62.25 
(CF3), 82.76 (d, JCF3,CH = 4.9 Hz, CF3), -134.24 (s, CF) ppm. 13C NMR (100 MHz, CDCl3): δ = 151.24 (C2, 
C6), 150.15 (C1ꞌ), 149.93 (C4), 146.28 (d, JC,F = 280.5 Hz, CF), 129.15 (C3'', C5''), 128.77 (C4''), 128.46 (d, 
JC,F = 2.0 Hz, C1''), 127.91 (d, JC,F = 6.9 Hz, C3', C5'), 126.92 (q, JC,F = 3.8 Hz, CCF3), 126.36 (d, JC,F = 5.0 Hz, 
C2'', C6''), 120.56 (C2', C6'), 111.67 (C3, C5), 111.14 (d, JC,F = 21.6 Hz, FCCN), 83.15 (qd, JC,F = 35.9 Hz, 
JC,F = 4.3 Hz, CHCF3) ppm. HRMS (ESI+): m/z calcd. for C22H15F4N3+ [M+H]+ 454.1149, found 454.1148. 
HPLC (0.1% TFA, 0 minμ 4% B → 15 minμ 100% B, flowμ 1 mL/min): tR = 15.84 min, λ = 214 nm. 
 
2-(5-Fluoro-4-phenyl-3-(pyridin-4-yl)-2-(trifluoromethyl)-2,3-dihydro-1H-imidazol-1-yl)pyridine 2s 
According to the TPIII, N-(1-ethoxy-2,2,2-trifluoroethyl)aminopyridine 1b (50 mg, 0.23 mmol) and N-(2,2,2-
trifluoro-1-phenylethyl)pyridin-4-amine 3b (87 mg, 0.35 mmol) were reacted with nBuLi (1.6 M in hexane, 
0.43 mL, 0.69 mmol) in dry THF (8 mL) for 4 h at 30 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate 1:1 → ethyl acetate) to give desired imidazole derivative 2s 
(75 mg, 85%) as a colorless oil. 
Rf (ethyl acetate) = 0.50. 1H NMR (600 MHz, CDCl3): δ = 8.40 – 8.30 (m, 2 H, 
H2pyrid-4-yl, H6pyrid-4-yl), 8.25 (ddd, JH6,H5 = 4.9 Hz, JH6,H4 = 1.9 Hz, J = 0.9 Hz, 1 H, 
H6pyrid-2-yl), 7.70 – 7.63 (m, 1 H, H4pyrid-2-yl), 7.49 – 7.44 (m, 2 H, H2ꞌꞌ, H6ꞌꞌ), 7.43 – 
7.36 (m, 2 H, H3ꞌꞌ, H5ꞌꞌ), 7.36 – 7.29 (m, 1 H, H4ꞌꞌ), 7.1λ (ddt, JH3,H4 = 8.4 Hz, 
JH3,H5 =  3.2 Hz, J = 0.9 Hz, 1H, H3pyrid-2-yl),  6.98 (ddd, JH5,H4 = 7.3 Hz, JH5,H6 = 4.9 Hz, J = 0.8 Hz, 1 H, H5pyrid-
2-yl), 6.86 – 6.76 (m, 2 H, H3pyrid-4-yl, H5pyrid-4-yl), 6.61 (dq, JCH,CF3 = 5.0 Hz, 1 H, CH) ppm. 19F NMR (380 MHz, 
CDCl3): δ = 82.69 (d, JCF3,CH = 5.1 Hz, CF3), 131.29 (t, J = 3.9 Hz, CF) ppm. 13C NMR (150 MHz, CDCl3): 
δ = 154.25 (d, JC,F = 7.0 Hz, H2pyrid-2-yl), 154.14 (H4pyrid-4-yl), 150.25 (C2pyrid-4-yl, C6pyrid-4-yl), 148.22 (C6pyrid-2-yl), 
147.65 (d, JC,F = 279.1 Hz, CF), 138.75 (C4pyrid-2-yl), 129.13 (C3'', C5''), 128.43 (d, JC,F = 6.8 Hz, C1''), 128.16 
(C4''), 126.10 (C2'', C6''), 122.85 (q, JC,F = 284.0 Hz, CF3), 119.06 (C5pyrid-2-yl), 113.68, (C3pyrid-4-yl, C5pyrid-4-yl), 
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110.81 (d, J = 9.2 Hz, C3pyrid-2-yl), 109.33 (d, JC,F = 25.4 Hz, FCCN), 78.03 (q, JC,F = 35.9 Hz, CHCF3). HRMS 
(ESI+): m/z calcd. for C20H15F4N4+ [M+H]+ 387.1227, found 387.1225. 
 
2-(2-(Difluoromethyl)-5-fluoro-4-phenyl-3-(pyridin-4-yl)-2,3-dihydro-1H-imidazol-1-yl)pyridine 2t 
According to the TPIII, N-(1-ethoxy-2,2-difluoroethyl)pyridin-2-amine 1t (36 mg, 0.18 mmol) and N-(2,2,2-
trifluoro-1-phenylethyl)pyridin-4-amine 3b (68 mg, 0.27 mmol) were reacted with nBuLi (2.5 M in hexane, 
0.24 mL, 0.60 mmol) in dry THF (6 mL) for 4 h at 30 °C. The crude product was purified by flash 
chromatography (SiO2, cyclohexane/ethyl acetate 1:1 → ethyl acetate) to give desired imidazole derivative 2t 
(50 mg, 75%) as a colorless oil. 
Rf (ethyl acetate) = 0.45. 1H NMR (400 MHz, CDCl3): δ = 8.31 (d, 
JH3,H2 = JH5,H6 = 5.4 Hz, 2 H, H2pyrid-4-yl, H6pyrid-4-yl), 8.24 (ddd, JH6,H5 = 5.0 Hz, 
JH6,H4 = 1.9 Hz, J = 0.9 Hz, 1 H, H6pyrid-2-yl), 7.64 (ddd, JH4,H3 = 8.4, JH4,H5 = 7.3 Hz, 
J = 1.9 Hz, 1 H, H4pyrid-2-yl), 7.47 (d, JH2'',H3'' = JH6'',H5'' = 7.2 Hz, 2 H, H2ꞌꞌ, H6ꞌꞌ), 
7.38 (dd, JH3'',H2'' = JH5'',H6'' = 8.5 Hz, JH3'',H4'' = JH5'',H4'' = 6.9 Hz, 2 H, H3ꞌꞌ, H5ꞌꞌ), 7.33 – 7.27 (m, 1 H, H4ꞌꞌ), 7.13 
(ddt, JH3,H4 = 8.4 Hz, JH3,H5 =  3.4 Hz, J = 1.0 Hz, 1 H, H3pyrid-2-yl),  6.94 (ddd, JH5,H4 = 7.3 Hz, JH5,H6 = 4.9 Hz, 
J = 0.9 Hz, 1 H, H5pyrid-2-yl), 6.84 – 6.73 (m, 2 H, H3pyrid-4-yl, H5pyrid-4-yl), 6.18 (m, 1 H, CH), 6.10 (td, 
JCHF2,CHF2 = 55.3 Hz, JCHF2,CH = 3.3 Hz, 1 H, CF2H) ppm. 19F NMR (380 MHz, CDCl3): δ = 129.27 (ddd, 
JCHF2,CHF2 = 287.6, JCHF2,CHF2 = 55.0, JCHF2,CH = 3.0 Hz), 132.99 (t, J = 4.1 Hz, CF), 137.21 (ddd, 
JCHF2,CHF2 = 287.6, JCHF2,CHF2 = 55.6, JCHF2,CH = 13.9 Hz) ppm. 13C NMR (100 MHz, CDCl3): δ = 154.55 
(H4pyrid-4-yl), 154.13 (d, JC,F = 6.7 Hz, H2pyrid-2-yl), 150.34 (C2pyrid-4-yl, C6pyrid-4-yl), 148.37 (C6pyrid-2-yl), 147.44 (d, 
JC,F = 279.4 Hz, CF), 138.59 (C4pyrid-2-yl), 129.06 (C3'', C5''), 128.82 (d, JC,F = 7.0 Hz, C1''), 127.80 (C4''), 
125.93 (d, JC,F = 4.9 Hz, C2'', C6''), 118.38 (C5pyrid-2-yl), 115.04 – 109.77 (m, CF2H), 113.80 (C3pyrid-4-yl, C5pyrid-
4-yl), 110.31 (d, JC,F = 9.3 Hz, C3pyrid-2-yl), 108.74 (d, JC,F = 24.2 Hz, FCCN), 81.11 – 79.62 (m, CHCF2H) ppm. 
HRMS (ESI+): m/z calcd. for C20H15F3N4+ [M+H]+ 369.1322, found 369.1322. 
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6.3 Mechanistic experiments and NMR-studies 
Deprotonation of N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-4-amine 1b with nBuLi 
 
In a dry and argon flushed NMR tube containing a thin, fused capillary tube with CD3OD, N,O-acetal 1b 
(25 mg, 0.11 mmol) was solved in freshly distilled THF (0.7 mL) and cooled to 78 °C. nBuLi (2.5 M in 
hexane, 0.05 mL, 0.11 mmol) was added at once. The NMR tube was well shaken to ensure a homogeneous 
distribution of the base. 
1H, and 13C NMR were measured at 30 °C. 
1H NMR: 
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13C NMR: 
 
 
HSQC: 
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Deprotonation of N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-4-amine 1b with nBuLi 
 
In a dry and argon flushed Schlenk-flask the N,O-acetal 1b (50 mg, 0.23 mmol) was solved in freshly distilled 
THF (3 mL) and cooled to 78 °C. nBuLi (2.5 M in hexane, 0.11 mL, 0.27 mmol) was added dropwise to the 
reaction mixture, which was stirred for 30 min at 78 °C. Subsequently iodomethane (35 mg, 0.25 mmol) was 
added to the solution. After 2 h the reaction mixture was quenched with methanol (2 mL) and the solvent was 
removed in vacuo. 
1H NMR (400 MHz, CDCl3): δ = 8.38 (d, J = 7.3 Hz, 2 H, H2, H6), 8.32 (d, J = 7.2 Hz, 2 H, H2ꞌ, H6ꞌ), 7.20 
(m, 2 H, H3ꞌ, H5ꞌ), 7.02 (d, J = 6.8 Hz, 2 H, H3, H5), 5.53 (q, J = 4.7 Hz, 1 H, CH), 5.38 (q, J = 4.7 Hz, 1 H, 
CHꞌ), 4.07 (s, 3 H, CH3ꞌ), 3.68 – 3.52 (m, 4 H, 2 × CH2), 3.08 (d, J = 1.3 Hz, 6 H, 2 × CH3), 1.28 – 1.23 (m, 
3 H, CH3), 1.23 – 1.19 (m, 3 H, CH3) ppm. 13C NMR (100 MHz, CDCl3): δ = 157.85 (C1), 157.10 (C1ꞌ), 
144.28 (C2ꞌ, C6ꞌ), 141.46 (C2, C6), 122.12 (q, JC,F =  287.5 Hz, CF3), 10λ.87 (C3ꞌ, C5ꞌ), 108.53 (C3, C5), 84.14 
– 83.02 (m, CHCF3), 66.96 (CH2), 66.78 (CH2), 45.73 (CH3), 31.36 (CH3), 14.61(CH2CH3) ppm. HRMS 
(ESI+): m/z calcd. for C10H14F3N2O + [M+H]+ 235.1053, found 253.10508. HRMS (ESI+): m/z calcd. for 
C11H16F3N2O + [M+H]+ 249.1209, found 249.1209. 
 
1H NMR: 
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13C NMR: 
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Reaction of N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b with two equivalents of nBuLi 
 
In a dry and argon flushed NMR tube, containing a thin, fused capillary tube with CD3OD, the CF3-amine 3b 
(25 mg, 0.10 mmol) was solved in freshly distilled THF (0.7 mL) and cooled to 78 °C. Two equivalents of 
nBuLi (2.5 M in hexane, 0.08 mL, 0.20 mmol) were added at once. The NMR tube was well shaken to ensure 
a homogeneous distribution of the base. 
19F NMR were measured at the stated temperatures below.  
After the measurement was completed, the mixture was quenched with water and extracted with Et2O 
(3 x 20 mL). The solvent was dried with MgSO4, filtered and evaporated to give a mixture of (E)- and (Z)-N-
(2-fluoro-1-phenylhex-1-en-1-yl)pyridin-4-amine 10b as a yellow oil. 
60 °C  
 
40 °C 
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20 °C 
 
 
10 °C 
 
 
20 °C 
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Reaction of N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b with two equivalents of nBuLi 
 
N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (30 mg, 0.12 mmol) was solved in freshly distilled THF  
(2 mL) in a dry and argon flushed flask, equipped with a magnetic stirrer and a septum and cooled to 40 °C. 
nBuLi (2.5 M in hexane, 0.11 mL, 0.26 mmol) was added dropwise with a syringe and the solution was warmed 
up to 20 C and stirred for 1.5 h at 20 °C. After the reaction was completed, sat. NH4Cl solution (5 mL) was 
added and the mixture was extracted three times with Et2O (3 x 20 mL). The solvent was dried with MgSO4, 
filtered and evaporated to give a mixture of (E)- and (Z)-N-(2-fluoro-1-phenylhex-1-en-1-yl)pyridin-4-amine 
10b as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 8.07 (d, JH2,H3 = JH6,H5 = 4.8 Hz, 2 H, H2Pyridyl, H6Pyridyl), 8.03 – 7.97 (m, 2 H, 
H2Pyridyl, H6Pyridyl), 7.43 (d, JH2',H3' = JH6',H5' = 7.4 Hz, 4 H, H2Phenyl, H6Phenyl), 7.29 – 7.19 (m, 4 H, H3Phenyl, 
H5Phenyl), 7.19 – 7.13 (m, 2 H, H4Phenyl), 6.44 – 6.38 (m, 2 H, H3Pyridyl, H5Pyridyl), 6.30 – 6.23 (m, 2 H, H3Pyridyl, 
H5Pyridyl), 5.89 (m, 2 H, NH), 2.35 (dtd, JCH2,CF = 23.9 Hz, JCH2,CH2 = 7.7 Hz, J = 5.2 Hz, 4 H, CH2), 1.58 – 1.42 
(m, 4 H, CH2), 1.25 (dtd, JCH2,CH2 = 14.6 Hz, JCH2,CH3 = 7.4 Hz, J = 3.4 Hz, 4 H, CH2), 0.79 (td, JCH3,CH2 = 7.3 Hz, 
J = 2.5 Hz, 6 H, CH3) ppm. 19F NMR (380 MHz, CDCl3): δ = 113.22 (t, JCF,CH2 = 22.1 Hz, CF), 113.52 (t, 
JCF,CH2 = 23.7 Hz, CF) ppm. 13C NMR (100 MHz, CDCl3): δ = 161.40 (d, JC,F = 264.3 Hz, CF), 153.90 (d, 
JC,F = 253.7 Hz, CF), 152.79 (C4Pyridyl), 150.91 (C4Pyridyl), 150.12 (C2Pyridyl, C6Pyridyl), 149.74 (C2Pyridyl, C6Pyridyl), 
134.21 (d, JC,F = 4.3 Hz, C1Phenyl), 133.98 (d, JC,F = 5.0 Hz, C1Pheny), 128.81 (CPhenyl), 128.78 (CPhenyl), 128.53 
(CPhenyl), 128.46 (CPhenyl), 127.92 (CPhenyl), 127.90 (CPhenyl), 127.75 (CPhenyl), 127.68 (CPhenyl), 119.53 (d, 
JC,F = 15.4 Hz, CNH), 117.61 (d, JC,F = 29.5 Hz, CNH), 109.99 (C3Pyridyl, C5Pyridyl), 108.67 (C3Pyridyl, C5Pyridyl), 
29.14 (CH2), 29.12 (d, JC,F = 25.3 Hz, CH2), 28.66 (d, JC,F = 25.3 Hz, CH2), 28.21 (CH2), 22.37 (CH2), 22.33 
(CH2), 13.89 (CH3), 13.85 (CH3) ppm. HRMS (ESI+): m/z calcd. for C17H20FN2+ [M+H]+ 271.1605, found 
271.1605. 
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1H NMR: 
 
 
19F NMR: 
V. EXPERIMENTAL PROCEDURES   
 
172 
 
13C NMR: 
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Reaction of N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b and N-(1-ethoxy-2,2,2-
trifluoroethyl)pyridin-4-amine 1b 
 
N-(2,2,2-trifluoro-1-phenylethyl)pyridin-4-amine 3b (57 mg, 0.23 mmol) was solved in freshly distilled THF 
(3 mL) in a dry and argon flushed flask, equipped with a magnetic stirrer and a septum and cooled to 20 °C. 
After dropwise addition of PhMgCl (2.8 M in hexane, 0.10 mL, 0.23 mmol), the solution was stirred for 30 min. 
In a second Schlenk-flask N-(1-ethoxy-2,2,2-trifluoroethyl)pyridin-4-amine 1b was solved in freshly distilled 
THF (3 mL) and cooled to 60 °C. nBuLi (1.6 M in hexane, 0.14 mL, 0.23 mmol) was added dropwise with a 
syringe and the solution was stirred at 60 °C for 30 min. Subsequently, the solution containing the 
deprotonated amine 4b was added to the second flask. After stirring the reaction mixture for 3 h, sat. NH4Cl 
solution (5 mL) was added and the mixture was extracted with Et2O (3 x 20 mL). The solvent was dried with 
MgSO4, filtered and evaporated to give a mixture of imidazole derivative 2b and both starting materials 3b and 
1b in a 1.7:1:1 ratio. 
The crude product mixture was analyzed via 19F NMR in CDCl3. 
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19F NMR: 
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7. Experimental Procedures and Analytical Data: 
ψ[CH(CF3)NH]-Gly Dipeptide Building Blocks for Peptide 
Synthesis 
 
4-Methoxy-N-(2,2,2-trifluoro-1-ethoxyethyl)aniline 35 
In a round bottom flask, p-Anisidine (1.50 g, 12.2 mmol) was dissolved in EtOH (20 mL) and TFAE (1.90 mL, 
14.6 mmol) and pTSA·H2O (116 mg, 0.61 mmol) were added to the solution. The resulting reaction mixture 
was refluxed at 80 °C until no further conversion was observed (4 h). After removal of the solvent, flash column 
chromatography (SiO2, gradient: cyclohexane → cyclohexane/CH2Cl2 1:4) furnished hemiaminal ether 35 as 
a colorless oil (2.31 g, 76%).  
1H NMR (400 MHz, DMSO-d6): δ = 6.91 – 6.81 (m, 2 H, 2 × Har), 6.80 – 6.72 (m, 
2 H, 2 × Har), 6.18 (d, JNH,CH = 10.5 Hz, 1 H, NH), 5.39 (dq, JCH,NH = 10.7 Hz, 
JCH,CF3 = 5.4 Hz, 1H, CH), 3.76 – 3.49 (m, 2 H, CH2), 3.66 (s, 3 H, CH3), 1.09 (t, 
JCH3,CH2 = 7.0 Hz, 3 H, CH3) ppm. 19F NMR (376 MHz, DMSO-d6): δ = -78.39 (d, JCF3,CH = 5.5 Hz, CF3) ppm. 
13C NMR (101 MHz, DMSO-d6): δ = 152.32 (Cq), 139.56 (Cq), 123.45 (q, JC,F = 283.9 Hz, CF3), 115.20 
(CHar), 114.42 (CHar), 81.63 (q, JC,F = 32.3 Hz, CCF3), 63.26 (CH2), 55.14 (CH3), 14.98 (CH3) ppm. HRMS 
(ESI+): m/z calcd. for C11H15F3NO2+ [M+H]+ 250.1049, found 250.1048. HPLC-MS (0.1% formic acid. 0 min: 
4% B → 2.8 min: 100% B, flow: 2.4 mL/min): tR = 2.32 min, λ = 220 nm.  
 
3,3,3-Trifluoro-2-4-methoxyphenylaminopropanenitrile 36 
A dry Schlenk flask was flushed with argon, equipped with a magnetic stirrer and a septum and charged with 
N-aryl hemiaminal ether 35 (5.00 g, 19.0 mmol) in dry MeCN (100 mL). The solution was cooled to 0 °C, 
boron trifluoride diethyl etherate (0.47 mL, 3.80 mmol) and then trimethylsilyl cyanide (3.57 mL, 28.5 mmol) 
were added dropwise, and the solution was stirred at 0 °C until complete consumption of the starting material 
(ca. 7 h). Then, the solution was quenched with saturated NaHCO3 solution (50 mL) and extracted with CH2Cl2 
(3 × 100 mL). The combined organic phases were dried over MgSO4, filtered and the solvent was evaporated 
in vacuo. Purification by flash chromatography (cyclohexane/ethyl acetate, 30:1 → 10:1) furnished the desired 
nitrile 36 (4.20 g, 96%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 6.89 – 6.85 (m, 2 H, H2, H6), 6.83 – 6.77 (m, 2 H, 
H3, H5), 4.69 (dq, JCH,NH = 11.2 Hz, JCH,CF3 = 6.0 Hz, 1 H, CH), 3.82 (d, 
JNH,CH = 11.3 Hz, 1 H, NH) 3.78 (s, 3 H, OCH3) ppm. 19F NMR (375 MHz, 
CDCl3): δ = -74.17 (d, JCF3,CH = 6.1 Hz, CF3) ppm. 13C NMR (150 MHz, 
CDCl3): δ = 155.68 (C4), 136.41 (C1), 121.75 (q, JC,F = 282.0 Hz, CF3) 118.94 (C3, C5), 115.29 (C2, C6), 
113.14 (CN), 55.59 (OCH3), 52.07 (q, JC,F = 35.2 Hz, CH) ppm. HRMS (ESI-): m/z calcd. for C10H8F3N2O- 
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[M-H]- 229.0594, found 229.0593. HPLC-MS (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): 
tR = 16.85 min, λ = 220 nm. 
 
3,3,3-Trifluoro-N2-4-methoxyphenylpropan-1,2-diamine 37 
A suspension of lithiumaluminium hydride (LAH) (2.80 g, 72.9 mmol) in dry diethyl ether (250 mL) was 
cooled to 0 °C, followed by the dropwise addition of a solution of nitrile 36 (4.20 g, 18.2 mmol) in dry diethyl 
ether (50 mL). The reaction mixture was allowed to warm up to r.t. and was stirred for 18 h. After cooling the 
mixture to 0 °C, the excess of LAH was carefully reacted with H2O (2 mL), a solution of aqueous KOH (15%, 
2 mL) and finally H2O (4 mL). The suspension was filtered over a thin pad of Hyflo®, which was washed with 
diethyl ether several times, before the solvent was removed in vacuo. Purification by flash chromatography 
(cyclohexane/ethyl acetate, 10:1) furnished the desired amine 37 (3.09 g, 73%) as a yellow oil.  
1H NMR (400 MHz, CDCl3): δ = 6.82 – 6.77 (m, 2 H, H2, H6), 6.72 – 6.67 (m, 
2 H, H3, H5), 4.08 (d, JNH,CH = 9.3 Hz, 1 H, NH), 3.83 – 3.70 (m, 1 H, CH), 3.75 
(s, 3 H, OCH3), 3.05 (d, JCH2,CH = 5.2 Hz, 2 H, CH2) ppm. 19F NMR (375 MHz, 
CDCl3): δ = -74.04 (d, JCF3,CH = 6.0 Hz, CF3) ppm. 13C NMR (101 MHz, CDCl3): 
δ = 153.20 (C4), 140.70 (C1), 126.27 (q, JC,F = 284.5 Hz, CF3), 115.63 (C3, C5), 115.03 (C2, C6), 58.53 (q, 
JC,F = 27.6 Hz, CH), 55.70 (OCH3), 40.60 (CH2) ppm. HRMS (ESI+): m/z calcd. for C10H14F3N2O+ [M+H]+ 
235.1053, found 235.1059. HPLC-MS (0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): 
tR = 10.25 min, λ = 220 nm. 
 
(9H-Fluoren-9-yl)methyl (3,3,3-trifluoro-2-((4-methoxyphenyl)amino)propyl)carbamate 38 
Fmoc-O-Succinimid (450 mg, 5.34 mmol) was added in small portions to a solution of amine 37 (1.25 g, 
5.34 mmol) and NaHCO3 (1.8 g, 5.34 mmol) in acetone/H2O (1:1, 200 mL) and the reaction mixture was stirred 
for 18 h at r.t. The mixture was acified with concentrated hydrochloric acid to pH = 2, before the aceton was 
removed in vacuo. The remaining aqueous solution was extracted with CH2Cl2 (3  200 mL) and the combined 
organic phases were washed with aqueous hydrochloric acid (1M, 100 mL) and saturated NaCl solution 
(100 mL). After drying the solvent with MgSO4, it was evaporated in vacuo. The crude product was 
recrystallized from CH2Cl2 to give 38 (1.64 g, 67%) was a white solid. 
1H NMR (800 MHz, DMSO-d6): δ = 7.87 (d, JH4,H3 = JH5,H6 = 7.5 Hz, 2 H, 
H4-, H5-Fmoc), 7.62(d, JH1,H2 = JH8,H7 = 7.6 Hz, 2 H, H1-, H8-Fmoc), 7.50 (t, 
JH3,H2 = JH3,H4 = JH6,H5 = JH6,H7 = 7.5 Hz, 2 H, H3-, H6-Fmoc), 7.28 (t, 
JH2,H1 = JH2,H3 = JH7,H6 = JH7,H8 = 6.9 Hz, 2 H, H2-, H7-Fmoc) 6.76 (d, JH2,H3 = JH6,H5 = 8.4 Hz, 2 H, H2, H6), 
6.66 (d, JH3,H2 = JH5,H6 = 8.4 Hz, 2 H, H3, H5), 5.06 – 5.03 (m, 1 H, NH-Fmoc), 4.30 (d, J = 7.0 Hz, 2 H, 
CH2-Fmoc), 4.14 (t, JC9,CH2-Fmoc = 7.0 Hz, 1 H, C9-Fmoc), 4.17 – 4.10 (m, 1 H, CH), 3.77 – 3.73 (m, 1 H, 
NH-PMP), 3.62 (s, 3 H, OCH3), 3.47 – 3.38 (m, 1 H, CH2), 3.29 – 3.22 (m, 1 H, CH2) ppm. 19F NMR 
(375 MHz, DMSO-d6): δ = -73.10 (d, JCF3,CH = 7.5 Hz, CF3) ppm. 13C NMR (150 MHz, DMSO-d6) δ = 156.96 
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(C=O-Urethan), 153.40 (C4), 143.55 (C1a-, C8a-Fmoc), 141.28 (C4a-, C5a-Fmoc), 140.15 (C1), 127.73 (C3-
, C6-Fmoc), 127.04 (C2-, C7-Fmoc), 124.91 (C1-, C8-Fmoc), 119.99 (C4-, C5-Fmoc), 115.51 (C3, C5), 114.88 
(C2, C6), 67.13 (CH2-Fmoc), 58.10 (q, JC,F = 27.1 Hz, CH) 55.64 (OCH3), 47.11 (C9-Fmoc), 40.25 (CH2) ppm. 
HRMS (ESI+): m/z calcd. for C25H23F3N2O3+ [M+H]+ 456.1655, found 457.1734. mp 173 °C. HPLC-MS 
(0.1% TFA. 0 minμ 4% B → 15 min: 100% B, flow: 1 mL/min): tR = 20.96 min, λ = 220 nm. 
 
(9H-Fluoren-9-yl)methyl (2-amino-3,3,3-trifluoropropyl)carbamate 31 
The fully protected diamine 38 (140 mg, 0.307 mmol) was solved in MeCN (25 mL) and cooled to 0 °C. A 
solution of ammonium cer(IV) nitrate (CAN) (842 mg, 1.54 mmol) in H2O (3 mL) was added dropwise, the 
reaction was allowed to warm up to r.t. and stirred for 2 h. After addition of aqueous NaHCO3 solution (20 mL), 
the mixture was extracted with ethyl acetate (4  25 mL) and the combined organic phases were dried with 
MgSO4, filtered and the solvent was removed in vacuo. Purification by flash chromatography 
(cyclohexane/ethyl acetate, 10:1) furnished the desired amine 31 (71 mg, 66%) as a yellow solid.  
1H NMR (600 MHz, CDCl3): δ = 7.77 (dt, JH4,H3 = JH5,H6 = 7.5 Hz, JH4,H2 = JH5-,H7-
Fmoc = 1.0 Hz, 2 H, H4-, H5-Fmoc), 7.59 (dt, JH1,H2 = JH8,H7 = 7.5 Hz, 
JH1,H3 = JH8,H6 = 1.0 Hz, 2 H, H1-, H8-Fmoc), 7.40 (td, JH3,H4 = JH6,H5 = 7.5 Hz, 
JH3,H1 = JH6,H8 = 1.0 Hz, JH3,H2 = JH6,H7 = 0.6 Hz, 2 H, H3-, H6-Fmoc), 7.32 (td, JH2,H1 = JH7,H8 = 7.5 Hz, 
JH2,H4 = JH7,H5= 1.0 Hz, 2 H, H2-, H7-Fmoc), 5.14 (s, 1 H, NH), 4.45 (d, J = 6.9 Hz, 2 H, CH2-Fmoc), 4.22 (t, 
JH9,CH2 = 6.9 Hz, 1 H, H9-Fmoc), 3.74 – 3.62 (m, 1H, CH2), 3.37 – 3.27 (m, 1 H, CH), 3.19 – 3.08 (m, 1 H, 
CH2) ppm. 19F NMR (375 MHz, CDCl3): δ = -74.73 (d, JCF3,CH = 6.8 Hz, CF3) ppm. 
13C NMR (150 MHz, CDCl3): δ = 156.50 (C=O-Urethan), 143.76 (C1a-, C8a-Fmoc), 141.32 (C4a-, C5a-
Fmoc), 127.71 (C3-, C6-Fmoc), 127.03 (C2-, C7-Fmoc), 124.95 (C1-, C8-Fmoc), 119.99 (C4-, C5-Fmoc), 
66.86 (CH2-Fmoc), 53.67 (q, JC,F = 28.9 Hz, CH), 47.07 (C9-Fmoc), 40.74 (CH2). ). HRMS (ESI+): m/z calcd. 
for C18H17F3N2O2+ [M+H]+ 350.1237 found 351.1325. mp 101 °C. HPLC-MS (0.1% TFA. 0 minμ 4% B → 
15 min: 100% B, flow: 1 mL/min): tR = 13.17 min, λ = 220 nm. 
 
(9H-fluoren-9-yl)methyl(2-chloro-3,3,3-trifluoropropyl)carbamate 40 
Amine 31 (50 mg, 0.14 mmol) was suspended in 6 M HCl (5 mL) and cooled to 0 °C. A solution of sodium 
nitrite (15 mg, 0.21 mmol) in H2O (1 mL) was added dropwise, the reaction was allowed to warm up to r.t. and 
stirred for 18 h. After addition of aqueous NaHCO3 solution (100 mL), the mixture was extracted with ethyl 
acetate (4  100 mL) and the combined organic phases were dried with MgSO4, filtered and the solvent was 
removed in vacuo. Purification by flash chromatography (cyclohexane/ethyl acetate, 30:1) furnished the 
desired choride 40 (30 mg, 58%) as a colorless oil.  
1H NMR (600 MHz, CDCl3): δ = 7.77 (dt, JH4,H3 = JH5,H6 = 7.6 Hz, JH4,H2 = JH5,H7 = 
1.0 Hz, 2 H, H4-, H5-Fmoc), 7.58 (d, JH1,H2 = JH8,H7 = 7.6 Hz, 2 H, H1-, H8-Fmoc), 7.41 
(tt, JH3,H4 = JH6,H5 = 7.5 Hz, JH3,H1 = JH6,H8 = 0.9 Hz, 2 H, H3-, H6-Fmoc), 7.33 (t, 
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JH2,H1 = JH7,H8 = 7.5 Hz, 2 H, H2-, H7-Fmoc), 5.16 (s, 1 H, NH), 4.47 (d, J = 6.9 Hz, 2 H, CH2-Fmoc), 
4.35 – 4.27 (m, 1 H, CH), 4.23 (t, JH9,CH2 = 6.7 Hz, 1 H, H9-Fmoc), 3.98 – 3.86 (m, 1 H, CH2), 3.52 – 3.35 (m, 
1 H, CH2) ppm. 19F NMR (375 MHz, CDCl3): δ = -73.27 (d, JCF3,CH = 6.7 Hz, CF3) ppm. 13C NMR 
(150 MHz, CDCl3): δ = 156.17 (C=O-Urethan), 143.71 (C1a-, C8a-Fmoc), 141.50 (C4a-, C5a-Fmoc), 127.96 
(C3-, C6-Fmoc), 127.23 (C2-, C7-Fmoc), 125.07 (C1-, C8-Fmoc), 123.50 (q, JC,F = 279.7 Hz, CF3), 120.21 
(C4-, C5-Fmoc), 67.28 (CH2-Fmoc), 56.36 (q, JC,F = 31.9 Hz, CH), 47.31 (C9-Fmoc), 42.16 (CH2) ppm. 
HRMS (ESI-): m/z calcd. for C19H16ClF3NO4- [M-HCOO]- 414.0735 found 414.0732.  
 
9H-fluoren-9-yl)methyl (3,3,3-trifluoro-2-hydroxypropyl)carbamate 41 
Amine 31 (200 mg, 0.57 mmol) was solved in acetic acid/H2O (4:1, 40 mL) and cooled to 0 °C. A solution of 
sodium nitrite (51 mg, 0.74 mmol) in H2O (2 mL) was added dropwise, the reaction was allowed to warm up 
to r.t. and stirred for 18 h. After addition of aqueous NaHCO3 solution (100 mL), the mixture was extracted 
with ethyl acetate (4  100 mL) and the combined organic phases were dried with MgSO4, filtered and the 
solvent was removed in vacuo. Purification by flash chromatography (cyclohexane/ethyl acetate, 20:1) 
furnished the desired compound 41 (105 mg, 52%) as a colorless oil.  
1H NMR (400 MHz, CDCl3): δ = 7.72 (dt, JH4,H3 = JH5,H6 = 7.6 Hz, 
JH4,H2 = JH5,H7 = 0.9 Hz, 2 H, H4-, H5-Fmoc), 7.56 (d, JH1,H2 = JH8,H7 = 7.5 Hz, 2 H, H1-, 
H8-Fmoc), 7.44 – 7.33 (m 2 H, H3-, H6-Fmoc), 7.33 – 7.20 (m, 2 H, H2-, H7-Fmoc), 
5.74 (t, JNH,CH2 = 6.0 Hz, 1 H, NH), 5.45 (d, JOH,CH2 = 5.9 Hz, 1 H. OH), 4.38 (d, J = 6.9 Hz, 2 H, CH2-Fmoc), 
4.18 (t, JH9,CH2 = 6.9 Hz, 1 H, H9-Fmoc), 4.01 (m, 1 H, CH), 3.65 – 3.54 (m, 1 H, CH2), 3.31 – 3.17 (m, 1 H, 
CH2) ppm. 19F NMR (375 MHz, CDCl3): δ = -78.28 (d, JCF3,CH = 7.1 Hz, CF3) ppm. 13C NMR (101 MHz, 
CDCl3): δ = 156.99 (C=O-Urethan), 143.85 (C1a-, C8a-Fmoc), 141.32 (C4a-, C5a-Fmoc), 127.75 (C3-, C6-
Fmoc), 127.11 (C2-, C7-Fmoc), 125.09 (C1-, C8-Fmoc), 120.00 (C4-, C5-Fmoc), 69.28 (q, JC,F = 31.9 Hz, 
CH), 66.85 (CH2-Fmoc), 47.22 (C9-Fmoc), 41.15 (CH2) ppm. HRMS (ESI-): m/z calcd. for C19H17F3NO5- [M-
HCOO]- 396.1064 found 396.1069.  
 
Benzyl (3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1,1,1-trifluoropropan-2-yl)-L-valinate 39 
(ψ[CH(CF3)NH]-Gly-Val) 
Compound 41 (51 mg, 0.15 mmol) was solved in dry CH2Cl2 (10 mL) and 
cooled to -78 °C. 2,6-Lutidine (37 L, 0.32 mmol) and Tf2O (27 L, 
0.16 mmol) was added to the reaction mixture which was subsequently 
allowed to warm up to 0 °C and stirred for 6 h. Benzyl L-valinate (36 mg, 0.17 mmol) solved in dry CH2Cl2 
(1 mL) was then added dropwise to the solution. After stirring the reaction mixture for 16 h, the solvent was 
removed in vacuo. 
HRMS (ESI+): m/z calcd. for C30H32F3N2O3+ [M+H]+ 541.2309 found 541.2314. 
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